{"id": "c495fada-84c3-4ed6-bc58-31d953a4d9f1", "page": 1, "type": "paragraph", "text": "Morbidity and Mortality Weekly Report"}
{"id": "48413f61-b450-476e-830c-2a352c143492", "page": 1, "type": "paragraph", "text": "Recommendations and Reports / Vol. 71 / No. 1"}
{"id": "2a842110-1acb-4bff-ae14-b07740153f07", "page": 1, "type": "paragraph", "text": "August 26, 2022"}
{"id": "577679e1-fce6-4c2a-9a5e-639f2ffc458f", "page": 1, "type": "paragraph", "text": "U.S. Department of Health and Human Services"}
{"id": "0cae5fcb-4ab4-4203-b5d1-4a539ea23e67", "page": 1, "type": "paragraph", "text": "Centers for Disease Control and Prevention"}
{"id": "56e9f6f8-d090-4d7a-b8ce-f64d2a19e657", "page": 1, "type": "paragraph", "text": "Prevention and Control of Seasonal Influenza with"}
{"id": "5b47ca3a-a894-4bd8-9014-0e277f8ef7c2", "page": 1, "type": "paragraph", "text": "Vaccines: Recommendations of the Advisory"}
{"id": "8a9528d7-cd2b-4aa1-9cc2-630d8e062acb", "page": 1, "type": "paragraph", "text": "Committee on Immunization Practices \u2014"}
{"id": "97a68a17-5572-423a-bd97-a2988c4d0cd9", "page": 1, "type": "paragraph", "text": "United States, 2022\u201323 Influenza Season"}
{"id": "16372a92-907a-4db9-9f9d-b46e25474bfd", "page": 2, "type": "paragraph", "text": "The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC),"}
{"id": "76f377b5-f8e4-40ff-bc4b-01b2d344d57e", "page": 2, "type": "paragraph", "text": "U.S. Department of Health and Human Services, Atlanta, GA 30329-4027."}
{"id": "99abc8eb-5662-4b42-92a1-34b4749c5efa", "page": 2, "type": "paragraph", "text": "Suggested citation: [Author names; first three, then et al., if more than six.] [Title]. MMWR Recomm Rep 2022;71(No. RR-#):[inclusive page numbers]."}
{"id": "282d0c15-e19f-420c-b12b-b18b3d274c5c", "page": 2, "type": "paragraph", "text": "Centers for Disease Control and Prevention"}
{"id": "fe4ee2a5-0cf8-45d4-909f-cb40282fe2b5", "page": 2, "type": "paragraph", "text": "Rochelle P. Walensky, MD, MPH, Director"}
{"id": "51e44009-aa78-4dfa-bd1a-492f55b60800", "page": 2, "type": "paragraph", "text": "Debra Houry, MD, MPH, Acting Principal Deputy Director"}
{"id": "753b2b90-e056-4c0a-bbf1-c81ecde38d6c", "page": 2, "type": "paragraph", "text": "Daniel B. Jernigan, MD, MPH, Deputy Director for Public Health Science and Surveillance"}
{"id": "f6f662d4-e8e0-42c8-aeb0-7c3eb93b8b6d", "page": 2, "type": "paragraph", "text": "Rebecca Bunnell, PhD, MEd, Director, Office of Science"}
{"id": "21fc7ba3-4365-4258-a89a-4cc9a34660a6", "page": 2, "type": "paragraph", "text": "Jennifer Layden, MD, PhD, Deputy Director, Office of Science"}
{"id": "f7b08a39-3a06-4d5c-8be3-2367cb1abc79", "page": 2, "type": "paragraph", "text": "Leslie Dauphin, PhD, Director, Center for Surveillance, Epidemiology, and Laboratory Services"}
{"id": "4a3e733d-82c1-4c8b-a75f-95c62f68b4fe", "page": 2, "type": "paragraph", "text": "MMWR Editorial and Production Staff (Serials)"}
{"id": "31d0947a-8f60-4007-82ec-d3bf6d11ae2d", "page": 2, "type": "paragraph", "text": "Charlotte K. Kent, PhD, MPH, Editor in Chief"}
{"id": "daba0666-5264-438a-8076-c265dfa747f6", "page": 2, "type": "paragraph", "text": "Brian A. King, PhD, MPH, Executive Editor"}
{"id": "13882536-7d5a-4010-9f8c-fcb8c1ef0c7e", "page": 2, "type": "paragraph", "text": "Christine G. Casey, MD, Editor"}
{"id": "f25f2800-5ba6-409e-a023-16ac2f288409", "page": 2, "type": "paragraph", "text": "Mary Dott, MD, MPH, Online Editor"}
{"id": "58708b7b-a896-4c56-a97b-ebf206eb30f0", "page": 2, "type": "paragraph", "text": "Terisa F. Rutledge, Managing Editor"}
{"id": "00deb02b-94f6-45d4-8ff7-332399a7153b", "page": 2, "type": "paragraph", "text": "David C. Johnson, Lead Technical Writer-Editor"}
{"id": "3d9f86fc-583a-402e-b9b8-6f9b02f852db", "page": 2, "type": "paragraph", "text": "Marella Meadows, Project Editor"}
{"id": "dd720214-2029-471c-87c1-cac203b5abe7", "page": 2, "type": "paragraph", "text": "Martha F. Boyd, Lead Visual Information Specialist"}
{"id": "9497dd83-b502-453f-bd11-a6b4c15fc525", "page": 2, "type": "paragraph", "text": "Alexander J. Gottardy, Maureen A. Leahy,"}
{"id": "9e3fd70d-b8b0-4817-9d70-6f47673a7b78", "page": 2, "type": "paragraph", "text": "Julia C. Martinroe, Stephen R. Spriggs,Tong Yang,"}
{"id": "b17c3a39-fd18-4936-954d-89749f0d58ba", "page": 2, "type": "paragraph", "text": "Visual Information Specialists"}
{"id": "c497e628-7e5c-4a4a-bf7b-f564397783bd", "page": 2, "type": "paragraph", "text": "Quang M. Doan, MBA, Phyllis H. King,"}
{"id": "e0333e44-76d3-4214-b5d1-4bc25544f84e", "page": 2, "type": "paragraph", "text": "Terraye M. Starr, Moua Yang,"}
{"id": "6d1db7ca-a0d5-402e-be9e-f093d9fbd13a", "page": 2, "type": "paragraph", "text": "Information Technology Specialists"}
{"id": "012085f3-5768-4207-8aa5-6b989ab0d378", "page": 2, "type": "paragraph", "text": "MMWR Editorial Board"}
{"id": "48c9f717-f346-4602-8386-7a2491146b43", "page": 2, "type": "paragraph", "text": "Timothy F. Jones, MD, Chairman"}
{"id": "f5c0db6e-45b8-4fff-bd63-91df0df1f2cb", "page": 2, "type": "paragraph", "text": "Matthew L. Boulton, MD, MPH"}
{"id": "bb7c9820-b7c5-4985-ae0e-7f3e06947a54", "page": 2, "type": "paragraph", "text": "Carolyn Brooks, ScD, MA"}
{"id": "94338d4f-8ca7-4fe0-b076-4263725f0ed0", "page": 2, "type": "paragraph", "text": "Jay C. Butler, MD"}
{"id": "48c65eea-a0a2-4f55-8654-72eee48872b2", "page": 2, "type": "paragraph", "text": "Virginia A. Caine, MD"}
{"id": "304fedd0-f9b4-49e0-b261-dde6e2507298", "page": 2, "type": "paragraph", "text": "Jonathan E. Fielding, MD, MPH, MBA"}
{"id": "27dadf52-3c15-44e0-a5d8-fbdec11c6464", "page": 2, "type": "paragraph", "text": "David W. Fleming, MD"}
{"id": "9447c0ad-9c7a-46b7-8971-adf01aeed326", "page": 2, "type": "paragraph", "text": "William E. Halperin, MD, DrPH, MPH"}
{"id": "277593c5-c21d-4010-8abc-e1f77c2af516", "page": 2, "type": "paragraph", "text": "Jewel Mullen, MD, MPH, MPA"}
{"id": "13513a3c-b915-4b25-bc06-afbe8028b2aa", "page": 2, "type": "paragraph", "text": "Jeff Niederdeppe, PhD"}
{"id": "f23d61a0-8bd3-4889-9fed-6bad65160da2", "page": 2, "type": "paragraph", "text": "Celeste Philip, MD, MPH"}
{"id": "5a8cf875-ab28-4863-a25b-405ec7d3ff1e", "page": 2, "type": "paragraph", "text": "Patricia Quinlisk, MD, MPH"}
{"id": "34f4c317-0fc2-41e7-8d0b-a93981a59e79", "page": 2, "type": "paragraph", "text": "Patrick L. Remington, MD, MPH"}
{"id": "f6a7a807-9558-46c3-bebf-d139520758c9", "page": 2, "type": "paragraph", "text": "Carlos Roig, MS, MA"}
{"id": "15ac8c86-78c7-4ee4-ae97-cf2b2fdca9c0", "page": 2, "type": "paragraph", "text": "William Schaffner, MD"}
{"id": "ea8f6d19-c2f2-49e6-a910-8caf671bd2d1", "page": 2, "type": "paragraph", "text": "Morgan Bobb Swanson, BS"}
{"id": "6333b5aa-7f50-49d9-9d0a-aaab73346f4f", "page": 2, "type": "paragraph", "text": "Ian Branam, MA,"}
{"id": "703f616c-72a9-47e4-bc78-90b785f414dc", "page": 2, "type": "paragraph", "text": "Acting Lead Health Communication Specialist"}
{"id": "7aba1dca-d408-4f22-88e6-69e5dbffa1c2", "page": 2, "type": "paragraph", "text": "Shelton Bartley, MPH, Symone Hairston, MPH"}
{"id": "dcf9094a-64d6-4bff-ac6d-2e6655dd3f18", "page": 2, "type": "paragraph", "text": "Leslie Hamlin, Lowery Johnson,"}
{"id": "43cf5419-7826-4dac-98d3-a19f4bb5a90a", "page": 2, "type": "paragraph", "text": "Health Communication Specialists"}
{"id": "f28be142-7ca5-4ce9-8e1b-aceae2def6a9", "page": 2, "type": "paragraph", "text": "Will Yang, MA,"}
{"id": "e2b593fe-a0ca-4d52-8cf5-5699782d6b1a", "page": 2, "type": "paragraph", "text": "Visual Information Specialist"}
{"id": "c5412171-b079-4d6e-a349-e414968c1bf9", "page": 2, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "35d068a0-f5a2-4b14-88ca-0451a1fd0956", "page": 2, "type": "paragraph", "text": "CONTENTS"}
{"id": "052749a1-a4b8-4420-ad50-f8328f6363ef", "page": 2, "type": "paragraph", "text": "Introduction.............................................................................................................2"}
{"id": "7d990066-95da-4694-a7e4-1b48e3f93025", "page": 2, "type": "paragraph", "text": "Methods.....................................................................................................................2"}
{"id": "5ae6fec7-abe1-4d1b-b595-bfc8e4985cc4", "page": 2, "type": "paragraph", "text": "Primary Changes and Updates..........................................................................6"}
{"id": "57da514d-e059-4d02-8187-1410ff70de40", "page": 2, "type": "paragraph", "text": "Recommendations for the Use of Influenza Vaccines, 2022\u201323............7"}
{"id": "00a29d43-2b06-4259-8034-7922ffadc3f2", "page": 2, "type": "paragraph", "text": "Influenza Vaccine Composition and Available Vaccines....................... 17"}
{"id": "57a14f3c-9548-48b9-a1e8-11e2c72ccf49", "page": 2, "type": "paragraph", "text": "Storage and Handling of Influenza Vaccines............................................. 20"}
{"id": "fd35b819-d0bd-4c29-b020-2f866a25e552", "page": 2, "type": "paragraph", "text": "Additional Sources of Information Regarding Influenza and"}
{"id": "1941668e-01ce-48fd-9b94-9b507ce948f4", "page": 2, "type": "paragraph", "text": "Influenza Vaccines............................................................................................ 21"}
{"id": "1ef7ddfa-4c09-44e4-8a95-777abe7710d4", "page": 2, "type": "paragraph", "text": "References.............................................................................................................. 22"}
{"id": "ff9bb810-e11a-46a6-853d-fc6bc15cf691", "page": 2, "type": "paragraph", "text": "CDC Adoption of ACIP Recommendations for MMWR"}
{"id": "cd6187e1-9c6e-4e00-8f5a-d2253f48c612", "page": 2, "type": "paragraph", "text": "Recommendations and Reports, MMWR Policy Notes, and"}
{"id": "b40d490b-c462-4d18-a005-93d4393e36c2", "page": 2, "type": "paragraph", "text": "Immunization Schedules (Child/Adolescent, Adult)"}
{"id": "42337091-16bf-436c-ba33-bf28f929405a", "page": 2, "type": "paragraph", "text": "Recommendations for routine use of vaccines in children,"}
{"id": "c09c1c80-d7c3-4291-ab02-c1af951be072", "page": 2, "type": "paragraph", "text": "adolescents, and adults are developed by the Advisory"}
{"id": "b0aea08d-096a-4c54-80bc-a6dbaa71575c", "page": 2, "type": "paragraph", "text": "Committee on Immunization Practices (ACIP). ACIP is"}
{"id": "4ef67031-e5f9-4e5f-a8da-c689d9f5c95e", "page": 2, "type": "paragraph", "text": "chartered as a Federal Advisory Committee to provide expert"}
{"id": "1eebfe8d-4e46-4c56-9aa1-ab518e2ba673", "page": 2, "type": "paragraph", "text": "external advice and guidance to the Director of CDC on"}
{"id": "b1303717-7da0-43c2-afac-7e581cb5db84", "page": 2, "type": "paragraph", "text": "use of vaccines and related agents for the control of vaccine"}
{"id": "cecc63b7-7652-4850-9cac-a196d1218318", "page": 2, "type": "paragraph", "text": "preventable diseases in the civilian population of the United"}
{"id": "19189abd-d3fd-4832-9f3b-82ed6a79d896", "page": 2, "type": "paragraph", "text": "States. Recommendations for routine use of vaccines in children"}
{"id": "40bff61c-3f61-4184-ba8d-568665f13061", "page": 2, "type": "paragraph", "text": "and adolescents are harmonized to the greatest extent possible"}
{"id": "e776c33c-9da7-4bb6-8d97-99d2323012e4", "page": 2, "type": "paragraph", "text": "with recommendations made by the American Academy of"}
{"id": "fb2855ba-473f-404b-9b07-5b462b4b9742", "page": 2, "type": "paragraph", "text": "Pediatrics (AAP), the American Academy of Family Physicians"}
{"id": "e94e5a48-fad6-410b-a855-6f6218b0598d", "page": 2, "type": "paragraph", "text": "(AAFP), and the American College of Obstetricians and"}
{"id": "85d2ec21-9380-41e5-ab51-3bfe12c9f8c7", "page": 2, "type": "paragraph", "text": "Gynecologists (ACOG). Recommendations for routine use of"}
{"id": "6dd0668f-446a-45ee-9701-b564b2402be5", "page": 2, "type": "paragraph", "text": "vaccinations in adults are harmonized with recommendations"}
{"id": "b10343d5-cb47-408e-9631-f742d37770ae", "page": 2, "type": "paragraph", "text": "of AAFP, ACOG, and the American College of Physicians"}
{"id": "eca4cedc-0446-4aab-abc4-cfdfabe4107a", "page": 2, "type": "paragraph", "text": "(ACP). ACIP recommendations approved by the CDC"}
{"id": "c9fa19de-2d5e-4ba3-b1af-ea227dcac6bc", "page": 2, "type": "paragraph", "text": "Director become agency guidelines on the date published in the"}
{"id": "7d544b4a-69f6-4913-9f31-47aec34f4591", "page": 2, "type": "paragraph", "text": "Morbidity and Mortality Weekly Report (MMWR). Additional"}
{"id": "b6afd037-4d30-4d69-8b4a-048818d0c235", "page": 2, "type": "paragraph", "text": "information is available at https://www.cdc.gov/vaccines/acip."}
{"id": "fd1cba63-b230-481c-8b0b-46861043be8b", "page": 3, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "226c3bcc-31aa-4dbf-8446-0c952ad009db", "page": 3, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "ab896f18-6da8-4429-a13d-8c23b7461e3c", "page": 3, "type": "paragraph", "text": "1"}
{"id": "dfeffeb2-1ee6-44cf-90d2-bc0eb6812faa", "page": 3, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "25760775-67e0-4f12-ad95-cf5c608bbfb1", "page": 3, "type": "paragraph", "text": "Prevention and Control of Seasonal Influenza with Vaccines:"}
{"id": "b4752007-3622-4eba-a993-d1344c35c274", "page": 3, "type": "paragraph", "text": "Recommendations of the Advisory Committee on Immunization"}
{"id": "fc6db8de-a838-42db-8b19-bd6f4cd389e4", "page": 3, "type": "paragraph", "text": "Practices \u2014 United States, 2022\u201323 Influenza Season"}
{"id": "b3217fd3-365e-45f2-8821-c66be9850954", "page": 3, "type": "paragraph", "text": "Lisa A. Grohskopf, MD1; Lenee H. Blanton, MPH1; Jill M. Ferdinands, PhD1; Jessie R. Chung, MPH1; Karen R. Broder, MD2;"}
{"id": "2dff3132-c361-46ca-a09d-fdbb06df0019", "page": 3, "type": "paragraph", "text": "H. Keipp Talbot, MD3; Rebecca L. Morgan, PhD4; Alicia M. Fry, MD1"}
{"id": "97152e6c-2211-4852-b808-9c462d954a9b", "page": 3, "type": "paragraph", "text": "1Influenza Division, National Center for Immunization and Respiratory Diseases, CDC; 2Immunization Safety Office, National Center for Emerging and"}
{"id": "c9c19c62-b9c2-4651-af31-1393d5e0bae0", "page": 3, "type": "paragraph", "text": "Zoonotic Infectious Diseases, CDC; 3Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee; 4Department of Health Research"}
{"id": "e4e9007a-cba3-4246-bd1b-adccad6460ec", "page": 3, "type": "paragraph", "text": "Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}
{"id": "648558af-a1b8-4a49-898a-1bdabbcb6221", "page": 3, "type": "paragraph", "text": "Summary"}
{"id": "48039ef5-33d5-4d0b-b75c-929c659d1122", "page": 3, "type": "paragraph", "text": "This report updates the 2021\u201322 recommendations of the Advisory Committee on Immunization Practices (ACIP) concerning"}
{"id": "ee0c21fc-03ff-4b2c-8b1d-782b6cd1d166", "page": 3, "type": "paragraph", "text": "the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2021;70[No. RR-5]:1\u201324). Routine annual"}
{"id": "40995077-8964-43bf-b738-8740a4501a11", "page": 3, "type": "paragraph", "text": "influenza vaccination is recommended for all persons aged \u22656 months who do not have contraindications. For each recipient,"}
{"id": "abd90c13-5a22-4f13-9902-f3deec2eee2e", "page": 3, "type": "paragraph", "text": "a licensed and age-appropriate vaccine should be used. With the exception of vaccination for adults aged \u226565 years, ACIP"}
{"id": "f8450813-37c6-439c-829d-30ead69877e7", "page": 3, "type": "paragraph", "text": "makes no preferential recommendation for a specific vaccine when more than one licensed, recommended, and age-appropriate"}
{"id": "6ff2ba24-2e67-4115-bfa7-b637c533a674", "page": 3, "type": "paragraph", "text": "vaccine is available. All seasonal influenza vaccines expected to be available in the United States for the 2022\u201323 season are"}
{"id": "caa99e54-e67e-4526-b871-a590a6a8bd2f", "page": 3, "type": "paragraph", "text": "quadrivalent, containing hemagglutinin (HA) derived from one influenza A(H1N1)pdm09 virus, one influenza A(H3N2) virus,"}
{"id": "2899c66f-9d73-40a7-9837-165aabe4cc44", "page": 3, "type": "paragraph", "text": "one influenza B/Victoria lineage virus, and one influenza B/Yamagata lineage virus. Inactivated influenza vaccines (IIV4s),"}
{"id": "3284b4f6-97df-481e-bdc2-77413254f5f7", "page": 3, "type": "paragraph", "text": "recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Trivalent"}
{"id": "335c8aeb-cb56-41c8-8753-7a99a075d3b1", "page": 3, "type": "paragraph", "text": "influenza vaccines are no longer available, but data that involve these vaccines are included for reference."}
{"id": "1c973cff-7fa4-4f19-9f68-e7860bdb437d", "page": 3, "type": "paragraph", "text": "Influenza vaccines might be available as early as July or August, but for most persons who need only 1 dose of influenza vaccine"}
{"id": "dbcc3658-04f1-4165-9b06-2d8189f131a1", "page": 3, "type": "paragraph", "text": "for the season, vaccination should ideally be offered during September or October. However, vaccination should continue after"}
{"id": "0d6be9ce-fc23-4426-81ae-a400fc01965b", "page": 3, "type": "paragraph", "text": "October and throughout the season as long as influenza viruses are circulating and unexpired vaccine is available. For most adults"}
{"id": "3934c869-ced0-4a60-8e66-0403dbc97781", "page": 3, "type": "paragraph", "text": "(particularly adults aged \u226565 years) and for pregnant persons in the first or second trimester, vaccination during July and August"}
{"id": "55dc1af6-0f42-4190-bea7-baba3216bcf7", "page": 3, "type": "paragraph", "text": "should be avoided unless there is concern that vaccination later in the season might not be possible. Certain children aged 6 months"}
{"id": "ccf39e4d-e8a2-481f-a374-c401cf413ced", "page": 3, "type": "paragraph", "text": "through 8 years need 2 doses; these children should receive the first dose as soon as possible after vaccine is available, including"}
{"id": "0529c73e-1225-4b20-a569-27b78cd52517", "page": 3, "type": "paragraph", "text": "during July and August. Vaccination during July and August can be considered for children of any age who need only 1 dose for"}
{"id": "4af9f34f-d3ce-4707-bc05-2ee0a0fd9b9a", "page": 3, "type": "paragraph", "text": "the season and for pregnant persons who are in the third trimester if vaccine is available during those months."}
{"id": "6356bbd6-178b-4ed3-bbd1-4591a76e761a", "page": 3, "type": "paragraph", "text": "Updates described in this report reflect discussions during public meetings of ACIP that were held on October 20, 2021;"}
{"id": "63ea6e9e-d93b-4bd1-ac92-7f0e3e3791a0", "page": 3, "type": "paragraph", "text": "January 12, 2022; February 23, 2022; and June 22, 2022. Primary updates to this report include the following three topics:"}
{"id": "7a023a16-d4b8-4125-8562-e3a2c9410649", "page": 3, "type": "paragraph", "text": "1) the composition of 2022\u201323 U.S. seasonal influenza vaccines; 2) updates to the description of influenza vaccines expected"}
{"id": "f63787dc-f851-4531-a341-f8b42ad4f648", "page": 3, "type": "paragraph", "text": "to be available for the 2022\u201323 season, including one influenza vaccine labeling change that occurred after the publication of"}
{"id": "96cf241f-d0f6-4211-ac40-0795a8857938", "page": 3, "type": "paragraph", "text": "the 2021\u201322 ACIP influenza recommendations; and 3) updates to the recommendations concerning vaccination of adults aged"}
{"id": "01ea4883-2aa2-4afc-9811-29dd1fabb7d4", "page": 3, "type": "paragraph", "text": "\u226565 years. First, the composition of 2022\u201323 U.S. influenza vaccines includes updates to the influenza A(H3N2) and influenza"}
{"id": "7b2efefd-1903-4476-8051-d1cdfb738bb6", "page": 3, "type": "paragraph", "text": "B/Victoria lineage components. U.S.-licensed influenza vaccines will contain HA derived from an influenza A/Victoria/2570/2019"}
{"id": "0a7421cb-cf9a-49dd-9d93-b5e6fcee01a2", "page": 3, "type": "paragraph", "text": "(H1N1)pdm09-like virus (for egg-based vaccines) or an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus (for cell"}
{"id": "1923b207-9192-41f1-b53e-a9cd3679d6c0", "page": 3, "type": "paragraph", "text": "culture\u2013based or recombinant vaccines); an influenza A/Darwin/9/2021 (H3N2)-like virus (for egg-based vaccines) or an influenza"}
{"id": "04503113-3821-4185-9c75-8e24479311fc", "page": 3, "type": "paragraph", "text": "A/Darwin/6/2021 (H3N2)-like virus (for cell culture\u2013based or recombinant vaccines); an influenza B/Austria/1359417/2021"}
{"id": "ad3c40fa-bdab-493e-96a2-e2fce5cbff5a", "page": 3, "type": "paragraph", "text": "(Victoria lineage)-like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus. Second, the approved age"}
{"id": "729d0af1-37be-480d-9a2c-cf099f5270a3", "page": 3, "type": "paragraph", "text": "indication for the cell culture\u2013based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), was changed in October"}
{"id": "c91c9182-ace0-4652-ae38-6ad0d44b3d5f", "page": 3, "type": "paragraph", "text": "2021 from \u22652 years to \u22656 months. Third, recommendations for vaccination of adults aged \u226565 years have been modified. ACIP"}
{"id": "77f828c8-a803-41c2-9c2e-01427475fa83", "page": 3, "type": "paragraph", "text": "recommends that adults aged \u226565 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines:"}
{"id": "1bdcdaeb-1ca4-47a6-a44f-92ac80ddaa33", "page": 3, "type": "paragraph", "text": "quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or"}
{"id": "4b0c707a-1e85-43fb-b0d9-e2ca74e71be1", "page": 3, "type": "paragraph", "text": "quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity for"}
{"id": "7f741b27-c5fe-4397-970e-712f5ffb941a", "page": 3, "type": "paragraph", "text": "vaccine administration, then any other age-appropriate influenza"}
{"id": "b1cff3b6-4eb5-46bc-ab3c-be4d7f9ca321", "page": 3, "type": "paragraph", "text": "vaccine should be used."}
{"id": "d7f89f76-2dbd-4810-868c-8907fff88c63", "page": 3, "type": "paragraph", "text": "This report focuses on recommendations for the use of vaccines"}
{"id": "6bf049a9-cd22-491d-b87b-3799a07a00b2", "page": 3, "type": "paragraph", "text": "for the prevention and control of seasonal influenza during the"}
{"id": "bcd9d284-faa7-4410-9170-cf14fe732a39", "page": 3, "type": "paragraph", "text": "Corresponding author: Lisa A. Grohskopf, Influenza Division,"}
{"id": "d0fdfb0f-e04a-4c5d-a57b-de6e91f266c3", "page": 3, "type": "paragraph", "text": "National Center for Immunization and Respiratory Diseases, CDC."}
{"id": "0cbf22df-4f00-41e6-8628-ee9ed1de6267", "page": 3, "type": "paragraph", "text": "Telephone: 404-639-2552; Email: lgrohskopf@cdc.gov."}
{"id": "d23a6f1c-6e26-4bf6-b45c-d3380ac78ea5", "page": 4, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "6b4c1cdb-6917-4342-98d2-ef28f04dbc76", "page": 4, "type": "paragraph", "text": "2"}
{"id": "e1f3bfe0-3628-4fa3-af34-68374c944025", "page": 4, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "810ce503-2d4f-4575-8140-458bb6b3c28e", "page": 4, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "34426a67-2e6b-483e-a255-5bf72526cebf", "page": 4, "type": "paragraph", "text": "2022\u201323 influenza season in the United States. A brief summary of the recommendations and a link to the most recent Background"}
{"id": "5553cfb6-9b88-475b-a0da-be4817a0c794", "page": 4, "type": "paragraph", "text": "Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html."}
{"id": "19e850ee-2cca-4399-bb90-8f921cbfb76f", "page": 4, "type": "paragraph", "text": "These recommendations apply to U.S.-licensed influenza vaccines used according to Food and Drug Administration\u2013licensed"}
{"id": "93f48cd1-6add-4d6f-8bc6-167e5bc84834", "page": 4, "type": "paragraph", "text": "indications. Updates and other information are available from CDC\u2019s influenza website (https://www.cdc.gov/flu). Vaccination"}
{"id": "38bf3714-1e79-41ac-aa2e-e4ab19f06087", "page": 4, "type": "paragraph", "text": "and health care providers should check this site periodically for additional information."}
{"id": "f11279d3-290d-40ed-999f-222e8a3f7a1a", "page": 4, "type": "paragraph", "text": "Introduction"}
{"id": "585831ef-f7d7-4ed3-b80c-c59ebb35d733", "page": 4, "type": "paragraph", "text": "Influenza viruses typically circulate annually in the United"}
{"id": "ec7c0082-7e95-442e-a02b-0316ebf58a58", "page": 4, "type": "paragraph", "text": "States, most commonly from the late fall through the early"}
{"id": "dc636853-0687-431f-a3d2-d582fbc73d63", "page": 4, "type": "paragraph", "text": "spring. Most persons who become ill after influenza virus"}
{"id": "2cc9d2f9-0ac8-4d1c-bbfb-e36283981f83", "page": 4, "type": "paragraph", "text": "infection recover without serious complications or sequelae."}
{"id": "5033e9c2-3e89-4007-ab4d-0f320fe451a1", "page": 4, "type": "paragraph", "text": "However, influenza can be associated with serious illnesses,"}
{"id": "73e0d920-e1ce-49d7-9646-1fca0482a272", "page": 4, "type": "paragraph", "text": "hospitalizations, and deaths, particularly among older adults,"}
{"id": "814e7cad-2834-4522-9813-a37423370bf7", "page": 4, "type": "paragraph", "text": "very young children, pregnant persons, and persons of all ages"}
{"id": "f26bc8e8-7b65-4ff0-8037-8c9f089d148f", "page": 4, "type": "paragraph", "text": "with certain chronic medical conditions (1\u20137). Influenza also is"}
{"id": "a368d819-42bf-48e7-8d19-0fe3db8815ae", "page": 4, "type": "paragraph", "text": "an important cause of missed work and school (8\u201310). Routine"}
{"id": "83feb42c-c886-4e8a-bfb2-bc3779d68c4b", "page": 4, "type": "paragraph", "text": "annual influenza vaccination for all persons aged \u22656 months"}
{"id": "04f7c40e-b7a5-4cf3-9a9a-546f7d8a4aa5", "page": 4, "type": "paragraph", "text": "who do not have contraindications has been recommended by"}
{"id": "2da61729-8666-4d5e-acb7-f695b676a289", "page": 4, "type": "paragraph", "text": "CDC and the Advisory Committee on Immunization Practices"}
{"id": "8f9f03c3-145b-4088-92ae-0991264aae97", "page": 4, "type": "paragraph", "text": "(ACIP) since 2010 (11)."}
{"id": "8abc2e52-1ad2-4d8b-b16b-83596965623c", "page": 4, "type": "paragraph", "text": "Vaccination provides important protection from influenza"}
{"id": "6c7f558b-064f-4ab9-86d7-27841bdd9fab", "page": 4, "type": "paragraph", "text": "illness and its potential complications. The effectiveness of"}
{"id": "608b0447-dab5-49ca-bdb4-1f0bc52554b9", "page": 4, "type": "paragraph", "text": "influenza vaccination varies depending on several factors,"}
{"id": "a6d6c68d-efff-4ece-a167-8434ff2076b4", "page": 4, "type": "paragraph", "text": "such as the age and health of the recipient; the type of vaccine"}
{"id": "849beb7e-8387-479d-bd6a-a8a9ecd99906", "page": 4, "type": "paragraph", "text": "administered; the types, subtypes (for influenza A), and lineages"}
{"id": "e818dd82-ea19-41e7-9e6b-0d3ce94df0d0", "page": 4, "type": "paragraph", "text": "(for influenza B) of circulating influenza viruses; and the degree"}
{"id": "82afff34-499d-41b5-85b4-f20a24271f07", "page": 4, "type": "paragraph", "text": "of similarity between circulating viruses and those included in"}
{"id": "80f8be44-0365-4082-81e9-ab9551af4056", "page": 4, "type": "paragraph", "text": "the vaccine (12). During each of the six influenza seasons from"}
{"id": "d5f5f198-1b1a-4732-b819-79137cf68cf2", "page": 4, "type": "paragraph", "text": "2010\u201311 through 2015\u201316, influenza vaccination prevented"}
{"id": "a1a06762-0e90-4415-bd09-bcc5fceb21e7", "page": 4, "type": "paragraph", "text": "an estimated 1.6\u20136.7 million illnesses, 790,000\u20133.1 million"}
{"id": "41d62683-28e4-4f41-8d81-cf359cb1b315", "page": 4, "type": "paragraph", "text": "outpatient medical visits, 39,000\u201387,000 hospitalizations, and"}
{"id": "51555c0c-71cd-497e-9384-69e1bb3480ab", "page": 4, "type": "paragraph", "text": "3,000\u201310,000 respiratory and circulatory deaths each season"}
{"id": "7db14351-639d-4cd4-a731-dfd4860dabb7", "page": 4, "type": "paragraph", "text": "in the United States (13). During the severe 2017\u201318 season,"}
{"id": "b8542a56-51df-4ba7-9cea-29af20dabe7b", "page": 4, "type": "paragraph", "text": "notable for an unusually long duration of widespread high"}
{"id": "0ece849f-4a45-41f0-8681-7cd36eb7a7a0", "page": 4, "type": "paragraph", "text": "influenza activity throughout the United States and higher"}
{"id": "04cf9c12-a841-4fa7-ad3f-dd85e5424f02", "page": 4, "type": "paragraph", "text": "rates of outpatient visits and hospitalizations compared with"}
{"id": "d75a24e2-1468-4bd7-8b78-ec564bd94250", "page": 4, "type": "paragraph", "text": "recent seasons, vaccination prevented an estimated 7.1 million"}
{"id": "87cab219-7eb4-4ab4-9f03-3cafd0fcf3a4", "page": 4, "type": "paragraph", "text": "illnesses, 3.7 million medical visits, 109,000 hospitalizations,"}
{"id": "c0a71740-c50f-4e2f-9b70-00478389d3aa", "page": 4, "type": "paragraph", "text": "and 8,000 deaths (14), despite an overall estimated vaccine"}
{"id": "d94f8937-fd07-40ea-a24d-8df042ba8636", "page": 4, "type": "paragraph", "text": "effectiveness of 38% (62% against influenza A[H1N1]pdm09"}
{"id": "6251e2c6-d4b7-4be6-b314-e01ff07073b6", "page": 4, "type": "paragraph", "text": "viruses, 22% against influenza A[H3N2] viruses, and 50%"}
{"id": "ccb6cf7e-32ea-49f4-818c-9d4ab95fea54", "page": 4, "type": "paragraph", "text": "against influenza B viruses) (14)."}
{"id": "a7f37fd8-bb0c-45b1-b373-d267851cd542", "page": 4, "type": "paragraph", "text": "Influenza circulated at historically low levels in the United"}
{"id": "16cc1df3-07aa-473e-b7d3-e83d6b5aab4f", "page": 4, "type": "paragraph", "text": "States and globally during the 2020\u201321 influenza season"}
{"id": "728ede6c-4127-4387-b148-58be4a325278", "page": 4, "type": "paragraph", "text": "(15). This was coincident with widespread implementation"}
{"id": "fe903492-a3b8-47ac-82ec-5ab538f213f0", "page": 4, "type": "paragraph", "text": "of nonpharmaceutical interventions (e.g., masking, social"}
{"id": "a4e10b87-4509-46e5-b88c-c79bebf0e8b7", "page": 4, "type": "paragraph", "text": "distancing, and suspension of in-person work and school)"}
{"id": "67342503-bc10-40fa-b0cd-e7e44493909f", "page": 4, "type": "paragraph", "text": "intended to prevent transmission of SARS-CoV-2 (the virus"}
{"id": "87a78590-f8b7-408f-be5c-f77f3fe97e0e", "page": 4, "type": "paragraph", "text": "that causes COVID-19). Influenza activity increased during the"}
{"id": "9742f021-75b9-4897-9801-bd2ae4cbbba0", "page": 4, "type": "paragraph", "text": "2021\u201322 season, although severity indicators (e.g., influenza-"}
{"id": "c983bf31-e11d-4b55-99db-69bb445e554b", "page": 4, "type": "paragraph", "text": "associated hospitalizations and deaths) were overall lower than"}
{"id": "d9b31b40-4b50-43ff-bb08-24096d31c880", "page": 4, "type": "paragraph", "text": "in recent previous seasons (16). Timing, intensity, and severity"}
{"id": "895d863d-3b52-4d98-874f-b24a2971bdc6", "page": 4, "type": "paragraph", "text": "of the 2022\u201323 influenza season cannot be predicted. Influenza"}
{"id": "ab382714-401b-4eba-bd07-86c805a03e89", "page": 4, "type": "paragraph", "text": "vaccination remains an important tool for the prevention of"}
{"id": "01d08f81-8967-4ee9-8ef4-1226d40087e0", "page": 4, "type": "paragraph", "text": "potentially severe respiratory illness, which might decrease"}
{"id": "455d4c20-62e7-45a8-8e25-a8a31c0d9c0d", "page": 4, "type": "paragraph", "text": "stress on the U.S. health care system during ongoing circulation"}
{"id": "266c5e01-3a56-4ffe-a28e-74515a200515", "page": 4, "type": "paragraph", "text": "of SARS-CoV-2. Guidance for vaccine planning during the"}
{"id": "b8d6da2b-6d08-43b4-b002-aaf1df99fb20", "page": 4, "type": "paragraph", "text": "COVID-19 pandemic is available at https://www.cdc.gov/"}
{"id": "67595bd8-9e5e-47d9-bd46-2a2654fa457e", "page": 4, "type": "paragraph", "text": "vaccines/pandemic-guidance/index.html."}
{"id": "2c4a0ee0-82d3-49eb-8a94-dad000a7c88f", "page": 4, "type": "paragraph", "text": "This report updates the 2021\u201322 ACIP recommendations"}
{"id": "323f5552-942c-4e14-89c5-c973c566bc22", "page": 4, "type": "paragraph", "text": "regarding the use of seasonal influenza vaccines (17) and"}
{"id": "77386bb0-8f97-4873-a12a-de087016532f", "page": 4, "type": "paragraph", "text": "provides recommendations and guidance for vaccination"}
{"id": "1b739e69-9ac3-4272-aa49-f859f78ab4bf", "page": 4, "type": "paragraph", "text": "providers regarding the use of influenza vaccines in the"}
{"id": "368d5885-4641-40c0-a795-839a841524cb", "page": 4, "type": "paragraph", "text": "United States for the 2022\u201323 season. Various formulations"}
{"id": "45099194-39b1-4d2f-bd3e-e253c13b1ee0", "page": 4, "type": "paragraph", "text": "of influenza vaccines are available (Table 1). Contraindications"}
{"id": "c9672c33-b8b4-4906-908a-de042c52ae92", "page": 4, "type": "paragraph", "text": "and precautions for the use of influenza vaccines are"}
{"id": "ee198a01-8583-4ce0-9d2c-5792f04d34e4", "page": 4, "type": "paragraph", "text": "summarized (Tables 2 and 3). Abbreviations are used in this"}
{"id": "88d0146e-577a-4cb4-b7e1-fb28830ff299", "page": 4, "type": "paragraph", "text": "report to denote the various types of vaccines (Box)."}
{"id": "b5c9e855-b389-4df3-ab80-bb04884e2a52", "page": 4, "type": "paragraph", "text": "This report focuses on recommendations and guidance"}
{"id": "522ad779-cce7-4e29-b155-d15106133697", "page": 4, "type": "paragraph", "text": "for the use of seasonal influenza vaccines for the prevention"}
{"id": "80416208-517f-4ffd-a812-2a7f210f1f75", "page": 4, "type": "paragraph", "text": "and control of influenza during the 2022\u201323 season in the"}
{"id": "5a65a524-7ec9-4ebb-b070-6e564e069196", "page": 4, "type": "paragraph", "text": "United States. A summary of these recommendations and a"}
{"id": "b5ced18e-ce6e-4b20-a819-5f376ff4da51", "page": 4, "type": "paragraph", "text": "Background Document containing additional information on"}
{"id": "99cc910c-c1f7-4461-8f3e-199ca94b3a7e", "page": 4, "type": "paragraph", "text": "influenza, influenza-associated illness, and influenza vaccines"}
{"id": "adaae45f-c779-4fd7-8e52-8aa4fec45ddc", "page": 4, "type": "paragraph", "text": "are available at https://www.cdc.gov/vaccines/hcp/acip-recs/"}
{"id": "949e5c81-2a8f-41ef-b029-7d0afe5d0a34", "page": 4, "type": "paragraph", "text": "vacc-specific/flu.html."}
{"id": "4cf5451b-e987-4a09-817a-661987e3aa40", "page": 4, "type": "paragraph", "text": "Methods"}
{"id": "62b64ade-40f6-43e3-8521-2be79bad1d4e", "page": 4, "type": "paragraph", "text": "ACIP provides annual recommendations for the use of"}
{"id": "930654a8-8e4d-45db-a422-dcfeb5d3e451", "page": 4, "type": "paragraph", "text": "influenza vaccines for the prevention and control of seasonal"}
{"id": "4d7a31b0-7397-435a-8090-9b30f7679078", "page": 4, "type": "paragraph", "text": "influenza in the United States. The ACIP Influenza Work"}
{"id": "ed9d2c68-7e5f-4c17-85db-457dd9adc8ba", "page": 4, "type": "paragraph", "text": "Group meets by teleconference once to twice per month"}
{"id": "fff4816b-7cdd-4b0a-ae3f-ee3075fc346b", "page": 4, "type": "paragraph", "text": "throughout the year. Work group membership includes several"}
{"id": "835e6617-81f5-4960-a8b7-d9d478bec3eb", "page": 4, "type": "paragraph", "text": "voting members of ACIP, representatives of ACIP liaison"}
{"id": "af8da9a8-e92b-40a1-b972-2005b60687ef", "page": 4, "type": "paragraph", "text": "organizations, and consultants. Discussions include topics"}
{"id": "4965fbd3-1dd6-48dd-a6d4-360f8767e9cb", "page": 4, "type": "paragraph", "text": "such as influenza surveillance, vaccine effectiveness and safety,"}
{"id": "c48b8795-3b44-4a93-9cd1-2116283539ec", "page": 4, "type": "paragraph", "text": "vaccination coverage, program feasibility, cost effectiveness,"}
{"id": "e0fa3647-c6ac-43d2-911b-7139db0290e7", "page": 4, "type": "paragraph", "text": "and vaccine supply. Presentations are requested from invited"}
{"id": "2e1728be-d8a3-49b2-8f9b-76ec3bc4f585", "page": 4, "type": "paragraph", "text": "experts, and published and unpublished data are discussed."}
{"id": "98edd6aa-b333-4235-9ea4-1a175c927a8f", "page": 4, "type": "paragraph", "text": "The Background Document that supplements this report is"}
{"id": "be0a8049-d128-4af6-8ea3-a892f8bc65dc", "page": 4, "type": "paragraph", "text": "updated periodically to reflect recent additions to the literature"}
{"id": "8a294751-7d14-4f4e-9995-04a4bc077fe0", "page": 5, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "2c487447-2ed0-44de-9136-9c8aa81ada07", "page": 5, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "2c5f1c4f-b16e-41c1-8d51-8746efdabde6", "page": 5, "type": "paragraph", "text": "3"}
{"id": "61f8c582-b317-4429-9748-f69287d52902", "page": 5, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "32477696-a2f6-45c5-b152-7c8e64dcf64d", "page": 5, "type": "paragraph", "text": "TABLE 1. Influenza vaccines \u2014 United States, 2022\u201323 influenza season*"}
{"id": "f46be206-2d17-44eb-b12a-9517d03d6a03", "page": 5, "type": "paragraph", "text": "Trade name (manufacturer)"}
{"id": "c18791a9-a27f-47a8-afda-5b32cd1dcf38", "page": 5, "type": "paragraph", "text": "Presentations"}
{"id": "0e3721fa-914f-460a-9730-7399c74410d6", "page": 5, "type": "paragraph", "text": "Age indication"}
{"id": "bff127f0-ff88-4a45-be38-99bfc637e4d3", "page": 5, "type": "paragraph", "text": "\u00b5g HA (IIV4s and RIV4)"}
{"id": "2390a9fc-1689-48ef-9798-1674bc9a766a", "page": 5, "type": "paragraph", "text": "or virus count (LAIV4)"}
{"id": "77c44b70-2497-4b2e-9c8d-9beb2e85a2c6", "page": 5, "type": "paragraph", "text": "for each vaccine virus (per dose)"}
{"id": "f160c383-7dec-4915-9360-f9d0e6ff5d42", "page": 5, "type": "paragraph", "text": "Route"}
{"id": "137126f6-074c-4d7e-af13-c5751bcced41", "page": 5, "type": "paragraph", "text": "Mercury"}
{"id": "0fd71a0f-033b-4ed3-acde-7d2e01d599ca", "page": 5, "type": "paragraph", "text": "(from thimerosal, if present),"}
{"id": "38a8074f-bd00-4a34-95bf-0ffdcf372222", "page": 5, "type": "paragraph", "text": "\u00b5g/0.5 mL"}
{"id": "de7ba5cd-2b7e-4a38-939c-878bfb8a2d1b", "page": 5, "type": "paragraph", "text": "IIV4 (standard-dose, egg-based vaccines\u2020)"}
{"id": "51543973-11d0-4303-a8f7-406d40c565cc", "page": 5, "type": "paragraph", "text": "Afluria Quadrivalent"}
{"id": "4fbf9cdb-a2d5-471b-94fc-03ca69c5fd96", "page": 5, "type": "paragraph", "text": "(Seqirus)"}
{"id": "1f8ab4a9-e0ce-4f54-8090-65e5bd1578cd", "page": 5, "type": "paragraph", "text": "0.5-mL PFS\u00a7"}
{"id": "692111e7-7cbd-4758-8a11-8d72f5a95580", "page": 5, "type": "paragraph", "text": "\u22653 yrs\u00a7"}
{"id": "4aac95e9-21c8-4f83-b4fe-bc6c607bc3c2", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "5b1f2d0a-d56d-4c1b-a375-c2660d49644e", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "0ae84ffe-bd17-4456-b01c-1c220e8fc766", "page": 5, "type": "paragraph", "text": "\u2014**"}
{"id": "31c0e649-4f2e-459b-a535-52906875ce97", "page": 5, "type": "paragraph", "text": "5.0-mL MDV\u00a7"}
{"id": "391137e1-4947-450b-8147-2e237f629057", "page": 5, "type": "paragraph", "text": "\u22656 mos\u00a7"}
{"id": "8994c725-f489-4e91-ad12-9fc225da43f2", "page": 5, "type": "paragraph", "text": "(needle and syringe)"}
{"id": "f4be285b-c28f-496f-9619-4d2eb6bea0fb", "page": 5, "type": "paragraph", "text": "18 through 64 yrs"}
{"id": "15bc15d8-6873-4604-9ef5-ff536e22a536", "page": 5, "type": "paragraph", "text": "(jet injector)"}
{"id": "c4a27766-a7ac-4826-8550-ea3a7e3b3454", "page": 5, "type": "paragraph", "text": "7.5 \u00b5g/0.25 mL"}
{"id": "da33c228-c247-4a44-930a-95fb61528c80", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "6e3d22e0-51a3-4822-b9a7-0bc823c51f9a", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "a58bcc8d-a744-40f7-aee4-c1a481eb17ba", "page": 5, "type": "paragraph", "text": "24.5"}
{"id": "9555b165-7778-4b8f-8b7b-72a531a1e832", "page": 5, "type": "paragraph", "text": "Fluarix Quadrivalent"}
{"id": "9a2225b1-1e4c-4c39-a612-4fe005f2771d", "page": 5, "type": "paragraph", "text": "(GlaxoSmithKline)"}
{"id": "c16fe4cf-7233-42b9-a89a-78cc4e333d5b", "page": 5, "type": "paragraph", "text": "0.5-mL PFS"}
{"id": "46bd7178-e5c4-4ac2-a144-a2893e24d47f", "page": 5, "type": "paragraph", "text": "\u22656 mos"}
{"id": "5dc6e8cb-3a6d-476d-8f1a-9a5b31c56892", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "e130a811-9d33-44f0-a876-baf9b880e2f6", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "e3ca99ec-0f83-4e50-9634-bed6c9f7529b", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "8dc2a2dc-9b48-4b0d-b4d9-4b19a7c38bac", "page": 5, "type": "paragraph", "text": "FluLaval Quadrivalent"}
{"id": "f7b97436-a408-4433-94cc-ed1e98aa7b2a", "page": 5, "type": "paragraph", "text": "(GlaxoSmithKline)"}
{"id": "bc1d60a9-705c-46ea-9c35-4109a78e7795", "page": 5, "type": "paragraph", "text": "0.5-mL PFS"}
{"id": "c467fe3c-425d-4b36-b389-4f63f87c0b11", "page": 5, "type": "paragraph", "text": "\u22656 mos"}
{"id": "272ea409-a7f8-49c9-bdc9-ca34a39a3efa", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "7c569589-882e-4f30-9059-80315fcbc448", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "87fa3eab-4d9b-402f-a1f5-8580ac24bec7", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "e157be24-514c-44fa-a9c2-2e5e87c00dac", "page": 5, "type": "paragraph", "text": "Fluzone Quadrivalent"}
{"id": "8b6a194a-4767-440e-9fea-c17c59ab3f45", "page": 5, "type": "paragraph", "text": "(Sanofi Pasteur)"}
{"id": "644a5c9b-9633-4084-9815-a96815d75552", "page": 5, "type": "paragraph", "text": "0.5-mL PFS\u2020\u2020"}
{"id": "86420ec4-a337-4ceb-a087-9bd067d83c80", "page": 5, "type": "paragraph", "text": "\u22656 mos\u2020\u2020"}
{"id": "1f1fcae5-3555-4816-a1a1-17cea1decb4a", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "46e75a7e-08fb-48b2-b12e-d69e01dc948c", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "563d4b17-b317-4330-ba6d-545cf5b7559b", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "ae21d375-c603-473e-baca-f18775f78df0", "page": 5, "type": "paragraph", "text": "0.5-mL SDV\u2020\u2020"}
{"id": "4aec619c-78b2-404a-a394-800a48e33db9", "page": 5, "type": "paragraph", "text": "\u22656 mos\u2020\u2020"}
{"id": "26daeade-bed3-49c0-9036-79a67380332f", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "dcc1efd6-a60c-40f7-b05e-4509472b99c4", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "d88d604e-855a-4ed4-a8c8-0fb6baa97882", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "174ceb46-4acb-4807-a7a2-8e525a0a9d05", "page": 5, "type": "paragraph", "text": "5.0-mL MDV\u2020\u2020"}
{"id": "9d24721c-e474-4055-b03b-6a1e28d3ddb8", "page": 5, "type": "paragraph", "text": "\u22656 mos\u2020\u2020"}
{"id": "6867d127-c5a8-488b-8908-1aee39bf6125", "page": 5, "type": "paragraph", "text": "7.5 \u00b5g/0.25 mL"}
{"id": "b7109532-ac13-4f82-9648-95fd3adb1e07", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "58ccbc40-dcd7-45a1-83c0-09534aebec84", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "f6f7dd22-b211-4e97-baa7-46d187d42402", "page": 5, "type": "paragraph", "text": "25"}
{"id": "851c2323-2126-4ceb-85ce-7fc4e54ce657", "page": 5, "type": "paragraph", "text": "ccIIV4 (standard-dose, cell culture\u2013based vaccine)"}
{"id": "2f5ffc0a-643d-46be-9549-ceaafa53442c", "page": 5, "type": "paragraph", "text": "Flucelvax Quadrivalent"}
{"id": "20e8ecaf-b17e-4bc8-b5b5-5b30e77d60a5", "page": 5, "type": "paragraph", "text": "(Seqirus)"}
{"id": "f1084728-e6fa-4a18-9292-42e36431d81f", "page": 5, "type": "paragraph", "text": "0.5-mL PFS"}
{"id": "10681d0c-9b4a-4477-9134-41b5df8f6de3", "page": 5, "type": "paragraph", "text": "\u22656 mos"}
{"id": "127b6b91-5485-4609-99dd-60df0cdac9c6", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "009dbdb9-b2b9-44ba-9c14-9e4c1dd56f57", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "ff40e97e-197f-4d06-856d-13ff6a24af39", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "792a715a-5846-4bfe-b4c0-d8cdb6fc75b7", "page": 5, "type": "paragraph", "text": "5.0-mL MDV"}
{"id": "8b5d4c78-53e3-403d-a4e8-3526ab208883", "page": 5, "type": "paragraph", "text": "\u22656 mos"}
{"id": "c7d1decc-a069-414e-9409-76901f0eec04", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "62aa1f68-73e7-4721-a62f-49f710b44d97", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "f45955e2-985a-4972-b796-d6097ea9aa2f", "page": 5, "type": "paragraph", "text": "25"}
{"id": "46917109-0cb4-469e-ab70-d86b81e715d7", "page": 5, "type": "paragraph", "text": "HD-IIV4 (high-dose, egg-based vaccine\u2020)"}
{"id": "e97aca73-5ba4-4b29-ab5e-e6d828494a32", "page": 5, "type": "paragraph", "text": "Fluzone High-Dose Quadrivalent"}
{"id": "a4d599e3-33c2-469e-963b-41a0d6f59132", "page": 5, "type": "paragraph", "text": "(Sanofi Pasteur)"}
{"id": "9ad103fe-68dc-4f6b-8250-a63fbde87e58", "page": 5, "type": "paragraph", "text": "0.7-mL PFS"}
{"id": "6f7bdf0a-228e-47b1-b788-0a6baf19edac", "page": 5, "type": "paragraph", "text": "\u226565 yrs"}
{"id": "ef21b6ae-8469-48aa-ae85-c2ac2423a5f9", "page": 5, "type": "paragraph", "text": "60 \u00b5g/0.7 mL"}
{"id": "3ba9d990-718e-4bf3-8131-4bcb5d39e1dc", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "e52ceda4-7eac-470f-b0f7-f1374859383e", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "c794ccf9-f591-46e5-b966-6ec45af4359a", "page": 5, "type": "paragraph", "text": "aIIV4 (standard-dose, egg-based vaccine\u2020 with MF59 adjuvant)"}
{"id": "84de728a-dd4e-4324-a4c3-84e8ac9228ba", "page": 5, "type": "paragraph", "text": "Fluad Quadrivalent"}
{"id": "7ef41c6b-ef58-4c79-80df-8a3f8685a5b9", "page": 5, "type": "paragraph", "text": "(Seqirus)"}
{"id": "93e4422a-0d56-4a48-96be-4f79a937b8fb", "page": 5, "type": "paragraph", "text": "0.5-mL PFS"}
{"id": "4f03db90-8097-487e-b07d-ae12a81c1b3b", "page": 5, "type": "paragraph", "text": "\u226565 yrs"}
{"id": "f41eba4e-a5d9-4e18-8e47-6c6f5c4743e3", "page": 5, "type": "paragraph", "text": "15 \u00b5g/0.5 mL"}
{"id": "99a4fa52-0938-4a8b-8147-74a10fa77c68", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "ed2cfea4-85ff-4df7-ad78-47d91fccb1b3", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "49d0dbd1-2733-403f-a644-c60c8b353665", "page": 5, "type": "paragraph", "text": "RIV4 (recombinant HA vaccine)"}
{"id": "74dd96f1-68b1-4f20-87a4-9c9924fd32ac", "page": 5, "type": "paragraph", "text": "Flublok Quadrivalent"}
{"id": "2cdf04f3-9a0d-4d9f-aeb1-05cc87e458d5", "page": 5, "type": "paragraph", "text": "(Sanofi Pasteur)"}
{"id": "a9dbf0b9-4345-408e-a695-fb1cedb3f6fc", "page": 5, "type": "paragraph", "text": "0.5-mL PFS"}
{"id": "d5940db7-e908-4721-b846-90e735977528", "page": 5, "type": "paragraph", "text": "\u226518 yrs"}
{"id": "ce4ce483-19af-4ab1-aed6-ab76e83b5715", "page": 5, "type": "paragraph", "text": "45 \u00b5g/0.5 mL"}
{"id": "d45471f9-0026-4b1b-bc8e-28367027eb0b", "page": 5, "type": "paragraph", "text": "IM\u00b6"}
{"id": "08cf1e01-a0ca-40dc-9bfc-ee48567643ef", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "556b9239-85bb-4629-b409-37ebda8560de", "page": 5, "type": "paragraph", "text": "LAIV4 (egg-based vaccine\u2020)"}
{"id": "5bc2cff1-d2c9-425c-9e11-51898014cbf8", "page": 5, "type": "paragraph", "text": "FluMist Quadrivalent"}
{"id": "e5a8d920-b589-4fd6-b244-7e3e710cb9b6", "page": 5, "type": "paragraph", "text": "(AstraZeneca)"}
{"id": "3414b00d-8b18-4ed2-be08-9ce0b3015bdf", "page": 5, "type": "paragraph", "text": "0.2-mL prefilled single-"}
{"id": "a1adee59-7204-4ef7-b8f1-64a15e47961c", "page": 5, "type": "paragraph", "text": "use intranasal sprayer"}
{"id": "0ade9889-06e3-4fb5-b49e-62b7cf20d1f5", "page": 5, "type": "paragraph", "text": "2 through 49 yrs"}
{"id": "0886aa21-af5b-4bb7-8b96-fa750ad45b97", "page": 5, "type": "paragraph", "text": "106.5\u20137.5 fluorescent"}
{"id": "5adca8a5-541a-4de0-90e9-ec98acb7baf0", "page": 5, "type": "paragraph", "text": "focus units/0.2 mL"}
{"id": "4b61801c-694b-4d99-b7ea-1acbc07fd545", "page": 5, "type": "paragraph", "text": "NAS"}
{"id": "ffc1e0f0-574b-4b7a-b617-0a41203d8752", "page": 5, "type": "paragraph", "text": "\u2014"}
{"id": "c9d9af86-7784-48b1-8a9b-d59870b0f282", "page": 5, "type": "paragraph", "text": "Abbreviations: ACIP = Advisory Committee on Immunization Practices; FDA = Food and Drug Administration; HA = hemagglutinin; IIV4 = inactivated influenza"}
{"id": "bece5e98-6f56-4c46-8a2e-7f02e0b7d0bb", "page": 5, "type": "paragraph", "text": "vaccine, quadrivalent; IM = intramuscular; LAIV4 = live attenuated influenza vaccine, quadrivalent; MDV = multidose vial; NAS = intranasal; PFS = prefilled syringe;"}
{"id": "c9865305-b909-4d38-8743-698535524c53", "page": 5, "type": "paragraph", "text": "RIV4 = recombinant influenza vaccine, quadrivalent; SDV = single-dose vial."}
{"id": "47eb8149-4a55-456d-9b39-f880e1cc9d6e", "page": 5, "type": "paragraph", "text": "* Vaccination providers should consult FDA-approved prescribing information for 2022\u201323 influenza vaccines for the most complete and updated information,"}
{"id": "ff2337cf-6c2b-4891-bfc7-60e9c6c87460", "page": 5, "type": "paragraph", "text": "including but not limited to indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda."}
{"id": "ea3e6e68-e136-45d6-a860-9da2544a56ed", "page": 5, "type": "paragraph", "text": "gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states. Availability and characteristics of specific products and presentations might change"}
{"id": "1673199c-c6b8-4467-9e1f-b7536714f1c4", "page": 5, "type": "paragraph", "text": "or differ from what is described in this table and in the text of this report."}
{"id": "0cecf4ff-dace-48a9-be0e-9860b68b8917", "page": 5, "type": "paragraph", "text": "\u2020 Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, ACIP recommends"}
{"id": "69a6374d-96af-4d43-8a97-6b13eedb4a93", "page": 5, "type": "paragraph", "text": "that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status."}
{"id": "9a560115-186e-4d29-9705-bc33bf42b965", "page": 5, "type": "paragraph", "text": "Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or"}
{"id": "683421f1-093b-4c30-8901-cc12521ecf7e", "page": 5, "type": "paragraph", "text": "recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated in an inpatient or outpatient medical setting"}
{"id": "5852d9b4-90ca-4d0a-a8a2-ac4c6202d74a", "page": 5, "type": "paragraph", "text": "(including but not necessarily limited to hospitals, clinics, health departments, and physician offices) supervised by a health care provider who is able to recognize"}
{"id": "78cc355f-29e1-445a-bc0f-b300abd563d2", "page": 5, "type": "paragraph", "text": "and manage severe allergic reactions, if a vaccine other than ccIIV4 or RIV4 is used."}
{"id": "a38f9423-0416-48e7-a610-9ba71eb532cc", "page": 5, "type": "paragraph", "text": "\u00a7 The approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged \u22653 years. However, 0.25-mL"}
{"id": "822be2a3-956a-4e31-9f6c-207789028371", "page": 5, "type": "paragraph", "text": "prefilled syringes are not expected to be available for the 2022\u201323 season. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a"}
{"id": "98c36501-490d-4228-a331-b3ba439f0de8", "page": 5, "type": "paragraph", "text": "multidose vial."}
{"id": "c1cb9c53-df30-45df-9a62-d810960448a0", "page": 5, "type": "paragraph", "text": "\u00b6 IM-administered influenza vaccines should be given by needle and syringe only, with the exception of the MDV presentation of Afluria Quadrivalent, which may"}
{"id": "b7d520c2-f480-4c8e-83c2-be9278401251", "page": 5, "type": "paragraph", "text": "alternatively be given by the PharmaJet Stratis jet injector for persons aged 18 through 64 years only. For adults and older children, the recommended site for"}
{"id": "9c0a5f42-2e4d-4470-9401-f698f761d3aa", "page": 5, "type": "paragraph", "text": "intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Additional"}
{"id": "14b10d1c-8926-4569-bd9f-98b510d5778a", "page": 5, "type": "paragraph", "text": "specific guidance regarding site selection and needle length for intramuscular administration is available in the ACIP General Best Practice Guidelines for Immunization,"}
{"id": "c3f1b8b0-2e41-4d8e-9eb8-89b4ba150d27", "page": 5, "type": "paragraph", "text": "available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html."}
{"id": "da1f9f70-328c-44f9-a907-3d9a975fa8d7", "page": 5, "type": "paragraph", "text": "** Not applicable."}
{"id": "c4f70314-f426-46eb-8f43-9a1c26969470", "page": 5, "type": "paragraph", "text": "\u2020\u2020 Fluzone Quadrivalent is currently approved for ages 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL prefilled syringes are not expected"}
{"id": "6621e336-5f48-482e-b46f-f8d0e5aaa495", "page": 5, "type": "paragraph", "text": "to be available for the 2022\u201323 influenza season. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL"}
{"id": "8f11f0aa-aa3a-4f1b-a8a3-207830f99e66", "page": 5, "type": "paragraph", "text": "per dose."}
{"id": "16867e87-bb9b-4c66-a3fc-9b08e7d516f5", "page": 5, "type": "paragraph", "text": "related to recommendations made in previous seasons and"}
{"id": "5f0d6bf5-4dc9-4b39-9343-3b4e6ebea8a3", "page": 5, "type": "paragraph", "text": "minor changes in guidance for the use of influenza vaccines (e.g.,"}
{"id": "a9f39639-202c-40c4-b47e-f89497c44292", "page": 5, "type": "paragraph", "text": "guidance for timing of vaccination and other programmatic"}
{"id": "cae8f663-a482-4e1c-bcdd-b3e4a36e29e2", "page": 5, "type": "paragraph", "text": "issues, guidance for dosage in specific populations, guidance"}
{"id": "375f364b-e933-4830-8c60-97bc278c1389", "page": 5, "type": "paragraph", "text": "for selection of vaccines for specific populations that are"}
{"id": "6190c4d8-64bc-4292-b152-9caa0be26734", "page": 5, "type": "paragraph", "text": "already recommended for vaccination, and changes that"}
{"id": "43e617df-852d-4291-8195-e7a61817e9da", "page": 5, "type": "paragraph", "text": "reflect use that is consistent with indications and prescribing"}
{"id": "44826d7d-daa5-4b04-9b4b-e45ffa022b9a", "page": 5, "type": "paragraph", "text": "information licensed by the Food and Drug Administration"}
{"id": "7168bf06-787b-43c4-85db-7fc26a2744e5", "page": 5, "type": "paragraph", "text": "[FDA]). The summary included in the Background Document"}
{"id": "79801a7d-1763-4635-b429-205acad191a9", "page": 5, "type": "paragraph", "text": "for such topics is not a systematic review; it is intended"}
{"id": "69f2d0a5-6aed-45ca-8da3-0b5b16004433", "page": 5, "type": "paragraph", "text": "to provide an overview of current literature, with updated"}
{"id": "c58682fb-7384-4c79-bb94-01f9ec80a266", "page": 5, "type": "paragraph", "text": "articles being identified primarily through a broad search for"}
{"id": "2607e6f9-2d55-4d48-8fda-2baea552ecf6", "page": 6, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "9ae85d0e-705a-4b39-b9d5-923c10568d93", "page": 6, "type": "paragraph", "text": "4"}
{"id": "90018bb0-ed78-436c-9354-01ca368ac968", "page": 6, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "a676baa0-60fa-43b7-96b1-a4191f422851", "page": 6, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "c9bcb4b9-0a12-4c7d-9519-a6851fe44389", "page": 6, "type": "paragraph", "text": "TABLE 2. Contraindications and precautions for the use of influenza vaccines \u2014 United States, 2022\u201323 influenza season*"}
{"id": "c001feed-1359-4c8d-a08c-4a88a265fbd9", "page": 6, "type": "paragraph", "text": "Vaccine type"}
{"id": "7e083b28-71cd-4f7a-bc6d-497268195c93", "page": 6, "type": "paragraph", "text": "Contraindications"}
{"id": "ae1b922f-dfc8-438c-8c58-05ca2f38bb8d", "page": 6, "type": "paragraph", "text": "Precautions"}
{"id": "365e2bcd-e4b7-4658-a122-8e538ad56612", "page": 6, "type": "paragraph", "text": "Egg-based IIV4s"}
{"id": "fe2616e3-2f86-40cf-87aa-d2685db447db", "page": 6, "type": "paragraph", "text": "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to any"}
{"id": "f44133b4-e4b3-4b1d-a28d-e35be409683a", "page": 6, "type": "paragraph", "text": "component of the vaccine\u2020 or to a previous dose of any influenza"}
{"id": "5648cfe8-aa16-4b06-96fd-01eeab94899e", "page": 6, "type": "paragraph", "text": "vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV)\u00a7"}
{"id": "b39fbbac-63f8-433b-ab31-65c2221a166d", "page": 6, "type": "paragraph", "text": "\u2022 Moderate or severe acute illness with or without fever"}
{"id": "47a999bc-07a7-45c8-b019-7b9e685e4bf9", "page": 6, "type": "paragraph", "text": "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"}
{"id": "ecd81fbc-d2ab-454e-8ba5-451f7a28121e", "page": 6, "type": "paragraph", "text": "influenza vaccine"}
{"id": "a583b6cb-1459-4489-9647-32aeddc7b961", "page": 6, "type": "paragraph", "text": "ccIIV4"}
{"id": "47210c45-6b88-44c8-9cff-30c51dff929f", "page": 6, "type": "paragraph", "text": "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to a previous"}
{"id": "0eb73127-9ed6-42e7-9832-5a7a262dc76f", "page": 6, "type": "paragraph", "text": "dose of any ccIIV or any component of ccIIV4\u00a7"}
{"id": "851dd07c-d92a-4810-a7ef-475e8078c22d", "page": 6, "type": "paragraph", "text": "\u2022 Moderate or severe acute illness with or without fever"}
{"id": "8892d7fb-ddf7-4b49-ab6c-a92535d60b8a", "page": 6, "type": "paragraph", "text": "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"}
{"id": "0679b92d-67ea-4138-931e-1ae5aeadeeb4", "page": 6, "type": "paragraph", "text": "influenza vaccine"}
{"id": "56150a62-ff91-4d51-bbfc-84241f1647ea", "page": 6, "type": "paragraph", "text": "\u2022 History of severe allergic reaction to a previous dose of any other"}
{"id": "d5f76e6d-bb7f-4420-8d58-348bc18902de", "page": 6, "type": "paragraph", "text": "influenza vaccine (i.e., any egg-based IIV, RIV, or LAIV)\u00b6"}
{"id": "aa680622-b8c8-4d81-a043-94b90ded090d", "page": 6, "type": "paragraph", "text": "RIV4"}
{"id": "99c3658e-5166-4985-a2c3-13ecf29d3d8f", "page": 6, "type": "paragraph", "text": "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to a previous"}
{"id": "76e4bb25-9fbc-4f94-9eed-b70af45c6f68", "page": 6, "type": "paragraph", "text": "dose of any RIV or any component of RIV4\u00a7"}
{"id": "68d4e9f4-8d25-457c-8d0d-fc922a0fcdcf", "page": 6, "type": "paragraph", "text": "\u2022 Moderate or severe acute illness with or without fever"}
{"id": "9c6a5fcb-3a09-4c55-935d-20093495150f", "page": 6, "type": "paragraph", "text": "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"}
{"id": "f350cbec-3656-470c-a057-514c21cb60d6", "page": 6, "type": "paragraph", "text": "influenza vaccine"}
{"id": "51cbed48-302d-4072-aea7-5616fa6c6fe7", "page": 6, "type": "paragraph", "text": "\u2022 History of severe allergic reaction to a previous dose of any other"}
{"id": "26bff0e6-6166-46e4-8e38-7b0b6859c278", "page": 6, "type": "paragraph", "text": "influenza vaccine (i.e., any egg-based IIV, ccIIV, or LAIV)\u00b6"}
{"id": "5ebf7cd2-2bc9-436e-9a0a-ef7a70411fd5", "page": 6, "type": "paragraph", "text": "LAIV4"}
{"id": "5d741e18-64d4-4c57-95d7-8a0b1c1a31e7", "page": 6, "type": "paragraph", "text": "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to any"}
{"id": "614a9290-6688-444b-8e8d-77d99e3d6f41", "page": 6, "type": "paragraph", "text": "component of the vaccine\u2020 or to a previous dose of any influenza"}
{"id": "e59fb901-6536-4646-80f8-f642ef06a12b", "page": 6, "type": "paragraph", "text": "vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV)\u00a7"}
{"id": "dd3be038-4718-415e-872f-938baee003b8", "page": 6, "type": "paragraph", "text": "\u2022 Concomitant aspirin- or salicylate-containing therapy in children"}
{"id": "fe8f711c-3029-4e78-8746-004b376dff28", "page": 6, "type": "paragraph", "text": "and adolescents\u00a7"}
{"id": "30e6ede3-42b5-4fa0-a970-540196fe4347", "page": 6, "type": "paragraph", "text": "\u2022 Children aged 2 through 4 years who have received a diagnosis of"}
{"id": "584c3511-54dc-4ca1-8164-2c35b710f199", "page": 6, "type": "paragraph", "text": "asthma or whose parents or caregivers report that a health care"}
{"id": "e5742f0d-d998-49f6-90b5-a49401ef0df8", "page": 6, "type": "paragraph", "text": "provider has told them during the preceding 12 months that their"}
{"id": "c208282a-706e-4c49-bbe9-c6421d2a4c80", "page": 6, "type": "paragraph", "text": "child had wheezing or asthma or whose medical record indicates a"}
{"id": "849a6ec0-f889-4e15-9828-c967cb4f4446", "page": 6, "type": "paragraph", "text": "wheezing episode has occurred during the preceding 12 months"}
{"id": "ef987841-8505-454f-a8c1-0510637978cc", "page": 6, "type": "paragraph", "text": "\u2022 Children and adults who are immunocompromised due to any cause,"}
{"id": "fe79c46f-b13f-4387-95de-0f48d210397d", "page": 6, "type": "paragraph", "text": "including but not limited to immunosuppression caused by"}
{"id": "98abeee9-a57b-4cd8-9810-c986086181d9", "page": 6, "type": "paragraph", "text": "medications, congenital or acquired immunodeficiency states, HIV"}
{"id": "cafb28ac-d1db-4bbb-a509-f14a3dc5e098", "page": 6, "type": "paragraph", "text": "infection, anatomic asplenia, or functional asplenia (e.g., due to sickle"}
{"id": "1572fb53-fe2f-4ab0-8bae-c0589921dc24", "page": 6, "type": "paragraph", "text": "cell anemia)"}
{"id": "92600766-c844-44bb-87a4-c2b147ac9eee", "page": 6, "type": "paragraph", "text": "\u2022 Close contacts and caregivers of severely immunosuppressed persons"}
{"id": "c288602f-fd51-4ac1-8b7b-7fbf7c7a5f0d", "page": 6, "type": "paragraph", "text": "who require a protected environment"}
{"id": "0564ee15-ee72-427f-83c2-df7fc2f489b7", "page": 6, "type": "paragraph", "text": "\u2022 Pregnancy"}
{"id": "11e1570e-0141-4f3c-ac72-eecadf9b8193", "page": 6, "type": "paragraph", "text": "\u2022 Persons with active communication between the CSF and the"}
{"id": "c687ebf0-797e-41ec-bfc8-77f7010ee3be", "page": 6, "type": "paragraph", "text": "oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak"}
{"id": "d0dd22ba-1398-406b-b819-b82d70bda5cc", "page": 6, "type": "paragraph", "text": "\u2022 Persons with cochlear implants**"}
{"id": "ef249fd7-de18-4e2e-80f9-a210a0836f85", "page": 6, "type": "paragraph", "text": "\u2022 Receipt of influenza antiviral medication within the previous 48 hours"}
{"id": "27e3de17-88bd-444b-b6d9-019834cd584b", "page": 6, "type": "paragraph", "text": "for oseltamivir and zanamivir, previous 5 days for peramivir, and"}
{"id": "3681f807-e50e-4be7-a3d7-4a5aca106331", "page": 6, "type": "paragraph", "text": "previous 17 days for baloxavir\u2020\u2020"}
{"id": "9e9b60b4-fa7b-49d8-9c8e-115242bcd14e", "page": 6, "type": "paragraph", "text": "\u2022 Moderate or severe acute illness with or without fever"}
{"id": "bbd14c7c-2879-458e-abd6-94ad0ff43892", "page": 6, "type": "paragraph", "text": "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"}
{"id": "4ddd2350-5f2f-4f10-bf46-0322199de048", "page": 6, "type": "paragraph", "text": "influenza vaccine"}
{"id": "54abbc8e-0429-4617-889c-94965541d431", "page": 6, "type": "paragraph", "text": "\u2022 Asthma in persons aged \u22655 years"}
{"id": "10eaf4f6-54de-4bda-ae13-adac956af443", "page": 6, "type": "paragraph", "text": "\u2022 Other underlying medical conditions that might predispose to"}
{"id": "3d60ceda-e186-494e-b235-2aa5a5d03578", "page": 6, "type": "paragraph", "text": "complications after wild-type influenza infection (e.g., chronic"}
{"id": "23d27754-48e6-41be-bb17-140bc4b7e050", "page": 6, "type": "paragraph", "text": "pulmonary, cardiovascular [except isolated hypertension], renal,"}
{"id": "c7ec9d7c-3ba7-41a3-9d53-1b3a4e38bea2", "page": 6, "type": "paragraph", "text": "hepatic, neurologic, hematologic, or metabolic disorders [including"}
{"id": "026a2cd3-5c47-4964-a960-bcfc34fd5eea", "page": 6, "type": "paragraph", "text": "diabetes mellitus])"}
{"id": "082b1c68-b9d2-460d-b83f-22df278ffb31", "page": 6, "type": "paragraph", "text": "Abbreviations: ACIP = Advisory Committee on Immunization Practices; ccIIV = cell culture\u2013based inactivated influenza vaccine (any valency); ccIIV4 = cell culture\u2013"}
{"id": "f0800a0d-02fd-4a4c-a0a7-34c389d9aebc", "page": 6, "type": "paragraph", "text": "based inactivated influenza vaccine, quadrivalent; CSF = cerebrospinal fluid; FDA = Food and Drug Administration; IIV = inactivated influenza vaccine (any valency);"}
{"id": "88b8cfa5-630a-46ad-b0aa-97d871665e93", "page": 6, "type": "paragraph", "text": "IIV4 = inactivated influenza vaccine, quadrivalent; LAIV = live attenuated influenza vaccine (any valency); LAIV4 = live attenuated influenza vaccine, quadrivalent;"}
{"id": "2655729f-642e-4eea-85b1-2d19fe705bd6", "page": 6, "type": "paragraph", "text": "RIV = recombinant influenza vaccine (any valency); RIV4 = recombinant influenza vaccine, quadrivalent."}
{"id": "995fe406-1d57-496d-8d3a-4d86a8459737", "page": 6, "type": "paragraph", "text": "* When a contraindication is present, a vaccine should not be administered. When a precaution is present, vaccination should generally be deferred but might be"}
{"id": "cf0f9a94-29d4-43ac-8b52-6d374c38c91a", "page": 6, "type": "paragraph", "text": "indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction (see ACIP General Best Practice Guidelines for Immunization,"}
{"id": "d7048648-26a2-4788-b59a-9fbf5f194645", "page": 6, "type": "paragraph", "text": "available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html). Vaccination providers should check FDA-approved prescribing information for"}
{"id": "4681f83f-2182-4faf-aca9-4366b32d3f9d", "page": 6, "type": "paragraph", "text": "2022\u201323 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions."}
{"id": "0fa76217-d5e6-46ee-bdf4-930eb1690669", "page": 6, "type": "paragraph", "text": "Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states."}
{"id": "1fca05e7-7379-4c2a-9ffc-14a407ef15e1", "page": 6, "type": "paragraph", "text": "\u2020 Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, ACIP recommends"}
{"id": "ef9e762a-e3f7-43c5-be77-58569a96f82b", "page": 6, "type": "paragraph", "text": "that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status."}
{"id": "4551aafd-3f26-4899-9e5c-db0eb6e4f8db", "page": 6, "type": "paragraph", "text": "Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or"}
{"id": "269d072a-7d9a-4942-a54c-b9e3f1ffffca", "page": 6, "type": "paragraph", "text": "recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated in an inpatient or outpatient medical setting,"}
{"id": "50ba7f96-cc5a-4f96-a0ba-2a312b7aebfa", "page": 6, "type": "paragraph", "text": "including but not necessarily limited to hospitals, clinics, health departments, and physician offices, if a vaccine other than ccIIV4 or RIV4 is used. Vaccine administration"}
{"id": "00e21acf-66c4-41b2-a646-c3379ca9488d", "page": 6, "type": "paragraph", "text": "should be supervised by a health care provider who is able to recognize and manage severe allergic reactions."}
{"id": "26da9356-52c9-4767-8888-51d12d0a767c", "page": 6, "type": "paragraph", "text": "\u00a7 Labeled contraindication noted in package insert."}
{"id": "ff2aa91e-20ac-4131-86d1-ecd1edce9bb6", "page": 6, "type": "paragraph", "text": "\u00b6 If administered, vaccination should occur in a medical setting and should be supervised by a health care provider who can recognize and manage severe allergic"}
{"id": "b2544099-1dc3-40a9-b01f-a3543352a3a8", "page": 6, "type": "paragraph", "text": "reactions. Providers can consider consultation with an allergist in such cases, to assist in identification of the component responsible for the allergic reaction."}
{"id": "57597aa3-8de8-4114-83a4-e16cd62d0210", "page": 6, "type": "paragraph", "text": "** Age-appropriate injectable vaccines are recommended for persons with cochlear implant due to the potential for CSF leak, which might exist for a period after"}
{"id": "f5383c58-fe5f-4359-a9f4-bfe59f691d4f", "page": 6, "type": "paragraph", "text": "implantation. Providers might consider consultation with a specialist concerning risk for persistent CSF leak if an age-appropriate inactivated or recombinant"}
{"id": "079d0c9b-e66b-441d-9c56-23ec305356c0", "page": 6, "type": "paragraph", "text": "vaccine cannot be used."}
{"id": "02ea770d-5f32-4f63-bec3-b33e4c65f2e0", "page": 6, "type": "paragraph", "text": "\u2020\u2020 Use of LAIV4 in context of influenza antivirals has not been studied; however, interference with activity of LAIV4 is biologically plausible, and this possibility is noted"}
{"id": "147fcb07-eacd-4740-b2bd-0a7e0c20c776", "page": 6, "type": "paragraph", "text": "in the package insert for LAIV4. In the absence of data supporting an adequate minimum interval between influenza antiviral use and LAIV4 administration, the"}
{"id": "59b6d4f9-2d34-4775-8442-512b1fede783", "page": 6, "type": "paragraph", "text": "intervals provided are based on the half-life of each antiviral. The interval between influenza antiviral receipt and LAIV4 for which interference might potentially"}
{"id": "3b9fed1e-8add-4392-bae5-14531d494855", "page": 6, "type": "paragraph", "text": "occur might be further prolonged in the presence of medical conditions that delay medication clearance (e.g., renal insufficiency). Influenza antivirals might also"}
{"id": "b3d26dca-b0c2-4d34-90e4-a5cf09410423", "page": 6, "type": "paragraph", "text": "interfere with LAIV4 if initiated within 2 weeks after vaccination. Persons who receive antivirals during the period starting with the specified time before receipt"}
{"id": "1a0a7876-133b-4031-b36a-a0ad73b985e1", "page": 6, "type": "paragraph", "text": "of LAIV4 through 2 weeks after receipt of LAIV4 should be revaccinated with an age-appropriate IIV or RIV4."}
{"id": "63868cb4-bfdd-4b92-89cf-53857db0d39c", "page": 7, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "211b8933-73b1-4945-968b-d2577c3c3467", "page": 7, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "eef72e89-cd50-4e8f-b14a-95e6412b3129", "page": 7, "type": "paragraph", "text": "5"}
{"id": "dfc9e88f-98f8-4cd4-9755-9a3a5629189e", "page": 7, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "1f0b7aed-a803-4fbc-8a55-af36b9b2278b", "page": 7, "type": "paragraph", "text": "TABLE 3. Influenza vaccine contraindications and precautions for persons with a history of severe allergic reaction to a previous dose of an"}
{"id": "c3ff479b-0698-4a69-9317-f23fe88e0b70", "page": 7, "type": "paragraph", "text": "influenza vaccine* \u2014 United States, 2022\u201323 influenza season"}
{"id": "00bfaf0a-611d-4a3d-8294-ab9009a3f8df", "page": 7, "type": "paragraph", "text": "Vaccine (of any valency) associated with"}
{"id": "4ed65ae8-52af-489d-974a-1328f734195c", "page": 7, "type": "paragraph", "text": "previous severe allergic reaction"}
{"id": "bb2115e2-4bc3-4feb-a6d5-82819a24ce7c", "page": 7, "type": "paragraph", "text": "(e.g., anaphylaxis)"}
{"id": "269ee3d4-e31c-48bb-8f2b-91d4c055ae24", "page": 7, "type": "paragraph", "text": "Available 2022\u201323 influenza vaccines"}
{"id": "5536c030-6e73-4697-874a-a20f293a8083", "page": 7, "type": "paragraph", "text": "Egg-based IIV4s and LAIV4"}
{"id": "93728ccb-d527-44b0-a44c-d979461a576f", "page": 7, "type": "paragraph", "text": "ccIIV4"}
{"id": "09507579-eaeb-4e7d-9b24-1a97f630e9ed", "page": 7, "type": "paragraph", "text": "RIV4"}
{"id": "bcc2295d-44d9-4f05-8fb4-b0e3de9000ba", "page": 7, "type": "paragraph", "text": "Any egg-based IIV or LAIV"}
{"id": "0ec3676d-a3c9-4f09-bd70-1441ff979a2b", "page": 7, "type": "paragraph", "text": "Contraindication\u2020"}
{"id": "286a94df-3c02-4f38-aaef-93481f313a72", "page": 7, "type": "paragraph", "text": "Precaution\u00a7"}
{"id": "c36bff01-8d06-442a-9e8e-bf304ac598de", "page": 7, "type": "paragraph", "text": "Precaution\u00a7"}
{"id": "20843c3b-1df5-4203-a679-2ec009a51987", "page": 7, "type": "paragraph", "text": "Any ccIIV"}
{"id": "782363d5-2211-48c3-beef-b3cf6c6757b6", "page": 7, "type": "paragraph", "text": "Contraindication\u2020"}
{"id": "753786ff-761c-4426-80d7-c3e5b371fd72", "page": 7, "type": "paragraph", "text": "Contraindication\u2020"}
{"id": "537fdee1-d0d0-4fc4-8884-038577e3901d", "page": 7, "type": "paragraph", "text": "Precaution\u00a7"}
{"id": "c04ab487-22d5-429d-981e-89f36a09c08a", "page": 7, "type": "paragraph", "text": "Any RIV"}
{"id": "baa3f0f1-b517-483c-bb98-e1c115bc8586", "page": 7, "type": "paragraph", "text": "Contraindication\u2020"}
{"id": "521905ec-4a97-4ddd-92b4-d908d11870fd", "page": 7, "type": "paragraph", "text": "Precaution\u00a7"}
{"id": "2f94a4b0-0924-43e3-bd78-44076b3031a0", "page": 7, "type": "paragraph", "text": "Contraindication\u2020"}
{"id": "c0e751e2-b8c3-4d9a-bcd7-25e25d5e73dd", "page": 7, "type": "paragraph", "text": "Unknown influenza vaccine"}
{"id": "ef99cf54-a904-4869-9b45-de0757b65c88", "page": 7, "type": "paragraph", "text": "Allergist consultation recommended"}
{"id": "a88ec31e-aa20-40f3-b47c-ffe8102fe0d7", "page": 7, "type": "paragraph", "text": "Abbreviations: ACIP = Advisory Committee on Immunization Practices; ccIIV = cell culture\u2013based inactivated influenza vaccine (any valency); ccIIV4 = cell culture\u2013"}
{"id": "c3516cc5-4762-4068-9abf-e3c838a591d6", "page": 7, "type": "paragraph", "text": "based inactivated influenza vaccine, quadrivalent; FDA = Food and Drug Administration; IIV = inactivated influenza vaccine (any valency); IIV4 = inactivated influenza"}
{"id": "60bd1371-10ec-47b4-8dca-99f1f4aa340c", "page": 7, "type": "paragraph", "text": "vaccine, quadrivalent; LAIV = live attenuated influenza vaccine (any valency); LAIV4 = live attenuated influenza vaccine, quadrivalent; RIV = recombinant influenza"}
{"id": "7c8829a9-e9dc-4503-a092-7091dba3bee3", "page": 7, "type": "paragraph", "text": "vaccine (any valency); RIV4 = recombinant influenza vaccine, quadrivalent."}
{"id": "88a18610-6c1c-4aec-90f5-e0077f18d134", "page": 7, "type": "paragraph", "text": "* Vaccination providers should check FDA-approved prescribing information for 2022\u201323 influenza vaccines for the most complete and updated information, including"}
{"id": "b1a171e1-17ef-497e-b333-5999c9ca291d", "page": 7, "type": "paragraph", "text": "(but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/"}
{"id": "68c521b6-3ec4-4006-bcd3-45832f7e2f8e", "page": 7, "type": "paragraph", "text": "vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states."}
{"id": "d4bdfa39-d5dc-4bbe-95ce-e7a3c4183572", "page": 7, "type": "paragraph", "text": "\u2020 When a contraindication is present, a vaccine should not be administered, consistent with ACIP General Best Practice Guidelines for Immunization (Kroger A, Bahta L,"}
{"id": "c91fc7c3-6255-41d1-9fd4-3117fb2d0bf1", "page": 7, "type": "paragraph", "text": "Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices [ACIP]. https://www."}
{"id": "8c7784f7-3e0b-4182-a8ad-69f00ec6db12", "page": 7, "type": "paragraph", "text": "cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html). In addition to the contraindications based on history of severe allergic reaction to influenza vaccines that"}
{"id": "f7c2a50a-e2ae-4ba3-ab2e-dabe08c79703", "page": 7, "type": "paragraph", "text": "are noted in the table, each individual influenza vaccine is contraindicated for persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component"}
{"id": "e222ca1d-a90a-413b-ae3b-0e3823e3eac3", "page": 7, "type": "paragraph", "text": "of that vaccine. Vaccine components can be found in package inserts. Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication"}
{"id": "6b29ea9f-6746-4860-9d86-a0f9a02f4c09", "page": 7, "type": "paragraph", "text": "to the use of egg-based IIV4s and LAIV4, ACIP recommends that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine"}
{"id": "7ea9a5f4-396a-444a-9a59-62727ba5f699", "page": 7, "type": "paragraph", "text": "that is otherwise appropriate for their age and health status. Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema"}
{"id": "5854705c-0a6a-4b05-b638-4cee83fdf8ab", "page": 7, "type": "paragraph", "text": "or swelling, respiratory distress, lightheadedness, or recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated"}
{"id": "818f36ea-c30d-467c-83e9-e24f0517afd9", "page": 7, "type": "paragraph", "text": "in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices), if a vaccine other"}
{"id": "a56fa893-2d5e-4df0-aabb-78d8cde7cd6a", "page": 7, "type": "paragraph", "text": "than ccIIV4 or RIV4 is used. Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic reactions."}
{"id": "24ef3100-d64d-4d23-a48c-0138e5588fe9", "page": 7, "type": "paragraph", "text": "\u00a7 When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for"}
{"id": "37ffe368-713c-4014-9d1a-9cef7889a1cb", "page": 7, "type": "paragraph", "text": "an adverse reaction, consistent with ACIP General Best Practice Guidelines for Immunization (Kroger A, Bahta L, Hunter P. General best practice guidelines for"}
{"id": "67d4a052-fff0-4c00-bf0f-438386b0cc64", "page": 7, "type": "paragraph", "text": "immunization: best practices guidance of the Advisory Committee on Immunization Practices [ACIP]. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/"}
{"id": "61de2cf9-3fd1-4f93-ac5e-ad0e8168fa70", "page": 7, "type": "paragraph", "text": "index.html). Providers can consider using the following vaccines in these instances; however, vaccination should occur in an inpatient or outpatient medical setting"}
{"id": "5e196c24-03ff-4e5c-99ab-f7ab2bc0a572", "page": 7, "type": "paragraph", "text": "with supervision by a health care provider who is able to recognize and manage severe allergic reactions: 1) for persons with a history of severe allergic reaction"}
{"id": "169772fb-3e1f-449b-9e17-219dd26c3d77", "page": 7, "type": "paragraph", "text": "(e.g., anaphylaxis) to any egg-based IIV or LAIV of any valency, the provider can consider administering ccIIV4 or RIV4; 2) for persons with a history of severe allergic"}
{"id": "0cec4406-3bc6-4460-b0d8-f8f63842838a", "page": 7, "type": "paragraph", "text": "reaction (e.g., anaphylaxis) to any ccIIV of any valency, the provider can consider administering RIV4; and 3) for persons with a history of severe allergic reaction (e.g.,"}
{"id": "04af4230-b87c-4743-b31f-8be808803ca7", "page": 7, "type": "paragraph", "text": "anaphylaxis) to any RIV of any valency, the provider can consider administering ccIIV4. Providers can also consider consulting with an allergist to help determine"}
{"id": "5cc6b0de-4c25-428c-89f1-1b16b30fbdea", "page": 7, "type": "paragraph", "text": "which vaccine component is responsible for the allergic reaction."}
{"id": "1d95ac31-afc6-46d3-ac0d-49b326c26e12", "page": 7, "type": "paragraph", "text": "English-language articles on influenza and influenza vaccines."}
{"id": "be8b42b7-afc0-4ce8-b131-94355de0e65f", "page": 7, "type": "paragraph", "text": "Typically, systematic review and evaluation of evidence using"}
{"id": "9e27dd58-bd2f-4757-ae6a-328eea02ae85", "page": 7, "type": "paragraph", "text": "the Grading of Recommendations Assessment, Development"}
{"id": "95dd8e12-48b2-45b0-864d-78b08bb39cb3", "page": 7, "type": "paragraph", "text": "and Evaluation (GRADE) approach (18) are performed for"}
{"id": "82cf3193-88cc-4e4b-9920-893283573785", "page": 7, "type": "paragraph", "text": "new recommendations or substantial changes in the current"}
{"id": "8b351bf0-1625-464a-ad90-266f3743f441", "page": 7, "type": "paragraph", "text": "recommendations (e.g., expansion of the recommendation"}
{"id": "b11f08f0-7b13-4c34-8d24-1ef6c77dca15", "page": 7, "type": "paragraph", "text": "for influenza vaccination to new populations not previously"}
{"id": "332fe236-a5b4-4771-b4c7-c647ea1b1842", "page": 7, "type": "paragraph", "text": "recommended for vaccination or potential preferential"}
{"id": "2c7b603c-caad-4f4a-9e39-8d22387f28cb", "page": 7, "type": "paragraph", "text": "recommendations for specific vaccines). Systematic review,"}
{"id": "91403311-679a-41a7-ac04-d83bf0f825e2", "page": 7, "type": "paragraph", "text": "GRADE, and the ACIP Evidence to Recommendations"}
{"id": "4d0a79b7-0978-45f6-be7a-681362df3721", "page": 7, "type": "paragraph", "text": "Framework were used in the development of the updated"}
{"id": "4643172c-ff68-4f2a-bf65-57fb732a9a76", "page": 7, "type": "paragraph", "text": "recommendations for influenza vaccination of adults aged"}
{"id": "19f1b2c5-b0f0-4f06-9bca-19f93d9a5b2e", "page": 7, "type": "paragraph", "text": "\u226565 years discussed in this document."}
{"id": "9a865f8a-f53c-4037-833a-6d320e2ca59c", "page": 7, "type": "paragraph", "text": "Primary updates and changes to the recommendations"}
{"id": "d1d7f0f7-4389-490c-82a0-a99fffb814d9", "page": 7, "type": "paragraph", "text": "described in this report include 1) the vaccine virus"}
{"id": "e8f08f1c-d343-4b50-802c-4a68f89e3c72", "page": 7, "type": "paragraph", "text": "composition for 2022\u201323 U.S. seasonal influenza vaccines;"}
{"id": "74c37d2c-a490-4bc3-a42d-7e3d39b2ad56", "page": 7, "type": "paragraph", "text": "2) updates to the description of influenza vaccines expected to"}
{"id": "a34eaaf3-3ef2-4465-baa1-72a5ba0660f6", "page": 7, "type": "paragraph", "text": "be available for the 2022\u201323 season, including one influenza"}
{"id": "d7d8791d-aeb1-4c97-b24d-f710c134f831", "page": 7, "type": "paragraph", "text": "vaccine labeling change that occurred after the publication"}
{"id": "2f5c8948-20d2-40ea-945d-09e58f14ca40", "page": 7, "type": "paragraph", "text": "of the 2021\u201322 ACIP influenza recommendations; and"}
{"id": "683f5720-0ce3-40b5-a8cf-f0641d48f7a1", "page": 7, "type": "paragraph", "text": "3) updates to the recommendations concerning vaccination of"}
{"id": "04cc98be-34ba-4355-809e-079fdbb6e969", "page": 7, "type": "paragraph", "text": "adults aged \u226565 years. Information relevant to these changes"}
{"id": "4e796749-fef3-4fc8-b32f-47afcf142912", "page": 7, "type": "paragraph", "text": "includes the following:"}
{"id": "3c2f33d0-4633-4d5b-a367-ab44c8e2c691", "page": 7, "type": "paragraph", "text": "\u2022 Recommendations for the composition of Northern"}
{"id": "49bbbd1c-ab0b-4256-a855-a90c3fb9c152", "page": 7, "type": "paragraph", "text": "Hemisphere influenza vaccines are made by the World Health"}
{"id": "759195ee-3fa6-45d6-9777-99e6b75479b0", "page": 7, "type": "paragraph", "text": "Organization (WHO), which organizes a consultation, usually"}
{"id": "bad30216-c81e-44d8-afd6-096ce8bcead8", "page": 7, "type": "paragraph", "text": "in February of each year. Surveillance data are reviewed, and"}
{"id": "30dabb93-3acd-4421-ae02-ec801cd22b0d", "page": 7, "type": "paragraph", "text": "candidate vaccine viruses are discussed. Information about the"}
{"id": "b74d0cfe-5270-4285-9489-dbb5114cc4eb", "page": 7, "type": "paragraph", "text": "WHO meeting on February 25, 2022, for selection of the"}
{"id": "d9110c20-c359-486c-a5f7-f0f43a1f6437", "page": 7, "type": "paragraph", "text": "2022\u201323 Northern Hemisphere vaccine viruses is available at"}
{"id": "c726dd49-02a5-453e-85d9-b68df2e88cd1", "page": 7, "type": "paragraph", "text": "https://www.who.int/news/item/25-02-2022-"}
{"id": "d7a569e8-313e-4d5a-838b-74267d7e2027", "page": 7, "type": "paragraph", "text": "recommendations-announced-for-influenza-vaccine-"}
{"id": "9c0536ab-0323-4c35-aa75-6b2b8fc5ccda", "page": 7, "type": "paragraph", "text": "composition-for-the-2022-2023-northern-hemisphere-"}
{"id": "86854519-ae22-497a-907a-e8ff5a63c93e", "page": 7, "type": "paragraph", "text": "influenza-season. Subsequently, FDA, which has regulatory"}
{"id": "e0c30c56-9c1c-4eda-ae6c-9082b32e8b03", "page": 7, "type": "paragraph", "text": "authority over vaccines in the United States, convenes a meeting"}
{"id": "5369913d-a496-4204-bd54-110fec913618", "page": 7, "type": "paragraph", "text": "of its Vaccines and Related Biological Products Advisory"}
{"id": "2a4da7a4-aae5-40ea-b20b-658ece66d9f5", "page": 7, "type": "paragraph", "text": "Committee (VRBPAC). This committee considers the"}
{"id": "f11791a7-e58d-4941-911a-a56bfaee83ea", "page": 7, "type": "paragraph", "text": "recommendations of WHO, reviews and discusses similar data,"}
{"id": "74914c99-3e17-4a16-a786-8ecb12bd682b", "page": 7, "type": "paragraph", "text": "and makes a final decision regarding vaccine virus composition"}
{"id": "cdc1cb52-fe0c-434c-9a6a-3be0e053f93d", "page": 7, "type": "paragraph", "text": "of influenza vaccines licensed and marketed in the United"}
{"id": "d4b44743-639c-462e-a05f-ec1dc2545d7f", "page": 7, "type": "paragraph", "text": "States. Materials from the VRBPAC discussion on March 3,"}
{"id": "d8c22761-8194-4688-b01d-2040ce86bf6c", "page": 7, "type": "paragraph", "text": "2022, during which the composition of the 2022\u201323 U.S."}
{"id": "cfa1539f-642e-491d-aa82-986f2bd91922", "page": 7, "type": "paragraph", "text": "influenza vaccines was discussed, are available at https://www."}
{"id": "31a5bac4-0bd8-4b36-a65c-b170fe8afd73", "page": 7, "type": "paragraph", "text": "fda.gov/advisory-committees/advisory-committee-calendar/"}
{"id": "8222e755-8848-4f7a-ae3d-755414fbfc4f", "page": 7, "type": "paragraph", "text": "vaccines-and-related-biological-products-advisory-committee-"}
{"id": "33915559-ef80-489e-ace6-99c5a54c7cd0", "page": 7, "type": "paragraph", "text": "march-3-2022-meeting-announcement."}
{"id": "414d21ec-e519-4df1-88c5-1675ba833c8e", "page": 8, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "6b5b106c-041c-447c-baec-bac91f44d9c2", "page": 8, "type": "paragraph", "text": "6"}
{"id": "b6c070cf-947a-4899-b965-a6fab1b93c27", "page": 8, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "1a7314c1-a2e7-4cb4-aee8-ca2db2404169", "page": 8, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "5c5faca8-9cc7-4436-aff7-41e178785cf6", "page": 8, "type": "paragraph", "text": "BOX. Abbreviation conventions for influenza vaccines discussed in"}
{"id": "50245450-ea37-4e3d-85bb-ab82e2012f38", "page": 8, "type": "paragraph", "text": "this report"}
{"id": "b623dcea-22ee-4518-b5f2-cf3639d93eb4", "page": 8, "type": "paragraph", "text": "\u2022 Main influenza vaccine types:"}
{"id": "849ebdbf-b870-4bd4-bbc2-f47fc2c4c3d1", "page": 8, "type": "paragraph", "text": "\u0171 IIV = inactivated influenza vaccine"}
{"id": "3581f46f-6286-4463-a674-044132769fde", "page": 8, "type": "paragraph", "text": "\u0171 RIV = recombinant influenza vaccine"}
{"id": "f6d566ed-eab9-47a2-b72b-a1d47af54c07", "page": 8, "type": "paragraph", "text": "\u0171 LAIV = live attenuated influenza vaccine"}
{"id": "e3a6bb64-801e-4c76-af84-dc659ddf8290", "page": 8, "type": "paragraph", "text": "\u2022 Numerals following letter abbreviations indicate"}
{"id": "cd99c0e1-385b-4630-9b41-93718368871e", "page": 8, "type": "paragraph", "text": "valency (the number of influenza virus hemagglutinin"}
{"id": "49029968-6d2a-459e-9015-596f27b34e9a", "page": 8, "type": "paragraph", "text": "[HA] antigens represented in the vaccine):"}
{"id": "f60f911d-a8b5-48dd-b8e9-c27ec38bab37", "page": 8, "type": "paragraph", "text": "\u0171 4 for quadrivalent vaccines: one A(H1N1), one"}
{"id": "3809c34f-de75-4d88-a340-5da06c90a93a", "page": 8, "type": "paragraph", "text": "A(H3N2), and two B viruses (one from each lineage)"}
{"id": "df6aca13-94e3-4326-955b-8318a33e0cba", "page": 8, "type": "paragraph", "text": "\u0171 3 for trivalent vaccines: one A(H1N1), one"}
{"id": "eb50c4c8-3447-4c84-b3a1-56ec956a101f", "page": 8, "type": "paragraph", "text": "A(H3N2), and one B virus (from one lineage)"}
{"id": "8e56d26b-892f-4eb3-b50b-e39de74aeccc", "page": 8, "type": "paragraph", "text": "\u2022 All influenza vaccines expected to be available in the"}
{"id": "a198b21f-4f20-4e0b-bbbb-c4055b03363f", "page": 8, "type": "paragraph", "text": "United States for the 2022\u201323 season are quadrivalent"}
{"id": "c46ce610-8c31-4197-b245-8b6ea5c3da31", "page": 8, "type": "paragraph", "text": "vaccines. However, abbreviations for trivalent vaccines"}
{"id": "f19dd959-ed01-490d-b1bd-3d93bc66addf", "page": 8, "type": "paragraph", "text": "(e.g., IIV3) might be used in this report when"}
{"id": "fdb19c11-9a07-4630-a8e5-eb8e8c49b1e8", "page": 8, "type": "paragraph", "text": "discussing information specific to trivalent vaccines."}
{"id": "b517a792-f849-40c9-9e78-8e9b26851356", "page": 8, "type": "paragraph", "text": "\u2022 Abbreviations for general vaccine categories (e.g., IIV)"}
{"id": "607ebd69-e0f7-4245-b39c-31682de53e99", "page": 8, "type": "paragraph", "text": "might be used when discussing information that is not"}
{"id": "e5badae7-1520-4e8a-84a6-faaed05a370c", "page": 8, "type": "paragraph", "text": "specific to either trivalent or quadrivalent vaccines."}
{"id": "661139c8-3c0f-4b84-9c12-72b57792a5df", "page": 8, "type": "paragraph", "text": "\u2022 Prefixes are used when necessary to refer to certain"}
{"id": "141e9b09-c8bb-4d11-a62e-c702eb293fdd", "page": 8, "type": "paragraph", "text": "specific IIVs:"}
{"id": "77d0604d-05d6-4401-8dd6-44c3361fd5f6", "page": 8, "type": "paragraph", "text": "\u0171 a for MF59-adjuvanted inactivated influenza"}
{"id": "91dec960-1139-4cdd-aa67-9a6bc055c2dd", "page": 8, "type": "paragraph", "text": "vaccine (e.g., aIIV3 and aIIV4)"}
{"id": "f59dd8b2-297e-48d1-a5d1-e6406d7ba86c", "page": 8, "type": "paragraph", "text": "\u0171 cc for cell culture\u2013based inactivated influenza"}
{"id": "5427dabf-084e-4492-ad1a-e092a7a3db7d", "page": 8, "type": "paragraph", "text": "vaccine (e.g., ccIIV3 and ccIIV4)"}
{"id": "cc090172-9cfb-4919-aa93-21c9217ca4f8", "page": 8, "type": "paragraph", "text": "\u0171 HD for high-dose inactivated influenza vaccine"}
{"id": "b91a4e87-fe70-4ebb-8410-658db2b90372", "page": 8, "type": "paragraph", "text": "(e.g., HD-IIV3 and HD-IIV4)"}
{"id": "3c1f4563-e8eb-452c-b388-a7ca06f466fe", "page": 8, "type": "paragraph", "text": "\u0171 SD for standard-dose inactivated influenza vaccine"}
{"id": "4ab5d4df-6c61-4387-8b03-1d8bdad36169", "page": 8, "type": "paragraph", "text": "(e.g. SD-IIV3 and SD-IIV4)"}
{"id": "5e8e8709-4f03-449b-a68d-703abaa94aea", "page": 8, "type": "paragraph", "text": "\u2022 Regarding recommendations concerning newly licensed"}
{"id": "71846c3c-8d96-4a91-88fd-eae8705a99fd", "page": 8, "type": "paragraph", "text": "influenza vaccines and changes to the licensed indications"}
{"id": "180a62af-8abc-429b-a4b8-7e2ff173fcaf", "page": 8, "type": "paragraph", "text": "for existing vaccines, ACIP relies on FDA for review of"}
{"id": "c9bc1bcc-5422-4a5d-9998-88f1e402f009", "page": 8, "type": "paragraph", "text": "safety, immunogenicity, and efficacy and effectiveness data"}
{"id": "04e5061c-75ae-4c94-bcd9-4fc4efd67396", "page": 8, "type": "paragraph", "text": "pertaining to licensure and labeling of influenza vaccines."}
{"id": "66c771d7-6ad9-4c19-a31d-08c862e67a91", "page": 8, "type": "paragraph", "text": "Vaccines that are expected to be available for the 2022\u201323"}
{"id": "cf7ba407-ed7f-4cf0-b086-922aad91c654", "page": 8, "type": "paragraph", "text": "season are described (see Vaccines Available for the"}
{"id": "11cd020c-963e-4aaf-9fb4-a64de1e815be", "page": 8, "type": "paragraph", "text": "2022\u201323 Season) (Table 1). Regulatory information"}
{"id": "eb47b8d8-f2f2-4a79-89e4-a1f6637ee678", "page": 8, "type": "paragraph", "text": "pertinent to the change in age indication for Flucelvax"}
{"id": "37a37dcd-7e05-4a65-a928-069d0d424f90", "page": 8, "type": "paragraph", "text": "Quadrivalent discussed in this report is available at https://"}
{"id": "8a582401-54b3-42fd-ba00-f66c920907ba", "page": 8, "type": "paragraph", "text": "www.fda.gov/vaccines-blood-biologics/vaccines/"}
{"id": "9a2f5508-6dc5-4fb5-a8d6-7b6f1b78f0bb", "page": 8, "type": "paragraph", "text": "flucelvax-quadrivalent."}
{"id": "29b50ab6-0bee-494b-a797-21247527ca35", "page": 8, "type": "paragraph", "text": "\u2022 Regarding updated recommendations for influenza"}
{"id": "0a17df02-1d6a-473e-a2f0-a85965b0c6b3", "page": 8, "type": "paragraph", "text": "vaccines for adults aged \u226565 years, a summary of the review"}
{"id": "94cd6754-0b08-4a18-a0a1-8e7cda507f97", "page": 8, "type": "paragraph", "text": "of evidence on this topic is available at https://www.cdc."}
{"id": "bbef0158-68fc-4d7f-8d5d-deb174330aae", "page": 8, "type": "paragraph", "text": "gov/vaccines/acip/recs/grade/influenza-older-adults.html."}
{"id": "11640621-af35-42de-aac2-40c035332bbf", "page": 8, "type": "paragraph", "text": "A summary of the ACIP Evidence to Recommendations"}
{"id": "35a577e1-bab5-4e24-9590-df53692f2eee", "page": 8, "type": "paragraph", "text": "Framework for this discussion is available at https://www."}
{"id": "575ddf3f-e4ec-48a3-a72c-e2279ff6d20e", "page": 8, "type": "paragraph", "text": "cdc.gov/vaccines/acip/recs/grade/influenza-older-adults-"}
{"id": "58c0b2c0-7dfc-4cf1-9693-bbaf2b5248d4", "page": 8, "type": "paragraph", "text": "etr.html."}
{"id": "ddf38272-50a8-44e2-b84b-426887eb25d8", "page": 8, "type": "paragraph", "text": "Primary Changes and Updates"}
{"id": "eb0b8955-d1cd-42f8-9eb9-6b778f196734", "page": 8, "type": "paragraph", "text": "Routine annual influenza vaccination of all persons aged"}
{"id": "a6537d10-5054-45bd-8348-9c6d99f0906d", "page": 8, "type": "paragraph", "text": "\u22656 months who do not have contraindications continues to be"}
{"id": "ec1b232a-d65b-4340-9c20-6edf90d2991d", "page": 8, "type": "paragraph", "text": "recommended. Primary updates in this report include the following:"}
{"id": "f71903f9-5c6b-445c-b24c-3a187f29775b", "page": 8, "type": "paragraph", "text": "1. The composition of the 2022\u201323 U.S. seasonal influenza"}
{"id": "be4aabe2-9e38-44c8-bb58-c945869ef837", "page": 8, "type": "paragraph", "text": "vaccines includes updates to the influenza A(H3N2)"}
{"id": "a969550d-a611-406c-add4-7eefaf9cefde", "page": 8, "type": "paragraph", "text": "and influenza B/Victoria components. For the 2022\u201323"}
{"id": "34b2519b-e696-4b1d-8a1d-7b00f06137d8", "page": 8, "type": "paragraph", "text": "season, U.S.-licensed influenza vaccines will contain"}
{"id": "ed5615fd-3da8-482d-b257-f633b2d7b9ab", "page": 8, "type": "paragraph", "text": "hemagglutinin (HA) derived from an influenza"}
{"id": "9477d26f-93e4-4bc6-9abc-aede55915676", "page": 8, "type": "paragraph", "text": "A/Victoria/2570/2019 (H1N1)pdm09-like virus (for egg-"}
{"id": "7da23a8f-71e9-4566-9148-3467583ad86f", "page": 8, "type": "paragraph", "text": "based vaccines) or an influenza A/Wisconsin/588/2019"}
{"id": "de8050d2-0304-49a1-aae3-8f539ae1c365", "page": 8, "type": "paragraph", "text": "(H1N1)pdm09-like virus (for cell culture\u2013based and"}
{"id": "86c55f99-1d0f-43e0-96a0-7d981ac3cd5a", "page": 8, "type": "paragraph", "text": "recombinant vaccines); an influenza A/Darwin/9/2021"}
{"id": "da3a94a3-3160-46d1-9e9f-84ff4d8ad6ec", "page": 8, "type": "paragraph", "text": "(H3N2)-like virus (for egg-based vaccines) or an"}
{"id": "f31f70b9-521b-411a-a36f-28d0122c4e20", "page": 8, "type": "paragraph", "text": "influenza A/Darwin/6/2021 (H3N2)-like virus (for cell"}
{"id": "1702a665-4fb0-49ea-aa0d-9f9660d50526", "page": 8, "type": "paragraph", "text": "culture\u2013based or recombinant vaccines); an influenza"}
{"id": "62ce9b7e-c46c-47e9-a34d-b8f457b18aaa", "page": 8, "type": "paragraph", "text": "B/Austria/1359417/2021 (Victoria lineage)-like virus;"}
{"id": "6a21219e-41ca-4cb0-b498-eead17f96173", "page": 8, "type": "paragraph", "text": "and an influenza B/Phuket/3073/2013 (Yamagata"}
{"id": "89b0d125-dfba-465e-86a8-bb6bab8d2858", "page": 8, "type": "paragraph", "text": "lineage)-like virus."}
{"id": "4e35140d-4ce1-4c4d-bbfb-7d695e226233", "page": 8, "type": "paragraph", "text": "2. Influenza vaccines expected to be available for the 2022\u201323"}
{"id": "8ca4a3ff-3b82-4a6b-a77d-5287ef50f9ff", "page": 8, "type": "paragraph", "text": "season, their age indications, and their presentations are"}
{"id": "4427e14c-476b-408a-9044-6b86b2e3a1fa", "page": 8, "type": "paragraph", "text": "described (Table 1). Afluria Quadrivalent is not expected"}
{"id": "f2fbd7ec-130c-4365-88ff-68c4c6f3b5b5", "page": 8, "type": "paragraph", "text": "to be available in a 0.25-mL prefilled syringe presentation."}
{"id": "63c10645-4eda-4d55-9b11-87e6de43d5ef", "page": 8, "type": "paragraph", "text": "When using Afluria Quadrivalent for children aged"}
{"id": "f42a6256-cede-45bb-8183-a344bdcbfe09", "page": 8, "type": "paragraph", "text": "6 through 35 months (who require a 0.25-mL dose), the"}
{"id": "b033a0ac-c61c-4364-b415-c1fec97e789c", "page": 8, "type": "paragraph", "text": "dose must be obtained from a multidose vial. One labeling"}
{"id": "e04d165e-d4cb-4de3-9c1f-503869715a9f", "page": 8, "type": "paragraph", "text": "change is described. In October 2021, FDA granted"}
{"id": "1b30bbbc-d550-4062-aabc-0b611e36c549", "page": 8, "type": "paragraph", "text": "approval for the use of Flucelvax Quadrivalent (cell culture\u2013"}
{"id": "9b5a9e30-a6ef-4d3b-8a13-ab3ad417b0ee", "page": 8, "type": "paragraph", "text": "based quadrivalent inactivated influenza vaccine [ccIIV4])"}
{"id": "b9b9b23a-4320-4fd7-a459-bca20c1a608b", "page": 8, "type": "paragraph", "text": "for children aged 6 months through <2 years. As of March"}
{"id": "e8ed2954-3e63-415d-ad23-c17d08283478", "page": 8, "type": "paragraph", "text": "2021, Flucelvax Quadrivalent had been approved for"}
{"id": "d776230d-fc0b-48f5-aaef-7b32b577c89c", "page": 8, "type": "paragraph", "text": "persons aged \u22652 years. Approval for children aged 6 months"}
{"id": "d0d973d3-b306-4a3a-9ab2-2bd651072ceb", "page": 8, "type": "paragraph", "text": "through <2 years was based on results of a randomized,"}
{"id": "7426d1d9-7841-4aa5-afda-503dd1f41eed", "page": 8, "type": "paragraph", "text": "observer-blind study that compared immunogenicity and"}
{"id": "6ab0b6d0-7967-45aa-b8ae-5a4dff204593", "page": 8, "type": "paragraph", "text": "safety of Flucelvax Quadrivalent with that of a licensed"}
{"id": "3c1d3d2e-9167-4eb8-addf-d461bcb2aef4", "page": 8, "type": "paragraph", "text": "comparator IIV4 among 2,402 children aged 6 through"}
{"id": "e9c56cc6-be74-4451-a60c-a67a18d64098", "page": 8, "type": "paragraph", "text": "47 months, of whom 894 were aged 6 through 23 months."}
{"id": "d1d76caf-2f19-4f15-8232-faaaa2953703", "page": 8, "type": "paragraph", "text": "Flucelvax Quadrivalent is now approved for persons aged"}
{"id": "36e9e523-174a-4ce7-a18f-cee22121d13d", "page": 8, "type": "paragraph", "text": "\u22656 months."}
{"id": "4edaa148-22e5-4816-bbc8-c7afc2baf242", "page": 8, "type": "paragraph", "text": "3. On the basis of review of evidence concerning high-dose"}
{"id": "beb612e9-ddfa-4170-bec4-0ea5cc1071c5", "page": 8, "type": "paragraph", "text": "inactivated influenza vaccine (HD-IIV), recombinant"}
{"id": "37b3213b-803c-49f8-855c-8cac925c9e16", "page": 8, "type": "paragraph", "text": "influenza vaccine (RIV), and MF59-adjuvanted"}
{"id": "e38110b9-e1ff-475c-bd0c-f62f09eec9a9", "page": 8, "type": "paragraph", "text": "inactivated influenza vaccine (aIIV), recommendations"}
{"id": "37d948ad-cfc8-44a9-95a1-c80b25b5ff39", "page": 8, "type": "paragraph", "text": "for influenza vaccination of persons aged \u226565 years"}
{"id": "215d3671-ec63-49ba-87e4-60b7ecfdef3b", "page": 9, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "e29ac070-ff88-484d-a8cf-c0299acb5ca5", "page": 9, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "6404a16c-1780-4208-8c66-a97445f9a9a0", "page": 9, "type": "paragraph", "text": "7"}
{"id": "6188e55c-e490-4866-a32c-574b52f94d70", "page": 9, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "4fdb8e4e-564c-4e9d-9374-90ec0f313ec1", "page": 9, "type": "paragraph", "text": "have been modified. ACIP recommends that adults"}
{"id": "7ab5cda5-858e-4310-b7c4-0dcf3e97d565", "page": 9, "type": "paragraph", "text": "aged \u226565 years preferentially receive any one of the"}
{"id": "b2878159-9189-4c27-befe-5db55643740c", "page": 9, "type": "paragraph", "text": "following higher dose or adjuvanted influenza vaccines:"}
{"id": "27962297-bbde-4d13-84f2-00b44e9cb98e", "page": 9, "type": "paragraph", "text": "quadrivalent high-dose inactivated influenza vaccine"}
{"id": "24ee6a69-b8b0-457d-95a9-31e35db02d90", "page": 9, "type": "paragraph", "text": "(HD-IIV4), quadrivalent recombinant influenza vaccine"}
{"id": "4c1792af-c2dd-4c94-b2db-1aca4c98ac40", "page": 9, "type": "paragraph", "text": "(RIV4), or quadrivalent adjuvanted inactivated influenza"}
{"id": "ea872467-e757-4072-b97c-16d3949812c0", "page": 9, "type": "paragraph", "text": "vaccine (aIIV4). If none of these three vaccines is available"}
{"id": "c20aa10c-2cfc-4ecc-a159-9dc9d62a6861", "page": 9, "type": "paragraph", "text": "at an opportunity for vaccine administration, then any"}
{"id": "0c49ddc9-ced8-40ed-b33b-6a40483cf4b3", "page": 9, "type": "paragraph", "text": "other age-appropriate influenza vaccine should be used."}
{"id": "3a7673ed-d22e-4985-a0b8-c10bfb7308f8", "page": 9, "type": "paragraph", "text": "Higher dose vaccines include HD-IIV4 and RIV4, both"}
{"id": "89844b38-4561-4b60-b315-a2cdb6d9b0f8", "page": 9, "type": "paragraph", "text": "of which contain a higher dose of HA antigen per virus"}
{"id": "134ac7c0-28d9-4e82-9c7b-030ee1b46170", "page": 9, "type": "paragraph", "text": "than standard-dose vaccines (60 \u00b5g for HD-IIV4 and"}
{"id": "e174eb03-14a6-4b46-93d0-ed051f106537", "page": 9, "type": "paragraph", "text": "45 \u00b5g for RIV4, compared with 15 \u00b5g for standard-dose"}
{"id": "e4b7d575-390c-4844-86ac-0dfd89ccac26", "page": 9, "type": "paragraph", "text": "inactivated vaccines). Adjuvanted inactivated influenza"}
{"id": "bfaa1d9f-f2ad-4337-80a8-bb5ef7098eab", "page": 9, "type": "paragraph", "text": "vaccine (aIIV4) contains MF59 adjuvant."}
{"id": "30356619-9b7c-4eef-ac93-b4c039c035fb", "page": 9, "type": "paragraph", "text": "Recommendations for the Use of"}
{"id": "298c652e-4836-4cec-b418-906276d56624", "page": 9, "type": "paragraph", "text": "Influenza Vaccines, 2022\u201323"}
{"id": "19e17459-211c-4cbf-b081-b62e31473bd7", "page": 9, "type": "paragraph", "text": "Groups Recommended for Vaccination"}
{"id": "9aaabb8c-f71e-40ca-b75e-beac2fc59760", "page": 9, "type": "paragraph", "text": "Routine annual influenza vaccination is recommended for all"}
{"id": "a058181b-3ff0-49a7-95a4-e2c2fc99119e", "page": 9, "type": "paragraph", "text": "persons aged \u22656 months who do not have contraindications."}
{"id": "298efda9-5340-4e32-9cb0-ba448c733e72", "page": 9, "type": "paragraph", "text": "Recommendations regarding timing of vaccination,"}
{"id": "2b18add7-8cbd-46a6-984b-74a85eeeb10b", "page": 9, "type": "paragraph", "text": "considerations for specific populations, the use of specific"}
{"id": "39dee6a5-2c33-4ff7-b9e7-82fc412a5611", "page": 9, "type": "paragraph", "text": "vaccines, and contraindications and precautions are summarized"}
{"id": "85ae38df-d0d8-4f62-9d94-f2bdc39f302a", "page": 9, "type": "paragraph", "text": "in the sections that follow."}
{"id": "cb1024b8-79b8-4b86-9145-5e970892eaee", "page": 9, "type": "paragraph", "text": "Timing of Vaccination"}
{"id": "836de61d-0a8c-48c1-b8cf-2bea6ea21489", "page": 9, "type": "paragraph", "text": "Because timing of the onset, peak, and decline of influenza"}
{"id": "bd8fb3f2-33f1-4ec7-b520-a7ca89005228", "page": 9, "type": "paragraph", "text": "activity varies, the ideal time to start vaccinating cannot be"}
{"id": "2aeb8fb1-ba9b-45df-849d-b64e6dee2f16", "page": 9, "type": "paragraph", "text": "predicted each season. Decisions about timing necessitate"}
{"id": "f0c1b048-d1e7-4efe-abf2-5beb12ab9c5e", "page": 9, "type": "paragraph", "text": "balancing considerations regarding this unpredictability of"}
{"id": "5e8053cf-96c5-4355-b9f8-45c0709120ca", "page": 9, "type": "paragraph", "text": "the influenza season, possible waning of vaccine-induced"}
{"id": "2ddad3ed-48f8-46f8-aef4-df9248959fdb", "page": 9, "type": "paragraph", "text": "immunity over the course of a season, and programmatic"}
{"id": "f6607a4a-504a-442a-bf7f-e53d2358c05b", "page": 9, "type": "paragraph", "text": "considerations. Influenza vaccines might be available as early"}
{"id": "62200eef-2d58-402b-abe6-e38c9ebd28b5", "page": 9, "type": "paragraph", "text": "as July or August; however, vaccination during these months"}
{"id": "c5b3c011-af07-401c-a319-f8a37f12a4d8", "page": 9, "type": "paragraph", "text": "is not recommended for most groups because of the possible"}
{"id": "5b47dc94-9206-4e83-966f-d186d05f31ee", "page": 9, "type": "paragraph", "text": "waning of immunity over the course of the influenza season"}
{"id": "19ec9f36-afb3-4b64-87b1-428165cf0b54", "page": 9, "type": "paragraph", "text": "(19\u201332). For most persons who need only 1 dose of influenza"}
{"id": "7a98144a-cf0f-43bf-82b0-f4223fd09fb8", "page": 9, "type": "paragraph", "text": "vaccine for the season, vaccination should ideally be offered"}
{"id": "6bfc6426-8c3a-478e-b5b9-6e9737a9eaef", "page": 9, "type": "paragraph", "text": "during September or October. However, vaccination should"}
{"id": "46f940aa-a9c2-4d22-ac73-d16533917feb", "page": 9, "type": "paragraph", "text": "continue after October and throughout the influenza season as"}
{"id": "cf5d3172-78ed-43d9-b966-d4456e692e87", "page": 9, "type": "paragraph", "text": "long as influenza viruses are circulating and unexpired vaccine"}
{"id": "4d4ee4e1-c152-4738-98b8-f561e666dea1", "page": 9, "type": "paragraph", "text": "is available."}
{"id": "f1dacef1-4568-48e6-bd99-5bddf6976697", "page": 9, "type": "paragraph", "text": "Considerations for timing of vaccination include the"}
{"id": "77d57549-ce69-469d-a753-4bfd391c2a1d", "page": 9, "type": "paragraph", "text": "following:"}
{"id": "cc297ce8-c57b-4fd2-bd09-0dd1ab6e46ee", "page": 9, "type": "paragraph", "text": "\u2022 For most adults (particularly adults aged \u226565 years)"}
{"id": "219ed46b-fc3b-466c-8b51-9154508d9331", "page": 9, "type": "paragraph", "text": "and for pregnant persons in the first or second"}
{"id": "ade0ff4d-488e-455a-a42c-352748727d4d", "page": 9, "type": "paragraph", "text": "trimester: Vaccination during July and August should be"}
{"id": "0f3443fd-f7f2-4524-8308-6e22acfb86fc", "page": 9, "type": "paragraph", "text": "avoided unless there is concern that vaccination later in"}
{"id": "bf50ad9a-e409-48f5-8155-12b279632bf9", "page": 9, "type": "paragraph", "text": "the season might not be possible."}
{"id": "3ca2818c-6150-48b4-abb6-095adf35d0c2", "page": 9, "type": "paragraph", "text": "\u2022 Children who require 2 doses: Certain children aged"}
{"id": "48807740-13ae-43da-8bc2-07cb768546fb", "page": 9, "type": "paragraph", "text": "6 months through 8 years require 2 doses of influenza"}
{"id": "8dc4c860-f37c-4a76-90c8-b85e0100bf88", "page": 9, "type": "paragraph", "text": "vaccine for the season (see Children Aged 6 Months"}
{"id": "ccbec0ff-609f-47c0-b5d4-0426df36dd18", "page": 9, "type": "paragraph", "text": "Through 8 Years: Number of Influenza Vaccine Doses)"}
{"id": "b6be1c1e-ffdc-49b3-8086-f426ed3ec986", "page": 9, "type": "paragraph", "text": "(Figure). These children should receive their first dose as"}
{"id": "72f57bf9-e39a-485a-afd0-a607827e07fc", "page": 9, "type": "paragraph", "text": "soon as possible (including during July and August, if"}
{"id": "771d8a95-6c32-4a70-92df-a5524937ec0e", "page": 9, "type": "paragraph", "text": "vaccine is available) to allow the second dose (which must"}
{"id": "64e4e75d-45ed-4667-bcd0-121ad26bd113", "page": 9, "type": "paragraph", "text": "be administered \u22654 weeks later) to be received, ideally, by"}
{"id": "40eb7902-f66d-4f81-8d2d-33d90656b895", "page": 9, "type": "paragraph", "text": "the end of October."}
{"id": "74d24373-720b-4a3a-ba53-175d8072ae7b", "page": 9, "type": "paragraph", "text": "\u2022 Children who require only 1 dose: Vaccination during"}
{"id": "1b53e7c8-58b8-4b54-9287-2c35726aa947", "page": 9, "type": "paragraph", "text": "July and August can be considered for children of any age"}
{"id": "2553fcb0-2c65-4c9a-9fbf-399adf23dd07", "page": 9, "type": "paragraph", "text": "who need only 1 dose of influenza vaccine for the season."}
{"id": "df06a3c5-ee79-48e3-868f-acd0d83b9de1", "page": 9, "type": "paragraph", "text": "While waning of immunity after vaccination over the"}
{"id": "51be155f-fc4a-4c0e-a66a-9b65097e1bd8", "page": 9, "type": "paragraph", "text": "course of the season has been observed among all age"}
{"id": "6c15eac5-a8c4-477b-b975-0ec2046bd49d", "page": 9, "type": "paragraph", "text": "groups (19\u201332), there are fewer published studies reporting"}
{"id": "051db02b-a89c-444e-93c5-3ebff498732a", "page": 9, "type": "paragraph", "text": "results specifically among children (19\u201322). Moreover,"}
{"id": "abc69824-5d96-481f-a070-2ae944ff2dd0", "page": 9, "type": "paragraph", "text": "children in this group might visit health care providers"}
{"id": "874c841d-ef29-44ac-a5af-80460a142e18", "page": 9, "type": "paragraph", "text": "during the late summer months for medical examinations"}
{"id": "e4131cc8-e953-4e6d-9ee2-90e1bcea0722", "page": 9, "type": "paragraph", "text": "before the start of school. Vaccination can be considered"}
{"id": "06bdf928-1d3a-4940-bb68-157b465dca15", "page": 9, "type": "paragraph", "text": "at this time because it represents a vaccination opportunity."}
{"id": "5b0247c9-7a50-4a73-8d7f-22911775aa51", "page": 9, "type": "paragraph", "text": "\u2022 Pregnant persons in the third trimester: Vaccination"}
{"id": "b5cb17f9-c2bb-4199-b42f-aa858a1d1ed4", "page": 9, "type": "paragraph", "text": "during July and August can be considered for pregnant"}
{"id": "976222e1-ab70-428d-b59a-16def9117f1d", "page": 9, "type": "paragraph", "text": "persons who are in the third trimester because vaccination"}
{"id": "eabf8054-f80a-4ed8-9889-770056cd97bd", "page": 9, "type": "paragraph", "text": "might reduce risk for influenza illness in their infants"}
{"id": "59bb7877-11a3-4f36-b45b-67d2aadf764d", "page": 9, "type": "paragraph", "text": "during the first months after birth, when they are too"}
{"id": "69270da6-84ab-4cab-b167-fc300137b3e5", "page": 9, "type": "paragraph", "text": "young to receive influenza vaccine (33\u201336). For pregnant"}
{"id": "881acdd2-6bfc-40ba-8a42-6384ea5046d7", "page": 9, "type": "paragraph", "text": "persons in the first or second trimester during July and"}
{"id": "fa48695e-83e7-4e44-9199-e7b8ef977976", "page": 9, "type": "paragraph", "text": "August, waiting to vaccinate until September or October"}
{"id": "d9015fb5-8822-4f53-a572-e0d40af8bbb2", "page": 9, "type": "paragraph", "text": "is preferable, unless there is concern that later vaccination"}
{"id": "0bce853f-a940-4015-8bb8-2cff93b28d6a", "page": 9, "type": "paragraph", "text": "might not be possible."}
{"id": "3c02d1a4-8137-4519-918b-fbe460a0cc15", "page": 9, "type": "paragraph", "text": "Community vaccination programs should balance"}
{"id": "5e02160a-c095-4b9a-a904-b77bcc93db0f", "page": 9, "type": "paragraph", "text": "maximizing the likelihood of persistence of vaccine-induced"}
{"id": "6206b6d7-384d-44b1-9e65-a69dfcbd0566", "page": 9, "type": "paragraph", "text": "protection through the season with avoiding missed"}
{"id": "4122fc41-dc9b-426b-b17e-981aa22e4dbb", "page": 9, "type": "paragraph", "text": "opportunities to vaccinate or vaccinating after onset of"}
{"id": "0beddda5-8205-46b1-b473-d91c142e7e89", "page": 9, "type": "paragraph", "text": "influenza circulation occurs. Efforts should be structured to"}
{"id": "3a65e676-b693-42d2-bbe8-7e34030e69a0", "page": 9, "type": "paragraph", "text": "optimize vaccination coverage before influenza activity in the"}
{"id": "c495053f-9d7b-4cb9-aae3-7b84a791d22b", "page": 9, "type": "paragraph", "text": "community begins. Vaccination should continue to be offered"}
{"id": "949478cf-df9d-4b33-bb6e-9e7b52a7922e", "page": 9, "type": "paragraph", "text": "as long as influenza viruses are circulating and unexpired"}
{"id": "4aa6bfe9-9cba-4768-a9ac-b2f4213d26b8", "page": 9, "type": "paragraph", "text": "vaccine is available. To avoid missed opportunities for"}
{"id": "0b271770-f2a0-4f5a-a2fa-9befaa95bfc5", "page": 10, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "119cb321-c3ee-427c-9c4a-61e0ba6fc0bc", "page": 10, "type": "paragraph", "text": "8"}
{"id": "33c753c5-1620-43d9-b14c-de32aaceba36", "page": 10, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "209fa64f-59ab-4d47-a46c-8af9a8c9523d", "page": 10, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "3f080666-8a7d-4a9b-976d-dcae15659034", "page": 10, "type": "paragraph", "text": "FIGURE. Influenza vaccine dosing algorithm for children aged"}
{"id": "5ca0af8e-54ee-4e7b-a044-9f0145a799df", "page": 10, "type": "paragraph", "text": "6 months through 8 years* \u2014 Advisory Committee on Immunization"}
{"id": "ce4b78f7-fd4d-4b76-949b-0981e2e6683c", "page": 10, "type": "paragraph", "text": "Practices, United States, 2022\u201323 influenza season"}
{"id": "7f509e52-320c-49bd-ada4-756a7eaa7dcb", "page": 10, "type": "paragraph", "text": "Did the child receive \u22652 doses of"}
{"id": "9496193d-f2b2-4b7d-8fce-7cf5fc41647b", "page": 10, "type": "paragraph", "text": "trivalent or quadrivalent in\ufb02uenza vaccine"}
{"id": "10e9d630-ee5f-4f8c-bedd-2287277dbd11", "page": 10, "type": "paragraph", "text": "before July 1, 2022?"}
{"id": "7d2c4d1a-886e-4bd0-a8f1-07f79b1bb269", "page": 10, "type": "paragraph", "text": "(Doses need not have been received"}
{"id": "553bc73d-8ee2-4e7f-927f-49445f8754bc", "page": 10, "type": "paragraph", "text": "during same or consecutive seasons.)"}
{"id": "6c77e302-a653-486f-becf-dac6184e8b8a", "page": 10, "type": "paragraph", "text": "Yes"}
{"id": "8fe1720d-921e-4c80-ba0b-f222ed647d69", "page": 10, "type": "paragraph", "text": "No or unknown"}
{"id": "9641dabc-dc15-4925-98b5-772d403547d1", "page": 10, "type": "paragraph", "text": "1 dose of"}
{"id": "c7e41f46-a32a-4b1b-9fdd-375d9bfa8709", "page": 10, "type": "paragraph", "text": "2022\u201323"}
{"id": "2fa1d757-a2b3-469d-bf59-50e64ae74c51", "page": 10, "type": "paragraph", "text": "in\ufb02uenza vaccine"}
{"id": "780f32c1-d703-46ae-9653-19267906864c", "page": 10, "type": "paragraph", "text": "2 doses of"}
{"id": "e4926733-1898-4522-8623-45457d1801ca", "page": 10, "type": "paragraph", "text": "2022\u201323"}
{"id": "b91b1e96-31a2-4add-b6f1-ae4adefde27f", "page": 10, "type": "paragraph", "text": "in\ufb02uenza vaccine"}
{"id": "e6751ac7-b7ea-4fea-b911-df462afb9e6b", "page": 10, "type": "paragraph", "text": "(administered"}
{"id": "2bf3c231-2414-4176-bcff-a416e95c5aea", "page": 10, "type": "paragraph", "text": "\u22654 weeks apart)"}
{"id": "e096ce21-5ea8-42be-8909-13109a1d127a", "page": 10, "type": "paragraph", "text": "* Children aged 6 months through 8 years who require 2 doses of influenza"}
{"id": "364d2498-df4b-4846-afc6-d1723ecfbbf8", "page": 10, "type": "paragraph", "text": "vaccine should receive their first dose as soon as possible (including during"}
{"id": "dbb0bd98-c829-447a-b12c-209d7ea02b3c", "page": 10, "type": "paragraph", "text": "July and August, if vaccine is available) to allow the second dose (which must"}
{"id": "71830359-a30f-48ef-b7f2-969c93a18300", "page": 10, "type": "paragraph", "text": "be administered \u22654 weeks later) to be received, ideally, by the end of October."}
{"id": "2b2a92e2-abaa-4fdd-9719-855500c4a6d3", "page": 10, "type": "paragraph", "text": "For children aged 8 years who require 2 doses of vaccine, both doses should"}
{"id": "e541768a-014f-4ba7-a2b3-0be40ade5656", "page": 10, "type": "paragraph", "text": "be administered even if the child turns age 9 years between receipt of dose 1"}
{"id": "629e44e0-26e2-4450-9aed-c8927972e937", "page": 10, "type": "paragraph", "text": "and dose 2."}
{"id": "04986fe7-1a3a-4918-b22a-b1131cf3755e", "page": 10, "type": "paragraph", "text": "vaccination, providers should offer vaccination during routine"}
{"id": "5d4ee07c-2540-493b-8d69-43b11ab5139f", "page": 10, "type": "paragraph", "text": "health care visits and hospitalizations. No recommendation is"}
{"id": "99c1a3b8-a684-4252-b447-b4a03b52d88d", "page": 10, "type": "paragraph", "text": "made for revaccination (i.e., providing a booster dose) later"}
{"id": "40dc2faa-4f45-48c1-985b-11320044a897", "page": 10, "type": "paragraph", "text": "in the season of persons who have been fully vaccinated for"}
{"id": "c3948bd1-f559-414a-93a6-d3704f630323", "page": 10, "type": "paragraph", "text": "the season, regardless of when the current season vaccine"}
{"id": "dcd17b91-341e-4fad-9dc1-8689fb5c4152", "page": 10, "type": "paragraph", "text": "was received."}
{"id": "a1fb9c54-9ef8-436d-b60d-a9d0d1bddba5", "page": 10, "type": "paragraph", "text": "During the 2022\u201323 influenza season, SARS-CoV-2"}
{"id": "ca8a89bf-16ca-4de2-9e97-a6894ade2265", "page": 10, "type": "paragraph", "text": "is expected to continue to circulate in the United States,"}
{"id": "ce41aa4b-20dc-4a4c-82c9-c94253142f7b", "page": 10, "type": "paragraph", "text": "and COVID-19 vaccinations are expected to continue."}
{"id": "8cb74522-38bd-46d6-bc11-af9625869ed0", "page": 10, "type": "paragraph", "text": "Current guidance for the administration of COVID-19"}
{"id": "70294e38-e7cc-4117-95eb-6fa9405aafb2", "page": 10, "type": "paragraph", "text": "vaccines (\u201cCoadministration of COVID-19 vaccines"}
{"id": "5a029735-29b4-40a6-8ea2-8cf146c9c0d6", "page": 10, "type": "paragraph", "text": "with other vaccines\u201d at https://www.cdc.gov/vaccines/"}
{"id": "b1b084d8-6d47-4719-820a-eccaefc614cf", "page": 10, "type": "paragraph", "text": "covid-19/clinical-considerations/interim-considerations-us."}
{"id": "eedecbae-12ec-4a78-9b13-a4daba013394", "page": 10, "type": "paragraph", "text": "html#recommendations) indicates that these vaccines can be"}
{"id": "4162a923-e556-4549-b9ce-144e181376f2", "page": 10, "type": "paragraph", "text": "administered with influenza vaccines; providers should consult"}
{"id": "d9121d70-eb6c-475d-8f7a-c16628cf02c8", "page": 10, "type": "paragraph", "text": "this page for updated information. Guidance for vaccine"}
{"id": "fefe7c19-f0fd-43ba-b82a-d60aa071d9a9", "page": 10, "type": "paragraph", "text": "planning during the COVID-19 pandemic is available at"}
{"id": "e4e5eedd-4a93-434f-acc5-37e80a95010c", "page": 10, "type": "paragraph", "text": "https://www.cdc.gov/vaccines/pandemic-guidance/index.html."}
{"id": "299208a8-143c-431f-a181-5d6100484146", "page": 10, "type": "paragraph", "text": "Optimally, vaccination should occur before onset of influenza"}
{"id": "e58901e6-4335-4423-a5e4-25def90a7079", "page": 10, "type": "paragraph", "text": "activity in the community. However, because timing of the onset,"}
{"id": "570e1be7-3cb2-49d7-83b6-2fc1ad2eade4", "page": 10, "type": "paragraph", "text": "peak, and decline of influenza activity varies, the ideal time to"}
{"id": "14cb4ca0-aef8-42f2-8e88-3cf572261183", "page": 10, "type": "paragraph", "text": "start vaccinating cannot be predicted each season. Moreover,"}
{"id": "52728732-6a96-4295-9b60-4e7306596c08", "page": 10, "type": "paragraph", "text": "more than one outbreak might occur in a community in a single"}
{"id": "6a4f2940-079d-4377-b082-0b7a414bb57b", "page": 10, "type": "paragraph", "text": "year. In the United States, localized outbreaks indicating the"}
{"id": "5a278966-c889-48f8-86aa-981408ae506d", "page": 10, "type": "paragraph", "text": "start of seasonal influenza activity can occur as early as October."}
{"id": "1232aa3b-e1f9-454d-919a-f5c512e1b5d0", "page": 10, "type": "paragraph", "text": "However, in 29 (76%) of 38 influenza seasons from 1982\u201383"}
{"id": "1fc0a63e-2def-44b1-ab8e-a99f474ca7a3", "page": 10, "type": "paragraph", "text": "through 2019\u201320, peak influenza activity (which often is close"}
{"id": "07cbcc9b-6ab5-44c4-a8ab-4cbbd2042a8f", "page": 10, "type": "paragraph", "text": "to the midpoint of influenza activity for the season) has not"}
{"id": "71e2fe4e-51dd-4208-b04a-974bf14d1638", "page": 10, "type": "paragraph", "text": "occurred until January or later, and in 23 (61%) seasons, the"}
{"id": "fd7b9628-f7c9-451f-ad2e-34590e0eb21a", "page": 10, "type": "paragraph", "text": "peak was in February or later (37). Activity peaked in February"}
{"id": "7253bbfd-465b-4105-bc9b-c93ba703fd7f", "page": 10, "type": "paragraph", "text": "in 17 (45%) of these seasons (37)."}
{"id": "9b26d666-dc76-4a98-98b1-4c64b335c9bc", "page": 10, "type": "paragraph", "text": "An increasing number of observational studies (19\u201332) have"}
{"id": "2946fda1-2d05-40d7-9e2d-a1855155f553", "page": 10, "type": "paragraph", "text": "reported decreases in vaccine effectiveness with increasing"}
{"id": "514c0286-2946-4f48-affb-adf02f1b770d", "page": 10, "type": "paragraph", "text": "time postvaccination within a single influenza season. Waning"}
{"id": "9e933485-73c4-424f-bc74-ac2c21246e83", "page": 10, "type": "paragraph", "text": "effects have not been observed consistently across age groups,"}
{"id": "44df913f-6bff-48f2-93d2-7559dc6b98b6", "page": 10, "type": "paragraph", "text": "influenza viruses (types, subtypes, and lineages), or seasons."}
{"id": "77491f7a-4e64-40fc-8532-59b9530c168e", "page": 10, "type": "paragraph", "text": "Certain studies suggest waning occurs to a greater degree"}
{"id": "f3ce7581-ab63-4b21-b604-d87726ed08a9", "page": 10, "type": "paragraph", "text": "against influenza A(H3N2) viruses than against influenza"}
{"id": "1930cbac-f97a-42ff-a0bf-6a4946a262b3", "page": 10, "type": "paragraph", "text": "A(H1N1) or influenza B viruses (26,27). This effect also"}
{"id": "11e69d42-6dbe-4a42-88eb-d10c977003f6", "page": 10, "type": "paragraph", "text": "might vary with recipient age; in certain studies, waning"}
{"id": "960324a1-a9f9-42b1-9b17-79b05956ea5f", "page": 10, "type": "paragraph", "text": "was more pronounced among older adults (19,23,26,30,32)"}
{"id": "0629a0fe-4c21-4d2b-8953-0c2936dae648", "page": 10, "type": "paragraph", "text": "and younger children (19). Relatively fewer reports include"}
{"id": "b2228259-bff6-482d-b86a-45ec144c652c", "page": 10, "type": "paragraph", "text": "results specific to children (19\u201322); findings suggestive of"}
{"id": "fa0b14e3-a52b-426b-8554-83900ff50cb4", "page": 10, "type": "paragraph", "text": "waning have been reported in certain studies (19\u201321) but"}
{"id": "975da5a6-c3ae-4ce7-a4a6-abab801edbc1", "page": 10, "type": "paragraph", "text": "not others (22). Rates of decline in vaccine effectiveness also"}
{"id": "876b6743-6b56-42fb-acbb-731798f10b12", "page": 10, "type": "paragraph", "text": "varied. A multiseason (2011\u201312 through 2014\u201315) analysis"}
{"id": "84f9feb2-94b3-4a08-8a28-39e5a19c9c10", "page": 10, "type": "paragraph", "text": "from the U.S. Influenza Vaccine Effectiveness (U.S. Flu"}
{"id": "39a8a051-ab53-4af7-b8d2-1b1a7f75a5f0", "page": 10, "type": "paragraph", "text": "VE) Network found that vaccine effectiveness decreased by"}
{"id": "44c4c6d5-e1de-4ff2-bd54-76a67098d1fe", "page": 10, "type": "paragraph", "text": "approximately 7% per month for influenza A(H3N2) and"}
{"id": "ac01ffd3-e405-4280-b544-a67f52692548", "page": 10, "type": "paragraph", "text": "influenza B and 6%\u201311% per month for influenza A(H1N1)"}
{"id": "f4c18213-4557-4a6a-bac7-e53607fce1a9", "page": 10, "type": "paragraph", "text": "pdm09 (25). Vaccine effectiveness remained greater than zero"}
{"id": "f835f4cf-7b7c-4517-bbbf-3935b975f506", "page": 10, "type": "paragraph", "text": "for at least 5\u20136 months after vaccination. In the Hospitalized"}
{"id": "8e0df53c-8d7a-4e76-9acd-62a61fb8843a", "page": 10, "type": "paragraph", "text": "Adult Influenza Vaccine Effectiveness Network (HAIVEN)"}
{"id": "a75c4356-36d8-4943-8334-62dd32ea66fa", "page": 10, "type": "paragraph", "text": "during the 2015\u201316 through 2018\u201319 seasons, vaccine"}
{"id": "2e62c026-8404-4506-b3ab-d1e80c07c4c0", "page": 10, "type": "paragraph", "text": "effectiveness against influenza-associated hospitalizations"}
{"id": "5375194c-a67f-4b0c-abb7-18b9b8601e68", "page": 10, "type": "paragraph", "text": "declined by approximately 8%\u20139% per month for all adults"}
{"id": "4bd336cd-79de-4147-a528-68a947abf90d", "page": 10, "type": "paragraph", "text": "and approximately 10%\u201311% per month for those aged"}
{"id": "79351330-2c09-4886-a68d-6c8e6f7e2100", "page": 10, "type": "paragraph", "text": "\u226565 years (32). An analysis of the 2010\u201311 through 2013\u201314"}
{"id": "d9044351-1974-4206-a717-2f41bf64ca27", "page": 10, "type": "paragraph", "text": "seasons noted estimated effectiveness ranging from 54% to"}
{"id": "6b918a95-4c5a-4889-afc7-18e0555ec7ea", "page": 10, "type": "paragraph", "text": "67% during days 0\u2013180 postvaccination; estimated vaccine"}
{"id": "0f980743-ff5b-4c13-a485-5a17a3b62010", "page": 10, "type": "paragraph", "text": "effectiveness was not significant during the period between"}
{"id": "09a94736-2823-40b4-9416-c9f6ed0663a1", "page": 10, "type": "paragraph", "text": "days 181 and 365 (20). A third multiseason analysis (2010\u201311"}
{"id": "6a3ed0f8-5297-40cb-93da-a57382278de2", "page": 10, "type": "paragraph", "text": "through 2014\u201315) conducted in Europe noted a decline"}
{"id": "43eed1e2-7d3f-4a3d-9a3b-482789844d1d", "page": 10, "type": "paragraph", "text": "in vaccine effectiveness to 0% at 111 days postvaccination"}
{"id": "feef8451-7196-4f6d-8b88-743734cb5b24", "page": 10, "type": "paragraph", "text": "against influenza A(H3N2) viruses. Vaccine effectiveness"}
{"id": "2412830b-32a5-436b-a2e6-c8a33e3c0f36", "page": 10, "type": "paragraph", "text": "against influenza B viruses decreased more slowly, and vaccine"}
{"id": "41fd6728-96ba-4a7e-9b4a-79cd14a15133", "page": 10, "type": "paragraph", "text": "effectiveness against influenza A(H1N1)pdm09 viruses"}
{"id": "dbeb80ce-81d5-4ef8-a5d2-1bb17a599fb2", "page": 10, "type": "paragraph", "text": "remained roughly stable at 50%\u201355% throughout the influenza"}
{"id": "35728127-b80d-44b5-aeba-2ad310a3e587", "page": 10, "type": "paragraph", "text": "season (27). A meta-analysis of 14 studies examining waning"}
{"id": "6695c098-dbf5-466c-895b-c2138f7b67e9", "page": 10, "type": "paragraph", "text": "of influenza vaccine effectiveness using the test-negative design"}
{"id": "8c8aa6e7-27b1-4a11-930d-0abce66c8d4e", "page": 10, "type": "paragraph", "text": "found a significant decline in effectiveness within 180 days"}
{"id": "d38cc7b6-d516-479f-80bd-cdc5b7a26246", "page": 10, "type": "paragraph", "text": "after vaccination against influenza A (H3N2) and influenza B"}
{"id": "8a889d33-7440-4485-8041-b6ed903ba00a", "page": 10, "type": "paragraph", "text": "but not against influenza A(H1N1) (38). In addition to the"}
{"id": "df119781-04bf-4146-91d6-2d506da66b2e", "page": 10, "type": "paragraph", "text": "factors observed to be associated with waning immunity across"}
{"id": "caf4b69d-95e1-492a-a149-9f67df321cf7", "page": 10, "type": "paragraph", "text": "studies, observed decreases in protection might be at least in"}
{"id": "318c38f0-1e05-42db-9670-d769a16fa15e", "page": 11, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "457fd3f1-e37e-49f0-8439-0b67909f629f", "page": 11, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "0dd68925-0764-4836-8e73-3488354c51d0", "page": 11, "type": "paragraph", "text": "9"}
{"id": "1f251cc4-c313-43b7-9c1c-33a88231f0bb", "page": 11, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "b0488123-bd29-4fa8-a76a-21072ba5b877", "page": 11, "type": "paragraph", "text": "part attributable to bias, unmeasured confounding, or the"}
{"id": "5bc43b0c-9bdc-4e3e-a754-f6be88e56b90", "page": 11, "type": "paragraph", "text": "late-season emergence of antigenic drift variants of influenza"}
{"id": "e4dd6732-8f64-42eb-9e5f-35b4822225cf", "page": 11, "type": "paragraph", "text": "viruses that are less well-matched to the vaccine viruses."}
{"id": "f30af002-1f87-456e-a4c2-e75f9013378e", "page": 11, "type": "paragraph", "text": "Varying data concerning the presence and rate of waning"}
{"id": "4ac48f3d-cbec-4ca9-93c8-06999f99c93b", "page": 11, "type": "paragraph", "text": "immunity after influenza vaccination, coupled with the"}
{"id": "735fdff8-993c-4d67-afd5-52c75a155c04", "page": 11, "type": "paragraph", "text": "unpredictable timing of the influenza season each year, prevent"}
{"id": "028cf31b-6996-433b-b949-48f1445e3816", "page": 11, "type": "paragraph", "text": "determination of an optimal time to vaccinate. Programmatic"}
{"id": "301d5350-46ec-43b6-a274-48292314305c", "page": 11, "type": "paragraph", "text": "issues also are a consideration. Although delaying vaccination"}
{"id": "aa0c1132-f1a7-4d81-9250-ce53ce731fa5", "page": 11, "type": "paragraph", "text": "might result in greater immunity later in the season, deferral"}
{"id": "b24b9428-e839-41de-b735-fb252a58a1ff", "page": 11, "type": "paragraph", "text": "also might result in missed opportunities to vaccinate as"}
{"id": "bcc8247a-9e8c-4d84-90b7-ca63823ecc9a", "page": 11, "type": "paragraph", "text": "well as difficulties in vaccinating a population within a more"}
{"id": "0d03f74f-bf5f-4777-986a-488fb2e2c1f3", "page": 11, "type": "paragraph", "text": "constrained period. The potential contributions of these factors"}
{"id": "bd4db868-e1dc-4d5b-868c-6212e03c00c5", "page": 11, "type": "paragraph", "text": "among persons aged \u226565 years have been assessed using a"}
{"id": "86d03054-d3c3-4de6-ae29-54cc146b923a", "page": 11, "type": "paragraph", "text": "simulated mathematical model examining various scenarios"}
{"id": "54dbe12f-0173-45f2-8cb1-b15afb34c63a", "page": 11, "type": "paragraph", "text": "of vaccination timing, timing of onset of the influenza season,"}
{"id": "49e59045-adb0-4939-a2cf-f284cf920a7c", "page": 11, "type": "paragraph", "text": "vaccine effectiveness, and rate of waning (39). In this model,"}
{"id": "c585360b-21fc-4398-a26f-0e79477d4801", "page": 11, "type": "paragraph", "text": "during an influenza season beginning in October and peaking"}
{"id": "080ac708-108f-4298-b9cb-13895f148298", "page": 11, "type": "paragraph", "text": "in January, delaying vaccination until October resulted in"}
{"id": "949491b0-f73e-40b7-904e-539a18cd7d7b", "page": 11, "type": "paragraph", "text": "more hospitalizations if >14% of persons aged \u226565 years who"}
{"id": "91578cb4-ce3a-4e57-adc8-d3a8a4127f5a", "page": 11, "type": "paragraph", "text": "would have been vaccinated in August or September failed to"}
{"id": "4c05c1b1-e854-4b39-a8cb-a8553c550030", "page": 11, "type": "paragraph", "text": "get vaccinated. However, these predictions varied considerably"}
{"id": "f89078eb-f90a-453b-8c54-628ad090f040", "page": 11, "type": "paragraph", "text": "with assumed timing of season onset, rate of waning immunity,"}
{"id": "1e089b4a-da16-48c5-bc5b-6c905109b9b6", "page": 11, "type": "paragraph", "text": "and vaccine effectiveness."}
{"id": "dd0ed9f6-f118-42a8-aee9-e9f5c7c79a3e", "page": 11, "type": "paragraph", "text": "Vaccination efforts should continue throughout the season"}
{"id": "4ad2b1ea-3bff-4658-b9b8-dcfd48740cd5", "page": 11, "type": "paragraph", "text": "because the duration of the influenza season varies, and"}
{"id": "2d110e62-d58a-4c92-bb19-e18d4e8e145c", "page": 11, "type": "paragraph", "text": "influenza activity might not occur in certain communities"}
{"id": "9c94500b-3056-40df-8d65-23d9518e2600", "page": 11, "type": "paragraph", "text": "until February, March, or later. Providers should offer influenza"}
{"id": "a4253a31-e495-4866-9552-5542c647ac3a", "page": 11, "type": "paragraph", "text": "vaccine routinely, and organized vaccination campaigns should"}
{"id": "8d13532e-1a87-4d3f-9b17-29d67e0c4bbe", "page": 11, "type": "paragraph", "text": "continue throughout the influenza season, including after"}
{"id": "0768f125-aa8f-40ac-89b4-6b3b20821e64", "page": 11, "type": "paragraph", "text": "influenza activity has begun in the community. Although"}
{"id": "578678e9-4ef3-447e-b6a9-d214e2908ba5", "page": 11, "type": "paragraph", "text": "vaccination by the end of October is recommended, vaccine"}
{"id": "1b36e641-bf23-4e0b-b7ef-aad04ef1aaed", "page": 11, "type": "paragraph", "text": "administered in December or later, even if influenza activity has"}
{"id": "5b7be361-5f4b-4bd7-9823-5200c9d8230e", "page": 11, "type": "paragraph", "text": "already begun, might be beneficial in most influenza seasons."}
{"id": "5a9be0fa-b990-4fd0-8b0f-8a1f2e3c44f5", "page": 11, "type": "paragraph", "text": "Providers should offer influenza vaccination to unvaccinated"}
{"id": "48d34639-676d-4aa1-9255-92f13b066038", "page": 11, "type": "paragraph", "text": "persons who have already become ill with influenza during the"}
{"id": "7433f261-6043-4ecb-aaec-209f09ba00cf", "page": 11, "type": "paragraph", "text": "season because the vaccine might protect them against other"}
{"id": "06139a30-291c-4db8-8f18-c46e5da98c79", "page": 11, "type": "paragraph", "text": "circulating influenza viruses."}
{"id": "b5522aa5-3886-43b1-8a9d-dd8ecf7b4be3", "page": 11, "type": "paragraph", "text": "Guidance for Influenza Vaccination in"}
{"id": "0c5221f4-1a2f-46e7-acb7-09805b7ec934", "page": 11, "type": "paragraph", "text": "Specific Populations and Situations"}
{"id": "d1342348-f276-4574-a46a-188650167b84", "page": 11, "type": "paragraph", "text": "Populations at Higher Risk for Medical"}
{"id": "8c5bed11-cdd0-4a15-a342-f1425217176f", "page": 11, "type": "paragraph", "text": "Complications Attributable to Severe Influenza"}
{"id": "8bc1d20f-8e94-4f19-910b-fa02f64473bb", "page": 11, "type": "paragraph", "text": "All persons aged \u22656 months who do not have contraindications"}
{"id": "4505b4c2-4e8a-4527-b38c-4ef85fca7713", "page": 11, "type": "paragraph", "text": "should be vaccinated annually. However, vaccination to prevent"}
{"id": "8eccf6db-0fda-42da-bb8d-dd4b637d7803", "page": 11, "type": "paragraph", "text": "influenza is particularly important for persons who are at"}
{"id": "9ac28363-6454-4d8b-ba03-13a9c289b705", "page": 11, "type": "paragraph", "text": "increased risk for severe illness and complications from influenza"}
{"id": "c2fc8199-beb6-42f4-b3e5-8395dfd1f837", "page": 11, "type": "paragraph", "text": "and for influenza-related outpatient, emergency department,"}
{"id": "d77f703d-44ad-4c77-ab9e-186d4c5a3733", "page": 11, "type": "paragraph", "text": "or hospital visits. When vaccine supply is limited, vaccination"}
{"id": "493d1c05-363f-494c-a718-77255c0b9864", "page": 11, "type": "paragraph", "text": "efforts should focus on vaccination of persons at higher risk for"}
{"id": "2e08e15a-a5e6-4456-9c45-46cde752ac37", "page": 11, "type": "paragraph", "text": "medical complications attributable to severe influenza who do"}
{"id": "728476dd-2b66-488c-84ae-76b633cb4430", "page": 11, "type": "paragraph", "text": "not have contraindications. These persons include the following"}
{"id": "17ba5240-1431-4b38-a841-e7f93dde3c97", "page": 11, "type": "paragraph", "text": "(no hierarchy is implied by order of listing):"}
{"id": "49e6bf1d-9731-477b-8679-5348fb0b95ca", "page": 11, "type": "paragraph", "text": "\u2022 All children aged 6 through 59 months."}
{"id": "e9409248-fa2d-416b-90e0-99d1491f3018", "page": 11, "type": "paragraph", "text": "\u2022 All persons aged \u226550 years."}
{"id": "3d415873-35e6-409b-bd66-73728c898d4b", "page": 11, "type": "paragraph", "text": "\u2022 Adults and children who have chronic pulmonary"}
{"id": "3b38c415-86b3-40b2-9e71-de7055f549b8", "page": 11, "type": "paragraph", "text": "(including asthma), cardiovascular (excluding isolated"}
{"id": "f951271c-1d90-4811-abe3-60aedd5d9420", "page": 11, "type": "paragraph", "text": "hypertension), renal, hepatic, neurologic, hematologic, or"}
{"id": "3a664489-17d8-47dd-a4cc-e418e99e596f", "page": 11, "type": "paragraph", "text": "metabolic disorders (including diabetes mellitus)."}
{"id": "e0ab28bd-e9e7-499d-a870-17b73e806dfb", "page": 11, "type": "paragraph", "text": "\u2022 Persons who are immunocompromised due to any cause"}
{"id": "ae6d658c-d44e-49f1-acb4-837b83647f08", "page": 11, "type": "paragraph", "text": "(including but not limited to immunosuppression caused"}
{"id": "94fb9c55-155e-400f-a814-7bf1736b7023", "page": 11, "type": "paragraph", "text": "by medications or HIV infection)."}
{"id": "2858bcb3-f775-45b5-a13e-07cde350316a", "page": 11, "type": "paragraph", "text": "\u2022 Persons who are or will be pregnant during the influenza season."}
{"id": "eda75efa-8aaf-41b0-a962-56031d58450b", "page": 11, "type": "paragraph", "text": "\u2022 Children and adolescents (aged 6 months through"}
{"id": "de0439b6-8a33-46e7-ba99-cdf6c8116776", "page": 11, "type": "paragraph", "text": "18 years) who are receiving aspirin- or salicylate-containing"}
{"id": "3afe80ac-c549-4dd5-b42c-eed3c345db44", "page": 11, "type": "paragraph", "text": "medications and who might be at risk for experiencing"}
{"id": "1207e8f7-7dd1-4808-86c6-2a3a378b897a", "page": 11, "type": "paragraph", "text": "Reye syndrome after influenza virus infection."}
{"id": "d56a973d-9c90-463b-b890-13f54ba5b558", "page": 11, "type": "paragraph", "text": "\u2022 Residents of nursing homes and other long-term care"}
{"id": "688223ae-2d73-448a-b615-d78c9f8b64df", "page": 11, "type": "paragraph", "text": "facilities."}
{"id": "dcc54eda-356c-49e9-8f00-fe09fbe5c4a8", "page": 11, "type": "paragraph", "text": "\u2022 American Indian or Alaska Native persons."}
{"id": "6788285f-4978-417e-9e08-51899b942505", "page": 11, "type": "paragraph", "text": "\u2022 Persons who are extremely obese (body mass index \u226540"}
{"id": "8b47873b-4ac8-4b4e-b1df-842904358458", "page": 11, "type": "paragraph", "text": "for adults)."}
{"id": "82cde047-9f3d-4de5-8d23-6628892d3117", "page": 11, "type": "paragraph", "text": "An IIV4 or RIV4 (as appropriate for the recipient\u2019s age)"}
{"id": "2a8b9eb7-db40-4cfc-8114-4647568d3a81", "page": 11, "type": "paragraph", "text": "is suitable for persons in all risk groups. LAIV4 is not"}
{"id": "8346cd9a-2e62-467d-9b90-284c03f8a352", "page": 11, "type": "paragraph", "text": "recommended for certain populations, including certain of"}
{"id": "94a5e64e-25fd-4948-903b-3a67e802839c", "page": 11, "type": "paragraph", "text": "these listed groups. Contraindications and precautions for the"}
{"id": "484bfe70-7d72-4b28-b88c-e89be153c843", "page": 11, "type": "paragraph", "text": "use of LAIV4 are noted (Tables 2 and 3)."}
{"id": "a5f856f2-e230-42d4-beaa-91d2538714bd", "page": 11, "type": "paragraph", "text": "Persons Who Live with or Care for Persons at"}
{"id": "e0c00c5f-ff5e-4b8e-bfd1-9c034d13770b", "page": 11, "type": "paragraph", "text": "Higher Risk for Influenza-Related Complications"}
{"id": "dc93ba89-0c1e-4391-a79f-a1d1c3e49e1f", "page": 11, "type": "paragraph", "text": "All persons aged \u22656 months without contraindications"}
{"id": "b7284b33-7660-464c-96b0-65065972d575", "page": 11, "type": "paragraph", "text": "should be vaccinated annually. However, emphasis also should"}
{"id": "0f1db691-8cab-403b-8a13-b39511a384bc", "page": 11, "type": "paragraph", "text": "be placed on vaccination of persons who live with or care for"}
{"id": "42a3d42c-8389-4b61-9b9f-0d1b63bf3172", "page": 11, "type": "paragraph", "text": "those who are at increased risk for medical complications"}
{"id": "1c61f7ee-6b03-4ed2-a33a-c88cc84916bd", "page": 11, "type": "paragraph", "text": "attributable to severe influenza. When vaccine supply is"}
{"id": "9c26aac4-9a03-4ab1-ac39-00b5dcad33ae", "page": 11, "type": "paragraph", "text": "limited, vaccination efforts should focus on administering"}
{"id": "0510d5a2-aeb1-48bb-93d5-773edab9c619", "page": 11, "type": "paragraph", "text": "vaccination to persons at higher risk for influenza-related"}
{"id": "ac2c618a-90b0-46be-878d-5eae31f693cc", "page": 11, "type": "paragraph", "text": "complications as well as persons who live with or care for such"}
{"id": "ee2bfce8-c1e7-4e1f-be43-80f7c79d51f7", "page": 11, "type": "paragraph", "text": "persons, including the following:"}
{"id": "5b6ca89f-1c17-452a-ba65-e307aa1ad6af", "page": 11, "type": "paragraph", "text": "\u2022 Health care personnel, including all paid and unpaid persons"}
{"id": "64691bbc-dbb9-49d7-8f89-8630f4c9b410", "page": 11, "type": "paragraph", "text": "working in health care settings who have the potential for"}
{"id": "61964557-c005-41f9-8d47-6f76008b2b37", "page": 11, "type": "paragraph", "text": "exposure to patients or to infectious materials. These"}
{"id": "ecf3a7d0-a30d-413d-8013-7fb6b1b4b273", "page": 11, "type": "paragraph", "text": "personnel might include but are not limited to physicians,"}
{"id": "91540547-33ad-4557-b09a-4ff14784674a", "page": 11, "type": "paragraph", "text": "nurses, nursing assistants, nurse practitioners, physician"}
{"id": "ee80d6c7-151d-4d7d-926b-eae25a6100c3", "page": 11, "type": "paragraph", "text": "assistants, therapists, technicians, emergency medical service"}
{"id": "bbb68dd7-5aa9-42fd-b611-f077bd407347", "page": 11, "type": "paragraph", "text": "personnel, dental personnel, pharmacists, laboratory"}
{"id": "e9385cb9-ece8-403b-9a93-8774776fb058", "page": 11, "type": "paragraph", "text": "personnel, autopsy personnel, students and trainees,"}
{"id": "8bb4e443-8117-40cd-9872-53fca8c3ba27", "page": 11, "type": "paragraph", "text": "contractual staff persons, and others not directly involved"}
{"id": "34dba355-7e6a-4665-8ce2-b972c82e962c", "page": 11, "type": "paragraph", "text": "in patient care but who might be exposed to infectious"}
{"id": "5f77dd08-6788-4374-a4e4-8b5564368b92", "page": 12, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "2706cfab-4d3a-4fd7-a5a4-62830fdd0cb3", "page": 12, "type": "paragraph", "text": "10"}
{"id": "5934591a-f844-483a-b536-e51ec1cb4728", "page": 12, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "a992ea9e-ad62-41cd-a90e-76d581aac58c", "page": 12, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "197e61b6-19e9-45b4-9810-5c5744d9dcb3", "page": 12, "type": "paragraph", "text": "agents (e.g., clerical, dietary, housekeeping, laundry, security,"}
{"id": "5e65b09d-fd83-4074-8572-0dd2b121b278", "page": 12, "type": "paragraph", "text": "maintenance, administrative, and billing staff persons and"}
{"id": "d6dbdd65-acdc-4653-a374-eda2da91f65d", "page": 12, "type": "paragraph", "text": "volunteers). ACIP guidance for vaccination of health care"}
{"id": "7949ccdf-4051-46be-9fa5-e30edf5c1f59", "page": 12, "type": "paragraph", "text": "personnel has been published previously (40)."}
{"id": "23a83a8d-b798-44d9-b88f-d8362d71bb10", "page": 12, "type": "paragraph", "text": "\u2022 Household contacts (including children aged \u22656 months)"}
{"id": "ea773d97-3f18-43b6-a31f-77b4e917af22", "page": 12, "type": "paragraph", "text": "and caregivers of children aged \u226459 months (<5 years) and"}
{"id": "3ebc2404-e980-44d8-8f78-1dbcab424a98", "page": 12, "type": "paragraph", "text": "adults aged \u226550 years, particularly contacts of children"}
{"id": "40f386fc-ae35-4447-a93f-f52a7a06502a", "page": 12, "type": "paragraph", "text": "aged <6 months."}
{"id": "f807ae9e-e85d-41d9-9c90-fbc33c190737", "page": 12, "type": "paragraph", "text": "\u2022 Household contacts (including children aged \u22656 months)"}
{"id": "5e37a071-3714-4771-b1ab-95911b8188a7", "page": 12, "type": "paragraph", "text": "and caregivers of persons with medical conditions that put"}
{"id": "fbcdde21-155f-44e5-b6ee-273675937ff8", "page": 12, "type": "paragraph", "text": "them at higher risk for severe complications from influenza."}
{"id": "4e713939-5f78-4ee3-9186-1fbb251c8453", "page": 12, "type": "paragraph", "text": "Health care personnel and persons who are contacts of"}
{"id": "e77bc9e9-d867-4d26-a541-c8585c5dbc6e", "page": 12, "type": "paragraph", "text": "persons in these groups (with the exception of contacts of"}
{"id": "667f6040-ec5b-441e-846d-411c0cbe7b37", "page": 12, "type": "paragraph", "text": "severely immunocompromised persons who require a protected"}
{"id": "cb0e8b2f-e9c1-43dc-8618-723c12157382", "page": 12, "type": "paragraph", "text": "environment) may receive any influenza vaccine that is otherwise"}
{"id": "eb84a4f6-aa3d-4ece-aa6f-072f665f545e", "page": 12, "type": "paragraph", "text": "indicated. Persons who care for severely immunocompromised"}
{"id": "9a0d2658-5961-4957-9da0-99a0253d0729", "page": 12, "type": "paragraph", "text": "persons requiring a protected environment should not receive"}
{"id": "0f49b2cb-0258-43cb-a9f6-bde678d75c77", "page": 12, "type": "paragraph", "text": "LAIV4. ACIP and the Healthcare Infection Control Practices"}
{"id": "fcaa4047-0c03-45f9-86b0-f85ee4fef0a8", "page": 12, "type": "paragraph", "text": "Advisory Committee (HICPAC) have previously recommended"}
{"id": "ff93a634-65b6-496f-afb6-5031c12abe72", "page": 12, "type": "paragraph", "text": "that health care personnel who receive LAIV should avoid"}
{"id": "513b526a-6232-4028-9861-aefb4d137570", "page": 12, "type": "paragraph", "text": "providing care for severely immunocompromised persons"}
{"id": "7cd7c48d-de1b-47bf-8e33-bb16a18e488b", "page": 12, "type": "paragraph", "text": "requiring a protected environment for 7 days after vaccination"}
{"id": "1c74b606-21c8-409f-888e-d174b82818b4", "page": 12, "type": "paragraph", "text": "and that hospital visitors who have received LAIV should avoid"}
{"id": "e707f185-d57f-45db-aba0-493c0cc0091a", "page": 12, "type": "paragraph", "text": "contact with such persons for 7 days after vaccination (41)."}
{"id": "37288923-9082-4cc5-9066-aaf544ab847b", "page": 12, "type": "paragraph", "text": "However, such persons need not be restricted from caring for"}
{"id": "f86a60e6-df9e-4e6b-a1cd-f8bab6c43baf", "page": 12, "type": "paragraph", "text": "or visiting less severely immunocompromised persons."}
{"id": "04c26e0c-1367-4a89-96b2-59095d04a967", "page": 12, "type": "paragraph", "text": "Influenza Vaccination of Persons with COVID-19"}
{"id": "ea571d20-2ef5-4edf-a8b9-3ff9c218c886", "page": 12, "type": "paragraph", "text": "Vaccination of persons who have tested positive for COVID-19"}
{"id": "17d4707d-793c-400e-887e-377b186f7e60", "page": 12, "type": "paragraph", "text": "or who are in quarantine after an exposure should include"}
{"id": "17200f1c-f6f0-49c6-a894-fe1e18badc27", "page": 12, "type": "paragraph", "text": "multiple considerations, such as whether bringing the person"}
{"id": "51e32ed4-c990-4b1c-985d-014e06b3f47d", "page": 12, "type": "paragraph", "text": "into a vaccination setting could expose others to COVID-19,"}
{"id": "a89d1a00-3624-4887-ada5-8a4902bb0e65", "page": 12, "type": "paragraph", "text": "whether the person is acutely ill and the severity of the illness, the"}
{"id": "e03dcfe3-5ebf-4e67-ac6c-901483b9de29", "page": 12, "type": "paragraph", "text": "presence of risk factors for severe influenza illness, the likelihood"}
{"id": "6173e243-3434-4a4f-93df-6a38d64cca53", "page": 12, "type": "paragraph", "text": "of being able to vaccinate at a later date, and the desire to avoid"}
{"id": "e4c5d431-5574-41b9-8074-889499ad06f0", "page": 12, "type": "paragraph", "text": "confusing postvaccination symptoms with those of COVID-19."}
{"id": "ecf2dda0-3ac7-46c1-b04a-9814c2228ae9", "page": 12, "type": "paragraph", "text": "Usually, persons who are in quarantine or isolation should not be"}
{"id": "ca014be7-296d-4e6c-8e49-5627665ddd42", "page": 12, "type": "paragraph", "text": "brought to a vaccination setting if doing so could expose others to"}
{"id": "64725768-f93b-4c40-a6bc-e37739e6e455", "page": 12, "type": "paragraph", "text": "COVID-19. For those who have moderate or severe COVID-19,"}
{"id": "9adc3edc-cd20-4a51-88fd-6593af66368f", "page": 12, "type": "paragraph", "text": "vaccination should usually be deferred until they have recovered,"}
{"id": "c43ba45d-172e-4dfd-9869-d16c2d5ca112", "page": 12, "type": "paragraph", "text": "which is consistent with ACIP General Best Practice Guidelines for"}
{"id": "4c1424f3-9798-43c5-ad6c-212b771b0dba", "page": 12, "type": "paragraph", "text": "Immunization (42). For persons who have mild or asymptomatic"}
{"id": "740799c5-c4d8-41ef-baf3-668ceebec4b5", "page": 12, "type": "paragraph", "text": "COVID-19, further deferral might be considered to avoid"}
{"id": "f3f70b36-2d46-4a34-8c22-08b003bafa0f", "page": 12, "type": "paragraph", "text": "confusing COVID-19 symptoms with postvaccination reactions."}
{"id": "8c83d575-0176-4445-b459-df415ee4fb1c", "page": 12, "type": "paragraph", "text": "Because recommendations for vaccination of this population"}
{"id": "99bdc4df-dd3d-4544-bb23-94b90484c60d", "page": 12, "type": "paragraph", "text": "might continue to evolve, clinicians should check CDC guidance"}
{"id": "1020ad94-3ca5-4eb4-b781-d62637657fc1", "page": 12, "type": "paragraph", "text": "(https://www.cdc.gov/vaccines/pandemic-guidance/index.html)"}
{"id": "812f0a24-56b3-4859-8c1e-2f88203ccf83", "page": 12, "type": "paragraph", "text": "for up-to-date information."}
{"id": "cb2c332b-e135-47aa-9eba-80cd85e663e5", "page": 12, "type": "paragraph", "text": "Children Aged 6 Through 35 Months: Influenza"}
{"id": "cbe46ce0-9ae8-459a-a2c5-40ae75cbcc4b", "page": 12, "type": "paragraph", "text": "Vaccine Dose Volumes"}
{"id": "3ddd5a87-717d-4b85-bcad-ee244f09f337", "page": 12, "type": "paragraph", "text": "Five IIV4s are approved for children aged \u22656 months (Table 1)."}
{"id": "beb55514-1c9f-4c5e-882c-d178ebc4a97b", "page": 12, "type": "paragraph", "text": "Four of these vaccines are egg based (Afluria Quadrivalent,"}
{"id": "a136cd80-9a54-4d7e-8ca5-69a5231d0ad0", "page": 12, "type": "paragraph", "text": "Fluarix Quadrivalent, Flulaval Quadrivalent, and Fluzone"}
{"id": "cc288faf-a04f-41c0-a250-7f6b613dc957", "page": 12, "type": "paragraph", "text": "Quadrivalent), and one is cell culture based (Flucelvax"}
{"id": "0533afbc-b08a-49e1-96c7-60b3ba512e63", "page": 12, "type": "paragraph", "text": "Quadrivalent). For these vaccines, the approved dose volumes"}
{"id": "610cd6ae-ccac-4489-9900-6e99f7edf699", "page": 12, "type": "paragraph", "text": "for children aged 6 through 35 months are as follows (Table 4):"}
{"id": "c4e6afcf-bbeb-4cca-89b2-9915e503bf27", "page": 12, "type": "paragraph", "text": "\u2022 Afluria Quadrivalent: 0.25 mL per dose. However, 0.25-mL"}
{"id": "e58862a2-8d9f-4506-9247-b85dc12e11a1", "page": 12, "type": "paragraph", "text": "prefilled syringes are not expected to be available for the"}
{"id": "e89fa6be-b4b2-4968-a487-79d2f16aedd8", "page": 12, "type": "paragraph", "text": "2022\u201323 season. For children aged 6 through 35 months, a"}
{"id": "72785a3d-d6b7-48a6-871d-e6b34437b0c1", "page": 12, "type": "paragraph", "text": "0.25-mL dose must be obtained from a multidose vial (43)."}
{"id": "5abe067c-c7ac-4df9-a76f-f9b9d130e792", "page": 12, "type": "paragraph", "text": "\u2022 Fluarix Quadrivalent: 0.5 mL per dose."}
{"id": "4062dfb2-6050-450c-b29c-fc0234a56582", "page": 12, "type": "paragraph", "text": "\u2022 Flucelvax Quadrivalent: 0.5 mL per dose."}
{"id": "4a161e65-620a-4dbc-84ab-33fc89473f84", "page": 12, "type": "paragraph", "text": "\u2022 FluLaval Quadrivalent: 0.5 mL per dose."}
{"id": "558a7415-ffa4-44d8-9f26-dd2e75fcfc38", "page": 12, "type": "paragraph", "text": "\u2022 Fluzone Quadrivalent: either 0.25 mL or 0.5 mL per dose."}
{"id": "1843c37c-8079-4ce7-b6a9-424728a26b43", "page": 12, "type": "paragraph", "text": "Per the package insert, each dose may be given at either"}
{"id": "a4259241-1fe0-4201-a339-43c5075d4dc9", "page": 12, "type": "paragraph", "text": "volume (44); however, the 0.25-mL prefilled syringes are"}
{"id": "de1d623e-5b05-4f50-9da0-a1679bcc3e94", "page": 12, "type": "paragraph", "text": "no longer available."}
{"id": "331487f3-4955-4bba-861c-3ae1e7f3448a", "page": 12, "type": "paragraph", "text": "For all of these IIV4s, persons aged \u226536 months (\u22653 years)"}
{"id": "cbb5c783-baca-4665-a1e0-39d826896b2e", "page": 12, "type": "paragraph", "text": "should receive 0.5 mL per dose."}
{"id": "988ea289-3a67-440b-9c51-7b0678c46811", "page": 12, "type": "paragraph", "text": "Alternatively, healthy children aged \u226524 months (\u22652 years)"}
{"id": "2eb2d542-2a2d-4b9f-82d1-308ff61412fb", "page": 12, "type": "paragraph", "text": "may receive LAIV4, 0.2 mL intranasally (0.1 mL in each nostril)."}
{"id": "9e87f333-1242-459c-94c8-b3a50f17dffb", "page": 12, "type": "paragraph", "text": "LAIV4 is not recommended for certain populations and is not"}
{"id": "fa503aeb-86fb-432f-8a42-7fd489997694", "page": 12, "type": "paragraph", "text": "approved for children aged <2 years (see Contraindications and"}
{"id": "72474586-347c-4a70-b81d-3f62a7417847", "page": 12, "type": "paragraph", "text": "Precautions for the Use of LAIV4) (Table 2). RIV4 is not approved"}
{"id": "327bb8d3-7d51-4902-ae97-f6ac90ac99cf", "page": 12, "type": "paragraph", "text": "for children aged <18 years. High-dose inactivated influenza"}
{"id": "30bc593c-08dc-4a3a-84de-d813d3559bcd", "page": 12, "type": "paragraph", "text": "vaccine (HD-IIV4) and adjuvanted inactivated influenza vaccine"}
{"id": "a3b3ce6e-f818-43e6-9bf7-86e4a114b9e5", "page": 12, "type": "paragraph", "text": "(aIIV4) are not approved for persons aged <65 years."}
{"id": "1f1c4a35-49a4-4a92-99ea-8356661d3b56", "page": 12, "type": "paragraph", "text": "Care should be taken to administer an age-appropriate vaccine at"}
{"id": "53905e90-d924-4398-a2e0-71d845d91146", "page": 12, "type": "paragraph", "text": "the appropriate volume for each dose. For IIV4s, the recommended"}
{"id": "cd594030-5215-4d18-b3a4-0e0a7391ab4f", "page": 12, "type": "paragraph", "text": "volume may be administered from a prefilled syringe containing the"}
{"id": "81c295c9-b86b-4949-9010-8fbf5901a6c3", "page": 12, "type": "paragraph", "text": "appropriate volume (as supplied by the manufacturer), a single-dose"}
{"id": "7f49144d-d227-4b19-a868-2de3e2937051", "page": 12, "type": "paragraph", "text": "vial, or a multidose vial. Single-dose vials should be used for only"}
{"id": "186ae0a9-e676-4e74-8c24-4ccb8722d446", "page": 12, "type": "paragraph", "text": "1 dose, and multidose vials should be used only for the maximum"}
{"id": "0e99c6a2-4af8-4420-91bb-85b1a099013a", "page": 12, "type": "paragraph", "text": "number of doses specified in the package insert. Any vaccine"}
{"id": "e6bdb134-8322-4e02-a6c1-9b3958dc29d9", "page": 12, "type": "paragraph", "text": "remaining in a vial after the maximum number of doses has been"}
{"id": "8ab0c4b5-abcf-4210-a8ac-162e8ac3ade1", "page": 12, "type": "paragraph", "text": "removed should be discarded, regardless of the volume of the doses"}
{"id": "aef1b41d-c510-43fc-82a2-1e0cc1516fe5", "page": 12, "type": "paragraph", "text": "obtained or any remaining volume in the vial."}
{"id": "1698b7cf-c725-4109-a15c-e5eb2f6c3b34", "page": 12, "type": "paragraph", "text": "Children Aged 6 Months Through 8 Years:"}
{"id": "f33702d7-ee19-49d4-bd22-f0464b8f519c", "page": 12, "type": "paragraph", "text": "Number of Influenza Vaccine Doses"}
{"id": "d1dd629f-da58-4210-83b7-673a12d70cc5", "page": 12, "type": "paragraph", "text": "Children aged 6 months through 8 years require 2 doses of"}
{"id": "d01ae68a-17a5-417c-bf3c-531b2b4f2521", "page": 12, "type": "paragraph", "text": "influenza vaccine administered a minimum of 4 weeks apart"}
{"id": "f82692e7-d846-44cc-96e4-611a534f6f26", "page": 12, "type": "paragraph", "text": "during their first season of vaccination for optimal protection"}
{"id": "5438ee97-34f4-410f-b819-e8897f2f05ed", "page": 12, "type": "paragraph", "text": "(45\u201348). Determination of the number of doses needed is"}
{"id": "a8e9aa70-19cf-4e08-bea4-634d0e1f312b", "page": 12, "type": "paragraph", "text": "based on 1) the child\u2019s age at the time of the first dose of"}
{"id": "6c6b5212-d90b-4232-a981-a80e16668ef9", "page": 12, "type": "paragraph", "text": "2022\u201323 influenza vaccine and 2) the number of doses of"}
{"id": "6bdd2a8a-9a43-46a9-92a4-bd43c3187404", "page": 12, "type": "paragraph", "text": "influenza vaccine received in previous influenza seasons."}
{"id": "32290605-d66c-481f-8f8d-bdc8d7e0473f", "page": 13, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "02f40b53-411e-4ce5-8cde-46ef35c1cdde", "page": 13, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "1722497c-e97a-4c48-be5b-a2c3119d3496", "page": 13, "type": "paragraph", "text": "11"}
{"id": "37aa6eeb-bd07-4142-a689-83e35cfd1d14", "page": 13, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "8131df0e-7d5a-4156-975c-89e6093c6748", "page": 13, "type": "paragraph", "text": "TABLE 4. Dose volumes for inactivated influenza vaccines approved"}
{"id": "d3e9012a-12a9-4ed3-9c45-cc4caed93659", "page": 13, "type": "paragraph", "text": "for children aged 6 through 35 months* \u2014 United States, 2022\u201323"}
{"id": "068d3c0d-94e8-4596-9dcb-36e86f5cbeda", "page": 13, "type": "paragraph", "text": "influenza season"}
{"id": "090604fa-9aba-4057-9091-bcef8e2b5fce", "page": 13, "type": "paragraph", "text": "Trade name (Manufacturer)"}
{"id": "e77110f4-0c50-4f37-a1e8-ca2a0c50d0eb", "page": 13, "type": "paragraph", "text": "Dose volume for children"}
{"id": "d9f10cc7-3546-4f6a-9ef9-aaaee30eadb6", "page": 13, "type": "paragraph", "text": "aged 6 through 35 mos"}
{"id": "7746e83f-f368-496f-83af-2e151ca87a14", "page": 13, "type": "paragraph", "text": "(\u00b5g HA per vaccine virus)"}
{"id": "377d7efd-61be-40a2-a8c5-2f83f9aaaae7", "page": 13, "type": "paragraph", "text": "Afluria Quadrivalent (Seqirus)"}
{"id": "938966ea-8541-4fbb-ae2f-3c3f8ad97322", "page": 13, "type": "paragraph", "text": "0.25 mL (7.5 \u00b5g)\u2020"}
{"id": "7e3050e5-e012-444f-9fc3-9d59d626d6bb", "page": 13, "type": "paragraph", "text": "Fluarix Quadrivalent"}
{"id": "e0b08a84-bbd4-40b2-b82a-90df32d4a7d5", "page": 13, "type": "paragraph", "text": "(GlaxoSmithKline)"}
{"id": "7cd89ca2-b7d6-4d12-a166-2d9931310510", "page": 13, "type": "paragraph", "text": "0.5 mL (15 \u00b5g)"}
{"id": "7f640a2b-3b1b-4922-8cbe-21d11014fc1d", "page": 13, "type": "paragraph", "text": "Flucelvax Quadrivalent (Seqirus)"}
{"id": "043352e5-a208-44ed-82d9-98dd48e069b5", "page": 13, "type": "paragraph", "text": "0.5 mL (15 \u00b5g)"}
{"id": "9a4aa565-f073-4e27-a5ce-40dcd24de5a9", "page": 13, "type": "paragraph", "text": "FluLaval Quadrivalent"}
{"id": "63f9eaf1-cd50-4b6c-8a4a-c4c45c2fde9f", "page": 13, "type": "paragraph", "text": "(GlaxoSmithKline)"}
{"id": "9aca10d9-0be1-4867-b05c-fda7cb756b7f", "page": 13, "type": "paragraph", "text": "0.5 mL (15 \u00b5g)"}
{"id": "e029fd30-f91f-4666-9985-27b1d62b2de0", "page": 13, "type": "paragraph", "text": "Fluzone Quadrivalent (Sanofi"}
{"id": "0717b352-13d2-403c-8ec1-9fe1d5d48840", "page": 13, "type": "paragraph", "text": "Pasteur)"}
{"id": "a3776798-891f-4120-838f-3839a2d0642e", "page": 13, "type": "paragraph", "text": "0.5 mL (15 \u00b5g)\u00a7"}
{"id": "1257de1e-428c-46dd-ab20-a231e2a2cf96", "page": 13, "type": "paragraph", "text": "Abbreviation: HA = hemagglutinin."}
{"id": "3c44646b-a970-4bbb-8b20-16b89112a225", "page": 13, "type": "paragraph", "text": "* For persons aged \u226536 months (\u22653 years), the dose volume is 0.5 mL per dose"}
{"id": "2f5691ff-1571-4fb7-8234-5045bf153801", "page": 13, "type": "paragraph", "text": "for all inactivated influenza vaccines with the exception of Fluzone High-Dose"}
{"id": "3ddff6de-2c0c-4069-9537-970b43113d4d", "page": 13, "type": "paragraph", "text": "Quadrivalent (HD-IIV4), which is licensed for persons aged \u226565 years and for"}
{"id": "d94c08d3-ff4d-49f7-b155-8ce18cbe9d38", "page": 13, "type": "paragraph", "text": "which the dose volume is 0.7 mL per dose."}
{"id": "db2744ef-8fdf-4f32-a922-1eee2f16b2fa", "page": 13, "type": "paragraph", "text": "\u2020 The approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged"}
{"id": "76d73382-5edc-42f7-97e3-121d8838054c", "page": 13, "type": "paragraph", "text": "6 through 35 months and 0.5 mL for persons aged \u22653 years. However, 0.25-mL"}
{"id": "c02ed5ad-da0b-4a81-95b5-ce35cbcfebf0", "page": 13, "type": "paragraph", "text": "prefilled syringes are not expected to be available for the 2022\u201323 season. For"}
{"id": "2b481603-fe6f-4673-9760-ae6cca5ecbc4", "page": 13, "type": "paragraph", "text": "children aged 6 through 35 months, a 0.25-mL dose must be obtained from a"}
{"id": "6f714ac2-9ba2-456b-a8ed-3cc909d077bc", "page": 13, "type": "paragraph", "text": "multidose vial."}
{"id": "19c5b948-5917-4d45-9b12-adb9ceff56e9", "page": 13, "type": "paragraph", "text": "\u00a7 Per the package insert, Fluzone Quadrivalent is currently approved for children"}
{"id": "2505e8ad-f9eb-4435-a881-483dd161274c", "page": 13, "type": "paragraph", "text": "aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL"}
{"id": "6674889b-e24f-44bf-90c5-85dd99dd6e8f", "page": 13, "type": "paragraph", "text": "prefilled syringes are no longer available. If a prefilled syringe of Fluzone"}
{"id": "4527f14c-5357-439e-9eb4-ef207e83c37d", "page": 13, "type": "paragraph", "text": "Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL"}
{"id": "e8d39f63-8645-4f9e-b8e2-d559d117ac7a", "page": 13, "type": "paragraph", "text": "per dose. The 0.5-mL single-dose vials should be accessed for only 1 dose and"}
{"id": "5d47f384-e6ed-4fb8-9446-32a2e57a5e63", "page": 13, "type": "paragraph", "text": "multidose vials for only 10 doses, regardless of the volume of the doses obtained"}
{"id": "06cbbb0c-5d7b-4f35-96c4-187b7aa43675", "page": 13, "type": "paragraph", "text": "or any remaining volume in the vial. Any vaccine remaining in a vial after the"}
{"id": "20e3c17a-9e6c-4ca9-a800-287ec2fff76c", "page": 13, "type": "paragraph", "text": "maximum number of doses has been removed should be discarded."}
{"id": "07533cb1-0258-4136-a5e4-5be203c835d2", "page": 13, "type": "paragraph", "text": "\u2022 For children aged 6 months through 8 years, the number"}
{"id": "b3ac56ea-fb28-4164-aa04-cbb59af6e84e", "page": 13, "type": "paragraph", "text": "of doses of influenza vaccine needed for the 2022\u201323"}
{"id": "ba36107b-4cfe-4f2f-8323-cedf2731c049", "page": 13, "type": "paragraph", "text": "influenza season is determined as follows (Figure):"}
{"id": "a1222921-3eab-4378-a18a-9fea66b18804", "page": 13, "type": "paragraph", "text": "\u0171 Those who have previously received \u22652 total doses of"}
{"id": "02baff7a-41ae-4138-bd49-485df6483a0d", "page": 13, "type": "paragraph", "text": "trivalent or quadrivalent influenza vaccine \u22654 weeks apart"}
{"id": "b4adbdff-7b98-4472-a6ee-594fbdee7fb0", "page": 13, "type": "paragraph", "text": "before July 1, 2022, require only 1 dose for the 2022\u201323"}
{"id": "f6efac7b-4553-4129-abca-27b7b63a0632", "page": 13, "type": "paragraph", "text": "season. The 2 previous doses of influenza vaccine do not"}
{"id": "fe1160a5-9764-4e86-b96a-a437144a7e18", "page": 13, "type": "paragraph", "text": "need to have been received in the same season or"}
{"id": "0e964168-5403-45d3-9365-2dc3d56dbb10", "page": 13, "type": "paragraph", "text": "consecutive seasons."}
{"id": "5bf8424c-2ede-42c8-aa03-228c1df629df", "page": 13, "type": "paragraph", "text": "\u0171 Those who have not previously received \u22652 doses of"}
{"id": "4811d7be-6250-4815-a8a8-82d623162505", "page": 13, "type": "paragraph", "text": "trivalent or quadrivalent influenza vaccine \u22654 weeks"}
{"id": "ddbb4909-f98c-4a46-906f-170f55f5ce25", "page": 13, "type": "paragraph", "text": "apart before July 1, 2022, or whose previous influenza"}
{"id": "6700114e-f31d-428f-9384-8c12c8909927", "page": 13, "type": "paragraph", "text": "vaccination history is unknown, require 2 doses for the"}
{"id": "4fb9b3d9-d713-4db5-8a06-cc3bebdded0f", "page": 13, "type": "paragraph", "text": "2022\u201323 season. The interval between the 2 doses"}
{"id": "e1f58625-8765-4bf7-86d6-2d14c640f372", "page": 13, "type": "paragraph", "text": "should be \u22654 weeks. Children aged 6 months through"}
{"id": "a9dbd109-0d26-4c23-9ec3-9a3d1e098d34", "page": 13, "type": "paragraph", "text": "8 years who require 2 doses of influenza vaccine should"}
{"id": "46bef717-4fcb-4e62-bfa3-0cdfd848d289", "page": 13, "type": "paragraph", "text": "receive their first dose as soon as possible (including"}
{"id": "71c390b3-3e09-4657-805c-1f87933eb724", "page": 13, "type": "paragraph", "text": "during July and August, if vaccine is available) to allow"}
{"id": "5e310a55-0a07-4036-8bb8-b06fc145c41e", "page": 13, "type": "paragraph", "text": "the second dose (which must be administered \u22654 weeks"}
{"id": "10b67cd7-1381-48ba-9743-6f675bdad67e", "page": 13, "type": "paragraph", "text": "later) to be received, ideally, by the end of October."}
{"id": "e88e5248-c764-4eff-ad59-3cc6d4fffd71", "page": 13, "type": "paragraph", "text": "Two doses are recommended even if the child turns age"}
{"id": "90739875-dc4e-4dd2-9f6c-1f91595c864a", "page": 13, "type": "paragraph", "text": "9 years between receipt of dose 1 and dose 2."}
{"id": "7e6ce1df-6cae-460f-a8e4-e178a58aa784", "page": 13, "type": "paragraph", "text": "\u2022 Adults and children aged \u22659 years need only 1 dose of"}
{"id": "4c023a2f-0d3b-4108-ac2c-c47b4721f809", "page": 13, "type": "paragraph", "text": "influenza vaccine for the 2022\u201323 season."}
{"id": "3d375caf-3088-4daf-a9de-88022a75d2b4", "page": 13, "type": "paragraph", "text": "Pregnant Persons"}
{"id": "770e00d7-474e-41a3-b4e8-5ea127c8d328", "page": 13, "type": "paragraph", "text": "Pregnant and postpartum persons have been observed to be at"}
{"id": "41418b4e-5aba-4ae8-8e13-22bd65c3c6f8", "page": 13, "type": "paragraph", "text": "higher risk for severe illness and complications from influenza,"}
{"id": "36b06bb0-9cec-4051-8187-db953202802f", "page": 13, "type": "paragraph", "text": "particularly during the second and third trimesters. Influenza"}
{"id": "49f40d0c-5790-4da0-bc3c-c08750bc4c1f", "page": 13, "type": "paragraph", "text": "vaccination during pregnancy is associated with reduced risk"}
{"id": "e65df6bf-e9d4-4715-91ce-3087d1f86a98", "page": 13, "type": "paragraph", "text": "for respiratory illness and influenza among pregnant and"}
{"id": "e3b36bf2-9556-4bcf-b660-9ed0dd432016", "page": 13, "type": "paragraph", "text": "postpartum persons as well as infants during the first several"}
{"id": "fac04f2c-fddf-4853-98c4-71acbdaf5719", "page": 13, "type": "paragraph", "text": "months of life (33\u201336,49). ACIP and the American College"}
{"id": "23bc08af-a471-4902-a3bc-e1c954c58090", "page": 13, "type": "paragraph", "text": "of Obstetricians and Gynecologists recommend that persons"}
{"id": "5ed261f8-be85-476b-9eae-3d7d0da618d1", "page": 13, "type": "paragraph", "text": "who are pregnant or who might be pregnant or postpartum"}
{"id": "fa421776-58e3-4084-9fa7-3c8072eac868", "page": 13, "type": "paragraph", "text": "during the influenza season receive influenza vaccine (50). Any"}
{"id": "ad04d24f-0a79-4cff-9d3e-781c3342b1e3", "page": 13, "type": "paragraph", "text": "licensed, recommended, and age-appropriate IIV4 or RIV4"}
{"id": "02216ef3-c647-4701-b7aa-9c9bb9517341", "page": 13, "type": "paragraph", "text": "may be used. LAIV4 should not be used during pregnancy but"}
{"id": "a9e5c39e-6ca9-46e2-a73e-453dfb49cecf", "page": 13, "type": "paragraph", "text": "can be used postpartum. Influenza vaccine can be administered"}
{"id": "9b9aaab4-15eb-4a0c-b54b-b86d27114b0f", "page": 13, "type": "paragraph", "text": "at any time during pregnancy (i.e., during any trimester), before"}
{"id": "d241a091-aff4-4e33-a1b3-fc667a375090", "page": 13, "type": "paragraph", "text": "and during the influenza season. Early vaccination (i.e., during"}
{"id": "422abec8-e9c9-4b40-8e21-8cc056be6be3", "page": 13, "type": "paragraph", "text": "July and August) can be considered for persons who are in"}
{"id": "5c579a32-f606-44e3-8c0a-444eaec7c0b8", "page": 13, "type": "paragraph", "text": "the third trimester during these months if vaccine is available"}
{"id": "cb64f7de-5c6a-42a5-bad2-abd63f90d062", "page": 13, "type": "paragraph", "text": "because this can provide protection for the infant during the"}
{"id": "9744f097-4cba-4e94-b949-f1e72f62aa65", "page": 13, "type": "paragraph", "text": "first months of life when they are too young to be vaccinated."}
{"id": "cdcf2ced-1479-4fc5-9705-3a3e3d0065e9", "page": 13, "type": "paragraph", "text": "Although experience with the use of IIVs during pregnancy"}
{"id": "230c53a7-f3c1-4f09-81af-709b3ae500b9", "page": 13, "type": "paragraph", "text": "is substantial, data specifically reflecting administration of"}
{"id": "028ed060-8658-4b0e-aa35-722c003b1673", "page": 13, "type": "paragraph", "text": "influenza vaccines during the first trimester are limited (see"}
{"id": "afddbb1b-f67d-4989-babf-aaab03b9104b", "page": 13, "type": "paragraph", "text": "Safety of Influenza Vaccines in the supplementary Background"}
{"id": "5a7e9139-551d-4eed-9deb-e5bc3a6f5544", "page": 13, "type": "paragraph", "text": "Document). Most studies have not noted an association between"}
{"id": "66760428-eea3-4a22-93be-e58f264c93b0", "page": 13, "type": "paragraph", "text": "influenza vaccination and adverse pregnancy outcomes, including"}
{"id": "6acae295-f0d8-454b-8246-9dba3fc4d744", "page": 13, "type": "paragraph", "text": "spontaneous abortion (miscarriage) (51\u201361). One observational"}
{"id": "251fd357-fc1b-4018-b6c5-6f8b0045a6a1", "page": 13, "type": "paragraph", "text": "Vaccine Safety Datalink (VSD) study conducted during the"}
{"id": "b802c534-d08e-4f41-9267-bc0580ea4dfc", "page": 13, "type": "paragraph", "text": "2010\u201311 and 2011\u201312 seasons noted an association between"}
{"id": "f96d69a4-8735-4f7e-bc50-14b96ca30380", "page": 13, "type": "paragraph", "text": "receipt of IIV containing influenza A(H1N1)pdm09 and risk"}
{"id": "84fb93bd-66a0-4023-8c84-b3d6996e2b2d", "page": 13, "type": "paragraph", "text": "for miscarriage in the 28 days after receipt of IIV, when an"}
{"id": "bd9b0ee0-52af-410e-b7f2-f4ed46b34dfe", "page": 13, "type": "paragraph", "text": "H1N1pdm09-containing vaccine also had been received the"}
{"id": "f67e9ec8-159e-4c3e-ac89-921f753dd091", "page": 13, "type": "paragraph", "text": "previous season (62). However, in a larger VSD follow-up study,"}
{"id": "3c658724-5f60-4e3c-af7b-4670f8625d13", "page": 13, "type": "paragraph", "text": "IIV was not associated with an increased risk for miscarriage"}
{"id": "f136fd98-1012-4e32-8659-6969ec49c32b", "page": 13, "type": "paragraph", "text": "during the 2012\u201313, 2013\u201314, and 2014\u201315 seasons, regardless"}
{"id": "16394ca1-beb8-4f27-bdd4-4c78f8170f42", "page": 13, "type": "paragraph", "text": "of previous season vaccination (63)."}
{"id": "b5273445-23ec-401d-9619-738d63389c65", "page": 13, "type": "paragraph", "text": "Substantially less experience exists with more recently licensed"}
{"id": "3060800e-9f9e-4fc0-82d6-b3164322f693", "page": 13, "type": "paragraph", "text": "IIVs (e.g., quadrivalent and cell culture\u2013based vaccines) during"}
{"id": "6fdafbc4-6609-4c1c-a693-e32077f75b12", "page": 13, "type": "paragraph", "text": "pregnancy than with previously available products. For RIV"}
{"id": "beec12bb-8017-49b4-8c5d-454272f1ff65", "page": 13, "type": "paragraph", "text": "(available as RIV3 from 2013\u201314 through 2017\u201318 and as"}
{"id": "25133178-bfd7-4cf6-8925-192c5ddc59ed", "page": 13, "type": "paragraph", "text": "RIV4 since 2017\u201318), data are limited to reports of pregnancies"}
{"id": "bf3e813e-3589-46cf-8867-a38e902c27a1", "page": 13, "type": "paragraph", "text": "occurring incidentally during clinical trials, Vaccine Adverse Event"}
{"id": "45bcb840-c731-4cd4-b672-d7c9dc6424ee", "page": 13, "type": "paragraph", "text": "Reporting System (VAERS) reports, and pregnancy registries."}
{"id": "2ab25ebc-3bb1-4e99-b514-e5890fd395d6", "page": 13, "type": "paragraph", "text": "Pregnancy registries and surveillance studies exist for certain"}
{"id": "9b8283fa-debb-49b9-9ec4-f4db5d4f9776", "page": 13, "type": "paragraph", "text": "products, for which information can be found in package inserts."}
{"id": "41eb8ecd-22d8-4eba-b661-f753c4ddf1f1", "page": 13, "type": "paragraph", "text": "Older Adults"}
{"id": "6fe061c7-f3d8-463b-bc02-0a07383b4683", "page": 13, "type": "paragraph", "text": "ACIP recommends that adults aged \u226565 years preferentially"}
{"id": "3ea621a2-2a60-47c2-8220-a577678a28b5", "page": 13, "type": "paragraph", "text": "receive any one of the following higher dose or adjuvanted"}
{"id": "68795054-d894-4328-824a-ce99161d5757", "page": 14, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "73a3c0db-9883-48c1-a72c-e1bbb49f0073", "page": 14, "type": "paragraph", "text": "12"}
{"id": "622327d3-c1c9-4c1f-935b-f52e413f5cf6", "page": 14, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "6dab7ec5-8910-4528-aaec-5593560644cc", "page": 14, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "7ee9f482-51c7-4426-9b10-62d51d589641", "page": 14, "type": "paragraph", "text": "influenza vaccines: quadrivalent high-dose inactivated influenza"}
{"id": "9246bd9a-b759-462b-9bf5-0fd61555ff52", "page": 14, "type": "paragraph", "text": "vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine"}
{"id": "437d455d-2a16-4026-812f-d02b9028ec31", "page": 14, "type": "paragraph", "text": "(RIV4), or quadrivalent adjuvanted inactivated influenza"}
{"id": "cae9167e-8393-44f6-9a6f-c67362aebd2d", "page": 14, "type": "paragraph", "text": "vaccine (aIIV4). If none of these three vaccines is available at"}
{"id": "e9ff3270-fc60-4360-bc0e-700f71be74dd", "page": 14, "type": "paragraph", "text": "an opportunity for vaccine administration, then any other age-"}
{"id": "17b07bc5-53f6-412e-aac4-e8d345e93ded", "page": 14, "type": "paragraph", "text": "appropriate influenza vaccine should be administered."}
{"id": "c15a0a5d-3c0a-4a1e-8209-07e71e824082", "page": 14, "type": "paragraph", "text": "Older adults (aged \u226565 years) are at increased risk for severe"}
{"id": "a2387fdc-509d-44c0-9e24-813deb618877", "page": 14, "type": "paragraph", "text": "influenza-associated illness, hospitalization, and death compared"}
{"id": "ab3c4349-18f2-48c1-a5a2-14c189ebf48e", "page": 14, "type": "paragraph", "text": "with younger persons (4,16,64). Influenza vaccines are often less"}
{"id": "72a69e46-95ec-479c-b595-2706edba96a5", "page": 14, "type": "paragraph", "text": "effective in this population (65). HD-IIV, RIV, and aIIV have"}
{"id": "5844ea0f-9359-46c0-b159-cb7f38b61dc2", "page": 14, "type": "paragraph", "text": "been evaluated in comparison with nonadjuvanted SD-IIVs in"}
{"id": "da48275e-1f4a-411f-84e9-6fc1cb53c542", "page": 14, "type": "paragraph", "text": "this age group. Two of these vaccines, HD-IIV and RIV, are"}
{"id": "9d6d83f5-23a7-4988-9df8-84c528a90036", "page": 14, "type": "paragraph", "text": "higher dose vaccines, which contain an increased dose of HA"}
{"id": "4736c489-f32c-4819-8366-1d6db8b967a2", "page": 14, "type": "paragraph", "text": "antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g"}
{"id": "0f249c14-22c7-435e-8941-ae65c60ccd0d", "page": 14, "type": "paragraph", "text": "for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for"}
{"id": "75ce55fa-8775-40c0-b1fd-3294c9214c67", "page": 14, "type": "paragraph", "text": "standard-dose inactivated vaccines). The adjuvanted vaccine"}
{"id": "27671570-f91a-4088-8714-91d80501b609", "page": 14, "type": "paragraph", "text": "contains 15 \u00b5g of HA per virus, similarly to nonadjuvanted"}
{"id": "a9e7ca4b-aade-497f-9e3c-4af5900afe55", "page": 14, "type": "paragraph", "text": "SD-IIVs, but contains the adjuvant MF59."}
{"id": "e1ed0a59-b3fd-479a-8aa3-245b30c4ad29", "page": 14, "type": "paragraph", "text": "HD-IIV, RIV, and aIIV have shown relative benefit compared"}
{"id": "6892af68-0f7d-4d7a-8cd2-e5f19aace2d8", "page": 14, "type": "paragraph", "text": "with SD-IIVs in certain studies, with the most evidence available"}
{"id": "8d4da620-f6f9-4a2b-9f31-d97bcdb01019", "page": 14, "type": "paragraph", "text": "for HD-IIV3. Randomized efficacy studies comparing these"}
{"id": "f44cbbfa-2a3f-4311-a261-ed29ec8c32e6", "page": 14, "type": "paragraph", "text": "vaccines with nonadjuvanted SD-IIVs against laboratory-"}
{"id": "5ee63217-7897-4c08-afdb-c58aaff9808f", "page": 14, "type": "paragraph", "text": "confirmed influenza outcomes are few in number (66\u201368) and"}
{"id": "b8af1c82-2efa-4574-b41c-06f121031253", "page": 14, "type": "paragraph", "text": "cover few influenza seasons. Observational studies, predominantly"}
{"id": "b9570e93-c33c-4da3-ae7d-0f0e6ae50360", "page": 14, "type": "paragraph", "text": "retrospective cohort studies using diagnostic code\u2013defined (rather"}
{"id": "80db74ee-70f6-4eca-993e-bb78734b6ccf", "page": 14, "type": "paragraph", "text": "than laboratory-confirmed) outcomes, are more numerous and"}
{"id": "143ad1a8-dbf8-4ddd-9583-02e5f3046fdc", "page": 14, "type": "paragraph", "text": "include more influenza seasons (69\u201379). Certain observational"}
{"id": "5a11386d-c5a5-404c-a405-c5d83fe02d67", "page": 14, "type": "paragraph", "text": "studies have reported relative benefit for HD-IIV, RIV, and aIIV"}
{"id": "0edd837c-22b5-4d59-93ab-67bbdf2d1685", "page": 14, "type": "paragraph", "text": "in comparison with nonadjuvanted SD-IIVs, particularly in"}
{"id": "5478c442-1f72-4711-8f3e-24fb6a177338", "page": 14, "type": "paragraph", "text": "prevention of influenza-associated hospitalizations. The size of"}
{"id": "37e1c164-80a2-4da5-863d-180c796eef29", "page": 14, "type": "paragraph", "text": "this relative benefit has varied from season to season and is not"}
{"id": "d73cbb08-6d0e-41f5-bad8-53048700704d", "page": 14, "type": "paragraph", "text": "seen in all studies in all seasons, making it difficult to generalize"}
{"id": "7013021d-617a-4579-8490-e635c359ac46", "page": 14, "type": "paragraph", "text": "the findings to all or most seasons. Studies directly comparing"}
{"id": "f48a0a48-e5d3-4d78-9a70-801df5241c97", "page": 14, "type": "paragraph", "text": "HD-IIV, RIV, and aIIV with one another are few and do not"}
{"id": "ef5d1b7e-6155-4c14-856c-e16ee9ec37a8", "page": 14, "type": "paragraph", "text": "support a conclusion that any one of these vaccines is consistently"}
{"id": "36e6c423-ee63-4307-a229-377b9d076207", "page": 14, "type": "paragraph", "text": "superior to the others across seasons (70\u201372,79\u201381)."}
{"id": "4a0073bd-b874-4e2a-b631-1ca193526422", "page": 14, "type": "paragraph", "text": "Of note, for the 2020\u201321 season, quadrivalent formulations"}
{"id": "cffea445-5918-4760-9ee0-1f33bea32db0", "page": 14, "type": "paragraph", "text": "of high-dose (HD-IIV4) and adjuvanted (aIIV4) influenza"}
{"id": "87a66192-2d72-4420-af3d-b0d77039a9c2", "page": 14, "type": "paragraph", "text": "vaccines were introduced. Trivalent formulations of"}
{"id": "249ee1a8-1ca7-49b9-801e-dffc7149010a", "page": 14, "type": "paragraph", "text": "these vaccines are no longer available. Data summarizing"}
{"id": "ec305ec2-b306-44f9-bd80-14fcabbfca89", "page": 14, "type": "paragraph", "text": "comparisons of these newer quadrivalent formulations relative"}
{"id": "8e5cdf76-dfb8-45d3-842c-d40c98ba50f5", "page": 14, "type": "paragraph", "text": "to nonadjuvanted SD-IIV4s against laboratory-confirmed"}
{"id": "5cc74657-495c-42f7-b723-18e1a28b0284", "page": 14, "type": "paragraph", "text": "influenza outcomes are not yet available."}
{"id": "3d4ced13-f778-407e-9e77-356c19c9b6a8", "page": 14, "type": "paragraph", "text": "Literature concerning the efficacy, effectiveness, and safety of"}
{"id": "6441ebd6-dd9c-486f-b08a-ccd4b859da8a", "page": 14, "type": "paragraph", "text": "HD-IIV, RIV, and aIIV versus nonadjuvanted SD-IIVs and of each"}
{"id": "d9db7949-af11-4e92-b8e0-fa5fe575a5af", "page": 14, "type": "paragraph", "text": "of these three vaccines with one another was reviewed, focusing"}
{"id": "e4bb04d3-b2f3-454c-b5bd-49ab0efb525f", "page": 14, "type": "paragraph", "text": "on published studies performed during nonpandemic influenza"}
{"id": "5439b144-422f-4cda-b63d-5d25fbd2bee3", "page": 14, "type": "paragraph", "text": "seasons. A description of the systematic review and GRADE is"}
{"id": "f9749cc4-9965-4dfe-8dea-97830c2d4936", "page": 14, "type": "paragraph", "text": "available at https://www.cdc.gov/vaccines/acip/recs/grade/influenza-"}
{"id": "e0bbdde3-c875-4c82-8ee3-67e093edab29", "page": 14, "type": "paragraph", "text": "older-adults.html. An abbreviated summary follows."}
{"id": "d585625c-d08c-4fab-98e4-1ef121ba1ef0", "page": 14, "type": "paragraph", "text": "Randomized Studies Comparing HD-IIV, RIV, and aIIV"}
{"id": "0841f149-f509-48ab-892b-c8fc74c96f99", "page": 14, "type": "paragraph", "text": "with Nonadjuvanted SD-IIVs: Prevention of Influenza"}
{"id": "f0c9613a-f98a-4c28-bd80-dbda90abba90", "page": 14, "type": "paragraph", "text": "Illnesses. Randomized studies comparing HD-IIV, RIV,"}
{"id": "7826eb2f-b906-44e1-8e6e-5579ebf0196d", "page": 14, "type": "paragraph", "text": "and aIIV with nonadjuvanted SD-IIVs against laboratory-"}
{"id": "71f6c259-2488-4083-b8c0-82d231b4b200", "page": 14, "type": "paragraph", "text": "confirmed influenza illness are few in number and were"}
{"id": "d90535d7-7181-4cdb-87f9-9a6f63d1c7b8", "page": 14, "type": "paragraph", "text": "conducted over few influenza seasons. HD-IIV3 was more"}
{"id": "306e0699-da97-4ea9-a006-3b3338022c3b", "page": 14, "type": "paragraph", "text": "effective than SD-IIV3 in prevention of polymerase chain"}
{"id": "9ab30ff7-2958-46d2-9f48-9a7e02ba8aca", "page": 14, "type": "paragraph", "text": "reaction (PCR)- or culture-confirmed influenza-like illness"}
{"id": "2ff499ac-4c50-40be-993f-3a1afcd5a706", "page": 14, "type": "paragraph", "text": "(ILI) in a two-season randomized study conducted among"}
{"id": "5bfd1676-1efd-4aeb-85a2-9089d7ba29d6", "page": 14, "type": "paragraph", "text": "32,000 persons aged \u226565 years (relative efficacy: 24%;"}
{"id": "98ba3c20-b0af-467c-bdaf-37723aecdcbe", "page": 14, "type": "paragraph", "text": "95% CI: 10%\u201336%; certainty level: 1, high) (66). Two single-"}
{"id": "96464ad1-2a6b-4ce2-a2c5-c0fb544b0aba", "page": 14, "type": "paragraph", "text": "season randomized trials of RIV versus nonadjuvanted SD-IIV,"}
{"id": "602809ef-cb05-44a5-9062-c2aedcd8b47d", "page": 14, "type": "paragraph", "text": "one a comparison of RIV3 versus nonadjuvanted SD-IIV3 that"}
{"id": "4460aaf8-ad23-40c0-a49a-d360c1618935", "page": 14, "type": "paragraph", "text": "assessed culture-confirmed ILI (67) and the other a comparison"}
{"id": "200ebd26-f8f5-44b1-995d-63a178acd0b7", "page": 14, "type": "paragraph", "text": "of RIV4 versus nonadjuvanted SD-IIV4 that examined PCR-"}
{"id": "e2cd1ff0-3cf5-43c0-997c-2da7f1ca22a4", "page": 14, "type": "paragraph", "text": "confirmed ILI (68), did not demonstrate relative benefit of"}
{"id": "8b74cf78-d182-4d94-9ae8-4f949dcc3a05", "page": 14, "type": "paragraph", "text": "RIV among those aged \u226565 years (pooled relative efficacy:"}
{"id": "93056b6b-a6b4-4da3-ad20-6decba7168ff", "page": 14, "type": "paragraph", "text": "18%; 95% CI: \u221217% to 43%; certainty level: 2, moderate)."}
{"id": "f269b205-ac87-4675-9f97-7d1b8b00f2a9", "page": 14, "type": "paragraph", "text": "The larger of these two studies noted a relative benefit of RIV4"}
{"id": "cd92bc22-bdbc-4452-a71d-7e875a30a734", "page": 14, "type": "paragraph", "text": "over nonadjuvanted SD-IIV4 in prevention of PCR-confirmed"}
{"id": "3fac78fc-c433-42db-bbfb-abd3f54d83b9", "page": 14, "type": "paragraph", "text": "influenza among the full study population of persons aged"}
{"id": "648a5a5f-d424-46a9-b8a0-9edbbb8a629a", "page": 14, "type": "paragraph", "text": "\u226550 years (relative efficacy: 30%; 95% CI: 10%\u201347%) as well"}
{"id": "22e6e15c-fb23-4775-a4f9-fe31df56f062", "page": 14, "type": "paragraph", "text": "as against culture-confirmed ILI among those aged \u226565 years"}
{"id": "d1299ccc-637f-4efd-8295-8e660b9e811d", "page": 14, "type": "paragraph", "text": "(relative efficacy: 42%; 95% CI: 9%\u201365%) (68). No data are"}
{"id": "598a97b8-f54e-44ba-ace2-c09c87198ac1", "page": 14, "type": "paragraph", "text": "available from randomized trials of aIIV versus nonadjuvanted"}
{"id": "43118226-df8b-4a0b-aee3-fe93a723350d", "page": 14, "type": "paragraph", "text": "SD-IIVs against laboratory-confirmed influenza outcomes"}
{"id": "920bfd3b-cd09-4092-9375-33194fb76fce", "page": 14, "type": "paragraph", "text": "during nonpandemic influenza seasons."}
{"id": "d18db97b-29c0-41d3-a8ce-a9d76211eb5a", "page": 14, "type": "paragraph", "text": "Randomized Studies Comparing HD-IIV, RIV, and aIIV"}
{"id": "e1265112-7a25-4096-ad6d-1e91046060f1", "page": 14, "type": "paragraph", "text": "with Nonadjuvanted SD-IIVs: Prevention of Influenza-"}
{"id": "0c52cc27-2d78-4ae8-b861-384cba679a25", "page": 14, "type": "paragraph", "text": "Associated Hospitalizations and Other Serious Events. No"}
{"id": "3afb5916-2ff4-493b-8192-08a73f2660dc", "page": 14, "type": "paragraph", "text": "data are available from randomized trials evaluating prevention"}
{"id": "366013f9-d1ef-40ca-81e8-867eb0037d70", "page": 14, "type": "paragraph", "text": "of laboratory-confirmed influenza-associated hospitalizations"}
{"id": "eb5b5c7a-f0cb-4da3-9685-7c6c80e9f351", "page": 14, "type": "paragraph", "text": "as a primary outcome. In a secondary analysis from a two-"}
{"id": "a795d6ef-7fd7-445f-aa6c-d7b16f13191c", "page": 14, "type": "paragraph", "text": "season randomized trial of HD-IIV3 versus nonadjuvanted"}
{"id": "5fa771a8-ae33-400c-a431-49a65b2b1696", "page": 14, "type": "paragraph", "text": "SD-IIV3 assessing serious adverse events (SAEs) (including"}
{"id": "6c468c89-27e1-4293-8d8b-6f748d3eed1a", "page": 14, "type": "paragraph", "text": "hospitalizations) associated with laboratory confirmation of"}
{"id": "92763dda-a2fa-4ef5-a93b-1ce807c81c0b", "page": 14, "type": "paragraph", "text": "influenza performed outside of the study (82) and a post hoc"}
{"id": "e789f07e-51ca-44e5-a9f4-c9d11353d2f5", "page": 14, "type": "paragraph", "text": "analysis of pneumonia- and influenza-related hospitalizations"}
{"id": "58b1b0d5-8c52-4080-a212-0ddd3ff3e602", "page": 14, "type": "paragraph", "text": "from a randomized study of HD-IIV3 versus nonadjuvanted"}
{"id": "78792587-e295-44fe-a2d2-bbabd9b25942", "page": 14, "type": "paragraph", "text": "SD-IIV4 (83), there was no difference in risk for these"}
{"id": "c3ac5bdc-948e-48ec-9e60-0a60067d4c89", "page": 14, "type": "paragraph", "text": "events between the two groups (certainty level: 2, moderate)."}
{"id": "84bbdfc6-5403-42ac-940a-23b7200e1c05", "page": 14, "type": "paragraph", "text": "However, additional data are available from two single-"}
{"id": "787a0995-281f-42e3-9d0d-0f7969769cea", "page": 14, "type": "paragraph", "text": "season, cluster-randomized studies conducted among U.S."}
{"id": "ad8169e0-e41f-4e54-bddd-0458f0160724", "page": 14, "type": "paragraph", "text": "nursing homes (in which nursing homes were randomized to"}
{"id": "1e78fa0d-2be0-4983-900a-ac9c1562a8a9", "page": 14, "type": "paragraph", "text": "vaccine groups rather than individual persons) that examined"}
{"id": "0ee57bdc-d716-46e4-aeb7-6e4b56bd4ed8", "page": 14, "type": "paragraph", "text": "prevention of pneumonia and influenza diagnostic\u2013coded"}
{"id": "eceb1687-e74d-45d1-91fa-eebbdaece288", "page": 14, "type": "paragraph", "text": "hospitalizations. One such study noted a benefit of HD-IIV3"}
{"id": "79b55d98-17f9-4929-b4bc-5b0ce935a904", "page": 14, "type": "paragraph", "text": "relative to nonadjuvanted SD-IIV3 (adjusted relative risk:"}
{"id": "b21c5f2e-bc97-4ee9-a2b3-3470904d07b8", "page": 14, "type": "paragraph", "text": "0.79; 95% CI: 0.66\u20130.95; certainty level: 2, moderate) (84)."}
{"id": "e568846c-d9c4-42cb-be8f-a2ed9b490ecf", "page": 15, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "119b51d5-55b4-47c6-9521-f01f5993818d", "page": 15, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "d587b479-f71b-4a64-a8d8-e126fbe354dc", "page": 15, "type": "paragraph", "text": "13"}
{"id": "648a2ab3-e936-4542-98b8-de768d2cf11f", "page": 15, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "e40bd4ef-0554-444d-b7fb-903d911ba018", "page": 15, "type": "paragraph", "text": "The second noted a benefit of aIIV3 relative to nonadjuvanted"}
{"id": "0c804f01-31ef-48f4-918b-c005698dec43", "page": 15, "type": "paragraph", "text": "SD-IIV3 (adjusted hazard ratio: 0.79; 95% CI: 0.65\u20130.96;"}
{"id": "4a3e13a6-dd21-4796-984e-1f2a1a67c09b", "page": 15, "type": "paragraph", "text": "certainty level: 2, moderate) (85)."}
{"id": "ce07dec3-f2b4-435f-843a-35e1383ad0a3", "page": 15, "type": "paragraph", "text": "Observational Studies Comparing HD-IIV, RIV, and aIIV"}
{"id": "945ec4f4-259f-4a0b-818e-9dfc95c1b014", "page": 15, "type": "paragraph", "text": "with Nonadjuvanted SD-IIVs: Prevention of Influenza-"}
{"id": "85ac9fbc-d3bb-4cad-b782-d842cca402ca", "page": 15, "type": "paragraph", "text": "Associated Hospitalizations and Deaths. Observational studies"}
{"id": "f5b4ee8a-311a-40c6-8c9e-63cdbf7f8786", "page": 15, "type": "paragraph", "text": "comparing HD-IIV and aIIV with nonadjuvanted SD-IIVs"}
{"id": "a16936aa-2201-406b-8f8b-3550b96bd93c", "page": 15, "type": "paragraph", "text": "are more numerous than randomized studies and cover more"}
{"id": "1beb0799-8d17-4880-82db-74e5889c9a1e", "page": 15, "type": "paragraph", "text": "influenza seasons. Many of these studies assessed diagnostic"}
{"id": "30e0f29d-17fc-4449-877e-7452ac89166f", "page": 15, "type": "paragraph", "text": "code\u2013defined (rather than laboratory-confirmed) outcomes. In"}
{"id": "a67a67f8-d837-4040-a7cf-bcad1c7eceee", "page": 15, "type": "paragraph", "text": "these studies, an overall modest relative benefit in prevention of"}
{"id": "b747670d-c6a6-48c9-ba93-91fe6b05772b", "page": 15, "type": "paragraph", "text": "diagnostic code\u2013defined influenza-associated hospitalizations"}
{"id": "3f96221e-9951-40b0-88a8-841c1f7dc108", "page": 15, "type": "paragraph", "text": "has been observed for HD-IIV3 (70\u201377) and aIIV3 (70\u201372)"}
{"id": "34555d5a-04d3-4c44-aced-e773a2d1e831", "page": 15, "type": "paragraph", "text": "versus nonadjuvanted SD-IIV3s. Relative benefit was not found"}
{"id": "6eb65f1b-4295-46a0-89aa-e2089c206e2a", "page": 15, "type": "paragraph", "text": "in every study for all evaluated seasons for either HD-IIV3 or"}
{"id": "f6a96a55-41f0-4332-b6d8-9a7ac298ce5d", "page": 15, "type": "paragraph", "text": "aIIV3. Published observational studies of RIV are fewer than for"}
{"id": "6ccf75db-8105-4b1d-9355-12dd5ee56371", "page": 15, "type": "paragraph", "text": "HD-IIV and aIIV. A retrospective analysis of relative effectiveness"}
{"id": "4b4fdf9b-839b-4d96-a383-106bdf385e68", "page": 15, "type": "paragraph", "text": "of RIV4 versus SD-IIV4 against influenza-coded hospitalizations"}
{"id": "2e745818-09ce-411d-a76b-23f6b4b215ac", "page": 15, "type": "paragraph", "text": "among Medicare beneficiaries during the 2019\u201320 season noted a"}
{"id": "42b86478-c9fd-4ed8-99dd-fa9510d07ae4", "page": 15, "type": "paragraph", "text": "relative effectiveness of 17% (95% CI: 9%\u201324%; certainty level:"}
{"id": "5d5cf4ce-d808-47f1-9ea0-d24cba142ee3", "page": 15, "type": "paragraph", "text": "3, low) (72). Observational studies that address relative benefit"}
{"id": "1a7faf9f-ff92-452b-9a20-6877589cb41e", "page": 15, "type": "paragraph", "text": "in protection against influenza-associated deaths are limited. Two"}
{"id": "b79a15d4-7fcb-4e2a-800a-45ed4a4b581e", "page": 15, "type": "paragraph", "text": "retrospective cohort studies including three influenza seasons noted"}
{"id": "2fe1e60a-2d1a-481d-a8bc-d83bd5846019", "page": 15, "type": "paragraph", "text": "a relative benefit of HD-IIV3 compared with nonadjuvanted"}
{"id": "fb032c3a-0d6e-4303-bc67-f2943441f5ff", "page": 15, "type": "paragraph", "text": "SD-IIV3 (69,78) diagnostic code\u2013defined deaths (pooled rate"}
{"id": "5db5311c-5b2b-4952-8b96-5b7212421064", "page": 15, "type": "paragraph", "text": "ratio: 0.69; 95% CI: 0.57\u20130.84; certainty level: 3, low)."}
{"id": "ddbb51b1-4c0c-4523-8388-6658ba6e9f93", "page": 15, "type": "paragraph", "text": "Observational Studies Comparing Effectiveness of"}
{"id": "9bd15c95-30dd-4665-a242-ece3bb24e4c0", "page": 15, "type": "paragraph", "text": "HD-IIV, RIV, and aIIV with One Another. Data reflecting"}
{"id": "566add85-22c8-4a71-8f1a-e45a58367e3c", "page": 15, "type": "paragraph", "text": "comparisons of HD-IIV, aIIV, and RIV with one another"}
{"id": "bd5eb3b1-651c-467b-95f0-1879233a8a9c", "page": 15, "type": "paragraph", "text": "are more limited than comparisons with nonadjuvanted"}
{"id": "b8237691-ca4a-435b-805e-eb5279cd2b1e", "page": 15, "type": "paragraph", "text": "SD-IIVs. Observational studies have compared HD-IIV3"}
{"id": "759580f6-8474-42d8-a274-a731a2e755c6", "page": 15, "type": "paragraph", "text": "versus aIIV3 (70\u201372,79\u201381), HD-IIV3 versus RIV4 (72),"}
{"id": "18010fb8-7231-41e4-95e2-11f0aa561c71", "page": 15, "type": "paragraph", "text": "and aIIV3 versus RIV4 (72). A retrospective cohort analysis"}
{"id": "fb19dbfd-9a60-45b2-8f12-8256ad291f34", "page": 15, "type": "paragraph", "text": "noted relative effectiveness of RIV4 compared with HD-IIV3"}
{"id": "7cbcaceb-c483-4fd2-aa94-fa88db236428", "page": 15, "type": "paragraph", "text": "(relative effectiveness: 11%; 95% CI: 3%\u201318%; certainty level:"}
{"id": "49183f00-7226-4927-a833-cc46a1bf1126", "page": 15, "type": "paragraph", "text": "3, low) and with aIIV3 (relative effectiveness: 11%; 95% CI:"}
{"id": "eb7d1aeb-df9f-4703-8eb8-1130e581286b", "page": 15, "type": "paragraph", "text": "3%\u201317%; certainty level: 3, low); these data covered only"}
{"id": "6005164e-214d-4ab5-9e08-0dcc878ceac4", "page": 15, "type": "paragraph", "text": "a single influenza season. Data do not point to a consistent"}
{"id": "645af1da-08b6-489b-9dbf-0f4f005ebfa0", "page": 15, "type": "paragraph", "text": "relative benefit of one of these three influenza vaccines over"}
{"id": "be1871cc-06b6-4761-931a-353a4d851af8", "page": 15, "type": "paragraph", "text": "another across multiple seasons."}
{"id": "f44a25d2-b9c2-4c7f-9342-3c2ed6244f9d", "page": 15, "type": "paragraph", "text": "Safety. In comparative safety studies, certain injection site"}
{"id": "79c49ebd-920f-4262-b36a-b09185305ea1", "page": 15, "type": "paragraph", "text": "and systemic reactions were observed more frequently in older"}
{"id": "d0f303e8-b946-4f71-b282-eb1711175c2f", "page": 15, "type": "paragraph", "text": "persons vaccinated with HD-IIV3 and aIIV3 compared with"}
{"id": "5641a8e6-017c-4d31-8457-0dd5561ca155", "page": 15, "type": "paragraph", "text": "nonadjuvanted SD-IIV3 (86,87). In a randomized trial of RIV4"}
{"id": "2b4ea8cc-0362-4b23-92b3-3c4593dd7e5b", "page": 15, "type": "paragraph", "text": "versus nonadjuvanted SD-IIV4 among persons aged \u226550 years,"}
{"id": "d5dcc32d-41ec-4798-83b5-302527b5efdf", "page": 15, "type": "paragraph", "text": "frequencies of solicited injection site events were similar or lower"}
{"id": "ff463ecf-e02f-402f-bd48-b46a045dfc8b", "page": 15, "type": "paragraph", "text": "among RIV4 recipients; frequency of fever was similar between"}
{"id": "b962722c-6abe-4198-bf57-1ad4a2f2562c", "page": 15, "type": "paragraph", "text": "the two vaccines. Frequencies of SAEs were similar between"}
{"id": "4932435d-5a0c-4202-a38f-b8062ee628ef", "page": 15, "type": "paragraph", "text": "the two groups, and none was judged to be related to a study"}
{"id": "a22d64df-a17e-4373-8a3b-8e6fa1609338", "page": 15, "type": "paragraph", "text": "vaccine (68). One postlicensure randomized clinical trial in the"}
{"id": "a5ac7efe-0b4a-4cf3-822f-41f6e26108c2", "page": 15, "type": "paragraph", "text": "United States evaluated the comparative safety of aIIV3 compared"}
{"id": "d9da23a4-d07c-4c72-95f8-6cb475c2d525", "page": 15, "type": "paragraph", "text": "with HD-IIV3 in 757 adults aged \u226565 years (88). For the primary"}
{"id": "aa2276bb-6ff0-4647-b87d-8b9e72a5865a", "page": 15, "type": "paragraph", "text": "outcome, the proportion of participants who reported moderate"}
{"id": "afee435b-2a50-4ba8-ad6c-e208ae91ab6b", "page": 15, "type": "paragraph", "text": "to severe injection site pain that limited or prevented activity"}
{"id": "f2b0953b-0cd6-437b-8745-46bc8093dc68", "page": 15, "type": "paragraph", "text": "after aIIV3 (12 participants [3.2%]) was noninferior compared"}
{"id": "7586d120-75b3-496f-85a3-f155ac755aba", "page": 15, "type": "paragraph", "text": "with the proportion reporting this outcome after vaccination"}
{"id": "f53e9eee-1efc-4be2-a2ee-739f9dc17a46", "page": 15, "type": "paragraph", "text": "with HD-IIV3 (22 participants [5.8%]). No participant sought"}
{"id": "f701104d-89b8-4efe-a580-e92003c50588", "page": 15, "type": "paragraph", "text": "medical care for a solicited reaction symptom, and none had a"}
{"id": "52a5aa63-90a1-4dba-a087-291809a4bced", "page": 15, "type": "paragraph", "text": "SAE determined by study investigators to be related to vaccine"}
{"id": "b60b150c-b7f4-4f2b-b2f6-2fe708fea3e9", "page": 15, "type": "paragraph", "text": "within 43 days after vaccination."}
{"id": "8c8a01af-e0ac-4828-8efd-2bd9224e7935", "page": 15, "type": "paragraph", "text": "Immunocompromised Persons"}
{"id": "f4335c68-0245-4fb7-841e-9e5266a54d42", "page": 15, "type": "paragraph", "text": "ACIP recommends that persons with compromised"}
{"id": "ce3eaf60-ead6-4209-a4cb-c8dc43c28f26", "page": 15, "type": "paragraph", "text": "immunity (including but not limited to persons with"}
{"id": "c70139e5-7d1e-4017-9770-e2842a3e0de6", "page": 15, "type": "paragraph", "text": "congenital and acquired immunodeficiency states, persons"}
{"id": "26918462-9b18-4124-ba17-5562c0aee22d", "page": 15, "type": "paragraph", "text": "who are immunocompromised due to medications, and"}
{"id": "3f740ef9-a3c5-4258-9462-422e1a44e196", "page": 15, "type": "paragraph", "text": "persons with anatomic and functional asplenia) should receive"}
{"id": "8d9346f0-3674-457c-8b07-c091db3ae1b3", "page": 15, "type": "paragraph", "text": "an age-appropriate IIV4 or RIV4. ACIP recommends that"}
{"id": "f3974bf8-2ed0-403c-96ac-d6623e6332d9", "page": 15, "type": "paragraph", "text": "LAIV4 not be used for these groups because of the uncertain"}
{"id": "ef28440b-223c-4004-b014-21229569b6d2", "page": 15, "type": "paragraph", "text": "but biologically plausible risk for disease attributable to the"}
{"id": "43fd54fa-6ec3-4610-9166-a2e9455fd0aa", "page": 15, "type": "paragraph", "text": "live vaccine virus. Use of LAIV4 in persons with these and"}
{"id": "ea8b9002-7e9b-442b-9567-cc2c4feb5554", "page": 15, "type": "paragraph", "text": "other conditions is discussed in more detail (see Dosage,"}
{"id": "2350f87b-9db3-43b1-9922-64358a5b6237", "page": 15, "type": "paragraph", "text": "Administration, Contraindications, and Precautions) (Table 2)."}
{"id": "4fe32ad1-7b43-4014-80bf-2408687eef5c", "page": 15, "type": "paragraph", "text": "Immunocompromised states comprise a heterogeneous"}
{"id": "3bc0bbbc-6c0e-4bfe-bf6c-ed423584464e", "page": 15, "type": "paragraph", "text": "range of conditions with varying risks for severe infections."}
{"id": "c698d851-99ce-42c3-86d2-83c8e8bfccae", "page": 15, "type": "paragraph", "text": "In many instances, limited data are available regarding the"}
{"id": "3bf81db6-3b40-462d-9375-40e3790450e4", "page": 15, "type": "paragraph", "text": "effectiveness of influenza vaccines in the setting of specific"}
{"id": "e27d638a-40b5-4e58-9bb4-c5a54ff226d1", "page": 15, "type": "paragraph", "text": "immunocompromised states (89). Timing of vaccination"}
{"id": "25d22da2-d934-4ced-bf56-3e9ae79e8c8e", "page": 15, "type": "paragraph", "text": "might be a consideration (e.g., vaccinating during a period"}
{"id": "4aa7ad1a-0ecb-4c21-90fc-0943829240ca", "page": 15, "type": "paragraph", "text": "either before or after an immunocompromising intervention)."}
{"id": "91c495de-25e0-48b4-9ecc-1bd3124e0c73", "page": 15, "type": "paragraph", "text": "The Infectious Diseases Society of America has published"}
{"id": "3cc7f9aa-5a1c-422e-8f74-f92872ab368e", "page": 15, "type": "paragraph", "text": "detailed guidance for the selection and timing of vaccines for"}
{"id": "2a10384a-19e1-4407-b332-a37df898d58f", "page": 15, "type": "paragraph", "text": "persons with specific immunocompromising conditions (90)."}
{"id": "4134e271-5bd3-4f06-bc57-6ae9cf0ac9cd", "page": 15, "type": "paragraph", "text": "Immune response to influenza vaccines might be blunted in"}
{"id": "cf0caed7-94e7-4544-ac45-fe2ddc4f288a", "page": 15, "type": "paragraph", "text": "persons with certain conditions, such as congenital immune"}
{"id": "9c3d53f4-9520-4660-984e-df7c9998d72b", "page": 15, "type": "paragraph", "text": "deficiencies, and in persons receiving cancer chemotherapy or"}
{"id": "2490c664-662d-49dc-85f9-4f18ae899974", "page": 15, "type": "paragraph", "text": "immunosuppressive medications."}
{"id": "e28f8e4a-c7a0-45ac-b53e-beeead8ba4e8", "page": 15, "type": "paragraph", "text": "Persons with a History of Guillain-Barr\u00e9 Syndrome"}
{"id": "a353aae6-7c7a-4437-9498-6e8838d62e31", "page": 15, "type": "paragraph", "text": "After Influenza Vaccination"}
{"id": "e188ccc3-d944-4815-8744-d5fbb2eed4ba", "page": 15, "type": "paragraph", "text": "A history of Guillain-Barr\u00e9 syndrome (GBS) within 6 weeks"}
{"id": "4a0cffdf-4d05-400e-a7e7-555316f9b6e8", "page": 15, "type": "paragraph", "text": "of a previous dose of any type of influenza vaccine is considered"}
{"id": "3e3d532b-0527-411b-84b9-51c0ab991995", "page": 15, "type": "paragraph", "text": "a precaution for influenza vaccination (Table 2). Persons"}
{"id": "2ff9a6a5-ecc0-4753-81cc-73433a28ca84", "page": 15, "type": "paragraph", "text": "who are not at higher risk for severe influenza complications"}
{"id": "02de71fe-3f9c-4917-9eab-db8d404dcabf", "page": 15, "type": "paragraph", "text": "(see Populations at Higher Risk for Medical Complications"}
{"id": "3a834e08-0336-485e-953b-18a4ffc695db", "page": 15, "type": "paragraph", "text": "Attributable to Severe Influenza) and who are known to have"}
{"id": "af5e5f02-afb8-4314-a3b7-7f133e57408b", "page": 15, "type": "paragraph", "text": "experienced GBS within 6 weeks of a previous influenza"}
{"id": "c8cc11e8-2ea2-47ac-a419-c1af3efd2847", "page": 15, "type": "paragraph", "text": "vaccination typically should not be vaccinated. As an alternative"}
{"id": "a31abaef-7017-4754-a99f-83446538a455", "page": 15, "type": "paragraph", "text": "to vaccination, providers might consider using influenza"}
{"id": "6563fb92-90cc-43ec-9ec5-540b39a96980", "page": 16, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "e0717bd1-7983-4f38-acfd-a9fe7417e3e1", "page": 16, "type": "paragraph", "text": "14"}
{"id": "9dc98d77-83bf-43c4-aca0-c8c4494ee5fb", "page": 16, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "3e524326-f151-4273-b9be-357dbfb1ec1d", "page": 16, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "bb48e7a7-4235-4006-aad1-5a42e81aa90e", "page": 16, "type": "paragraph", "text": "antiviral chemoprophylaxis for these persons (91). However,"}
{"id": "246a8ca8-7b8c-4d0c-a6be-9e37ecee8041", "page": 16, "type": "paragraph", "text": "the benefits of influenza vaccination might outweigh the"}
{"id": "272f7938-4e08-4159-a2c8-3c0f9cc1d3b2", "page": 16, "type": "paragraph", "text": "possible risks for certain persons who have a history of GBS"}
{"id": "8ce0acaf-8248-4281-9960-ececc56c988d", "page": 16, "type": "paragraph", "text": "within 6 weeks after receipt of influenza vaccine and who also"}
{"id": "6adf7c4f-a211-436c-aa42-0a6bc65fe7dd", "page": 16, "type": "paragraph", "text": "are at higher risk for severe complications from influenza."}
{"id": "8530028d-212f-4587-99bd-3fe56f79b9f3", "page": 16, "type": "paragraph", "text": "Persons with a History of Egg Allergy"}
{"id": "cc4b0ad2-5ece-4dee-8096-2282f24c7307", "page": 16, "type": "paragraph", "text": "Most available influenza vaccines, with the exceptions"}
{"id": "16bde27d-152a-4642-9ce6-1a01b4b8b647", "page": 16, "type": "paragraph", "text": "of RIV4 (Flublok Quadrivalent, licensed for those aged"}
{"id": "4bb617be-94cd-4e3e-aa62-83267de525bb", "page": 16, "type": "paragraph", "text": "\u226518 years) and ccIIV4 (Flucelvax Quadrivalent, licensed for"}
{"id": "a051869e-e313-4730-81ee-4815162b6dbc", "page": 16, "type": "paragraph", "text": "those aged \u22656 months), are prepared by propagation of virus"}
{"id": "905d7a5c-2ddd-4977-96d2-ec4a3a1fe9dd", "page": 16, "type": "paragraph", "text": "in embryonated eggs and might contain trace amounts of egg"}
{"id": "3d8026bf-985e-482e-8138-bc777c82d98b", "page": 16, "type": "paragraph", "text": "proteins, such as ovalbumin. For persons who report a history"}
{"id": "1ba2ef60-4842-401b-a259-2f1ff204510f", "page": 16, "type": "paragraph", "text": "of egg allergy, ACIP recommends the following:"}
{"id": "74fc1594-be97-4ba0-88c3-fb05323a3297", "page": 16, "type": "paragraph", "text": "\u2022 Persons with a history of egg allergy who have experienced only"}
{"id": "47e99e3c-38ab-44a5-8522-77cb672fca92", "page": 16, "type": "paragraph", "text": "urticaria (hives) after exposure to egg should receive influenza"}
{"id": "443fb87c-f9a2-4dbc-9d79-4c7f845e6839", "page": 16, "type": "paragraph", "text": "vaccine. Any licensed, recommended influenza vaccine (i.e.,"}
{"id": "6b83911c-2ea4-4b95-91ab-ce799bbc75db", "page": 16, "type": "paragraph", "text": "any IIV4, RIV4, or LAIV4) that is otherwise appropriate for"}
{"id": "1d653c33-ed43-4414-b2de-f17e9c3ef171", "page": 16, "type": "paragraph", "text": "the recipient\u2019s age and health status can be used."}
{"id": "b00f52f2-5da6-4c27-b121-deb829c80034", "page": 16, "type": "paragraph", "text": "\u2022 Persons who report having had reactions to egg involving"}
{"id": "6d3c0aa6-4008-4baf-9517-82c78c3f6eab", "page": 16, "type": "paragraph", "text": "symptoms other than urticaria (e.g., angioedema or"}
{"id": "4a733122-2a60-4dda-9348-d1a09ae15a27", "page": 16, "type": "paragraph", "text": "swelling, respiratory distress, lightheadedness, or recurrent"}
{"id": "f202bbde-3700-4e15-a27b-6ede42ec7c6b", "page": 16, "type": "paragraph", "text": "vomiting) or who required epinephrine or another"}
{"id": "ed6d2eaa-6af6-434e-ad26-170f1e6af298", "page": 16, "type": "paragraph", "text": "emergency medical intervention can similarly receive any"}
{"id": "301c0f61-9037-467f-aa5d-e6023418fa28", "page": 16, "type": "paragraph", "text": "licensed, recommended influenza vaccine (i.e., any IIV4,"}
{"id": "2a7b6e80-e554-4a73-b6b8-9f46ab8062ac", "page": 16, "type": "paragraph", "text": "RIV4, or LAIV4) that is otherwise appropriate for their"}
{"id": "fd9a4655-22b3-4abe-8e54-2386d17c2aeb", "page": 16, "type": "paragraph", "text": "age and health status. If a vaccine other than ccIIV4 or"}
{"id": "a21d3da1-4d3a-49eb-9488-913b58d7f2a1", "page": 16, "type": "paragraph", "text": "RIV4 is used, the selected vaccine should be administered"}
{"id": "8bf31b69-a789-4e89-940c-279806cd5c18", "page": 16, "type": "paragraph", "text": "in an inpatient or outpatient medical setting, including"}
{"id": "1306421b-9a1f-46ef-83ee-8c04da15b8aa", "page": 16, "type": "paragraph", "text": "but not necessarily limited to hospitals, clinics, health"}
{"id": "5325a8d2-ebf0-401b-9de7-66ba469020d5", "page": 16, "type": "paragraph", "text": "departments, and physician offices. Vaccine administration"}
{"id": "b9174437-c063-42dd-9759-c339dedeeae0", "page": 16, "type": "paragraph", "text": "should be supervised by a health care provider who is able"}
{"id": "7cff4744-6a67-4bf5-9e62-3108a3e8b046", "page": 16, "type": "paragraph", "text": "to recognize and manage severe allergic reactions."}
{"id": "ee5b5bbf-12d8-4707-8156-a6d1f89b280b", "page": 16, "type": "paragraph", "text": "All vaccination providers should be familiar with their"}
{"id": "029ac97c-79fa-4222-8aad-f35aec2cd4e8", "page": 16, "type": "paragraph", "text": "office emergency plan and be certified in cardiopulmonary"}
{"id": "54c1ae3e-3ea5-4bfd-b467-b152a46c5b38", "page": 16, "type": "paragraph", "text": "resuscitation (42). No postvaccination observation period is"}
{"id": "371decc3-eb7d-4ee1-8890-1cb7666c777d", "page": 16, "type": "paragraph", "text": "recommended specifically for egg-allergic persons. However,"}
{"id": "8a3edade-51bf-40b5-aeaf-9d3b87c8815e", "page": 16, "type": "paragraph", "text": "ACIP recommends that vaccination providers consider"}
{"id": "1173713b-eacb-40c1-9bd4-3f7602be9a9a", "page": 16, "type": "paragraph", "text": "observing patients (seated or supine) for 15 minutes after"}
{"id": "9a0ab85a-f51b-4e92-a2da-2bf4bbff16f8", "page": 16, "type": "paragraph", "text": "administration of any vaccine to decrease the risk for injury"}
{"id": "dc7d4599-ac78-4263-b26e-34ca6b4a39e3", "page": 16, "type": "paragraph", "text": "should syncope occur (42)."}
{"id": "231e5d93-64ad-4b16-9822-94f8b29235f0", "page": 16, "type": "paragraph", "text": "Persons with Previous Allergic Reactions to"}
{"id": "e6995c34-cd1c-4804-81a6-24d438c3228f", "page": 16, "type": "paragraph", "text": "Influenza Vaccines"}
{"id": "e2df4df5-a63b-4cb3-87c2-f3a89682ae4a", "page": 16, "type": "paragraph", "text": "As is the case for all vaccines, influenza vaccines contain"}
{"id": "038541a7-d768-4826-bc41-d9fe05898df2", "page": 16, "type": "paragraph", "text": "various components that might cause allergic and anaphylactic"}
{"id": "088a636c-2183-479f-9216-fc9c9c9a3426", "page": 16, "type": "paragraph", "text": "reactions. Most influenza vaccine package inserts list among"}
{"id": "aebe73d3-8bfa-4424-a77a-b880ea857a14", "page": 16, "type": "paragraph", "text": "contraindications to their use a history of previous severe"}
{"id": "11339416-939d-4cfd-a0a5-32da82715d05", "page": 16, "type": "paragraph", "text": "allergic reaction (e.g., anaphylaxis) to any component of the"}
{"id": "740bcb0e-b73c-4720-8cb6-96ec5bdb93b3", "page": 16, "type": "paragraph", "text": "vaccine or to a previous dose of any influenza vaccine. For"}
{"id": "66608e02-f2e8-46e1-85fb-cebbe68d7646", "page": 16, "type": "paragraph", "text": "ccIIV4 and RIV4, a history of a severe allergic reaction to any"}
{"id": "4cf9f0ac-5e82-4332-b4b9-55f9f63b40e9", "page": 16, "type": "paragraph", "text": "vaccine component is listed as a contraindication; no labeled"}
{"id": "b3810743-8a4d-426c-8a65-b9af4b0aa709", "page": 16, "type": "paragraph", "text": "contraindication is specified for a history of allergic reaction to"}
{"id": "1a5927a5-aaad-4859-a21f-46a10d69b296", "page": 16, "type": "paragraph", "text": "any other influenza vaccine. However, severe allergic reactions,"}
{"id": "739f5fe1-7cb2-4f5d-9f9f-bb3f74488f22", "page": 16, "type": "paragraph", "text": "although rare, can occur after influenza vaccination, even"}
{"id": "ad7c1d6a-84eb-4fbc-8ee1-855a2020a8e3", "page": 16, "type": "paragraph", "text": "among persons with no previous reactions or known allergies."}
{"id": "48a79c1c-68f2-479f-8572-ca7cb7c224c9", "page": 16, "type": "paragraph", "text": "Although vaccine components can be found in package inserts,"}
{"id": "283a4c5e-8e75-4991-9032-bcd38689b3c1", "page": 16, "type": "paragraph", "text": "identifying the causative component without further evaluation"}
{"id": "c38b1b0c-a38a-4f1c-81e4-3e766d3cad9b", "page": 16, "type": "paragraph", "text": "(i.e., through evaluation and testing for specific allergies) can"}
{"id": "3efba913-3109-4150-8a3d-4f8901da7bb2", "page": 16, "type": "paragraph", "text": "be difficult. Severe allergic reactions after vaccination with"}
{"id": "68f79ba3-4cd6-4bbc-94d0-bc638f360a23", "page": 16, "type": "paragraph", "text": "an RIV have been reported to VAERS, some of which have"}
{"id": "8a4089f8-0d12-48a2-b263-c3bafd6855a3", "page": 16, "type": "paragraph", "text": "occurred among persons reporting previous allergic reactions"}
{"id": "faf9e9fb-47b0-4ba8-b521-dc882b495b91", "page": 16, "type": "paragraph", "text": "to egg or to influenza vaccines and which might represent a"}
{"id": "4d91eb19-08c9-4162-9ba1-1b922bcfea0f", "page": 16, "type": "paragraph", "text": "predisposition to development of allergic manifestations in"}
{"id": "b73bbae6-cb54-428a-ad81-8e0b7e36592b", "page": 16, "type": "paragraph", "text": "affected persons (92\u201394). Because these rare but severe allergic"}
{"id": "0ccafba6-5ea2-483c-b5e3-8f7428e40b46", "page": 16, "type": "paragraph", "text": "reactions can occur, ACIP recommends the following for"}
{"id": "0e54540d-82fd-4e99-a6c2-21a965a8782c", "page": 16, "type": "paragraph", "text": "persons with a history of severe allergic reaction to a previous"}
{"id": "835eafa6-f352-4f12-a1f6-3d2b4033764c", "page": 16, "type": "paragraph", "text": "dose of an influenza vaccine (Table 3):"}
{"id": "e3582c58-0409-4064-9640-fca9d1931503", "page": 16, "type": "paragraph", "text": "\u2022 For egg-based IIV4s and LAIV4:"}
{"id": "26b57549-7acd-461e-b62b-9870f328122d", "page": 16, "type": "paragraph", "text": "\u0171 A history of severe allergic reaction (e.g., anaphylaxis)"}
{"id": "2df7ea65-7352-41bd-a5df-b3805d649167", "page": 16, "type": "paragraph", "text": "to any influenza vaccine (i.e., any egg-based IIV, ccIIV,"}
{"id": "eba07ca2-2ced-44e2-aa4a-28a2823d9567", "page": 16, "type": "paragraph", "text": "RIV, or LAIV of any valency) is a contraindication to"}
{"id": "5f19220f-9d27-408c-b6ab-62a326344d10", "page": 16, "type": "paragraph", "text": "future receipt of all egg-based IIV4s and LAIV4. Each"}
{"id": "cee941d9-0cf4-44b8-8b6d-2ee90f20d671", "page": 16, "type": "paragraph", "text": "individual egg-based IIV4 and LAIV4 is also"}
{"id": "83280de4-878f-4aaf-960c-6ad8c313eead", "page": 16, "type": "paragraph", "text": "contraindicated for persons who have had a severe"}
{"id": "d74be5c0-0c4a-4031-92da-161fca692752", "page": 16, "type": "paragraph", "text": "allergic reaction (e.g., anaphylaxis) to any component"}
{"id": "9e7ee94b-10ac-47a9-a8f5-9725cc229fe8", "page": 16, "type": "paragraph", "text": "of that vaccine (excluding egg) (see Persons with a"}
{"id": "0d919d7a-b0ed-432a-9e32-1bf61f086479", "page": 16, "type": "paragraph", "text": "History of Egg Allergy)."}
{"id": "4e9f0dce-715f-4a7b-8c8b-a177b865afa6", "page": 16, "type": "paragraph", "text": "\u2022 For ccIIV4:"}
{"id": "9ca707ca-a312-48e0-971e-015892de478a", "page": 16, "type": "paragraph", "text": "\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)"}
{"id": "5bee5dd2-8394-4d7c-b886-6a2440598ec2", "page": 16, "type": "paragraph", "text": "to any egg-based IIV, RIV, or LAIV of any valency is a"}
{"id": "8c1238e2-55cf-47b2-acde-fbf1175d0983", "page": 16, "type": "paragraph", "text": "precaution for the use of ccIIV4. If ccIIV4 is administered"}
{"id": "9a7813dd-9b6b-4d16-8fa8-ecfd08126a0e", "page": 16, "type": "paragraph", "text": "in such instances, vaccination should occur in an"}
{"id": "b295818b-cffb-4c78-a5b6-3bd3f415a73a", "page": 16, "type": "paragraph", "text": "inpatient or outpatient medical setting and should be"}
{"id": "8466f5b4-ee48-48d1-8d29-d72e4e2ecb54", "page": 16, "type": "paragraph", "text": "supervised by a health care provider who is able to"}
{"id": "0a43a0a1-66ea-4522-919b-f08bebeff3b2", "page": 16, "type": "paragraph", "text": "recognize and manage severe allergic reactions. Providers"}
{"id": "5a007b47-6d5b-41ab-8503-17c907ceae5e", "page": 16, "type": "paragraph", "text": "also can consider consultation with an allergist to help"}
{"id": "c38bfdd3-4dbd-4f6c-a061-3f56de83b30d", "page": 16, "type": "paragraph", "text": "determine the vaccine component responsible for the"}
{"id": "1847cbc7-7f8d-417a-8692-921dcf6013a8", "page": 16, "type": "paragraph", "text": "allergic reaction."}
{"id": "b9ddbb16-9f06-4b7e-9937-530895badf83", "page": 16, "type": "paragraph", "text": "\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)"}
{"id": "6fab9cdf-5098-4549-a96c-c2ef94f425fc", "page": 16, "type": "paragraph", "text": "to any ccIIV of any valency or to any component of"}
{"id": "0b816fff-d220-4cce-8087-1ea1a77c6d44", "page": 16, "type": "paragraph", "text": "ccIIV4 is a contraindication to future receipt of ccIIV4."}
{"id": "db65a9c7-098f-4278-8bb7-3ee4309935aa", "page": 16, "type": "paragraph", "text": "\u2022 For RIV4:"}
{"id": "8e65e1d0-567e-4c44-a05f-94c94ba195a1", "page": 16, "type": "paragraph", "text": "\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)"}
{"id": "758e7fa7-8b3e-44d7-b695-0529a854237c", "page": 16, "type": "paragraph", "text": "to any egg-based IIV, ccIIV, or LAIV of any valency is"}
{"id": "9f419e5c-278f-428a-89d5-b127e6a4c138", "page": 16, "type": "paragraph", "text": "a precaution for the use of RIV4. If RIV4 is administered"}
{"id": "21a04ab8-9c35-4559-a530-3d36dd05e1f5", "page": 16, "type": "paragraph", "text": "in such instances, vaccination should occur in an"}
{"id": "5df7e89e-efba-4235-aeb5-a237463e2af2", "page": 16, "type": "paragraph", "text": "inpatient or outpatient medical setting and should be"}
{"id": "b8947dc5-3a57-47d5-82f3-8c737d87b72c", "page": 16, "type": "paragraph", "text": "supervised by a health care provider who is able to"}
{"id": "3d216233-5137-4b8c-add6-c50ea11b10bb", "page": 16, "type": "paragraph", "text": "recognize and manage severe allergic reactions. Providers"}
{"id": "ebbd5a23-f82a-4fc5-b15a-85bbeb3f9a8a", "page": 17, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "4c860701-b59d-407e-9c0d-4cfe4cda2992", "page": 17, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "d8c2c5ab-4395-492d-bc0c-08b03fc3b5e7", "page": 17, "type": "paragraph", "text": "15"}
{"id": "c78cb866-3257-46e5-bfc2-7e4950a6f353", "page": 17, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "9a0a2463-3635-44ce-bcdf-bb8d57226f50", "page": 17, "type": "paragraph", "text": "can also consider consultation with an allergist to help"}
{"id": "77bc5cc3-51b0-47d8-a0df-fad64b50a159", "page": 17, "type": "paragraph", "text": "determine the vaccine component responsible for the"}
{"id": "c20e08af-9f3c-4098-8b3f-9a2069c61c88", "page": 17, "type": "paragraph", "text": "allergic reaction."}
{"id": "ae01eca6-2594-4eee-a2bc-cb9acb30e373", "page": 17, "type": "paragraph", "text": "\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)"}
{"id": "8b37a1ac-3b12-4c53-ae13-e7e8de40beac", "page": 17, "type": "paragraph", "text": "to any RIV of any valency or to any component of RIV4"}
{"id": "33989680-9020-4951-966a-bb2acbd7e403", "page": 17, "type": "paragraph", "text": "is a contraindication to future receipt of RIV4."}
{"id": "a686eb84-fe27-4f3d-96a1-a0dccd1da64b", "page": 17, "type": "paragraph", "text": "Vaccination Issues for Travelers"}
{"id": "228fc534-7ce8-4ce7-b548-be697cc88ff8", "page": 17, "type": "paragraph", "text": "In temperate climate regions of the Northern and Southern"}
{"id": "01d07c92-5cb1-4eee-add2-d29fa76a62cd", "page": 17, "type": "paragraph", "text": "Hemispheres, influenza activity is seasonal, occurring during"}
{"id": "83fd1db7-cbe7-4c65-843e-e2aacd44869b", "page": 17, "type": "paragraph", "text": "approximately October\u2013May in the Northern Hemisphere and"}
{"id": "84f06e26-7a6c-41e1-a445-d67b12a309db", "page": 17, "type": "paragraph", "text": "April\u2013September in the Southern Hemisphere. In the tropics,"}
{"id": "3bc5f06b-adc9-45c6-aca0-432ebeeafdb6", "page": 17, "type": "paragraph", "text": "influenza might occur throughout the year. Travelers can be"}
{"id": "37fe6239-6e46-460e-9f5b-8ec28d5df1d5", "page": 17, "type": "paragraph", "text": "exposed to influenza when traveling to an area where influenza"}
{"id": "0f2dee6f-8931-48e7-ba2a-4e3780ff8070", "page": 17, "type": "paragraph", "text": "is circulating or when traveling as part of large tourist groups"}
{"id": "503c0384-5445-4e23-a8c2-68ef98a01820", "page": 17, "type": "paragraph", "text": "(e.g., on cruise ships) that include persons from areas of the"}
{"id": "9f9a1cff-6d33-4d79-9498-00e0d46542d5", "page": 17, "type": "paragraph", "text": "world where influenza viruses are circulating (95\u201398)."}
{"id": "686c437b-4083-47fa-8970-151fe9c60d6c", "page": 17, "type": "paragraph", "text": "Travelers who want to reduce their risk for influenza should"}
{"id": "008f788d-fe6f-4160-9ced-959294f876c0", "page": 17, "type": "paragraph", "text": "consider influenza vaccination, preferably at least 2 weeks"}
{"id": "057b7cdd-1eba-4f3d-9903-85c34a6d9080", "page": 17, "type": "paragraph", "text": "before departure. In particular, persons who live in the United"}
{"id": "c2edcabb-8847-476b-866d-ccc3c8570f21", "page": 17, "type": "paragraph", "text": "States and are at higher risk for influenza complications and"}
{"id": "3d34eb50-88db-40ab-a7a9-f8f50f126c36", "page": 17, "type": "paragraph", "text": "who were not vaccinated with influenza vaccine during the"}
{"id": "ddeb4eba-59b0-418f-a74b-c5bd4107f587", "page": 17, "type": "paragraph", "text": "previous Northern Hemisphere fall or winter should consider"}
{"id": "e1c9693b-8179-4742-885b-9f72c60a1ecb", "page": 17, "type": "paragraph", "text": "receiving influenza vaccination before departure if they plan"}
{"id": "d29aae0c-2f48-4882-946f-04ae67bdfb96", "page": 17, "type": "paragraph", "text": "to travel to the tropics, to the Southern Hemisphere during"}
{"id": "d603f70e-3abf-4858-9d53-c88128fc13d9", "page": 17, "type": "paragraph", "text": "the Southern Hemisphere influenza season (April\u2013September),"}
{"id": "30ddd764-3dc6-4efa-ab57-b5bd72cd570f", "page": 17, "type": "paragraph", "text": "or with organized tourist groups or on cruise ships to any"}
{"id": "96a20b1f-06f7-4816-88e5-d4ad7196a014", "page": 17, "type": "paragraph", "text": "location. Persons at higher risk who received the previous"}
{"id": "9c315bb3-6113-4c5c-8f93-1e52f1da2796", "page": 17, "type": "paragraph", "text": "season\u2019s influenza vaccine before travel should consult with"}
{"id": "26a3c488-6a86-4bf5-98e8-e92540936e0a", "page": 17, "type": "paragraph", "text": "their health care provider to discuss the risk for influenza"}
{"id": "56a7d8e5-f5ce-4976-88aa-237d07f2e671", "page": 17, "type": "paragraph", "text": "and other travel-related diseases before embarking on travel"}
{"id": "2e870b81-fb2d-48c4-bba3-84d749fc45b1", "page": 17, "type": "paragraph", "text": "during the summer. All persons (regardless of risk status) who"}
{"id": "0dae7516-ef5c-4667-afab-6f2a471a076e", "page": 17, "type": "paragraph", "text": "are vaccinated in preparation for travel before the upcoming"}
{"id": "d3e8a675-e21d-4dd8-9ee1-cfdc680242f5", "page": 17, "type": "paragraph", "text": "influenza season\u2019s vaccine is available should receive the current"}
{"id": "f386a065-01fd-4a0c-bbdd-2769a1da8e1f", "page": 17, "type": "paragraph", "text": "vaccine the following fall or winter."}
{"id": "2ba65ad5-0d20-4da0-bbc0-a31e487cf183", "page": 17, "type": "paragraph", "text": "Influenza vaccine formulated for the Southern Hemisphere"}
{"id": "c5f360d5-8ecc-46c0-b3b6-a51f133f4af1", "page": 17, "type": "paragraph", "text": "might differ in viral composition from the Northern"}
{"id": "9c4dd462-d792-4147-90d9-d608b8385dce", "page": 17, "type": "paragraph", "text": "Hemisphere vaccine. For persons traveling to the Southern"}
{"id": "46e58a37-a104-40f4-b872-1e81c5790199", "page": 17, "type": "paragraph", "text": "Hemisphere during the Southern Hemisphere influenza"}
{"id": "3c7d2240-dbcb-44db-83ff-04709ad036a9", "page": 17, "type": "paragraph", "text": "season, receipt of a current U.S.-licensed Southern Hemisphere"}
{"id": "520e705c-6289-4fb3-b366-716f07a1f6d5", "page": 17, "type": "paragraph", "text": "influenza vaccine formulation before departure might be"}
{"id": "0f308bab-4ad0-4555-860b-56eacaf942e1", "page": 17, "type": "paragraph", "text": "reasonable but might not be feasible because of limited access to"}
{"id": "98139a50-537a-4ec2-8443-88e3994a73a5", "page": 17, "type": "paragraph", "text": "or unavailability of Southern Hemisphere formulations in the"}
{"id": "abbc54c2-496c-47dc-95fa-88ccd1d2f6a9", "page": 17, "type": "paragraph", "text": "United States. Most Southern Hemisphere influenza vaccine"}
{"id": "fe795229-22d7-4aef-b126-5e39cfe8fb8f", "page": 17, "type": "paragraph", "text": "formulations are not licensed in the United States, and they"}
{"id": "815245c4-5cdf-4c35-a9d2-43b05cd1d7e0", "page": 17, "type": "paragraph", "text": "are typically not commercially available. More information on"}
{"id": "bb7c3d05-9c87-44ce-9e48-830d17bf13b1", "page": 17, "type": "paragraph", "text": "influenza vaccines and travel is available at https://wwwnc.cdc."}
{"id": "eb9c98e8-096b-483e-98a2-46f835719370", "page": 17, "type": "paragraph", "text": "gov/travel/diseases/influenza-seasonal-zoonotic-and-pandemic."}
{"id": "4cb4ae61-7eed-4aae-8aee-3b8dfdc8a8f8", "page": 17, "type": "paragraph", "text": "Use of Influenza Antiviral Medications"}
{"id": "6679ef77-fd9c-41bf-a588-22cb242dfb8a", "page": 17, "type": "paragraph", "text": "Administration of IIV4 or RIV4 to persons receiving influenza"}
{"id": "cc1ee528-03e1-43b7-84f7-620144b191fd", "page": 17, "type": "paragraph", "text": "antiviral medications for treatment or chemoprophylaxis of"}
{"id": "6c5040ee-00a9-428a-8b3f-6004cc5a8b71", "page": 17, "type": "paragraph", "text": "influenza is acceptable. Data concerning vaccination with LAIV4"}
{"id": "af5c4ed5-8c7e-4d32-9930-b14e3d294dfa", "page": 17, "type": "paragraph", "text": "in the setting of influenza antiviral use are not available. However,"}
{"id": "3c57757c-8855-4433-86c1-d49a254470a8", "page": 17, "type": "paragraph", "text": "influenza antiviral medications might interfere with the action"}
{"id": "8ba4c857-4ea5-414c-861c-5cced3016bba", "page": 17, "type": "paragraph", "text": "of LAIV4 because this vaccine contains live influenza viruses."}
{"id": "09bda6e9-c8aa-45dc-83b4-53b7d269a7ef", "page": 17, "type": "paragraph", "text": "The package insert for LAIV4 notes that antiviral agents"}
{"id": "6eac2625-8358-48e7-a934-5e938f400719", "page": 17, "type": "paragraph", "text": "might reduce the effectiveness of the vaccine if given within"}
{"id": "fa0f66b3-7592-4a97-ac78-8e6d7fcb0ab1", "page": 17, "type": "paragraph", "text": "the interval from 48 hours before to 14 days after vaccination"}
{"id": "c10a512e-2321-4330-90e2-31e3fdc29f4c", "page": 17, "type": "paragraph", "text": "(99). However, the newer influenza antivirals peramivir and"}
{"id": "9132f1cb-0e6c-4ab6-aed2-94f8e69b6081", "page": 17, "type": "paragraph", "text": "baloxavir have longer half-lives than oseltamivir and zanamivir,"}
{"id": "a3614e15-2262-4404-9a93-e646d85f350c", "page": 17, "type": "paragraph", "text": "approximately 20 hours for peramivir (100) and 79 hours for"}
{"id": "290fc8ff-f5e9-423c-9706-910cdfc1eca8", "page": 17, "type": "paragraph", "text": "baloxavir (101), and could interfere with the replication of"}
{"id": "ed1036eb-32a7-4d90-8719-c70d73557a38", "page": 17, "type": "paragraph", "text": "LAIV4 if administered >48 hours before vaccination. Potential"}
{"id": "961e92c5-d7ce-437a-97e3-3264a1e60d43", "page": 17, "type": "paragraph", "text": "interactions between influenza antivirals and LAIV4 have not"}
{"id": "fa35dd0f-4834-42d2-b9b0-34955c568334", "page": 17, "type": "paragraph", "text": "been studied, and the ideal intervals between administration of"}
{"id": "0e34c064-0dbf-43db-b177-e28bc76da9a0", "page": 17, "type": "paragraph", "text": "these medications and LAIV4 are not known. Assuming a period"}
{"id": "3751e5cd-0195-41ae-bc01-843685760c41", "page": 17, "type": "paragraph", "text": "of at least 5 half-lives for substantial decrease in drug levels (102),"}
{"id": "72cc2e94-a76a-4c73-955b-1ccdbc769a76", "page": 17, "type": "paragraph", "text": "a reasonable assumption is that that peramivir might interfere"}
{"id": "c734be6e-fda1-4c71-993a-d3e66a5a1b9d", "page": 17, "type": "paragraph", "text": "with the mechanism of LAIV4 if administered from 5 days"}
{"id": "51453b23-2d88-4e40-9f4d-7701530a9e07", "page": 17, "type": "paragraph", "text": "before through 2 weeks after vaccination and baloxavir might"}
{"id": "7f65a190-e8f2-4a13-bf60-7fbd550f4904", "page": 17, "type": "paragraph", "text": "interfere if administered from 17 days before through 2 weeks"}
{"id": "d2ba6ec7-3b12-4cc1-b081-49680f6bb95e", "page": 17, "type": "paragraph", "text": "after vaccination. The interval between influenza antiviral receipt"}
{"id": "94121820-c0f8-440b-ab72-36819c05bb63", "page": 17, "type": "paragraph", "text": "and LAIV4 during which interference might occur could be"}
{"id": "41bc9994-69d1-4c0e-8682-7c15291698a8", "page": 17, "type": "paragraph", "text": "further prolonged in the presence of medical conditions that"}
{"id": "f2af74ab-2987-4fac-8342-62b49c06e37c", "page": 17, "type": "paragraph", "text": "delay medication clearance (e.g., renal insufficiency). Persons"}
{"id": "dabeeb60-02ea-49cf-9cd7-8eba24abb727", "page": 17, "type": "paragraph", "text": "who receive these medications during these periods before or"}
{"id": "5f647364-1963-4d1e-bbad-8355d9ab47da", "page": 17, "type": "paragraph", "text": "after receipt of LAIV4 should be revaccinated with another"}
{"id": "5d2886e3-f98b-4984-87f6-5e56a6388582", "page": 17, "type": "paragraph", "text": "appropriate influenza vaccine (e.g., IIV4 or RIV4)."}
{"id": "65f2bebc-7deb-4808-9384-26f149c75a65", "page": 17, "type": "paragraph", "text": "Administration of Influenza Vaccines with"}
{"id": "80fe4db0-f9d8-4bfc-a99e-8b69c4cd0c82", "page": 17, "type": "paragraph", "text": "Other Vaccines"}
{"id": "00df992a-8ad8-414d-a1e8-c8dba0235329", "page": 17, "type": "paragraph", "text": "IIV4s and RIV4 may be administered simultaneously or"}
{"id": "2d8d2f08-c3a5-4f59-b1fc-7d52e093f75e", "page": 17, "type": "paragraph", "text": "sequentially with other inactivated vaccines or live vaccines."}
{"id": "b427c832-1dcb-41d5-91ed-187a57e57890", "page": 17, "type": "paragraph", "text": "Injectable vaccines that are given concomitantly should"}
{"id": "b26fe94c-ae7d-44a3-a9af-61d606cdd3a2", "page": 17, "type": "paragraph", "text": "be administered at separate anatomic sites. LAIV4 can be"}
{"id": "a0edb626-c9d5-418f-9542-59d601fceddb", "page": 17, "type": "paragraph", "text": "administered simultaneously with other live or inactivated"}
{"id": "56e22b1c-4549-493a-9658-3642e4932e46", "page": 17, "type": "paragraph", "text": "vaccines. However, if two live vaccines are not given"}
{"id": "58165b6e-1c99-4a13-9943-aa3773ea8140", "page": 17, "type": "paragraph", "text": "simultaneously, at least 4 weeks should pass after administration"}
{"id": "bf1bb115-a640-47c9-b59f-715991dee23c", "page": 17, "type": "paragraph", "text": "of one live vaccine (such as LAIV4) before another live vaccine"}
{"id": "84a9ad57-dbe4-43c4-a6c7-03f1313b8f70", "page": 17, "type": "paragraph", "text": "is administered (42)."}
{"id": "477fee9d-56dd-4afd-912d-2859b3381c30", "page": 17, "type": "paragraph", "text": "Current guidance concerning administration of current U.S.-"}
{"id": "e77929f4-2093-4385-a181-e5d26a63056e", "page": 17, "type": "paragraph", "text": "approved or -authorized COVID-19 vaccines indicates that"}
{"id": "922d5450-62a3-46fb-8bd4-2ef22c6bbf36", "page": 17, "type": "paragraph", "text": "these vaccines may be given with influenza vaccines (https://"}
{"id": "99daf7bb-1b9a-4b39-a08e-2538581140d5", "page": 17, "type": "paragraph", "text": "www.cdc.gov/vaccines/covid-19/clinical-considerations/"}
{"id": "ee540ff2-24d9-4d06-bf4c-49ff79a23060", "page": 17, "type": "paragraph", "text": "interim-considerations-us.html). Providers should be aware of"}
{"id": "ffff0bbd-387f-4b75-b6a6-481b5539e5df", "page": 17, "type": "paragraph", "text": "the potential for increased reactogenicity with coadministration"}
{"id": "55ea2497-34b8-4164-ac07-405d15ec39e2", "page": 17, "type": "paragraph", "text": "and should consult updated CDC guidance as more"}
{"id": "616d2b6a-34ee-456f-9c75-a7334799ebfa", "page": 18, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "d9b134ba-e0e5-465f-8324-e04869917f6d", "page": 18, "type": "paragraph", "text": "16"}
{"id": "be4b75f7-a4e6-4ff2-8f0c-e3d41181a110", "page": 18, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "e0ca065a-d121-4f63-94e8-6bfc11cacecf", "page": 18, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "74aa13e2-f5dd-443c-8e70-a93b733c02c1", "page": 18, "type": "paragraph", "text": "information becomes available. If administered simultaneously,"}
{"id": "10e3e1e4-939d-470b-817d-bd82986a2fe0", "page": 18, "type": "paragraph", "text": "COVID-19 vaccines and influenza vaccines that might be"}
{"id": "79832c25-e4fd-45a8-a490-dc5b2873ba8d", "page": 18, "type": "paragraph", "text": "more likely to cause an injection site reaction (e.g., aIIV4"}
{"id": "c3e63bcf-20c7-412c-a1dc-979eb756c9e8", "page": 18, "type": "paragraph", "text": "or HD-IIV4) should be administered in different limbs, if"}
{"id": "216b6889-04e1-4686-8d15-cac39ec4602b", "page": 18, "type": "paragraph", "text": "possible. In an interim analysis of a study of concomitant"}
{"id": "b666a770-ce97-4978-b453-22b73d5c174b", "page": 18, "type": "paragraph", "text": "administration of HD-IIV4 and a booster dose of an mRNA"}
{"id": "0abf3ddf-beb2-4751-b0f4-e92bf4cdd6de", "page": 18, "type": "paragraph", "text": "COVID-19 vaccine (administered in separate upper arm sites)"}
{"id": "6143e944-0af7-4379-b052-db66f072a67f", "page": 18, "type": "paragraph", "text": "compared with administration of either vaccine alone among"}
{"id": "4ff3325f-0402-4d72-a8a6-843577a107ce", "page": 18, "type": "paragraph", "text": "296 persons aged \u226565 years, overall reactogenicity up to 7 days"}
{"id": "4dc31c81-df5a-4479-b6c1-dfa8f6ae9541", "page": 18, "type": "paragraph", "text": "postvaccination was similar between the coadministration"}
{"id": "009fbbf8-4322-477a-9502-013f9d9decc2", "page": 18, "type": "paragraph", "text": "group and the group that received the mRNA COVID-19"}
{"id": "2010f455-2b59-4d66-a660-e0f05ac889bb", "page": 18, "type": "paragraph", "text": "vaccine alone; reactogenicity rates in the group receiving"}
{"id": "17367589-a283-4ea1-bbd7-95bcdc880ad3", "page": 18, "type": "paragraph", "text": "HD-IIV4 alone were lower. No SAEs were observed. Immune"}
{"id": "be9df527-e543-41bd-9016-5ae001c2c9d6", "page": 18, "type": "paragraph", "text": "response was similar between the mRNA COVID-19 and"}
{"id": "283437f0-1406-43af-b8c9-633b2d032ed2", "page": 18, "type": "paragraph", "text": "coadministration groups (103)."}
{"id": "bd6d38e3-cafe-4495-acac-34586f87aaa8", "page": 18, "type": "paragraph", "text": "Relatively limited data are available on the concomitant"}
{"id": "002e1396-24b6-4209-9075-ccefe6ae7b1c", "page": 18, "type": "paragraph", "text": "administration of influenza vaccines with other vaccines."}
{"id": "3ee35faf-94d4-4314-a394-6f6074b438bd", "page": 18, "type": "paragraph", "text": "Studies of live attenuated zoster vaccine and IIV3 (104) or"}
{"id": "cefb2c7b-dc22-4944-9228-328d6de016b8", "page": 18, "type": "paragraph", "text": "IIV4 (105) among persons aged \u226550 years noted similar"}
{"id": "5d6ee1cd-c65a-4275-a0ae-50e17dfe361c", "page": 18, "type": "paragraph", "text": "antibody responses whether the two vaccines were administered"}
{"id": "93686ea7-0b30-47ea-a92b-10dee59fa4af", "page": 18, "type": "paragraph", "text": "concomitantly or 4 weeks apart. In certain studies, reduced"}
{"id": "a51883a0-9ea0-4010-bd71-e0abe0611a27", "page": 18, "type": "paragraph", "text": "responses have been noted to 13-valent pneumococcal"}
{"id": "c37abd57-b86a-4b0a-8243-59528348cb1e", "page": 18, "type": "paragraph", "text": "conjugate vaccine (PCV13) (106,107), tetanus antigens (108),"}
{"id": "adf4f7e6-467e-4344-b35a-b0d4a21f163d", "page": 18, "type": "paragraph", "text": "and pertussis antigens (108) when coadministered with IIV3"}
{"id": "ebdd22ce-6dca-4a27-95b9-c2212ed6d52e", "page": 18, "type": "paragraph", "text": "to adults; in most instances, the clinical significance of this is"}
{"id": "f3ce5cb9-5255-428d-ac5b-4b2fc5448b12", "page": 18, "type": "paragraph", "text": "uncertain. Simultaneous administration of IIV4 and 23-valent"}
{"id": "08f77ab2-4a48-4399-a454-0be07a0cb79f", "page": 18, "type": "paragraph", "text": "pneumococcal polysaccharide vaccine (PPSV23) to persons"}
{"id": "8f16f83b-cf59-4242-ac6b-f9bbef693c4b", "page": 18, "type": "paragraph", "text": "aged \u226565 years was associated with lower seroprotection rates"}
{"id": "aefebbce-b521-4280-9ebb-ad827203d629", "page": 18, "type": "paragraph", "text": "to one influenza B antigen at 4\u20136 weeks postvaccination"}
{"id": "1975f531-f156-4a13-b64f-ba17b12c6c06", "page": 18, "type": "paragraph", "text": "compared with sequential administration 2 weeks apart."}
{"id": "391ed741-44ef-4a60-a985-2eee7064e392", "page": 18, "type": "paragraph", "text": "Seroprotection was not significantly different between the"}
{"id": "1d835670-592e-469d-8174-2de0a4525254", "page": 18, "type": "paragraph", "text": "two groups for any of the four influenza antigens at 6 months"}
{"id": "06475ba1-c18f-43b9-8553-2b2318468b3a", "page": 18, "type": "paragraph", "text": "postvaccination (109). Reassuring safety profiles have been"}
{"id": "e9ce3a72-b375-44ec-8a9a-d0a3ce171ff9", "page": 18, "type": "paragraph", "text": "noted for simultaneous administration of IIVs with live"}
{"id": "49e45d7e-d2ef-4126-8cb5-0f551a7f4653", "page": 18, "type": "paragraph", "text": "attenuated zoster vaccine (104,105); PCV13 (106,107);"}
{"id": "3c93cc62-fb9f-44f4-a3cb-5ef489eb2ccd", "page": 18, "type": "paragraph", "text": "PPSV23 (109,110); tetanus toxoid, reduced diphtheria toxoid,"}
{"id": "8d7c6c7c-12af-4cd6-8094-6bec504a98f0", "page": 18, "type": "paragraph", "text": "and acellular pertussis (Tdap) vaccine among adults (108); and"}
{"id": "c8ecbae7-5051-49ba-ad26-6cbca288eb49", "page": 18, "type": "paragraph", "text": "Tdap in pregnancy (111). Although increased prevalence of"}
{"id": "09b96bed-fad4-4d7d-86bf-2d02ffdf2cb8", "page": 18, "type": "paragraph", "text": "injection site or systemic adverse reactions has been noted with"}
{"id": "9838f1a8-4216-461d-99ed-eb877f6d359e", "page": 18, "type": "paragraph", "text": "concurrent administration in certain studies, these symptoms"}
{"id": "acf34668-f143-4296-84d3-f09d1f11a0be", "page": 18, "type": "paragraph", "text": "have usually been reported to be mild or moderate."}
{"id": "a13c1469-71ef-4c9c-9a77-4774b465ccef", "page": 18, "type": "paragraph", "text": "Among children aged 6 through 23 months, coadministration"}
{"id": "9ec01101-43d1-4019-a994-1586539c0229", "page": 18, "type": "paragraph", "text": "of IIV3 and PCV13 was associated with increased risk"}
{"id": "e7105808-2311-456c-9c18-bf5c5899ae6b", "page": 18, "type": "paragraph", "text": "for fever on the day of vaccination and the day after (i.e.,"}
{"id": "8cf2986a-75b1-464e-a69e-8e38bf398de9", "page": 18, "type": "paragraph", "text": "days 0\u20131 postvaccination) in an observational study conducted"}
{"id": "940299af-1569-4a83-9feb-8ec0add7be22", "page": 18, "type": "paragraph", "text": "during the 2011\u201312 season (112). A randomized clinical"}
{"id": "ffe33578-258d-4bf7-bcc8-db7dd92cfb20", "page": 18, "type": "paragraph", "text": "trial during the 2017\u201318 influenza season suggested that"}
{"id": "0721231a-9d33-4e2c-bc35-21b89adfdc03", "page": 18, "type": "paragraph", "text": "delaying IIV4 administration by 2 weeks in children receiving"}
{"id": "f6670b5a-8990-4a63-b5b1-d32bbe6b54fe", "page": 18, "type": "paragraph", "text": "diphtheria and tetanus toxoids and acellular pertussis (DTaP)"}
{"id": "5a29b146-43f8-4be4-be7d-24fa515c0335", "page": 18, "type": "paragraph", "text": "and PCV13 did not reduce fever prevalence after vaccination"}
{"id": "2569bc2c-6c01-4d0f-a650-b0755f53c588", "page": 18, "type": "paragraph", "text": "(113). Increased risk for febrile seizures in this age group has"}
{"id": "2c80322f-cb19-4657-aa05-af325b7b45eb", "page": 18, "type": "paragraph", "text": "been noted within days 0\u20131 after coadministration of IIV"}
{"id": "3181f75b-eb2f-4884-936a-f456ba136fa0", "page": 18, "type": "paragraph", "text": "with PCV7, PCV13, or DTaP vaccines during the 2006\u201307"}
{"id": "6584248b-f927-4eb3-95b0-06a2d712779a", "page": 18, "type": "paragraph", "text": "through 2010\u201311 seasons (114) and with PCV13 during the"}
{"id": "81e18a9c-1428-4c32-85dc-d18bd6b52ae3", "page": 18, "type": "paragraph", "text": "2014\u201315 season (115). Although concerning to parents, most"}
{"id": "f2dd8ec4-f389-41c7-90cb-636f7464e0bd", "page": 18, "type": "paragraph", "text": "febrile seizures are brief and have a good prognosis (116)."}
{"id": "3fb78b27-6ab9-41d1-a1bb-3b054bfdfaaf", "page": 18, "type": "paragraph", "text": "After considering the risks and benefits, no changes in the"}
{"id": "71a09c4b-a379-4210-b24d-e107945e44e9", "page": 18, "type": "paragraph", "text": "recommendations for administration of these vaccines were"}
{"id": "2be93068-d13a-450a-92cd-f4a6686f5521", "page": 18, "type": "paragraph", "text": "made. Surveillance of febrile seizures is ongoing through"}
{"id": "19e8e79a-5c07-4b17-a9ea-90ccb3ead9ba", "page": 18, "type": "paragraph", "text": "VAERS, and the VSD annual influenza safety surveillance"}
{"id": "dc740063-808c-420a-a647-a7be84d5dc6d", "page": 18, "type": "paragraph", "text": "includes monitoring for seizures after vaccinations. Studies of"}
{"id": "efe60a99-cc49-459e-bea0-d7516082b0b8", "page": 18, "type": "paragraph", "text": "concomitant administration of LAIV with other vaccines are"}
{"id": "06f52d49-a82a-4edd-966e-f2682380883c", "page": 18, "type": "paragraph", "text": "limited. Concurrent administration of LAIV3 with measles,"}
{"id": "93156e43-9c72-48f8-8e08-98aa2c71bd95", "page": 18, "type": "paragraph", "text": "mumps, and rubella (MMR) and varicella vaccine to children"}
{"id": "57f2b3c3-6c0b-4d42-a127-9e966376b77b", "page": 18, "type": "paragraph", "text": "was not associated with diminished immunogenicity of"}
{"id": "a4b07aed-7202-4cc4-85d5-dee39def7df4", "page": 18, "type": "paragraph", "text": "antigens in any of the vaccines in one study (117); diminished"}
{"id": "775951dc-c41c-42c3-b3c0-df3d815ef273", "page": 18, "type": "paragraph", "text": "response to rubella was observed in another study examining"}
{"id": "e3684aad-faa8-41e5-905e-37bed7de56af", "page": 18, "type": "paragraph", "text": "coadministration of LAIV3 and MMR (118). No safety"}
{"id": "5e271ff2-106a-4419-bf87-832fd4aebaff", "page": 18, "type": "paragraph", "text": "concerns were noted in these studies."}
{"id": "d518cc38-32f7-42a4-a2c0-f480fc98b9bc", "page": 18, "type": "paragraph", "text": "In recent years, several vaccines containing nonaluminum"}
{"id": "4d2b8d97-8385-4a95-b57f-26d9d30922b7", "page": 18, "type": "paragraph", "text": "adjuvants have been licensed for use in the United States for"}
{"id": "ac849bfe-4f46-4a09-964d-b8093f66199b", "page": 18, "type": "paragraph", "text": "the prevention of various infectious diseases. These include"}
{"id": "018ce105-3e97-4ca1-b5ce-f936e2bbd443", "page": 18, "type": "paragraph", "text": "AS01B (in Shingrix, recombinant zoster subunit vaccine) (119),"}
{"id": "1277116c-69a4-4671-b978-0c5243bf1a03", "page": 18, "type": "paragraph", "text": "MF59 (in Fluad Quadrivalent [aIIV4]) (120), and cytosine"}
{"id": "9501e309-b45f-4f11-932c-8f4ee0418d71", "page": 18, "type": "paragraph", "text": "phosphoguanine oligodeoxynucleotide (in Heplisav-B, a"}
{"id": "8952d011-8464-4ce1-93ad-cf5d3c182d8d", "page": 18, "type": "paragraph", "text": "recombinant hepatitis B surface antigen vaccine) (121). Data are"}
{"id": "0edaefde-2405-4d49-a422-00dee82cd00b", "page": 18, "type": "paragraph", "text": "limited regarding coadministration of these vaccines with other"}
{"id": "8dd7223d-8e62-4673-9d42-3014f52b2a66", "page": 18, "type": "paragraph", "text": "adjuvanted or nonadjuvanted vaccines, including COVID-19"}
{"id": "1f0be9cd-4fd1-405b-a24c-8ed60e066b90", "page": 18, "type": "paragraph", "text": "vaccines. Coadministration of Shingrix with nonadjuvanted IIV4"}
{"id": "2376aca6-0f3b-4d3f-ba32-942d1a18391f", "page": 18, "type": "paragraph", "text": "has been studied, and no evidence of decreased immunogenicity or"}
{"id": "8dad1b6d-ad1f-4e54-8ec8-577e2ff716b8", "page": 18, "type": "paragraph", "text": "safety concerns was noted (122). The immunogenicity and safety"}
{"id": "6ef7870f-7189-4623-a814-79bbf1dba1af", "page": 18, "type": "paragraph", "text": "of simultaneous or sequential administration of two nonaluminum"}
{"id": "cab48179-22d1-4aea-b95f-f9c0489e18c9", "page": 18, "type": "paragraph", "text": "adjuvant\u2013containing vaccines have not been evaluated, and the"}
{"id": "ce83e4fd-1512-444f-b3a6-e52e02e21583", "page": 18, "type": "paragraph", "text": "ideal interval between such vaccines when given sequentially"}
{"id": "d23e18a3-c453-4671-8558-dca80a56a6b0", "page": 18, "type": "paragraph", "text": "is not known. In the study of Shingrix and IIV4 (122), most"}
{"id": "63214e4c-4249-4f44-bfc1-1ea45760be18", "page": 18, "type": "paragraph", "text": "reactogenicity symptoms resolved within 4 days. Because of"}
{"id": "746a0b8a-4430-4c63-98d1-8560bc10df2b", "page": 18, "type": "paragraph", "text": "the limited data on the safety of simultaneous administration"}
{"id": "c629b9b3-b534-4b59-93f1-99530f69bd28", "page": 18, "type": "paragraph", "text": "of two or more vaccines containing nonaluminum adjuvants"}
{"id": "af81579c-23ca-43d0-a8cd-336d1aeb9a25", "page": 18, "type": "paragraph", "text": "and the availability of nonadjuvanted influenza vaccine options,"}
{"id": "0a17f72e-b60a-4c1a-bd8f-44bb93873d09", "page": 18, "type": "paragraph", "text": "selection of a nonadjuvanted influenza vaccine may be considered"}
{"id": "bdcdf5ca-3c70-4282-8da0-4032320a5f8d", "page": 18, "type": "paragraph", "text": "in situations in which influenza vaccine and another vaccine"}
{"id": "ed02dafa-81fa-497d-8658-cef59015a8ec", "page": 18, "type": "paragraph", "text": "containing a nonaluminum adjuvant are to be administered"}
{"id": "a049e057-4255-49bd-8a2b-b0c1e32af5fe", "page": 18, "type": "paragraph", "text": "concomitantly. However, influenza vaccination should not be"}
{"id": "05969bc1-97c8-4779-9003-1adbc775aa84", "page": 18, "type": "paragraph", "text": "delayed if a specific vaccine is not available. As recommended for"}
{"id": "c2347a0f-8598-4b02-a9ca-7d0647a02f2e", "page": 18, "type": "paragraph", "text": "all vaccines, vaccines with nonaluminum adjuvants should be"}
{"id": "57916acb-e5bd-45ec-b806-340f8765227f", "page": 18, "type": "paragraph", "text": "administered at separate anatomic sites from other vaccines that"}
{"id": "142c0b1f-dbe5-4aa5-a521-a45df3afcb7e", "page": 18, "type": "paragraph", "text": "are given concomitantly (42)."}
{"id": "5557acf3-5377-48db-91c6-424185cb8973", "page": 19, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "b4fdff8b-387a-4869-97d5-cef516756df4", "page": 19, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "32c5f711-8ab1-4f68-99f5-5016ad1b9c63", "page": 19, "type": "paragraph", "text": "17"}
{"id": "534fa14e-1fc9-4cea-b749-be35280ce00a", "page": 19, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "1fb028dd-7b32-40f0-b67e-0200dfaf5c48", "page": 19, "type": "paragraph", "text": "Influenza Vaccine Composition and"}
{"id": "6082a302-c648-444e-834d-f18b1e4d5a05", "page": 19, "type": "paragraph", "text": "Available Vaccines"}
{"id": "f4abb123-0ef8-41ff-8b3b-4f604598bc87", "page": 19, "type": "paragraph", "text": "Influenza Vaccine Composition for the"}
{"id": "d117c30a-29af-4647-9fa6-e36f0282e5a0", "page": 19, "type": "paragraph", "text": "2022\u201323 Season"}
{"id": "cf94fb62-9fd3-4b97-9d47-5ea0926213f2", "page": 19, "type": "paragraph", "text": "All influenza vaccines licensed in the United States will"}
{"id": "7fbd3930-4dac-4c9c-8051-3c9dd7ee0f1d", "page": 19, "type": "paragraph", "text": "contain components derived from influenza viruses antigenically"}
{"id": "6b489498-47a4-4e6e-b845-af097a6d9583", "page": 19, "type": "paragraph", "text": "similar to those recommended by FDA (https://www.fda.gov/"}
{"id": "070fc804-30de-483b-ab59-8949bb9e9a56", "page": 19, "type": "paragraph", "text": "advisory-committees/advisory-committee-calendar/vaccines-"}
{"id": "5af1f3fe-ca1d-4ee6-99ef-1edda98dd2d8", "page": 19, "type": "paragraph", "text": "and-related-biological-products-advisory-committee-march-3-"}
{"id": "dfd1d034-f7fb-4fe2-8513-675c306b3ca2", "page": 19, "type": "paragraph", "text": "2022-meeting-announcement). All influenza vaccines expected"}
{"id": "f3544cb5-5fb8-4f5f-b6fc-7a353a1b68d7", "page": 19, "type": "paragraph", "text": "to be available in the United States for the 2022\u201323 season will be"}
{"id": "36086e8c-bc45-4eda-b7c2-302d776c74c4", "page": 19, "type": "paragraph", "text": "quadrivalent vaccines. For the 2022\u201323 season, U.S. egg-based"}
{"id": "62b25d24-ed56-4b40-99af-3f4c35569095", "page": 19, "type": "paragraph", "text": "influenza vaccines (i.e., vaccines other than ccIIV4 and RIV4)"}
{"id": "2b506ed9-721f-41ea-8827-05ec97459084", "page": 19, "type": "paragraph", "text": "will contain HA derived from"}
{"id": "e567e5be-6e18-4fa3-b8a6-d5a0dc57822b", "page": 19, "type": "paragraph", "text": "\u2022 an influenza A/Victoria/2570/2019 (H1N1)pdm09-like"}
{"id": "c8e86459-a72c-481d-9f7b-aff09d302ceb", "page": 19, "type": "paragraph", "text": "virus,"}
{"id": "2e5d9bdd-f314-46b7-9dc9-53927e9a367d", "page": 19, "type": "paragraph", "text": "\u2022 an influenza A/Darwin/9/2021 (H3N2)-like virus,"}
{"id": "9a5a11a4-1bf4-41bc-bca6-81b77a257dd0", "page": 19, "type": "paragraph", "text": "\u2022 an influenza B/Austria/1359417/2021 (Victoria lineage)-"}
{"id": "69d88310-ba94-4cd7-8617-96f5766c537d", "page": 19, "type": "paragraph", "text": "like virus, and"}
{"id": "cf549703-9d3a-40d2-94f8-78312c79af8e", "page": 19, "type": "paragraph", "text": "\u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage)-like"}
{"id": "3e2f1151-eb27-4ce4-abc3-88091e10427d", "page": 19, "type": "paragraph", "text": "virus."}
{"id": "1765dab5-17b4-403f-9b6f-77c9271b45ec", "page": 19, "type": "paragraph", "text": "For the 2022\u201323 season, U.S. cell culture\u2013based inactivated"}
{"id": "ff164c3c-8f6e-42b8-9860-f84190325279", "page": 19, "type": "paragraph", "text": "(ccIIV4) and recombinant (RIV4) influenza vaccines will"}
{"id": "ab3218b1-2dd3-4fb0-8d61-6becd07bac0a", "page": 19, "type": "paragraph", "text": "contain HA derived from"}
{"id": "c02f7c3b-b4f5-4e28-81a1-242d54256baf", "page": 19, "type": "paragraph", "text": "\u2022 an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like"}
{"id": "18a27a72-a63e-42ae-9689-b5a0dd9e1cb1", "page": 19, "type": "paragraph", "text": "virus,"}
{"id": "abf10c3d-7b47-4aab-be2f-da2a9aaa0e00", "page": 19, "type": "paragraph", "text": "\u2022 an influenza A/Darwin/6/2021 (H3N2)-like virus,"}
{"id": "ec27d358-17e0-4d94-8d43-c8b9c369dffe", "page": 19, "type": "paragraph", "text": "\u2022 an influenza B/Austria/1359417/2021 (Victoria lineage)-"}
{"id": "79ab8300-aed7-4b76-833c-39dd6c28d7bd", "page": 19, "type": "paragraph", "text": "like virus, and"}
{"id": "c71d2ff7-b51b-4dc2-bc93-e940f263b02c", "page": 19, "type": "paragraph", "text": "\u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus."}
{"id": "bd586525-25e7-4aff-8e9b-3eb73d35387b", "page": 19, "type": "paragraph", "text": "Vaccines Available for the 2022\u201323 Season"}
{"id": "74b04732-48a9-4172-87e9-3a7ee831aa8b", "page": 19, "type": "paragraph", "text": "Availability of specific types and brands of licensed seasonal"}
{"id": "ab75d344-d9b4-4068-881e-030bbff55404", "page": 19, "type": "paragraph", "text": "influenza vaccines in the United States is determined by"}
{"id": "bc6ef41f-3942-4107-bd2b-1ccd96a5191a", "page": 19, "type": "paragraph", "text": "the manufacturers of the vaccines. Information presented"}
{"id": "a6d5a499-ccaa-4aa2-bd34-005467c2116c", "page": 19, "type": "paragraph", "text": "concerning vaccines expected to be available and their approved"}
{"id": "b9b6ecad-a155-4140-b8b7-0570ba80cba7", "page": 19, "type": "paragraph", "text": "indications and usage reflects current knowledge and is subject"}
{"id": "182e1f97-155d-474c-91db-837a2d5aafd7", "page": 19, "type": "paragraph", "text": "to change."}
{"id": "4f0575c0-a9a7-42c7-815f-5895ecca395e", "page": 19, "type": "paragraph", "text": "Various influenza vaccines will be available for the 2022\u201323"}
{"id": "f485658a-0db0-465f-9171-d5afc3fe717b", "page": 19, "type": "paragraph", "text": "season (Table 1). For many vaccine recipients, more than"}
{"id": "f9aea559-3e32-475f-a755-0f3fbcefbb45", "page": 19, "type": "paragraph", "text": "one type or brand of vaccine might be appropriate within"}
{"id": "0e56328f-e602-478a-83b3-653651b17cce", "page": 19, "type": "paragraph", "text": "approved indications and ACIP recommendations. A licensed"}
{"id": "35b1be5c-3c6a-4a1b-999c-5dbb4e2c44a0", "page": 19, "type": "paragraph", "text": "influenza vaccine that is appropriate for the recipient\u2019s age"}
{"id": "8b0d94c0-f221-4991-9308-c090e817dc87", "page": 19, "type": "paragraph", "text": "and health status should be used. Specific age indications for"}
{"id": "6997aa0b-4f0b-4bef-a0e8-3616b87a6378", "page": 19, "type": "paragraph", "text": "licensed influenza vaccines are summarized (Table 1). Current"}
{"id": "88a18994-97a9-4daa-b8ac-d9233d1e786a", "page": 19, "type": "paragraph", "text": "prescribing information should be consulted for authoritative,"}
{"id": "6f85b97a-95ad-445e-8054-aa81ca04790e", "page": 19, "type": "paragraph", "text": "up-to-date information. Contraindications and precautions"}
{"id": "ea56b67a-6187-478d-81eb-449bbd34cafe", "page": 19, "type": "paragraph", "text": "for the different types of influenza vaccines are summarized"}
{"id": "f3ce2c6e-0222-4ad7-a3f1-056b31deece5", "page": 19, "type": "paragraph", "text": "(Tables 2 and 3), as are dose volumes (Table 4)."}
{"id": "e833fa06-7678-41ec-a231-cf6f458a968c", "page": 19, "type": "paragraph", "text": "Not all influenza vaccines are likely to be uniformly"}
{"id": "795f1ff2-db2a-492a-94cd-11655e2aeb78", "page": 19, "type": "paragraph", "text": "available in any specific practice setting or geographic locality."}
{"id": "f805afb8-4585-4c2b-8123-c7e9d937c365", "page": 19, "type": "paragraph", "text": "Vaccination should not be delayed to obtain a specific product"}
{"id": "d94917c2-f8ab-446a-bda4-4d545b36e30b", "page": 19, "type": "paragraph", "text": "when an appropriate one is available. Within these guidelines"}
{"id": "2bfc9f6a-c8c8-4824-90ca-ac2afe5fc691", "page": 19, "type": "paragraph", "text": "and approved indications, ACIP makes no preferential"}
{"id": "d38055c4-91dd-456f-865b-0806869ed79b", "page": 19, "type": "paragraph", "text": "recommendation for the use of any one influenza vaccine"}
{"id": "0405c104-c733-40ab-8e4c-90ac46c94c52", "page": 19, "type": "paragraph", "text": "over another when more than one licensed, recommended,"}
{"id": "eeb22545-e144-40f9-9caf-65b2c412ba64", "page": 19, "type": "paragraph", "text": "and age-appropriate vaccine is available, with the exception"}
{"id": "d016f855-e375-43ef-be60-65d3f5122a71", "page": 19, "type": "paragraph", "text": "of selection of influenza vaccines for persons aged \u226565 years"}
{"id": "ced34df3-ad21-4608-8c40-f212740759cd", "page": 19, "type": "paragraph", "text": "(see Older Adults)."}
{"id": "0937ba84-554b-423f-8e36-0b8c18fa73e8", "page": 19, "type": "paragraph", "text": "Since the publication of the previous season\u2019s"}
{"id": "c46b47c0-9813-4bf6-991c-bc1ae170281b", "page": 19, "type": "paragraph", "text": "recommendations, FDA has approved a labeling change for"}
{"id": "5c133ab2-8f82-4b84-8c15-085faa2dfa1b", "page": 19, "type": "paragraph", "text": "Flucelvax Quadrivalent (see Recent Influenza Vaccine Labeling"}
{"id": "06870143-1356-4e00-821b-5229527ec7b1", "page": 19, "type": "paragraph", "text": "Changes). Additional new licensures and changes to FDA-"}
{"id": "f42a68c5-4d0c-4c9b-a0a8-1431d01eb369", "page": 19, "type": "paragraph", "text": "approved labeling might occur after publication of this report."}
{"id": "4ea44cb2-6e66-4f4d-bcd0-73f907ab69e3", "page": 19, "type": "paragraph", "text": "As these changes occur and new vaccines become available,"}
{"id": "3451103d-14bb-4d4d-8ba8-1802ed653227", "page": 19, "type": "paragraph", "text": "they will be reflected in the online version of Table 1, available"}
{"id": "951ed8b9-1191-4c90-8564-e5c54b60f502", "page": 19, "type": "paragraph", "text": "at https://www.cdc.gov/flu/professionals/acip/2022-2023/"}
{"id": "969d6398-1f74-4b9c-8456-a8e8b1c66b0b", "page": 19, "type": "paragraph", "text": "acip-table.htm."}
{"id": "4051b948-976b-43d9-9f03-feb9b317f27a", "page": 19, "type": "paragraph", "text": "Dosage, Administration,"}
{"id": "431a788d-580a-4409-b3c6-afab64a708fe", "page": 19, "type": "paragraph", "text": "Contraindications, and Precautions"}
{"id": "18bd7ba8-7e21-49bd-8c60-3dbfae7f1d74", "page": 19, "type": "paragraph", "text": "Quadrivalent Inactivated Influenza Vaccines (IIV4s)"}
{"id": "920635a6-2083-41ef-bcb8-4706c8433fe5", "page": 19, "type": "paragraph", "text": "Available Vaccines. As in recent seasons, various inactivated"}
{"id": "a50c1190-4a07-422c-9c19-a48469d50c40", "page": 19, "type": "paragraph", "text": "influenza vaccines (IIVs) are expected to be available for"}
{"id": "6fcba007-9dc4-420d-bb9b-4ef4a42b9405", "page": 19, "type": "paragraph", "text": "2022\u201323 (Table 1); all are expected to be quadrivalent (IIV4s)."}
{"id": "f5f68e70-eecd-41bc-9850-c82c7ab45b8c", "page": 19, "type": "paragraph", "text": "Standard-dose, nonadjuvanted IIV4s are licensed for persons"}
{"id": "c8ee0261-1055-4fa4-bcd9-c409f0c60755", "page": 19, "type": "paragraph", "text": "aged as young as 6 months. However, for certain IIV4s, the"}
{"id": "64995b6c-a3eb-4dff-89a8-2caaa8fb1072", "page": 19, "type": "paragraph", "text": "approved dose volume for children aged 6 through 35 months"}
{"id": "b1290be5-35d7-49a4-8290-672ef0b58e11", "page": 19, "type": "paragraph", "text": "differs from that for older children and adults (Table 4). Two"}
{"id": "14fafafd-6590-4b07-8e77-6f519d8e58ca", "page": 19, "type": "paragraph", "text": "IIV4s, the MF59-adjuvanted IIV4 (aIIV4) and the high-dose"}
{"id": "fb09688f-0e30-4c37-9b2f-bd41c6e1c7f4", "page": 19, "type": "paragraph", "text": "IIV4 (HD-IIV4), are approved for persons aged \u226565 years. Care"}
{"id": "bafc3ddb-7fd4-47de-be37-7e90dc9cc846", "page": 19, "type": "paragraph", "text": "should be taken to administer the appropriate dose volume of"}
{"id": "a00c598e-7299-43c8-9367-0fa9140a94b8", "page": 19, "type": "paragraph", "text": "an age-appropriate vaccine to each recipient."}
{"id": "3869ae67-b6f6-438f-a691-1ed822532c5f", "page": 19, "type": "paragraph", "text": "Standard-dose, nonadjuvanted IIV4s contain 15 \u00b5g of HA"}
{"id": "239e318c-5928-4100-b2f1-6e8c1030fe00", "page": 19, "type": "paragraph", "text": "per vaccine virus in a 0.5-mL dose (7.5 \u00b5g of HA per vaccine"}
{"id": "407aea6f-44b6-42ed-9163-423c98eaec7d", "page": 19, "type": "paragraph", "text": "virus in a 0.25-mL dose). For 2022\u201323, this category is"}
{"id": "584d1fae-8b0a-4c52-92bc-acc8a2e90633", "page": 19, "type": "paragraph", "text": "expected to include five different vaccines (Table 1). Four of"}
{"id": "b9ed4453-f33b-43e4-b9d7-cd48ee64d032", "page": 19, "type": "paragraph", "text": "these are egg-based vaccines, and one is a cell culture\u2013based"}
{"id": "c7fc7398-ba39-4113-a9fb-ca082e288124", "page": 19, "type": "paragraph", "text": "vaccine. All are approved for persons aged \u22656 months. Egg-"}
{"id": "cd479c10-be7f-416c-81b4-a48a18195046", "page": 19, "type": "paragraph", "text": "based and cell culture\u2013based vaccines differ in the substrate in"}
{"id": "f59791d5-8e6b-4a29-8f05-40e25134ec15", "page": 19, "type": "paragraph", "text": "which reference vaccine viruses supplied to the manufacturer"}
{"id": "870bb143-f041-47af-a224-30e75bbeb59a", "page": 19, "type": "paragraph", "text": "are propagated in quantities sufficient to produce the needed"}
{"id": "70851f2a-ebe8-4bee-8973-471e68c00871", "page": 19, "type": "paragraph", "text": "number of doses of vaccine. For the IIV4s Afluria Quadrivalent"}
{"id": "6f1aee06-e7e6-4156-95b8-a17e520845af", "page": 19, "type": "paragraph", "text": "(43), Fluarix Quadrivalent (123), FluLaval Quadrivalent (124),"}
{"id": "aa2307c0-cc3a-4563-bcfc-7ad5c6ec9cc2", "page": 19, "type": "paragraph", "text": "and Fluzone Quadrivalent (44), reference vaccine viruses are"}
{"id": "e661b794-9099-46e7-b744-feecae760574", "page": 20, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "6ce964d8-829e-4e87-b982-388a328e6022", "page": 20, "type": "paragraph", "text": "18"}
{"id": "35925b2c-33bf-4b40-820e-7a045b2aacc8", "page": 20, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "6b4e533b-d2ed-41f1-8dfd-d4d3e567650d", "page": 20, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "b1b65e9f-f9b9-4041-881d-c7a407e2b071", "page": 20, "type": "paragraph", "text": "propagated in eggs. For Flucelvax Quadrivalent, reference"}
{"id": "9a5cee05-a2f2-4aef-80be-fd2babd7967e", "page": 20, "type": "paragraph", "text": "vaccine viruses are propagated in Madin-Darby canine kidney"}
{"id": "5dace160-cb2d-4589-a13d-f7c3d7553d83", "page": 20, "type": "paragraph", "text": "cells instead of eggs (125)."}
{"id": "f7d837e5-250e-44ce-acf3-ee810b07fcbf", "page": 20, "type": "paragraph", "text": "Two additional IIV4s that will be available for the 2022\u201323"}
{"id": "5db47374-3161-424a-a308-43f2eff43955", "page": 20, "type": "paragraph", "text": "season are approved for persons aged \u226565 years. These vaccines"}
{"id": "1e46138c-71e9-4770-b203-097cefac47c5", "page": 20, "type": "paragraph", "text": "are egg based. Quadrivalent high-dose inactivated influenza"}
{"id": "e04c77c1-3b05-459a-90e5-534bb634c08a", "page": 20, "type": "paragraph", "text": "vaccine (Fluzone High-Dose Quadrivalent; HD-IIV4) contains"}
{"id": "4f01c3bc-2030-4c0b-9371-3e8015b1626a", "page": 20, "type": "paragraph", "text": "60 \u00b5g of HA per vaccine virus (240 \u00b5g total) in a 0.7-mL dose"}
{"id": "de22628c-b9f9-42df-9149-45bf68af3165", "page": 20, "type": "paragraph", "text": "(126). Quadrivalent adjuvanted inactivated influenza vaccine"}
{"id": "3d27aca9-dbd5-45d0-b5c7-ea6278bd44ee", "page": 20, "type": "paragraph", "text": "(Fluad Quadrivalent; aIIV4) contains 15 \u00b5g of HA per vaccine"}
{"id": "43802f5a-9b94-423f-8e70-539cd0226f08", "page": 20, "type": "paragraph", "text": "virus (60 \u00b5g total) and MF59 adjuvant (120)."}
{"id": "8f303bf9-3693-42df-a841-6775ed56ebab", "page": 20, "type": "paragraph", "text": "Dosage and Administration. Standard-dose nonadjuvanted"}
{"id": "93a24a51-27bb-4724-b634-6134b60d5edb", "page": 20, "type": "paragraph", "text": "IIV4s are approved for children aged as young as 6 months."}
{"id": "42231138-1c66-420d-9cea-54aa74a02f07", "page": 20, "type": "paragraph", "text": "Certain of these IIV4s are approved at different dose volumes"}
{"id": "1ef64bc7-9b8d-4a3b-8730-bec2e58b7a05", "page": 20, "type": "paragraph", "text": "for very young children than for older children and adults. Care"}
{"id": "fdbc8ed2-6738-49df-a251-f877c7e42a11", "page": 20, "type": "paragraph", "text": "should be taken to administer an age-appropriate vaccine at"}
{"id": "432371ed-7029-48f0-a838-be5e5766f4eb", "page": 20, "type": "paragraph", "text": "the approved dose volume for each needed dose (see Children"}
{"id": "9b94c4e3-c193-44aa-8174-d1ae07c88761", "page": 20, "type": "paragraph", "text": "Aged 6 Through 35 Months: Influenza Vaccine Dose Volumes)"}
{"id": "08effd9d-9689-45d6-9020-afbeed5ec442", "page": 20, "type": "paragraph", "text": "(Tables 1 and 4):"}
{"id": "27c9857f-489e-4af6-ba61-c088deb95537", "page": 20, "type": "paragraph", "text": "\u2022 Afluria Quadrivalent: The approved dose volume for"}
{"id": "1a2dfea9-01e5-4114-abad-296ad260b662", "page": 20, "type": "paragraph", "text": "children aged 6 through 35 months is 0.25 mL per dose."}
{"id": "6ee4493f-5d69-45a8-a4f1-38eb0767c1e7", "page": 20, "type": "paragraph", "text": "Persons aged \u226536 months (\u22653 years) should receive 0.5 mL"}
{"id": "98e0c6ea-c145-4ccb-b4a3-93fd29243c92", "page": 20, "type": "paragraph", "text": "per dose."}
{"id": "f5f0749f-6eff-409d-975e-f17ff2220820", "page": 20, "type": "paragraph", "text": "\u2022 Fluarix Quadrivalent: The approved dose volume is 0.5 mL"}
{"id": "a95050f8-54e8-4976-a4ea-dfd0bc282dd7", "page": 20, "type": "paragraph", "text": "per dose for all persons aged \u22656 months."}
{"id": "92aa684a-677a-4b28-b58d-c86aa4ace383", "page": 20, "type": "paragraph", "text": "\u2022 Flucelvax Quadrivalent: The approved dose volume is"}
{"id": "14a2d779-af0a-4a64-bb35-d8c908724e7c", "page": 20, "type": "paragraph", "text": "0.5 mL per dose for all persons aged \u22656 months."}
{"id": "3d91bd76-abf1-4cca-9e65-685a2174954d", "page": 20, "type": "paragraph", "text": "\u2022 FluLaval Quadrivalent: The approved dose volume is"}
{"id": "771748b4-cb22-401a-b5f5-359787bae124", "page": 20, "type": "paragraph", "text": "0.5 mL per dose for all persons aged \u22656 months."}
{"id": "8b7dd569-46d5-45fe-b38a-252ba2d79403", "page": 20, "type": "paragraph", "text": "\u2022 Fluzone Quadrivalent: The approved dose volume for"}
{"id": "06122b2d-a6a6-47d4-8c6e-0993d110bcca", "page": 20, "type": "paragraph", "text": "children aged 6 through 35 months is either 0.25 mL or"}
{"id": "5efefea7-dfb3-4b62-9fa0-cdae309cb652", "page": 20, "type": "paragraph", "text": "0.5 mL per dose. Persons aged \u226536 months (\u22653 years)"}
{"id": "637ab73b-fd5a-4fcb-95b7-cec06f96ed90", "page": 20, "type": "paragraph", "text": "should receive 0.5 mL per dose."}
{"id": "612ed616-101c-4d07-a66d-aea55be3012e", "page": 20, "type": "paragraph", "text": "If prefilled syringes are not available, the appropriate volume"}
{"id": "065b1381-f885-400f-a0ce-4427d372f2f8", "page": 20, "type": "paragraph", "text": "can be administered from a single-dose or multidose vial. If"}
{"id": "1e61da00-953a-4803-8487-d6b12b04fcc7", "page": 20, "type": "paragraph", "text": "a 0.5-mL single-dose vial is used for a 0.25-mL dose for a"}
{"id": "31eaaafd-078c-4de5-ae59-c324f66adc66", "page": 20, "type": "paragraph", "text": "child aged 6 through 35 months, only half of the vial volume"}
{"id": "08126ec8-eefa-4f61-9864-fc22990d2fd9", "page": 20, "type": "paragraph", "text": "should be administered, and the remaining half should be"}
{"id": "3b169b68-b4d4-4250-a9dc-acf6a57a5b08", "page": 20, "type": "paragraph", "text": "discarded. Of note, dose volume is distinct from the number"}
{"id": "22b5206f-49e6-4942-8a1b-7a758cb89352", "page": 20, "type": "paragraph", "text": "of doses. Children in this age group who require 2 doses for"}
{"id": "97b8ba9e-a991-4ada-9f21-2dd2d06d0132", "page": 20, "type": "paragraph", "text": "2022\u201323 need 2 separate doses administered \u22654 weeks apart,"}
{"id": "de9bf263-84d9-45e3-8732-953a31c44722", "page": 20, "type": "paragraph", "text": "regardless of the specific IIV4 used and volume given for each"}
{"id": "85059e37-5718-4239-a0a1-5ab168ea7322", "page": 20, "type": "paragraph", "text": "dose (see Children Aged 6 Months Through 8 Years: Number"}
{"id": "18591168-ba67-426f-877a-1e32904858c6", "page": 20, "type": "paragraph", "text": "of Influenza Vaccine Doses) (Figure)."}
{"id": "491cc391-e32f-4825-ae9d-905a2ad212ac", "page": 20, "type": "paragraph", "text": "For children aged 36 months (3 years) through 17 years and"}
{"id": "31fe4762-cfbf-4b52-a37e-8a68973c1507", "page": 20, "type": "paragraph", "text": "adults aged \u226518 years, the dose volume for IIV4s is 0.5 mL per"}
{"id": "9abe5da0-45b9-4536-bb59-f37be93a831f", "page": 20, "type": "paragraph", "text": "dose, with the exception of Fluzone High-Dose Quadrivalent"}
{"id": "35dff804-3398-4596-bd69-b790434eea31", "page": 20, "type": "paragraph", "text": "(HD-IIV4, licensed for persons aged \u226565 years), for which"}
{"id": "5ec3d781-ec59-4615-96c5-bb854efe5fcf", "page": 20, "type": "paragraph", "text": "the correct volume is 0.7 mL per dose. If a smaller vaccine"}
{"id": "b7a8698a-11a7-4bb9-a66d-9f14ef12acc9", "page": 20, "type": "paragraph", "text": "dose (e.g., 0.25 mL) is inadvertently administered to a person"}
{"id": "a26951b3-47f7-4039-b2d8-04783a1b28b0", "page": 20, "type": "paragraph", "text": "aged \u226536 months, the remaining volume needed to make a full"}
{"id": "b9c0d407-21a4-429a-98fb-0681f101e98d", "page": 20, "type": "paragraph", "text": "dose should be administered during the same vaccination visit"}
{"id": "53553d00-cbef-40e2-b9cd-f8306605496a", "page": 20, "type": "paragraph", "text": "or, if measuring the needed remaining volume is a challenge,"}
{"id": "63470b6f-5a5b-470f-b1a9-5114c90a37d5", "page": 20, "type": "paragraph", "text": "administering a repeat dose at the full volume is acceptable."}
{"id": "c43e9c23-10e2-4e55-b222-be68ba7ccf35", "page": 20, "type": "paragraph", "text": "If the error is discovered later (after the recipient has left the"}
{"id": "210a4860-88f0-42c7-bbf8-cd5dc97f9994", "page": 20, "type": "paragraph", "text": "vaccination setting), a full dose should be administered as soon"}
{"id": "d9153760-0f85-4cbd-8c12-b80d9dabf254", "page": 20, "type": "paragraph", "text": "as the recipient can return. Vaccination with a formulation"}
{"id": "8fac0be5-1543-4fb3-995d-0dc04d1df12e", "page": 20, "type": "paragraph", "text": "approved for adult use should be counted as a single dose if"}
{"id": "2cc37ef3-40bc-4d38-b348-ab747efe2b72", "page": 20, "type": "paragraph", "text": "inadvertently administered to a child."}
{"id": "378249aa-ecd5-4d58-a93e-e23132e6a820", "page": 20, "type": "paragraph", "text": "IIV4s are administered intramuscularly (IM). For adults and"}
{"id": "caeb0a57-01a5-49d8-b984-a9b46562924f", "page": 20, "type": "paragraph", "text": "older children, the deltoid muscle is the preferred site. Infants"}
{"id": "b323ce73-86bb-4663-bbe8-a853d05d2747", "page": 20, "type": "paragraph", "text": "and younger children should be vaccinated in the anterolateral"}
{"id": "52e13508-8163-4802-ba87-facef33de4bb", "page": 20, "type": "paragraph", "text": "thigh. Additional specific guidance regarding site selection and"}
{"id": "8ac3e3ef-c664-423f-a07a-fa81a1b870a4", "page": 20, "type": "paragraph", "text": "needle length for IM injection is provided in the ACIP General"}
{"id": "871788fd-ff56-4584-8cd3-621c6070abbd", "page": 20, "type": "paragraph", "text": "Best Practice Guidelines for Immunization (42)."}
{"id": "188301fe-8a85-45bb-a07e-be102c3538b2", "page": 20, "type": "paragraph", "text": "One IIV4, Afluria Quadrivalent, is licensed for IM injection"}
{"id": "ead84e9b-fb05-4fb9-953b-1bb0e07ff0e9", "page": 20, "type": "paragraph", "text": "via the PharmaJet Stratis jet injector for persons aged 18"}
{"id": "b1c7a897-dadc-456a-9a66-8e0f53cbad45", "page": 20, "type": "paragraph", "text": "through 64 years (43). Persons in this age group may receive"}
{"id": "6c2ac6a1-85e6-4233-aab7-dcea10c57c8f", "page": 20, "type": "paragraph", "text": "Afluria Quadrivalent via either needle and syringe or this"}
{"id": "177cbb2f-83ca-49fc-89b8-cf23ad9bede2", "page": 20, "type": "paragraph", "text": "specific jet injection device. Children aged 6 months through"}
{"id": "141c774e-4709-4400-9971-0a447a23813d", "page": 20, "type": "paragraph", "text": "17 years and adults aged \u226565 years should receive this vaccine"}
{"id": "ea7f2689-a7d9-4c0c-9e95-760ad581291d", "page": 20, "type": "paragraph", "text": "by needle and syringe only. No other IIV4s are licensed for"}
{"id": "90b6ab67-f91a-474b-bf35-02500025a179", "page": 20, "type": "paragraph", "text": "administration by jet injector."}
{"id": "a2f5f4f8-c2fa-41e6-ab08-7f98e4a275f1", "page": 20, "type": "paragraph", "text": "Contraindications and Precautions for the Use of"}
{"id": "180e0f13-ba1f-4737-b357-613511ba20e1", "page": 20, "type": "paragraph", "text": "IIV4s. Manufacturer package inserts and updated CDC"}
{"id": "ea4192aa-9064-4e18-a45c-51824a5cddf0", "page": 20, "type": "paragraph", "text": "and ACIP guidance should be consulted for information on"}
{"id": "b3dad0d5-e718-4e4d-9d0e-b971126d4a05", "page": 20, "type": "paragraph", "text": "contraindications and precautions for individual influenza"}
{"id": "f1394706-0d2c-494d-97da-c19cd4f71264", "page": 20, "type": "paragraph", "text": "vaccines. Each IIV, whether egg-based or cell culture\u2013based,"}
{"id": "0a958662-dd78-4bc2-961a-7b60e3508127", "page": 20, "type": "paragraph", "text": "has a labeled contraindication for persons with a history of"}
{"id": "471224a5-95d4-485c-88f8-993d4b94e4ef", "page": 20, "type": "paragraph", "text": "a severe allergic reaction to any component of that vaccine"}
{"id": "660ee074-3e23-433b-83de-c06bf3c07ac2", "page": 20, "type": "paragraph", "text": "(Table 2). Although egg is a component of all IIV4s other"}
{"id": "de4d1ab5-ac2e-47de-a016-ee3382f2958b", "page": 20, "type": "paragraph", "text": "than ccIIV4, ACIP makes specific recommendations for"}
{"id": "b7f5f4c8-55ad-49f5-b46e-c56d0b1d2e12", "page": 20, "type": "paragraph", "text": "the use of influenza vaccine for persons with egg allergy"}
{"id": "fdc06fdd-50fb-45c4-9233-236ce01b39e7", "page": 20, "type": "paragraph", "text": "(see Persons with a History of Egg Allergy). All egg-based"}
{"id": "5021d2bb-7f61-4918-ad07-c980aed82cdb", "page": 20, "type": "paragraph", "text": "IIV4s are contraindicated in persons who have had a severe"}
{"id": "e32d34d5-d9e6-4af6-b9d2-131972b18d56", "page": 20, "type": "paragraph", "text": "allergic reaction (e.g., anaphylaxis) to a previous dose of any"}
{"id": "ee45ebf9-df39-4274-b90a-4edd2007f0b5", "page": 20, "type": "paragraph", "text": "influenza vaccine (any egg-based IIV, ccIIV, RIV, or LAIV of"}
{"id": "9a044c0e-107c-4e1b-b9ba-fd0c2fc70ec9", "page": 20, "type": "paragraph", "text": "any valency). Use of ccIIV4 is contraindicated in persons who"}
{"id": "4d3f34ca-532b-49f2-8c1b-8ddbd12cb879", "page": 20, "type": "paragraph", "text": "have had a severe allergic reaction (e.g., anaphylaxis) to any"}
{"id": "2df6e008-531d-4f81-9cce-b11c353c7f24", "page": 20, "type": "paragraph", "text": "ccIIV of any valency. A history of severe allergic reaction (e.g.,"}
{"id": "4c1a9073-2a3f-4dab-bf27-d08b4f305dc6", "page": 20, "type": "paragraph", "text": "anaphylaxis) to any other influenza vaccine (i.e., any egg-based"}
{"id": "77ecd53f-316d-458d-8bc4-8c0236b9c26c", "page": 20, "type": "paragraph", "text": "IIV, RIV, or LAIV of any valency) is a precaution for the use"}
{"id": "ef498ba4-9ee8-4203-8a9a-db9a2a52dbf7", "page": 20, "type": "paragraph", "text": "of ccIIV4 (see Persons with Previous Allergic Reactions to"}
{"id": "03e5ff33-2cc0-4dcf-aa00-91c1ca342722", "page": 20, "type": "paragraph", "text": "Influenza Vaccines) (Tables 2 and 3). If ccIIV4 is administered"}
{"id": "622e0b10-55ef-429d-b119-0c59f6dd8214", "page": 20, "type": "paragraph", "text": "in such an instance, vaccination should occur in an inpatient"}
{"id": "0c5c433a-3d4c-4e47-a35a-8a7cde206e0b", "page": 20, "type": "paragraph", "text": "or outpatient medical setting and should be supervised by a"}
{"id": "2f1c4d33-ddf6-4740-818d-7d7933c37034", "page": 20, "type": "paragraph", "text": "health care provider who is able to recognize and manage severe"}
{"id": "30e457d3-df20-4838-8817-f7cb253d111e", "page": 20, "type": "paragraph", "text": "allergic reactions. Providers can also consider consultation with"}
{"id": "be1f00c4-acc9-4abe-8b9e-9b171785f096", "page": 20, "type": "paragraph", "text": "an allergist to help identify the vaccine component responsible"}
{"id": "7c85a41e-a0ee-4c2b-a7d8-6399f951088c", "page": 20, "type": "paragraph", "text": "for the reaction. Information about vaccine components can"}
{"id": "3d54c195-9026-44fb-baed-dbc65dc1b5ee", "page": 21, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "71fca854-0a63-4940-aae6-1979485fd3ce", "page": 21, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "c4ae6c5d-9061-4347-9633-f5e2e2f54349", "page": 21, "type": "paragraph", "text": "19"}
{"id": "f20208dc-6f0d-4a0e-a819-05f6d11514d6", "page": 21, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "d93536db-f286-4680-8ff1-5c43bda94e20", "page": 21, "type": "paragraph", "text": "be found in the package inserts for each vaccine. Prophylactic"}
{"id": "f541a276-bec3-4a0d-b447-1de7d5057557", "page": 21, "type": "paragraph", "text": "use of antiviral agents is an option that can be considered"}
{"id": "3d43ac0f-de8e-4f65-8adc-07919363e391", "page": 21, "type": "paragraph", "text": "for preventing influenza among persons who cannot receive"}
{"id": "8712bb88-05ce-41c4-929b-abfb52da2bd9", "page": 21, "type": "paragraph", "text": "vaccine, particularly for those who are at higher risk for medical"}
{"id": "1b946eb9-0d3b-4016-8f97-094a150e599b", "page": 21, "type": "paragraph", "text": "complications attributable to severe influenza (91)."}
{"id": "3bfad6d7-f54f-4e41-9ce5-fd0b6929081b", "page": 21, "type": "paragraph", "text": "Moderate or severe acute illness with or without fever is"}
{"id": "53598ea1-40c7-4aa9-b308-5bca60808a62", "page": 21, "type": "paragraph", "text": "a general precaution for vaccination (42). A history of GBS"}
{"id": "8d22dfb2-9af2-48d3-a52a-cbc8b119b01d", "page": 21, "type": "paragraph", "text": "within 6 weeks after receipt of a previous dose of influenza"}
{"id": "0c44fd8e-e6c3-4de6-87b1-abfee9bfe9da", "page": 21, "type": "paragraph", "text": "vaccine is considered a precaution for the use of all influenza"}
{"id": "13557a8e-cd1b-4bc5-8e86-dcd5e43acda1", "page": 21, "type": "paragraph", "text": "vaccines (Table 2)."}
{"id": "f9708651-8576-4cf5-9fc7-246e4f776358", "page": 21, "type": "paragraph", "text": "Quadrivalent Recombinant Influenza Vaccine (RIV4)"}
{"id": "b07e1034-23b6-496e-a9f6-cf83c1c998f7", "page": 21, "type": "paragraph", "text": "Available Vaccine. One recombinant influenza vaccine,"}
{"id": "36b4bdff-8b23-4640-bdef-2bb110268a36", "page": 21, "type": "paragraph", "text": "Flublok Quadrivalent (RIV4), is expected to be available"}
{"id": "7f3483c5-0096-422a-98b2-af218ceb9fec", "page": 21, "type": "paragraph", "text": "during the 2022\u201323 influenza season. RIV4 is approved for"}
{"id": "904d6788-ea2b-4a33-836a-c7962916b26d", "page": 21, "type": "paragraph", "text": "persons aged \u226518 years. This vaccine contains recombinant HA"}
{"id": "af21ed18-7de3-41ea-8212-70ac569baf45", "page": 21, "type": "paragraph", "text": "produced in an insect cell line using genetic sequences from"}
{"id": "8bcffe9f-aa7d-44c0-8d26-74cf2f3678cb", "page": 21, "type": "paragraph", "text": "cell-derived influenza viruses and is manufactured without the"}
{"id": "6d2d2a50-000b-4df6-bb6c-715695e57499", "page": 21, "type": "paragraph", "text": "use of influenza viruses or eggs (127)."}
{"id": "0a371c18-93e3-4701-bfc7-7b7ea29cd582", "page": 21, "type": "paragraph", "text": "Dosage and Administration: RIV4 is administered by IM"}
{"id": "ce0c3258-9860-42b4-8a80-d3be0b059452", "page": 21, "type": "paragraph", "text": "injection via needle and syringe. A 0.5-mL dose contains 45 \u00b5g"}
{"id": "16580789-a9af-458b-b7b1-56c0b69b4082", "page": 21, "type": "paragraph", "text": "of HA derived from each vaccine virus (180 \u00b5g total)."}
{"id": "b6800bf7-2f66-4e7b-a9b0-d0f64182904e", "page": 21, "type": "paragraph", "text": "Contraindications and Precautions for the Use of RIV4."}
{"id": "b80d8330-2924-446a-b175-705c2e1b9ba1", "page": 21, "type": "paragraph", "text": "RIV4 is contraindicated in persons who have had a severe"}
{"id": "efadc6a1-b1fd-4c5b-b949-693cd2aa758c", "page": 21, "type": "paragraph", "text": "allergic reaction (e.g., anaphylaxis) to a previous dose of any"}
{"id": "903c03b1-4be2-474c-ac9d-7bcca19326fb", "page": 21, "type": "paragraph", "text": "RIV of any valency or any component of RIV4. A history of a"}
{"id": "8584ac5f-f5bb-4d4b-9ce7-8bd9dd29e0fb", "page": 21, "type": "paragraph", "text": "severe allergic reaction (e.g., anaphylaxis) to any other influenza"}
{"id": "371b8f62-cb40-4a70-8eaf-1845abd723a1", "page": 21, "type": "paragraph", "text": "vaccine (i.e., any egg-based IIV, ccIIV, or LAIV of any valency)"}
{"id": "319c2cce-e310-49fb-834d-d25f12e3695b", "page": 21, "type": "paragraph", "text": "is a precaution for the use of RIV4. If RIV4 is administered"}
{"id": "b9317d60-c5dc-4cfd-8548-a1c6ed131680", "page": 21, "type": "paragraph", "text": "in such an instance, vaccination should occur in an inpatient"}
{"id": "2e21174c-6bda-4dff-874f-831740a18655", "page": 21, "type": "paragraph", "text": "or outpatient medical setting and should be supervised by a"}
{"id": "71bbaac9-b7d6-425e-a308-8e8454761bef", "page": 21, "type": "paragraph", "text": "health care provider who is able to recognize and manage severe"}
{"id": "9ac64929-1e53-4183-9330-db8d2c3c0ebc", "page": 21, "type": "paragraph", "text": "allergic reactions. Providers can also consider consulting with"}
{"id": "e9b90801-e100-4bdc-9449-397fc2279ad5", "page": 21, "type": "paragraph", "text": "an allergist to help identify the vaccine component responsible"}
{"id": "07fa6117-e02e-49bd-afd2-3ea85a3a64ed", "page": 21, "type": "paragraph", "text": "for the reaction. Moderate or severe acute illness with or"}
{"id": "dace49bf-23e1-49f4-9867-ddac73d0e575", "page": 21, "type": "paragraph", "text": "without fever is a general precaution for vaccination (42). A"}
{"id": "27594e51-d788-4aeb-9223-8c09351547fa", "page": 21, "type": "paragraph", "text": "history of GBS within 6 weeks after receipt of a previous dose"}
{"id": "cf22c567-791b-4ba0-b14d-9d5d7af580b2", "page": 21, "type": "paragraph", "text": "of influenza vaccine is considered a precaution for the use of all"}
{"id": "22ad16c1-039a-482d-85c6-fb0e76508ac0", "page": 21, "type": "paragraph", "text": "influenza vaccines (Table 2). RIV4 is not licensed for children"}
{"id": "e23110c1-f7bb-479e-b43a-30906a2f5e71", "page": 21, "type": "paragraph", "text": "aged <18 years."}
{"id": "c09407c9-2703-46ee-952f-c571ae3dca67", "page": 21, "type": "paragraph", "text": "Quadrivalent Live Attenuated Influenza"}
{"id": "3df64775-89a7-4832-b4ac-73243a1b4b62", "page": 21, "type": "paragraph", "text": "Vaccine (LAIV4)"}
{"id": "7c0a31b2-ed06-4d0b-9ca6-ebb1d7ff843d", "page": 21, "type": "paragraph", "text": "Available Vaccine. One live attenuated influenza vaccine,"}
{"id": "a686b1f1-96b4-4833-a97c-45b41d4635f3", "page": 21, "type": "paragraph", "text": "FluMist Quadrivalent (LAIV4), is expected to be available"}
{"id": "8d36ae84-9973-4855-850d-2f5faf721dca", "page": 21, "type": "paragraph", "text": "during the 2022\u201323 influenza season. LAIV4 is approved"}
{"id": "c116ac50-c683-4437-8153-15229ce13eee", "page": 21, "type": "paragraph", "text": "for persons aged 2 through 49 years. LAIV4 contains live"}
{"id": "2bef1e78-8213-4368-863f-c608bfd0e232", "page": 21, "type": "paragraph", "text": "attenuated influenza viruses that are propagated in eggs. These"}
{"id": "aeed48c4-0e2b-4af7-b2e1-fa666353772d", "page": 21, "type": "paragraph", "text": "viruses are cold adapted (so that they replicate efficiently at"}
{"id": "71a148e0-8687-4efb-832a-967d325d2b94", "page": 21, "type": "paragraph", "text": "25\u00b0C) and temperature sensitive (so that their replication is"}
{"id": "8dd931a9-4dcf-4094-9a46-5c349972336f", "page": 21, "type": "paragraph", "text": "restricted at higher temperatures, 39\u00b0C for influenza A viruses"}
{"id": "e45b482f-d49a-4623-a655-e280ced71eba", "page": 21, "type": "paragraph", "text": "and 37\u00b0C for influenza B viruses). These viruses replicate in"}
{"id": "f9ff8272-77ba-4381-8a83-fceeb99e7aee", "page": 21, "type": "paragraph", "text": "the nasopharynx, which is necessary to promote an immune"}
{"id": "0590e951-b263-4862-83ec-af4ea3bbd682", "page": 21, "type": "paragraph", "text": "response (99). No preference is expressed for LAIV4 versus"}
{"id": "b87ee450-8c64-47f6-9117-f4441b2617a5", "page": 21, "type": "paragraph", "text": "other influenza vaccines used within specified indications."}
{"id": "99f23e6f-c1da-4fdd-8ff8-f8a494f23713", "page": 21, "type": "paragraph", "text": "Dosage and Administration. LAIV4 is administered"}
{"id": "4c3f0782-80ac-4c37-b243-59e2b0c4557c", "page": 21, "type": "paragraph", "text": "intranasally using the supplied prefilled, single-use sprayer"}
{"id": "8c2f9dff-6164-451f-ad15-3f5f85f3441e", "page": 21, "type": "paragraph", "text": "containing 0.2 mL of vaccine. Approximately 0.1 mL (i.e., half"}
{"id": "504e1361-85be-4bb0-967a-47210966fbaf", "page": 21, "type": "paragraph", "text": "of the total sprayer contents) is sprayed into the first nostril while"}
{"id": "8ca68bf8-fbb0-4d30-9eed-4ae572ee0acf", "page": 21, "type": "paragraph", "text": "the recipient is in the upright position. An attached dose-divider"}
{"id": "d72ae200-2c6e-400c-b406-5810b76ee8b5", "page": 21, "type": "paragraph", "text": "clip is removed from the sprayer to permit administration of the"}
{"id": "09783061-bfa0-4be0-809e-1f603fa9e1f4", "page": 21, "type": "paragraph", "text": "second half of the dose into the other nostril. If the recipient"}
{"id": "447e546c-76e3-44e4-93d4-013a6ae57944", "page": 21, "type": "paragraph", "text": "sneezes immediately after administration, the dose should"}
{"id": "3a4dd778-50e8-491b-afe0-93fe3b83dc81", "page": 21, "type": "paragraph", "text": "not be repeated. However, if nasal congestion is present that"}
{"id": "a5f618d7-2706-441e-8bc7-38f2ff7a21b0", "page": 21, "type": "paragraph", "text": "might impede delivery of the vaccine to the nasopharyngeal"}
{"id": "1df5ec2e-84ce-4cc2-a395-94d2570f5a29", "page": 21, "type": "paragraph", "text": "mucosa, deferral of administration should be considered until"}
{"id": "21ca0641-2e77-4f48-b119-d2100982d3d5", "page": 21, "type": "paragraph", "text": "resolution of the illness, or another appropriate vaccine should"}
{"id": "4d933233-97c5-4857-acde-bd181845b06b", "page": 21, "type": "paragraph", "text": "be administered instead. Each total dose of 0.2 mL contains"}
{"id": "30af0569-5ffd-415d-a139-88a7e23ee2e1", "page": 21, "type": "paragraph", "text": "106.5\u20137.5 fluorescent focus units of each vaccine virus (99)."}
{"id": "81f37e08-7e3e-4fa4-baf0-befbd46b61fc", "page": 21, "type": "paragraph", "text": "Contraindications and Precautions for the Use of LAIV4."}
{"id": "416907dd-8fd6-484c-bd80-8ef0de186d43", "page": 21, "type": "paragraph", "text": "Conditions considered by ACIP to be contraindications and"}
{"id": "5a9c02dd-5760-48ec-b768-34c0dd580606", "page": 21, "type": "paragraph", "text": "precautions for the use of LAIV4 are summarized (Table 2)."}
{"id": "421eb458-7bc1-4671-9ca1-16984abc53ee", "page": 21, "type": "paragraph", "text": "These include two labeled contraindications that appear in"}
{"id": "1d3aff97-0b00-4669-b545-1a438329f80a", "page": 21, "type": "paragraph", "text": "the package insert (99) and other conditions for which there"}
{"id": "71986835-732e-4124-9c65-f01fb1463dbb", "page": 21, "type": "paragraph", "text": "is uncertain but biologically plausible potential risk associated"}
{"id": "3e351523-fdc8-40d4-af59-afb9820cead1", "page": 21, "type": "paragraph", "text": "with live viruses or limited data for use of LAIV."}
{"id": "3b965f23-8d20-4426-88d8-47f7a18b1d07", "page": 21, "type": "paragraph", "text": "Contraindications to use of LAIV4 include the following:"}
{"id": "3dd93eb7-48eb-4878-bfff-ec4803d37219", "page": 21, "type": "paragraph", "text": "\u2022 Severe allergic reaction (e.g., anaphylaxis) to any component"}
{"id": "6a037168-b8df-4058-873c-a44b8d39cca3", "page": 21, "type": "paragraph", "text": "of the vaccine or to a previous dose of any influenza vaccine"}
{"id": "e80fbf75-4e8f-450d-82e6-cfdd111af87e", "page": 21, "type": "paragraph", "text": "(i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency;"}
{"id": "fdf240a9-0e08-4039-9c6f-82e5e140cf3b", "page": 21, "type": "paragraph", "text": "a labeled contraindication noted in the package insert)."}
{"id": "36214af5-fabf-4666-b007-48c44cf8e621", "page": 21, "type": "paragraph", "text": "However, ACIP makes an exception for allergy to egg (see"}
{"id": "244c6a26-0011-4f3f-b8d8-61557289158d", "page": 21, "type": "paragraph", "text": "Persons with a History of Egg Allergy)."}
{"id": "c683bc56-a9b6-44cb-a383-9d25a3df5a18", "page": 21, "type": "paragraph", "text": "\u2022 Children and adolescents receiving concomitant aspirin- or"}
{"id": "b8ba4f72-bb96-454b-b488-c5b405b3482c", "page": 21, "type": "paragraph", "text": "salicylate-containing medications, because of the potential"}
{"id": "e3466e30-749f-4a4c-90ec-913f395c0b39", "page": 21, "type": "paragraph", "text": "risk for Reye syndrome (a labeled contraindication noted"}
{"id": "18245c65-ba0f-43f7-b984-8368669190c2", "page": 21, "type": "paragraph", "text": "in the package insert)."}
{"id": "18596a59-adb3-4241-961a-97fcc482ee8a", "page": 21, "type": "paragraph", "text": "\u2022 Children aged 2 through 4 years who have received a"}
{"id": "82a7b4d7-7b87-479d-8651-95df418f6579", "page": 21, "type": "paragraph", "text": "diagnosis of asthma or whose parents or caregivers report"}
{"id": "e041a989-c62a-4dbc-b62e-1d2dd2ca0db2", "page": 21, "type": "paragraph", "text": "that a health care provider has told them during the"}
{"id": "dc454c09-8516-4678-9ab3-be9544bbb52f", "page": 21, "type": "paragraph", "text": "preceding 12 months that their child had wheezing or"}
{"id": "c30952d7-dde8-4411-a42f-fbe2f7b38e3e", "page": 21, "type": "paragraph", "text": "asthma or whose medical record indicates a wheezing"}
{"id": "8f06da1d-4fc0-4eb1-a00e-d60db792d6f7", "page": 21, "type": "paragraph", "text": "episode has occurred during the preceding 12 months."}
{"id": "59e0e936-0d6e-48d3-8cd4-90a75f9336fa", "page": 21, "type": "paragraph", "text": "\u2022 Children and adults who are immunocompromised due to"}
{"id": "b01395df-c81e-4153-87fb-9ee48c36f484", "page": 21, "type": "paragraph", "text": "any cause, including but not limited to immunosuppression"}
{"id": "deeeb0b4-d3e0-483b-87e2-1033324eda77", "page": 21, "type": "paragraph", "text": "caused by medications, congenital or acquired"}
{"id": "f61b2c6d-c048-4d63-ac92-a95cbe3beafc", "page": 22, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "e1b5ae2c-c3bc-43df-bd51-c280c280cd39", "page": 22, "type": "paragraph", "text": "20"}
{"id": "bc8cde0e-7083-4f9d-a9d8-13aa1199e547", "page": 22, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "27a3fe39-1ba8-4d36-b1c7-cb09cc86a247", "page": 22, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "8faa8dac-e697-4e20-8c7b-e755da25ad52", "page": 22, "type": "paragraph", "text": "immunodeficiency states, HIV infection, anatomic asplenia,"}
{"id": "58e49fba-38b9-4012-b1c9-c55223ff56dc", "page": 22, "type": "paragraph", "text": "or functional asplenia (such as that due to sickle cell anemia)."}
{"id": "c9787a4b-3ce8-4b07-af92-37cf5a13fd50", "page": 22, "type": "paragraph", "text": "\u2022 Close contacts and caregivers of severely immunosuppressed"}
{"id": "c96e87a7-f465-4122-9258-bf25322db769", "page": 22, "type": "paragraph", "text": "persons who require a protected environment."}
{"id": "d923a8d3-4c91-45c1-9531-9d8016e26294", "page": 22, "type": "paragraph", "text": "\u2022 Pregnancy."}
{"id": "455d173d-6728-45a8-8335-3441e5729684", "page": 22, "type": "paragraph", "text": "\u2022 Persons with active communication between the"}
{"id": "ac7efe81-6d89-4448-9d07-3145c28a2e4e", "page": 22, "type": "paragraph", "text": "cerebrospinal fluid (CSF) and the oropharynx, nasopharynx,"}
{"id": "30601eab-15be-48fe-a07f-c979837d00b4", "page": 22, "type": "paragraph", "text": "nose, or ear or any other cranial CSF leak."}
{"id": "b60004da-6bb9-422f-98df-1dc475828806", "page": 22, "type": "paragraph", "text": "\u2022 Persons with cochlear implants, because of the potential for"}
{"id": "cc2c8a1d-46cf-47fb-8dc1-4c3e02a035d5", "page": 22, "type": "paragraph", "text": "CSF leak that might exist for a period after implantation"}
{"id": "d5af916e-747e-4043-9059-941e41af239a", "page": 22, "type": "paragraph", "text": "(providers might consider consultation with a specialist"}
{"id": "e73e93f4-ca3d-42d1-813f-3968ebac75a2", "page": 22, "type": "paragraph", "text": "concerning the risk for persistent CSF leak if an age-appropriate"}
{"id": "019818c1-50f9-4226-bb3b-c1b86292bf07", "page": 22, "type": "paragraph", "text": "inactivated or recombinant vaccine cannot be used)."}
{"id": "0fb3bebd-8412-4eb3-900f-c493786bf43a", "page": 22, "type": "paragraph", "text": "\u2022 Receipt of influenza antiviral medication within the"}
{"id": "a1e1bb01-73c5-4720-b465-0fbbd076f797", "page": 22, "type": "paragraph", "text": "previous 48 hours for oseltamivir and zanamivir, previous"}
{"id": "f65f55a6-b08a-46fd-8e7d-5df48ef300d5", "page": 22, "type": "paragraph", "text": "5 days for peramivir, and previous 17 days for baloxavir."}
{"id": "bd450bd9-895f-4df2-a0a2-5ffa0a00316d", "page": 22, "type": "paragraph", "text": "The interval between influenza antiviral receipt and LAIV4"}
{"id": "b95280e2-af30-43a2-b385-66dc082d815a", "page": 22, "type": "paragraph", "text": "during which interference might potentially occur might"}
{"id": "7de8cf88-6bfe-449e-9135-e24e25ac3958", "page": 22, "type": "paragraph", "text": "be further prolonged in the presence of medical conditions"}
{"id": "e400aca8-4dc3-48f4-b5dc-6c5882808f09", "page": 22, "type": "paragraph", "text": "that delay medication clearance (e.g., renal insufficiency)."}
{"id": "7336a24e-86d4-44b5-b6d9-c91333bcbabe", "page": 22, "type": "paragraph", "text": "Precautions for use of LAIV4 include the following:"}
{"id": "b7f700e0-2d6c-4089-a276-df9572498abc", "page": 22, "type": "paragraph", "text": "\u2022 Moderate or severe acute illness with or without fever."}
{"id": "29993dc8-cdb4-4572-92d7-4f035191006b", "page": 22, "type": "paragraph", "text": "\u2022 History of GBS within 6 weeks after receipt of any"}
{"id": "81def74a-cda2-4fe7-85ec-8007cc09aca3", "page": 22, "type": "paragraph", "text": "influenza vaccine."}
{"id": "8b52eacf-aa75-45c9-82b0-5669724e7831", "page": 22, "type": "paragraph", "text": "\u2022 Asthma in persons aged \u22655 years."}
{"id": "115fccbb-d890-4ed1-ae38-1954c851c504", "page": 22, "type": "paragraph", "text": "\u2022 Other underlying medical condition (other than those"}
{"id": "b2ccf8a3-4995-4323-9e08-ab8b7918f420", "page": 22, "type": "paragraph", "text": "listed under contraindications) that might predispose to"}
{"id": "365d1fe4-587a-4ffe-bb0a-1bdbed987a6e", "page": 22, "type": "paragraph", "text": "complications after wild-type influenza virus infection"}
{"id": "8769fe81-e3d2-4a9f-b359-eb25ffd5e8f4", "page": 22, "type": "paragraph", "text": "(e.g., chronic pulmonary, cardiovascular [except isolated"}
{"id": "f3831e37-dcfc-452f-bc63-d12a8e515141", "page": 22, "type": "paragraph", "text": "hypertension], renal, hepatic, neurologic, hematologic, or"}
{"id": "f156ba88-126f-4214-a590-6cd09f8a4c2c", "page": 22, "type": "paragraph", "text": "metabolic disorders [including diabetes mellitus])."}
{"id": "e0b1a43f-b357-4ff2-b179-4fdb57a5aff2", "page": 22, "type": "paragraph", "text": "Recent Influenza Vaccine Labeling Changes"}
{"id": "1f172d8d-5a08-45a7-9de0-cebf61f1cad1", "page": 22, "type": "paragraph", "text": "Flucelvax Quadrivalent"}
{"id": "fd218cca-fa20-4eb8-acd2-86febe5f1e2e", "page": 22, "type": "paragraph", "text": "Since the publication of the 2021\u201322 ACIP influenza vaccine"}
{"id": "8598d9e0-a8e2-4032-bd24-0a2046373fc1", "page": 22, "type": "paragraph", "text": "recommendations, a labeling change for Flucelvax Quadrivalent"}
{"id": "16ddbf47-b0f7-402c-b7cf-7c1558fb3baf", "page": 22, "type": "paragraph", "text": "(ccIIV4) has occurred. Flucelvax Quadrivalent was initially"}
{"id": "590d56f6-c253-48f4-9553-2fcc7e6fc777", "page": 22, "type": "paragraph", "text": "approved in 2016 for persons aged \u22654 years. Approval for persons"}
{"id": "c9310035-4c15-40ae-9c6c-5fbd0421fa7b", "page": 22, "type": "paragraph", "text": "aged \u226518 years was based on a randomized immunogenicity"}
{"id": "67c54caf-8cdf-4e12-8b27-e4082b80d9c0", "page": 22, "type": "paragraph", "text": "and safety trial that compared Flucelvax Quadrivalent with the"}
{"id": "5cc36bb4-1c37-46f6-a6de-b75befe72655", "page": 22, "type": "paragraph", "text": "previously approved trivalent formulation of Flucelvax (ccIIV3),"}
{"id": "e7d671e7-7676-4dc7-9b13-28baf87f52cb", "page": 22, "type": "paragraph", "text": "which had previously been licensed for persons aged \u226518 years"}
{"id": "d3a5c53a-c6ca-4da1-a062-b861818bd02f", "page": 22, "type": "paragraph", "text": "on the basis of data from a randomized clinical efficacy trial."}
{"id": "4459b355-c16f-461d-bea9-55fee5b61254", "page": 22, "type": "paragraph", "text": "Approval for children aged 4 through 17 years also was based on"}
{"id": "b7aefcea-2e34-47aa-b54a-b6acfd4ab0a9", "page": 22, "type": "paragraph", "text": "immunogenicity and safety data compared with ccIIV3, with a"}
{"id": "6769c649-da9d-4a44-9e78-537f16a941fe", "page": 22, "type": "paragraph", "text": "postmarketing requirement to conduct a clinical efficacy study"}
{"id": "44456b7a-be64-49bf-9f71-9cee87933ffd", "page": 22, "type": "paragraph", "text": "(128). In March 2021, FDA approved Flucelvax Quadrivalent"}
{"id": "c062f85a-5c12-444f-a914-3119c77b1992", "page": 22, "type": "paragraph", "text": "for persons aged \u22652 years on the basis of a randomized clinical"}
{"id": "91d9efea-903e-49d0-9af6-83d8a925eeb4", "page": 22, "type": "paragraph", "text": "efficacy trial conducted among 4,514 children aged \u22652 to"}
{"id": "64249ff0-dc76-470f-9601-98be16eadb5b", "page": 22, "type": "paragraph", "text": "<18 years over three influenza seasons (Southern Hemisphere"}
{"id": "16769130-9169-45be-8486-940cbd1bef78", "page": 22, "type": "paragraph", "text": "2017 and Northern Hemisphere 2017\u201318 and 2018\u201319) (129)."}
{"id": "aaf27ff1-3d71-459d-8564-5c3a7466b029", "page": 22, "type": "paragraph", "text": "Subsequently, in October 2021, FDA approved Flucelvax"}
{"id": "44a53f3c-0486-443e-bb11-b0b85391b587", "page": 22, "type": "paragraph", "text": "Quadrivalent for persons aged \u22656 months. Approval was based"}
{"id": "0458e757-f086-4834-9cc0-bdea0c15cae5", "page": 22, "type": "paragraph", "text": "on a randomized immunogenicity and safety study conducted"}
{"id": "7716602b-6034-48e6-9785-2482f49e3557", "page": 22, "type": "paragraph", "text": "among 2,402 children aged 6 through 47 months (of whom 894"}
{"id": "3435cb6f-a410-4227-9221-e0275cb6fa4a", "page": 22, "type": "paragraph", "text": "were aged 6 through 23 months). Children were randomized"}
{"id": "174138fb-a62c-42ec-85b1-3acc834cc612", "page": 22, "type": "paragraph", "text": "in a 2:1 ratio to receive either Flucelvax Quadrivalent"}
{"id": "b757ef40-888a-4317-a81a-f8dcb797dde6", "page": 22, "type": "paragraph", "text": "(0.5 mL/dose containing 15 \u00b5g HA per virus for all ages) or a"}
{"id": "72c870d8-87f4-41e5-82ff-86eb91d7dae0", "page": 22, "type": "paragraph", "text": "licensed comparator egg-based IIV4 (0.25 mL/dose containing"}
{"id": "5a382598-c4a8-409f-b859-19623ef34c16", "page": 22, "type": "paragraph", "text": "7.5 \u00b5g HA per virus for those aged 6 through 35 months and"}
{"id": "c3b30229-975b-4581-90d0-ffc3572abafd", "page": 22, "type": "paragraph", "text": "0.5 mL/dose containing 15 \u00b5g HA per virus for those aged"}
{"id": "1969d415-0a41-429e-a54a-7f73bedfe00c", "page": 22, "type": "paragraph", "text": "36 through 47 months) (130). Flucelvax Quadrivalent met"}
{"id": "8b832671-302c-4ac1-b6a8-dad474ebba89", "page": 22, "type": "paragraph", "text": "prespecified immunogenicity criteria for all four viruses. No new"}
{"id": "b523e606-af04-4658-bffb-6fdbfd2d0b5d", "page": 22, "type": "paragraph", "text": "safety signals were noted, and prevalence of solicited injection"}
{"id": "0ba5de3f-d555-4c4e-9dea-a5e8766b5a1c", "page": 22, "type": "paragraph", "text": "site and systemic reactions was similar between the two groups."}
{"id": "7ac188dd-1dfb-4d32-aad2-02e2799270f5", "page": 22, "type": "paragraph", "text": "Storage and Handling of"}
{"id": "a8f07de2-620f-4c31-82b0-12bfd1d0c434", "page": 22, "type": "paragraph", "text": "Influenza Vaccines"}
{"id": "2eb9feab-9b9f-4339-876d-ff52254d576f", "page": 22, "type": "paragraph", "text": "In all instances, approved manufacturer packaging information"}
{"id": "1ad4083b-2d1f-48f7-8481-9fdcd835f04f", "page": 22, "type": "paragraph", "text": "should be consulted for authoritative guidance concerning storage"}
{"id": "03797518-6cd8-4f41-bfeb-2351d8549503", "page": 22, "type": "paragraph", "text": "and handling of specific influenza vaccines. Typically, influenza"}
{"id": "ff02c1e6-9fb6-4f6d-b658-97bccd96cd65", "page": 22, "type": "paragraph", "text": "vaccines should be protected from light and stored at temperatures"}
{"id": "b12a9049-10a3-4a80-9e56-c34a4ca48d7f", "page": 22, "type": "paragraph", "text": "that are recommended in the package insert. Recommended"}
{"id": "4c71f0cb-0314-48d5-b375-5fdaf23d1ffd", "page": 22, "type": "paragraph", "text": "storage temperatures are typically 36\u00b0F\u201346\u00b0F (2\u00b0C\u20138\u00b0C) and"}
{"id": "91f5405e-ccda-4988-8e4e-8dde082e18ab", "page": 22, "type": "paragraph", "text": "should be maintained at all times with adequate refrigeration"}
{"id": "5b104287-676d-4102-bb38-68e77b7567c9", "page": 22, "type": "paragraph", "text": "and temperature monitoring. Vaccine that has frozen should be"}
{"id": "3b6650b7-245b-4222-8cb4-717a0defbff4", "page": 22, "type": "paragraph", "text": "discarded. Specific recommendations for appropriate refrigerators"}
{"id": "53a5baa4-a275-41fe-a2c7-398d30b08069", "page": 22, "type": "paragraph", "text": "and temperature monitoring equipment can be found in the"}
{"id": "fd236576-aa77-444c-8f7c-9deeacda409b", "page": 22, "type": "paragraph", "text": "Vaccine Storage and Handling Toolkit, available at https://www."}
{"id": "7a7c55e5-f8f2-4afb-878a-176296d142e1", "page": 22, "type": "paragraph", "text": "cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html."}
{"id": "2609f495-7b9b-447f-b1e4-6b36b8c3eece", "page": 22, "type": "paragraph", "text": "Vaccines should not be used beyond the expiration date on"}
{"id": "f3d81c2f-d6f4-481c-bd64-61634f56ea18", "page": 22, "type": "paragraph", "text": "the label. In addition to the expiration date, multidose vials also"}
{"id": "8c31bf50-63e2-41b2-bdcc-6e872980ca70", "page": 22, "type": "paragraph", "text": "might have a beyond-use date (BUD), which specifies the number"}
{"id": "9ffd15f5-a614-4dd1-a13b-339f719cff32", "page": 22, "type": "paragraph", "text": "of days the vaccine can be kept once first accessed. After being"}
{"id": "8e93a1b9-19c7-45bc-aa84-20e4062baa3b", "page": 22, "type": "paragraph", "text": "accessed for the first dose, multidose vials should not be used after"}
{"id": "ae223cee-67a8-45b3-ad1f-ad6b344fc253", "page": 22, "type": "paragraph", "text": "the BUD. If no BUD is provided, then the listed expiration date"}
{"id": "b6264d6e-03c7-40d3-bab8-21c584eed09c", "page": 22, "type": "paragraph", "text": "is to be used. Multidose vials should be returned to recommended"}
{"id": "fb800090-b226-4f4f-a0a8-bfe55885b4fb", "page": 22, "type": "paragraph", "text": "storage conditions between uses. Package information might also"}
{"id": "48200d8f-c9b0-4c51-9fc6-1724ea7145f5", "page": 22, "type": "paragraph", "text": "specify a maximum number of doses contained in multidose vials"}
{"id": "2f8b9bce-7675-47f3-a209-e16fb39bea5e", "page": 22, "type": "paragraph", "text": "(regardless of remaining volume). No more than the specified"}
{"id": "c7fcbc8c-16d1-4c53-bf9c-594056ccec44", "page": 22, "type": "paragraph", "text": "number of doses should be removed, and any remainder should"}
{"id": "e2a572a3-1588-4dca-9962-ea2cbea8fd9f", "page": 22, "type": "paragraph", "text": "be discarded. Single-dose vials should not be accessed for more"}
{"id": "6731a3da-faa0-40a3-89a6-60b12a934a1d", "page": 22, "type": "paragraph", "text": "than 1 dose. Providers should contact the manufacturer for"}
{"id": "19c17cb6-3bba-4307-b9c0-29f400aeb9bd", "page": 22, "type": "paragraph", "text": "information on permissible temperature excursions and other"}
{"id": "f8259943-d78a-4939-b1db-e8fcc3c2e1f4", "page": 22, "type": "paragraph", "text": "departures from recommended storage and handling conditions"}
{"id": "10a0dcd4-31f1-4a19-bb47-a6bf6d34b514", "page": 22, "type": "paragraph", "text": "that are not discussed in the package labeling."}
{"id": "db0a4b0e-2d2b-4ff6-bbe9-bca2a1fb6858", "page": 23, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "297c93fd-99d3-45c1-89ae-95ec5e103e7e", "page": 23, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "18f305e0-5e9f-4ed5-b029-e134b7dcb2b5", "page": 23, "type": "paragraph", "text": "21"}
{"id": "4189eea7-af05-4ab8-b54c-3d735f6e70c0", "page": 23, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "92f1c26a-7294-40fa-93d4-76b31b27df0a", "page": 23, "type": "paragraph", "text": "Additional Sources of Information"}
{"id": "e05cf39a-63e0-454b-b1cb-a38fc8c8fa61", "page": 23, "type": "paragraph", "text": "Regarding Influenza and"}
{"id": "8de55bfb-2d99-43e1-b2e1-b92d441c7913", "page": 23, "type": "paragraph", "text": "Influenza Vaccines"}
{"id": "3d2e0b6b-d201-4db5-89ba-1f2630749ed0", "page": 23, "type": "paragraph", "text": "Influenza Surveillance, Prevention,"}
{"id": "5f0101e8-9e4e-4d21-a4f5-df80c6aabc04", "page": 23, "type": "paragraph", "text": "and Control"}
{"id": "9e16559b-304c-4f5e-bce7-399f9312aa31", "page": 23, "type": "paragraph", "text": "Updated information regarding influenza surveillance,"}
{"id": "3711caf2-7bac-4a92-a0d6-1b05e0d59d53", "page": 23, "type": "paragraph", "text": "detection, prevention, and control is available at https://"}
{"id": "52d986bc-aa22-4b87-aaa7-fa9f49ef8682", "page": 23, "type": "paragraph", "text": "www.cdc.gov/flu. U.S. surveillance data are updated weekly"}
{"id": "07e252f7-1ee9-40c7-81ab-1469e9c22c35", "page": 23, "type": "paragraph", "text": "throughout the year on FluView (https://www.cdc.gov/flu/"}
{"id": "9ce72ce9-5217-4dea-a635-9937d466e02a", "page": 23, "type": "paragraph", "text": "weekly) and can be viewed in FluView Interactive (https://"}
{"id": "3e32a6b2-f7a2-4086-81db-e985db86720c", "page": 23, "type": "paragraph", "text": "www.cdc.gov/flu/weekly/fluviewinteractive.htm). In addition,"}
{"id": "646f6ba1-6e62-4128-a9af-933684e46f0d", "page": 23, "type": "paragraph", "text": "periodic updates regarding influenza are published in MMWR"}
{"id": "fbba4664-d576-4a7f-a43a-bdcdf7473a3d", "page": 23, "type": "paragraph", "text": "(https://www.cdc.gov/mmwr/index.html). Additional"}
{"id": "8d63388f-e2ba-4a25-855e-b73222a6f029", "page": 23, "type": "paragraph", "text": "information regarding influenza and influenza vaccines can"}
{"id": "3ed0b3a9-cff6-4b93-86c0-34fc51aafb9d", "page": 23, "type": "paragraph", "text": "be obtained from CDCINFO by calling 1-800-232-4636."}
{"id": "baf7705c-5325-4a39-88f6-170f8e0e54ab", "page": 23, "type": "paragraph", "text": "State and local health departments should be consulted"}
{"id": "9741ebb7-a811-40f7-b214-5947b5d4a2bb", "page": 23, "type": "paragraph", "text": "about availability of influenza vaccines, access to vaccination"}
{"id": "c92cc7a4-36ce-498d-af6e-9099a2f8ae03", "page": 23, "type": "paragraph", "text": "programs, information related to state or local influenza"}
{"id": "9d324888-eb88-46b1-a8c0-c821c7b6a76d", "page": 23, "type": "paragraph", "text": "activity, reporting of influenza outbreaks and influenza-related"}
{"id": "f1bddf6b-5bb4-4551-8638-5864910368e5", "page": 23, "type": "paragraph", "text": "pediatric deaths, and advice concerning outbreak control."}
{"id": "bdbcf7c3-76db-444a-bb04-482069218608", "page": 23, "type": "paragraph", "text": "Vaccine Adverse Event Reporting System"}
{"id": "459cd70c-8e62-4ee3-af8a-341eaec3f51e", "page": 23, "type": "paragraph", "text": "The National Childhood Vaccine Injury Act of 1986 requires"}
{"id": "6fd36df4-a96c-426f-be90-fda94140697d", "page": 23, "type": "paragraph", "text": "health care providers to report any adverse event listed by the"}
{"id": "938649eb-758d-43f7-a253-f2885971ef71", "page": 23, "type": "paragraph", "text": "vaccine manufacturer as a contraindication to future doses of"}
{"id": "d7b9fa57-17fd-44c5-9448-79ebce7c188d", "page": 23, "type": "paragraph", "text": "the vaccine or any adverse event listed in the VAERS Table of"}
{"id": "5362ea36-10e2-4cf8-b7fe-64e3c52fb955", "page": 23, "type": "paragraph", "text": "Reportable Events Following Vaccination (https://vaers.hhs."}
{"id": "ebbf38fc-eb17-48f3-9995-ab16af8f5280", "page": 23, "type": "paragraph", "text": "gov/docs/VAERS_Table_of_Reportable_Events_Following_"}
{"id": "cb1d5c04-1369-41fd-9e8e-8b01be906d86", "page": 23, "type": "paragraph", "text": "Vaccination.pdf) that occurs within the specified period after"}
{"id": "1b6ce2c1-b1bc-4d73-afd0-7e0b69d8862a", "page": 23, "type": "paragraph", "text": "vaccination. In addition to mandated reporting, health care"}
{"id": "7816d214-bfeb-4461-94ec-0dbe220fb1c2", "page": 23, "type": "paragraph", "text": "providers are encouraged to report any clinically significant"}
{"id": "f36b2eff-b0be-4ed0-917c-f624a5886af7", "page": 23, "type": "paragraph", "text": "adverse event after vaccination to VAERS. Information on"}
{"id": "c3b44ade-da7b-44b8-9f75-049793469566", "page": 23, "type": "paragraph", "text": "how to report a vaccine adverse event is available at https://"}
{"id": "4c136588-345a-4df4-98ba-d3bed9ac2c73", "page": 23, "type": "paragraph", "text": "vaers.hhs.gov/index.html."}
{"id": "1bc0b487-522a-4ffe-8c64-f9af80048a36", "page": 23, "type": "paragraph", "text": "National Vaccine Injury Compensation"}
{"id": "9d21c0b8-9712-4136-920f-e823caf4f0a0", "page": 23, "type": "paragraph", "text": "Program"}
{"id": "9c0ca84e-9520-4e0a-aa5c-1786b1895cb3", "page": 23, "type": "paragraph", "text": "The National Vaccine Injury Compensation Program (VICP),"}
{"id": "013962ab-832d-4986-a9d2-e7fc0af94fd5", "page": 23, "type": "paragraph", "text": "established by the National Childhood Vaccine Injury Act of 1986,"}
{"id": "957abfe1-02f1-443f-9cc2-0c24281c40a3", "page": 23, "type": "paragraph", "text": "as amended, is a mechanism through which compensation can"}
{"id": "a04688e4-0cee-4220-9182-3102d2045d34", "page": 23, "type": "paragraph", "text": "be provided to persons who might have been injured as a result"}
{"id": "346b82d6-c0c5-404d-9188-0632b40d83cf", "page": 23, "type": "paragraph", "text": "of receiving a vaccine covered by VICP. The Vaccine Injury Table"}
{"id": "5514b2e2-d2bb-4b5c-bd5d-976647f0d64b", "page": 23, "type": "paragraph", "text": "(https://www.hrsa.gov/sites/default/files/hrsa/vicp/vaccine-injury-"}
{"id": "5286f2f5-d0b0-4d35-a99e-cda1c651dbad", "page": 23, "type": "paragraph", "text": "table-01-03-2022.pdf) lists the vaccines covered by VICP and"}
{"id": "850b3c4a-f1cf-408e-8265-0bb076b2609c", "page": 23, "type": "paragraph", "text": "the associated injuries and conditions that might receive a legal"}
{"id": "b2df8ee1-e831-4cd5-8927-a0feb8741fe7", "page": 23, "type": "paragraph", "text": "presumption of causation. If the injury or condition is not in the"}
{"id": "d947d858-8629-44c9-b870-f7352e52d80a", "page": 23, "type": "paragraph", "text": "table or does not meet the requirements in the table, persons must"}
{"id": "a161c3af-976d-4f06-ac6c-8b3189f7f888", "page": 23, "type": "paragraph", "text": "prove that the vaccine caused the injury or condition. Claims"}
{"id": "af47f45c-839e-472d-80e5-6432a616bbde", "page": 23, "type": "paragraph", "text": "must be filed with specified time frames. Persons of all ages who"}
{"id": "94242a38-84d0-4da7-acca-d462258c629b", "page": 23, "type": "paragraph", "text": "receive a VICP-covered vaccine might be eligible to file a claim."}
{"id": "96a3aa26-906a-4012-9923-c4da05b606ad", "page": 23, "type": "paragraph", "text": "Additional information is available at https://www.hrsa.gov/"}
{"id": "6c898f18-10ec-4f16-a9df-bfd8d7ef414e", "page": 23, "type": "paragraph", "text": "vaccine-compensation or by calling 1-800-338-2382."}
{"id": "950591d1-7495-42de-a1ed-943197c99445", "page": 23, "type": "paragraph", "text": "Additional Resources"}
{"id": "f0e4c0f9-4ca3-4371-92b1-e9a3815fdfc2", "page": 23, "type": "paragraph", "text": "ACIP Statements"}
{"id": "b28d27fa-77f9-4038-b6c1-f8b57005a2eb", "page": 23, "type": "paragraph", "text": "\u2022 General Best Practice Guidelines for Immunization: Best"}
{"id": "51271be4-c2e9-4c5d-9849-e16aa8498aa8", "page": 23, "type": "paragraph", "text": "Practices Guidance of the Advisory Committee on"}
{"id": "351694c8-5a34-4266-b163-8742b34859e6", "page": 23, "type": "paragraph", "text": "Immunization Practices (ACIP): https://www.cdc.gov/"}
{"id": "72ac9df6-ea93-498c-8a2b-1f0c553591be", "page": 23, "type": "paragraph", "text": "vaccines/hcp/acip-recs/general-recs/index.html"}
{"id": "772dd45b-4b10-4a3a-9a18-17235b8252cb", "page": 23, "type": "paragraph", "text": "\u2022 Immunization of Health Care Personnel: Recommendations"}
{"id": "3ffe6671-e1ca-4039-b470-2258550e0ea5", "page": 23, "type": "paragraph", "text": "of the Advisory Committee on Immunization Practices"}
{"id": "14d4eda4-1b6b-4816-bab4-3cea5ee0ae9d", "page": 23, "type": "paragraph", "text": "(ACIP), 2011. MMWR Recomm Rep 2011;60(No."}
{"id": "c5b2d4b2-6996-445c-86ce-9d85e521e60e", "page": 23, "type": "paragraph", "text": "RR-7):1\u201345: https://www.cdc.gov/mmwr/preview/"}
{"id": "5540a268-4ca7-48fa-a6f0-6258dcbac667", "page": 23, "type": "paragraph", "text": "mmwrhtml/rr6007a1.htm"}
{"id": "3ac8c623-e6ec-45c4-be6d-983dff7608e3", "page": 23, "type": "paragraph", "text": "\u2022 Recommended Adult Immunization Schedule for Ages"}
{"id": "5e8bb010-ce70-43f3-9042-d2a5c82421ed", "page": 23, "type": "paragraph", "text": "19 Years or Older, United States: https://www.cdc.gov/"}
{"id": "4d70d8c1-60f8-4b4f-8b26-8464e9713407", "page": 23, "type": "paragraph", "text": "vaccines/schedules/hcp/imz/adult.html"}
{"id": "c4f7606f-8ef9-4c75-b682-3b0a3aebe9f2", "page": 23, "type": "paragraph", "text": "\u2022 Recommended Child and Adolescent Immunization Schedule"}
{"id": "eca27404-1979-431d-81e1-e09096eef862", "page": 23, "type": "paragraph", "text": "for Ages 18 Years or Younger, United States: https://www.cdc."}
{"id": "4755ac03-8b41-4a40-a747-72752f82d012", "page": 23, "type": "paragraph", "text": "gov/vaccines/schedules/hcp/imz/child-adolescent.html"}
{"id": "e9a64ead-6fda-47db-b837-6945c4c8c21b", "page": 23, "type": "paragraph", "text": "COVID-19 Vaccine Recommendations and Guidance"}
{"id": "4c7c1301-095e-4d78-8676-3a6215e46f6d", "page": 23, "type": "paragraph", "text": "\u2022 ACIP recommendations for the use of COVID-19"}
{"id": "3823494a-9dcf-40e1-9c6e-da0fbaf373fd", "page": 23, "type": "paragraph", "text": "vaccines: https://www.cdc.gov/vaccines/hcp/acip-recs/"}
{"id": "f3919448-f255-4095-b41c-29fa38f461ab", "page": 23, "type": "paragraph", "text": "vacc-specific/covid-19.html"}
{"id": "bd409f40-50fe-4350-9167-e74196e3d20d", "page": 23, "type": "paragraph", "text": "\u2022 Clinical Care Considerations for COVID-19 Vaccination"}
{"id": "997f43a2-a0d0-48ad-9efc-39696ad514a5", "page": 23, "type": "paragraph", "text": "(contains clinical guidance and links to current ACIP"}
{"id": "b8fd6e4f-f19c-40b4-be8f-5a07f8885338", "page": 23, "type": "paragraph", "text": "recommendations): https://www.cdc.gov/vaccines/covid-"}
{"id": "299a19a4-6c30-48fd-860c-8e0f2ac2e970", "page": 23, "type": "paragraph", "text": "19/clinical-considerations/index.html"}
{"id": "cbfb718b-3c2a-4ade-80ea-b0f27dee5e6c", "page": 23, "type": "paragraph", "text": "\u2022 Interim Clinical Considerations for Use of COVID-19"}
{"id": "e747ce4c-e3db-4c5f-8eb1-7fa65738f88f", "page": 23, "type": "paragraph", "text": "Vaccines Currently Approved or Authorized in the United"}
{"id": "d3fe314e-2998-4f95-8d88-176b89b8c2ea", "page": 23, "type": "paragraph", "text": "States: https://www.cdc.gov/vaccines/covid-19/clinical-"}
{"id": "d66a6ce5-f97d-4ecf-bfad-992307134a06", "page": 23, "type": "paragraph", "text": "considerations/covid-19-vaccines-us.html"}
{"id": "6458a52b-8bc7-40a0-9d4b-0b08fa22461f", "page": 23, "type": "paragraph", "text": "\u2022 FDA COVID-19 Vaccines page: https://www.fda.gov/"}
{"id": "8e040099-bb66-4638-9589-0c7960de38aa", "page": 23, "type": "paragraph", "text": "emergency-preparedness-and-response/coronavirus-"}
{"id": "3eea8bd6-cf1f-4f0a-bf0f-d14db39123a5", "page": 23, "type": "paragraph", "text": "disease-2019-covid-19/covid-19-vaccines"}
{"id": "b1ea3ae5-8634-4a8f-82ff-2a5977586dcd", "page": 23, "type": "paragraph", "text": "Vaccine Information Sheets"}
{"id": "4bbce4d4-acea-4676-81e4-862d0662901b", "page": 23, "type": "paragraph", "text": "\u2022 IIV4 and RIV4: https://www.cdc.gov/vaccines/hcp/vis/"}
{"id": "53a249f8-aee5-447a-88c1-14bb2d7af8ad", "page": 23, "type": "paragraph", "text": "vis-statements/flu.pdf"}
{"id": "60b8d3db-af57-4ec1-b345-598094ddb84a", "page": 23, "type": "paragraph", "text": "\u2022 LAIV4: https://www.cdc.gov/vaccines/hcp/vis/vis-"}
{"id": "4f58be2a-a3ce-4413-9e56-ff379e39f73a", "page": 23, "type": "paragraph", "text": "statements/flulive.pdf"}
{"id": "82edcb91-5c55-496e-b9ff-abd371226185", "page": 24, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "6069ad1f-e2da-466a-9f3d-a5b4bde5a64b", "page": 24, "type": "paragraph", "text": "22"}
{"id": "b3590294-045a-428d-b6a4-76b3fa29ae0d", "page": 24, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "5648c037-55c3-480e-973f-6f1c9767da17", "page": 24, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "6413a784-ffd5-4f29-9c5c-e93478ee3aea", "page": 24, "type": "paragraph", "text": "Influenza Vaccine Package Inserts"}
{"id": "650baed7-c7ed-474c-9078-850fcb17b5c7", "page": 24, "type": "paragraph", "text": "\u2022 https://www.fda.gov/vaccines-blood-biologics/vaccines/"}
{"id": "024b77e0-5f88-44c6-9c99-eee4aeed199b", "page": 24, "type": "paragraph", "text": "vaccines-licensed-use-united-states"}
{"id": "aaf19e5c-12e1-4017-8dc2-de4eee564b75", "page": 24, "type": "paragraph", "text": "CDC Influenza Antiviral Guidance"}
{"id": "507bb008-f572-463d-bc74-960bfe1e7075", "page": 24, "type": "paragraph", "text": "\u2022 Influenza Antiviral Medications: Summary for Clinicians:"}
{"id": "33ea12aa-8c1c-4472-89b9-bbd343da3ef5", "page": 24, "type": "paragraph", "text": "https://www.cdc.gov/flu/professionals/antivirals/"}
{"id": "5f6b898a-807e-4364-b55e-6a7af85d8672", "page": 24, "type": "paragraph", "text": "summary-clinicians.htm"}
{"id": "736b584d-3947-42a4-b274-0ec0c441f283", "page": 24, "type": "paragraph", "text": "Infectious Diseases Society of America Influenza"}
{"id": "05009c98-8f0d-45a3-9f71-5fdf40c804b2", "page": 24, "type": "paragraph", "text": "Antiviral Guidance"}
{"id": "3302bdf0-8397-4299-acfe-f38549c885d5", "page": 24, "type": "paragraph", "text": "\u2022 Clinical Practice Guidelines by the Infectious Diseases"}
{"id": "62c0c85a-e482-4c7e-8ed0-cc4a7e6a0de7", "page": 24, "type": "paragraph", "text": "Society of America: 2018 Update on Diagnosis, Treatment,"}
{"id": "53241f8f-a90d-4161-b21c-bd31304fe94c", "page": 24, "type": "paragraph", "text": "Chemoprophylaxis, and Institutional Outbreak"}
{"id": "52da4dd9-c8e9-41dc-9fa4-855021bcd2ac", "page": 24, "type": "paragraph", "text": "Management of Seasonal Influenza: https://academic.oup."}
{"id": "90c543eb-84e0-468f-a046-f046626b0be5", "page": 24, "type": "paragraph", "text": "com/cid/article/68/6/e1/5251935"}
{"id": "edae9fdf-b296-4036-9a6e-d7916bb42299", "page": 24, "type": "paragraph", "text": "American Academy of Pediatrics Guidance"}
{"id": "1ba8c2e7-4892-46ce-a94a-cf2e251baaa4", "page": 24, "type": "paragraph", "text": "\u2022 American Academy of Pediatrics Recommendations for"}
{"id": "70f86f19-9f0a-41d2-9eab-083ed49d14fb", "page": 24, "type": "paragraph", "text": "Prevention and Control of Influenza in Children (Red"}
{"id": "41273717-26f9-471f-b144-54eea9a6a151", "page": 24, "type": "paragraph", "text": "Book Online): https://redbook.solutions.aap.org/selfserve/"}
{"id": "3b23f59a-dc2d-4dd9-b04c-73234a015fff", "page": 24, "type": "paragraph", "text": "sspage.aspx?selfservecontentid=influenza-resources"}
{"id": "2f7cfae2-4717-48e3-9fce-76bb70c20a6e", "page": 24, "type": "paragraph", "text": "Infectious Diseases Society of America Guidance"}
{"id": "8fac279d-7826-4a60-b4d2-77a3bcb4639c", "page": 24, "type": "paragraph", "text": "for Vaccination of Immunocompromised Hosts"}
{"id": "2893d7d2-26e2-4069-8d9f-1cb4d4ff3a2d", "page": 24, "type": "paragraph", "text": "\u2022 2013 IDSA Clinical Practice Guideline for Vaccination"}
{"id": "ad8a630b-f2c7-4347-bb79-3e4dc98a06cb", "page": 24, "type": "paragraph", "text": "of the Immunocompromised Host: https://academic.oup."}
{"id": "b1783a48-f56d-4cb9-9824-18cbaefecb80", "page": 24, "type": "paragraph", "text": "com/cid/article/58/3/e44/336537"}
{"id": "7422f1c7-0cf5-4dcb-8fcf-d909a561c98c", "page": 24, "type": "paragraph", "text": "American College of Obstetricians and"}
{"id": "bbd3381e-5915-4d74-8346-31ba9d956bcc", "page": 24, "type": "paragraph", "text": "Gynecologists"}
{"id": "a64e064c-085d-4288-a454-538ff6c0da93", "page": 24, "type": "paragraph", "text": "\u2022 Influenza Vaccination During Pregnancy, ACOG"}
{"id": "7f8b7dc4-a692-4cc4-96fd-b69e196c8a26", "page": 24, "type": "paragraph", "text": "Committee Opinion No. 732: https://www.acog.org/"}
{"id": "0a9d7dcb-844f-4bb4-815b-4b4bb123ac65", "page": 24, "type": "paragraph", "text": "clinical/clinical-guidance/committee-opinion/"}
{"id": "d859d8bd-1a33-4c9e-a609-90c1930e8759", "page": 24, "type": "paragraph", "text": "articles/2018/04/influenza-vaccination-during-pregnancy"}
{"id": "8a820a71-166c-45a4-9acf-db45338f8c71", "page": 24, "type": "paragraph", "text": "References"}
{"id": "9f8d5c52-7b11-400f-b1e5-6d558a34b100", "page": 24, "type": "paragraph", "text": "1. Barker WH. Excess pneumonia and influenza associated hospitalization"}
{"id": "8e6571ac-7cf0-4208-8547-f6005f0734f6", "page": 24, "type": "paragraph", "text": "during influenza epidemics in the United States, 1970\u201378. Am J Public"}
{"id": "3237f422-8f65-4a03-a933-ff8732d43c31", "page": 24, "type": "paragraph", "text": "Health 1986;76:761\u20135. PMID:3717461 https://doi.org/10.2105/"}
{"id": "1b0b70d6-8d93-4641-8e4e-cb035d3d3afb", "page": 24, "type": "paragraph", "text": "AJPH.76.7.761"}
{"id": "e86e0b14-6be1-44f2-aa2f-e06a730179fe", "page": 24, "type": "paragraph", "text": "2. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a"}
{"id": "86240e8e-b648-4cb1-8c40-9bb90e383757", "page": 24, "type": "paragraph", "text": "defined adult population. Am J Epidemiol 1980;112:798\u2013811."}
{"id": "eccb74a2-b07c-4ab0-ad3a-c31cfc5a5404", "page": 24, "type": "paragraph", "text": "PMID:7457471 https://doi.org/10.1093/oxfordjournals.aje.a113052"}
{"id": "e768e023-5277-43fe-8175-51b76f5bd7cf", "page": 24, "type": "paragraph", "text": "3. Coleman BL, Fadel SA, Fitzpatrick T, Thomas SM. Risk factors for"}
{"id": "5fa9f9a3-f38d-4d13-ae4f-634f8e67fe7a", "page": 24, "type": "paragraph", "text": "serious outcomes associated with influenza illness in high- versus low-"}
{"id": "4251486f-e0a0-46f2-bf5c-b2d10ac84c8c", "page": 24, "type": "paragraph", "text": "and middle-income countries: systematic literature review and meta-"}
{"id": "adaf12f1-de7c-4b0e-ae08-0bcc725f78ad", "page": 24, "type": "paragraph", "text": "analysis. Influenza Other Respir Viruses 2018;12:22\u20139. PMID:29197154"}
{"id": "24524f7c-3181-4982-b8b0-8ca89d83d14e", "page": 24, "type": "paragraph", "text": "https://doi.org/10.1111/irv.12504"}
{"id": "648d5d46-00ff-4b25-9bba-c5e00bb507e1", "page": 24, "type": "paragraph", "text": "4. Mullooly JP, Bridges CB, Thompson WW, et al.; Vaccine Safety Datalink"}
{"id": "f07d5a92-cd5f-4c86-8326-f8a4df001b42", "page": 24, "type": "paragraph", "text": "Adult Working Group. Influenza- and RSV-associated hospitalizations"}
{"id": "ce89726f-7ccc-4291-9d1e-65d8b1bebe15", "page": 24, "type": "paragraph", "text": "among adults. Vaccine 2007;25:846\u201355. PMID:17074423 https://doi."}
{"id": "18b7064e-59c6-4506-9fc5-a100880574da", "page": 24, "type": "paragraph", "text": "org/10.1016/j.vaccine.2006.09.041"}
{"id": "0d35327b-a672-4725-b7ac-bd6cd0341c37", "page": 24, "type": "paragraph", "text": "5. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza"}
{"id": "f0025f7b-63ac-4059-9bba-8c79799481c0", "page": 24, "type": "paragraph", "text": "in young children, 2004\u20132009. Pediatrics 2013;131:207\u201316."}
{"id": "aa64b308-820a-4d5e-b91b-69e6351e9f98", "page": 24, "type": "paragraph", "text": "PMID:23296444 https://doi.org/10.1542/peds.2012-1255"}
{"id": "aa8923ff-5835-4773-94a5-3bbeff1502bf", "page": 24, "type": "paragraph", "text": "6. Poehling KA, Edwards KM, Weinberg GA, et al.; New Vaccine"}
{"id": "b399623f-5b56-45e5-a0ed-eb0ff304c497", "page": 24, "type": "paragraph", "text": "Surveillance Network. The underrecognized burden of influenza in"}
{"id": "88741f45-af3d-4da2-a720-d14f02fd02b6", "page": 24, "type": "paragraph", "text": "young children. N Engl J Med 2006;355:31\u201340. PMID:16822994"}
{"id": "afe5bdd1-7a21-4d76-89db-0d6c0dcbc35d", "page": 24, "type": "paragraph", "text": "https://doi.org/10.1056/NEJMoa054869"}
{"id": "b829efaf-d582-4a69-83a6-8124bedcec9d", "page": 24, "type": "paragraph", "text": "7. Siston AM, Rasmussen SA, Honein MA, et al.; Pandemic H1N1"}
{"id": "098d717a-de1b-4fe9-83c8-a83d6c2c1c47", "page": 24, "type": "paragraph", "text": "Influenza in Pregnancy Working Group. Pandemic 2009 influenza"}
{"id": "b5298cf2-84ca-49e1-bff8-7d2129466035", "page": 24, "type": "paragraph", "text": "A(H1N1) virus illness among pregnant women in the United States."}
{"id": "bd75d6b0-cfa9-45ee-b89e-95b39f287007", "page": 24, "type": "paragraph", "text": "JAMA 2010;303:1517\u201325. PMID:20407061 https://doi.org/10.1001/"}
{"id": "f7e21fba-26b7-40e2-8db7-fcefc10d94cc", "page": 24, "type": "paragraph", "text": "jama.2010.479"}
{"id": "adcfcfca-b42b-4dab-9454-142df51695b2", "page": 24, "type": "paragraph", "text": "8. Fragaszy EB, Warren-Gash C, White PJ, et al.; Flu Watch Group. Effects"}
{"id": "47e55dbd-e3c7-4e7c-af75-51a683fcf545", "page": 24, "type": "paragraph", "text": "of seasonal and pandemic influenza on health-related quality of life,"}
{"id": "7c933df4-e0e2-49cf-b8c7-235368b2bbd2", "page": 24, "type": "paragraph", "text": "work and school absence in England: results from the Flu Watch cohort"}
{"id": "4ba4a8e9-4217-4716-9a3c-514a2977156c", "page": 24, "type": "paragraph", "text": "study. Influenza Other Respir Viruses 2018;12:171\u201382. PMID:28991409"}
{"id": "30214712-0ede-4f4c-ad64-72facf6c7938", "page": 24, "type": "paragraph", "text": "https://doi.org/10.1111/irv.12506"}
{"id": "458a4bc4-5149-4485-9aaa-40324057faf3", "page": 24, "type": "paragraph", "text": "9. Van Wormer JJ, King JP, Gajewski A, McLean HQ, Belongia EA."}
{"id": "680f0766-6464-41cc-9b56-a213bf4d2a0f", "page": 24, "type": "paragraph", "text": "Influenza and workplace productivity loss in working adults. J Occup"}
{"id": "0ca3c1e1-3ea7-45a9-97c5-763ac159f2c8", "page": 24, "type": "paragraph", "text": "Environ Med 2017;59:1135\u20139. PMID:28759481 https://doi."}
{"id": "fa2e9112-85da-43c8-a8a9-a94028393258", "page": 24, "type": "paragraph", "text": "org/10.1097/JOM.0000000000001120"}
{"id": "e0883ceb-0d10-432c-9d27-407c22ed1c7c", "page": 24, "type": "paragraph", "text": "10. Willis GA, Preen DB, Richmond PC, et al.; WAIVE Study Team. The"}
{"id": "9f479149-263c-4daf-9250-7bd83cb8c618", "page": 24, "type": "paragraph", "text": "impact of influenza infection on young children, their family and the"}
{"id": "72f3d536-7b82-4fbf-a4a9-ea252fb258a1", "page": 24, "type": "paragraph", "text": "health care system. Influenza Other Respir Viruses 2019;13:18\u201327."}
{"id": "13a6b84b-dac2-4556-a602-2c23bfcf52ef", "page": 24, "type": "paragraph", "text": "PMID:30137663 https://doi.org/10.1111/irv.12604"}
{"id": "ad1ff8ac-10f9-4854-a5ce-875007da3b58", "page": 24, "type": "paragraph", "text": "11. Fiore AE, Uyeki TM, Broder K, et al.; CDC. Prevention and control of"}
{"id": "fd5cbdc2-3ecf-4f55-811e-bfe028dee57a", "page": 24, "type": "paragraph", "text": "influenza with vaccines: recommendations of the Advisory Committee"}
{"id": "af86d687-7277-40ba-a7f5-5f24196e258c", "page": 24, "type": "paragraph", "text": "on Immunization Practices (ACIP), 2010. MMWR Recomm Rep"}
{"id": "e3f928e7-8e88-4e9c-ad5f-ea4a5dbd2592", "page": 24, "type": "paragraph", "text": "2010;59(No. RR-8):1\u201362. PMID:20689501"}
{"id": "0c21e8bc-99bf-4be7-a32d-9a9722d733a4", "page": 24, "type": "paragraph", "text": "12. CDC. How flu vaccine effectiveness and efficacy are measured: questions"}
{"id": "afc96a2c-d159-4f66-8d59-809cf7c1fd38", "page": 24, "type": "paragraph", "text": "and answers. Atlanta, GA: US Department of Health and Human"}
{"id": "592c6aa5-40be-47e5-80af-a6be52149406", "page": 24, "type": "paragraph", "text": "Services, CDC; 2016. https://www.cdc.gov/flu/vaccines-work/"}
{"id": "c398a029-1eb7-4080-a20c-289ef8298d33", "page": 24, "type": "paragraph", "text": "effectivenessqa.htm"}
{"id": "2dfc9f8e-ecab-4884-bbc2-9590d51b9957", "page": 24, "type": "paragraph", "text": "13. Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of"}
{"id": "50b259cc-c890-445f-b4fe-4c14193b141f", "page": 24, "type": "paragraph", "text": "seasonal influenza in the United States: a tool for strengthening influenza"}
{"id": "d3067805-5dfb-41d7-a13e-71d55e505a88", "page": 24, "type": "paragraph", "text": "surveillance and preparedness. Influenza Other Respir Viruses"}
{"id": "e64ca853-ca56-4012-abd1-40c9a5bd084a", "page": 24, "type": "paragraph", "text": "2018;12:132\u20137. PMID:29446233 https://doi.org/10.1111/irv.12486"}
{"id": "59b3d600-a3f3-4238-840d-92d0a839ce6a", "page": 24, "type": "paragraph", "text": "14. Rolfes MA, Flannery B, Chung JR, et al.; US Influenza Vaccine"}
{"id": "d0dfc056-9777-48be-85d2-81944a02a172", "page": 24, "type": "paragraph", "text": "Effectiveness (Flu VE) Network; Influenza Hospitalization Surveillance"}
{"id": "5c46b869-b72d-4496-aef9-dff4f23fae88", "page": 24, "type": "paragraph", "text": "Network; Assessment Branch, Immunization Services Division, CDC."}
{"id": "3f0e1ce2-92ca-412c-878f-4953d11c7bd5", "page": 24, "type": "paragraph", "text": "Effects of influenza vaccination in the United States during the 2017\u2013"}
{"id": "a500fe21-961f-41c9-be86-fbe7b0381fad", "page": 24, "type": "paragraph", "text": "2018 influenza season. Clin Infect Dis 2019;69:1845\u201353."}
{"id": "788070a3-0e04-433a-b0eb-68f5459998ac", "page": 24, "type": "paragraph", "text": "PMID:30715278 https://doi.org/10.1093/cid/ciz075"}
{"id": "e574519c-827b-4172-98b2-1d33a63c5974", "page": 24, "type": "paragraph", "text": "15. CDC. 2020\u201321 flu season summary FAQ. Atlanta, GA: US Department"}
{"id": "96594961-9294-4c60-9665-8510f6058e49", "page": 24, "type": "paragraph", "text": "of Health and Human Services, CDC; 2021. https://www.cdc.gov/flu/"}
{"id": "3bccc96b-162b-4709-95aa-c60bba3c03a6", "page": 24, "type": "paragraph", "text": "season/faq-flu-season-2020-2021.htm"}
{"id": "18114a20-0c96-4b14-a008-9fc0cca199f0", "page": 24, "type": "paragraph", "text": "16. CDC. Fluview. Weekly influenza surveillance report. Atlanta, GA: US"}
{"id": "851dff7e-31b7-4600-9fad-1026b92a483d", "page": 24, "type": "paragraph", "text": "Department of Health and Human Services, CDC; 2021. https://www."}
{"id": "6496903d-8d61-4f2d-add4-8bedf4da10b1", "page": 24, "type": "paragraph", "text": "cdc.gov/flu/weekly/index.htm"}
{"id": "68dbd060-8a67-4ea4-af1f-895c564cc113", "page": 24, "type": "paragraph", "text": "17. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control"}
{"id": "4eef780a-5b67-4add-b9c6-c2ac1f3ea558", "page": 24, "type": "paragraph", "text": "of seasonal influenza with vaccines: recommendations of the Advisory"}
{"id": "c6b63428-6610-460d-a015-e1e2c400c79d", "page": 24, "type": "paragraph", "text": "Committee on Immunization Practices, United States, 2021\u201322"}
{"id": "5287f765-5b3d-4e55-98eb-974d6cadb77a", "page": 24, "type": "paragraph", "text": "influenza season. MMWR Recomm Rep 2021;70(No. RR-5):1\u201328."}
{"id": "552b003f-552a-4d0f-990b-890413ced76a", "page": 24, "type": "paragraph", "text": "PMID:34448800 https://doi.org/10.15585/mmwr.rr7005a1"}
{"id": "4654f9b0-96ce-403e-bbef-3b0cff436f96", "page": 24, "type": "paragraph", "text": "18. Ahmed F. ACIP handbook for developing evidence-based"}
{"id": "f80ac85c-6abb-4978-9772-b5eb46359991", "page": 24, "type": "paragraph", "text": "recommendations, Version 1.2. Atlanta, GA: US Department of Health"}
{"id": "82df1356-fab3-4a19-97fd-a5ee3cea0d48", "page": 24, "type": "paragraph", "text": "and Human Services, CDC; 2013."}
{"id": "84dba6eb-fc1b-45ca-a516-002e6fb16699", "page": 25, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "12a392ec-02c9-460a-acc9-c0f9eef03ed3", "page": 25, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "c316fdf8-868b-4e1f-b66b-7bffa097d77b", "page": 25, "type": "paragraph", "text": "23"}
{"id": "678d52a1-b52f-494b-b642-3df925f5fcee", "page": 25, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "58b8df3c-aea9-413e-8666-0ec6b2138508", "page": 25, "type": "paragraph", "text": "19. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J,"}
{"id": "afff3d74-b5c1-4361-8e0a-3eec90ab50c3", "page": 25, "type": "paragraph", "text": "VanWormer JJ. Waning vaccine protection against influenza A (H3N2)"}
{"id": "dcfb855e-d8ee-42a0-b32a-e4da9d08ac00", "page": 25, "type": "paragraph", "text": "illness in children and older adults during a single season. Vaccine"}
{"id": "5a151dc2-5f14-4bc0-ab1a-8a9ec082b81d", "page": 25, "type": "paragraph", "text": "2015;33:246\u201351. PMID:24962752 https://doi.org/10.1016/j."}
{"id": "d912f1af-46cc-4106-9ef2-f1be2b7ee677", "page": 25, "type": "paragraph", "text": "vaccine.2014.06.052"}
{"id": "c078f314-ab4a-4d69-9637-d52169607769", "page": 25, "type": "paragraph", "text": "20. Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA,"}
{"id": "3a129f64-97fd-4e71-a207-41e1c1a0e5e5", "page": 25, "type": "paragraph", "text": "Brice GT. Influenza vaccine effectiveness: maintained protection"}
{"id": "30949441-725b-4468-b3b6-af3cdce3d7b0", "page": 25, "type": "paragraph", "text": "throughout the duration of influenza seasons 2010\u20132011 through"}
{"id": "3c6f4c2c-6ad1-4b3d-8856-9c8674fbfb3f", "page": 25, "type": "paragraph", "text": "2013\u20132014. Vaccine 2016;34:3907\u201312. PMID:27265447 https://doi."}
{"id": "049b49b4-d962-48bb-afdb-18a2e1361e3a", "page": 25, "type": "paragraph", "text": "org/10.1016/j.vaccine.2016.05.034"}
{"id": "314c258a-20b3-400c-aff7-29b4a65a8adc", "page": 25, "type": "paragraph", "text": "21. Ray GT, Lewis N, Klein NP, et al. Intraseason waning of influenza"}
{"id": "2b702587-3746-41e0-9095-687618076cbf", "page": 25, "type": "paragraph", "text": "vaccine effectiveness. Clin Infect Dis 2019;68:1623\u201330. PMID:30204855"}
{"id": "57599765-d137-405e-bf1c-39c744d19421", "page": 25, "type": "paragraph", "text": "https://doi.org/10.1093/cid/ciy770"}
{"id": "396ad726-8838-4088-99dc-e14cbc7f1f40", "page": 25, "type": "paragraph", "text": "22. Powell LN, B\u00e9gu\u00e9 RE. Influenza vaccine effectiveness among children"}
{"id": "9568e4f5-92f1-4cdd-b1f7-84d4043ed6a3", "page": 25, "type": "paragraph", "text": "for the 2017\u20132018 season. J Pediatric Infect Dis Soc 2020;9:468\u201373."}
{"id": "c54a9dd5-6d7d-4aac-9ede-b6929b38cdd1", "page": 25, "type": "paragraph", "text": "PMID:31774120 https://doi.org/10.1093/jpids/piz077"}
{"id": "3a6aebeb-1b82-4813-b597-280f93122071", "page": 25, "type": "paragraph", "text": "23. Castilla J, Mart\u00ednez-Baz I, Mart\u00ednez-Artola V, et al.; Primary Health"}
{"id": "9880c480-3cb1-44c0-babb-ecc5080d053f", "page": 25, "type": "paragraph", "text": "Care Sentinel Network; Network for Influenza Surveillance in Hospitals"}
{"id": "4e9d9053-dfda-4a82-9208-bcbf1976dfbd", "page": 25, "type": "paragraph", "text": "of Navarre. Decline in influenza vaccine effectiveness with time after"}
{"id": "6ec85748-d651-462b-bb1c-2a12a32b4b9c", "page": 25, "type": "paragraph", "text": "vaccination, Navarre, Spain, season 2011/12. Euro Surveill"}
{"id": "e0da8a83-d715-4a05-9498-a24c719dd35c", "page": 25, "type": "paragraph", "text": "2013;18:20388. PMID:23399423 https://doi.org/10.2807/"}
{"id": "1354eacc-f469-4dea-b6c8-fc5b574d0110", "page": 25, "type": "paragraph", "text": "ese.18.05.20388-en"}
{"id": "6bb498eb-8777-4dfd-a104-a6431a85d74b", "page": 25, "type": "paragraph", "text": "24. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine"}
{"id": "adb277f1-aa18-4ecf-a136-78352ebd5be4", "page": 25, "type": "paragraph", "text": "effectiveness against influenza A(H3) in 2011/12 among vaccination"}
{"id": "3be72135-b3d8-48a2-9783-3fe3a15ee7b5", "page": 25, "type": "paragraph", "text": "target groups in Europe: results from the I-MOVE multicentre case-"}
{"id": "50144ac9-0568-4a8c-9bb6-6fba516fe3f5", "page": 25, "type": "paragraph", "text": "control study. Euro Surveill 2013;18:20390. PMID:23399425 https://"}
{"id": "99d35ec7-ab7c-45d9-beff-9621c1ffda3d", "page": 25, "type": "paragraph", "text": "doi.org/10.2807/ese.18.05.20390-en"}
{"id": "23681a2c-7674-44b3-be83-0a86ccb448ab", "page": 25, "type": "paragraph", "text": "25. Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of"}
{"id": "4e184cb2-7e22-49f0-a106-76580a3df489", "page": 25, "type": "paragraph", "text": "influenza vaccine protection: evidence from the US Influenza Vaccine"}
{"id": "ef189684-3e89-4469-9c80-92409297ece0", "page": 25, "type": "paragraph", "text": "Effectiveness Network, 2011\u201312 through 2014\u201315. Clin Infect Dis"}
{"id": "e480d871-bcd3-4d45-a88a-a7360f268289", "page": 25, "type": "paragraph", "text": "2017;64:544\u201350. PMID:28039340"}
{"id": "d7fd7cf4-4f93-412d-b65a-0f900191c72c", "page": 25, "type": "paragraph", "text": "26. Puig-Barber\u00e0 J, Mira-Iglesias A, Tortajada-Girb\u00e9s M, et al.; Valencia"}
{"id": "2bb8d998-2242-441f-a508-5af87f4ae696", "page": 25, "type": "paragraph", "text": "Hospital Network for the Study of Influenza and other Respiratory"}
{"id": "89f2dc9a-ce39-4f07-bfa2-2aa1851eb45b", "page": 25, "type": "paragraph", "text": "Viruses (VAHNSI, Spain). Waning protection of influenza vaccination"}
{"id": "80156124-74cf-492c-a04d-5e149589ecfd", "page": 25, "type": "paragraph", "text": "during four influenza seasons, 2011/2012 to 2014/2015. Vaccine"}
{"id": "4fbff9c5-2a94-43dd-b4c2-2a74eb8c27c4", "page": 25, "type": "paragraph", "text": "2017;35:5799\u2013807. PMID:28941618 https://doi.org/10.1016/j."}
{"id": "936902dc-899f-414e-a5a8-db66356f598d", "page": 25, "type": "paragraph", "text": "vaccine.2017.09.035"}
{"id": "e2833963-1102-4d0c-8e0c-48c06d5f2bc6", "page": 25, "type": "paragraph", "text": "27. Kissling E, Nunes B, Robertson C, et al.; I-MOVE case\u2013control study"}
{"id": "d5f86df4-bd97-47fa-b202-01f083884edd", "page": 25, "type": "paragraph", "text": "team. I-MOVE multicentre case-control study 2010/11 to 2014/15: is"}
{"id": "ea984ed8-4f1a-4f14-8edf-ce8976144b1c", "page": 25, "type": "paragraph", "text": "there within-season waning of influenza type/subtype vaccine"}
{"id": "cc2451e0-b0b5-4439-a4a2-0c63de46cf26", "page": 25, "type": "paragraph", "text": "effectiveness with increasing time since vaccination? Euro Surveill"}
{"id": "701edd08-4798-4046-b805-23e507b66125", "page": 25, "type": "paragraph", "text": "2016;21. PMID:27124420 https://doi.org/10.2807/1560-7917."}
{"id": "480605e1-5740-4dbb-96d1-e25de536ecc6", "page": 25, "type": "paragraph", "text": "ES.2016.21.16.30201"}
{"id": "64e7965b-4a66-455e-bf39-8be2d110d4a5", "page": 25, "type": "paragraph", "text": "28. Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of"}
{"id": "9b645986-fc31-4473-b856-cecc7a03f5a8", "page": 25, "type": "paragraph", "text": "2011/12 trivalent seasonal influenza vaccine in preventing laboratory-"}
{"id": "906f9f98-becb-439a-a86d-1d04fa9c6f4d", "page": 25, "type": "paragraph", "text": "confirmed influenza in primary care in the United Kingdom: evidence"}
{"id": "0fc5fc16-89fa-42c7-8afe-56f4cbbfa65c", "page": 25, "type": "paragraph", "text": "of waning intra-seasonal protection. Euro Surveill 2013;18:20389."}
{"id": "d21b3b2c-c43a-4332-9948-7081799edca6", "page": 25, "type": "paragraph", "text": "PMID:23399424 https://doi.org/10.2807/ese.18.05.20389-en"}
{"id": "41af56cb-0939-47c3-92bc-138122e4d977", "page": 25, "type": "paragraph", "text": "29. Ng Y, Nandar K, Chua LAV, et al. Evaluating the effectiveness of the"}
{"id": "330ad367-df17-4360-97f4-fc6f899ab4bc", "page": 25, "type": "paragraph", "text": "influenza vaccine during respiratory outbreaks in Singapore\u2019s long term"}
{"id": "2e898958-cbd3-45ea-957c-2357271d591c", "page": 25, "type": "paragraph", "text": "care facilities, 2017. Vaccine 2019;37:3925\u201331. PMID:31160102"}
{"id": "152be9bb-40b4-4028-a41b-118cc20b93ba", "page": 25, "type": "paragraph", "text": "https://doi.org/10.1016/j.vaccine.2019.03.054"}
{"id": "3897ce0b-e6fe-4d6e-998c-bcfa3eaf8c7e", "page": 25, "type": "paragraph", "text": "30. Young BE, Mak TM, Ang LW, et al. Influenza vaccine failure in the"}
{"id": "09a575de-018a-41bc-8669-6b32e2764299", "page": 25, "type": "paragraph", "text": "tropics: a retrospective cohort study of waning effectiveness. Epidemiol"}
{"id": "ae974ec9-7ccf-4459-a679-ed3a19396ade", "page": 25, "type": "paragraph", "text": "Infect 2020;148:e299. PMID:33261680 https://doi.org/10.1017/"}
{"id": "a1569c6e-ec39-4c8a-9a2a-0dbfb4dd5385", "page": 25, "type": "paragraph", "text": "S0950268820002952"}
{"id": "76c56f2f-6ca7-49ad-af2e-014ef4ee4cbb", "page": 25, "type": "paragraph", "text": "31. Mira-Iglesias A, L\u00f3pez-Labrador FX, Garc\u00eda-Rubio J, et al. Influenza"}
{"id": "defe8dc2-8fe6-4a00-9cb6-05242c1bc429", "page": 25, "type": "paragraph", "text": "vaccine effectiveness and waning effect in hospitalized older adults."}
{"id": "d791f38d-4d0f-4fbd-b5a3-52c9dbbae96c", "page": 25, "type": "paragraph", "text": "Valencia Region, Spain, 2018/2019 season. Int J Environ Res Public"}
{"id": "57e7c148-1d62-4e6d-8ef6-595b2c4f2308", "page": 25, "type": "paragraph", "text": "Health 2021;18:1129. PMID:33514058 https://doi.org/10.3390/"}
{"id": "a17d7843-de28-46eb-9634-1eef179e034d", "page": 25, "type": "paragraph", "text": "ijerph18031129"}
{"id": "6db9e5ee-1a9c-40ab-af5f-e2636de7bf3c", "page": 25, "type": "paragraph", "text": "32. Ferdinands JM, Gaglani M, Martin ET, et al. Waning vaccine"}
{"id": "71446f39-cba0-4375-be71-087908bcaf67", "page": 25, "type": "paragraph", "text": "effectiveness against influenza-associated hospitalizations among adults,"}
{"id": "edb280f0-0272-46b6-9d2a-76630ba44141", "page": 25, "type": "paragraph", "text": "2015\u20132016 to 2018\u20132019, United States Hospitalized Adult Influenza"}
{"id": "0ce33f76-a739-4dff-be2d-bd2bbf6ab7d9", "page": 25, "type": "paragraph", "text": "Vaccine Effectiveness Network. Clin Infect Dis 2021;73:726\u20139."}
{"id": "47afde98-d959-4b6b-a348-cf5653d4caa2", "page": 25, "type": "paragraph", "text": "PMID:33462610 https://doi.org/10.1093/cid/ciab045"}
{"id": "eee3e4e4-7727-4832-88f0-79aa05c5027a", "page": 25, "type": "paragraph", "text": "33. Madhi SA, Cutland CL, Kuwanda L, et al.; Maternal Flu Trial (Matflu)"}
{"id": "5f4d48c5-ec29-475c-966c-530c193c9a37", "page": 25, "type": "paragraph", "text": "Team. Influenza vaccination of pregnant women and protection of their"}
{"id": "af8a35e2-6618-4d5a-8dde-45fa748c93ea", "page": 25, "type": "paragraph", "text": "infants. N Engl J Med 2014;371:918\u201331. PMID:25184864 https://doi."}
{"id": "e685b7b7-53be-4231-be59-34903c620fde", "page": 25, "type": "paragraph", "text": "org/10.1056/NEJMoa1401480"}
{"id": "1757df2f-d1cc-42c8-b50c-76b35bf7c7c0", "page": 25, "type": "paragraph", "text": "34. Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with"}
{"id": "9a7944ba-ab56-48d6-b086-2ed6e7dc0771", "page": 25, "type": "paragraph", "text": "trivalent inactivated influenza vaccine for prevention of influenza in"}
{"id": "7fce6186-5a78-4c6b-9df2-becb1842b49b", "page": 25, "type": "paragraph", "text": "infants in Mali: a prospective, active-controlled, observer-blind,"}
{"id": "4193ae4b-aeda-4e44-b446-aee0859a1b5e", "page": 25, "type": "paragraph", "text": "randomised phase 4 trial. Lancet Infect Dis 2016;16:1026\u201335."}
{"id": "2cb59508-0613-45e3-aa5b-c2eb6327e088", "page": 25, "type": "paragraph", "text": "PMID:27261067 https://doi.org/10.1016/S1473-3099(16)30054-8"}
{"id": "dd01b6da-883f-4476-806e-150464792e87", "page": 25, "type": "paragraph", "text": "35. Steinhoff MC, Katz J, Englund JA, et al. Year-round influenza"}
{"id": "04a1670f-9abb-468c-909e-d07e0aae482e", "page": 25, "type": "paragraph", "text": "immunisation during pregnancy in Nepal: a phase 4, randomised,"}
{"id": "6d9454ac-7445-43a9-a937-eb21e7f49f13", "page": 25, "type": "paragraph", "text": "placebo-controlled trial. Lancet Infect Dis 2017;17:981\u20139."}
{"id": "05abf188-54e6-40b4-ba9f-9c4c99fd018d", "page": 25, "type": "paragraph", "text": "PMID:28522338 https://doi.org/10.1016/S1473-3099(17)30252-9"}
{"id": "06b03ea6-85cc-42d4-b7aa-7c8951b733af", "page": 25, "type": "paragraph", "text": "36. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza"}
{"id": "28e5201e-9922-4570-8717-7b8ec1fc35dd", "page": 25, "type": "paragraph", "text": "immunization in mothers and infants. N Engl J Med 2008;359:1555\u201364."}
{"id": "93ce9657-92d8-4fd9-95b0-f9473cedf82f", "page": 25, "type": "paragraph", "text": "PMID:18799552 https://doi.org/10.1056/NEJMoa0708630"}
{"id": "2441fdd0-4fa7-4a89-a67c-17d3701d7594", "page": 25, "type": "paragraph", "text": "37. CDC. The flu season. Atlanta, GA: US Department of Health and"}
{"id": "394c83fb-5f33-4852-b766-f4e6df5d4773", "page": 25, "type": "paragraph", "text": "Human Services, CDC; 2015. https://www.cdc.gov/flu/about/season/"}
{"id": "3cd58d68-e086-4bc9-84e2-df68cdf9c2b2", "page": 25, "type": "paragraph", "text": "flu-season.htm"}
{"id": "06f167b2-2c0b-4732-9850-164598d091f7", "page": 25, "type": "paragraph", "text": "38. Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen MI. Duration of"}
{"id": "8f20e2c5-57e0-4e1a-9b69-febaefb88936", "page": 25, "type": "paragraph", "text": "influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-"}
{"id": "6f4637cb-dc25-4fe7-a799-8b11ec41ab6e", "page": 25, "type": "paragraph", "text": "regression of test-negative design case-control studies. J Infect Dis"}
{"id": "02e20bcd-bf2f-40ad-80ca-ae00b9598a69", "page": 25, "type": "paragraph", "text": "2018;217:731\u201341. PMID:29220496 https://doi.org/10.1093/infdis/jix632"}
{"id": "3ec5175d-e4d9-4fa4-9599-7bc2a6bd5909", "page": 25, "type": "paragraph", "text": "39. Ferdinands JM, Alyanak E, Reed C, Fry AM. Waning of influenza vaccine"}
{"id": "544b4427-d52d-4017-a703-627fed62c47c", "page": 25, "type": "paragraph", "text": "protection: exploring the trade-offs of changes in vaccination timing"}
{"id": "bb2b107d-29b4-47cd-8875-759835f99ba9", "page": 25, "type": "paragraph", "text": "among older adults. Clin Infect Dis 2020;70:1550\u20139. PMID:31257422"}
{"id": "edb62933-06f6-40a2-a989-31e1c8119624", "page": 25, "type": "paragraph", "text": "https://doi.org/10.1093/cid/ciz452"}
{"id": "5492ba8f-96f3-4e1b-bb35-6f77bb3e957c", "page": 25, "type": "paragraph", "text": "40. Advisory Committee on Immunization Practices; CDC. Immunization"}
{"id": "485aa85c-d7ab-43ff-875a-a262654b7239", "page": 25, "type": "paragraph", "text": "of health-care personnel: recommendations of the Advisory Committee"}
{"id": "ece91d09-5450-4d48-9409-36962f4f05e0", "page": 25, "type": "paragraph", "text": "on Immunization Practices (ACIP). MMWR Recomm Rep"}
{"id": "a26a039f-392a-4497-9db0-7a0d54b69902", "page": 25, "type": "paragraph", "text": "2011;60(No. RR-7):1\u201345. PMID:22108587"}
{"id": "b58f047e-f0aa-4736-9780-5a60da9cefaa", "page": 25, "type": "paragraph", "text": "41. Pearson ML, Bridges CB, Harper SA; Healthcare Infection Control"}
{"id": "2f3b4a5f-450a-4047-8ce2-643353db6eab", "page": 25, "type": "paragraph", "text": "Practices Advisory Committee (HICPAC); Advisory Committee on"}
{"id": "310d7ebb-87da-452f-a6f4-b45ce72eeeee", "page": 25, "type": "paragraph", "text": "Immunization Practices (ACIP). Influenza vaccination of healthcare"}
{"id": "79b1b1da-ea4f-48c4-b407-5b2478996c27", "page": 25, "type": "paragraph", "text": "personnel: recommendations of the Healthcare Infection Control"}
{"id": "d26e28bb-f489-4712-b164-4177729170d3", "page": 25, "type": "paragraph", "text": "Practices Advisory Committee (HICPAC) and the Advisory Committee"}
{"id": "4a896ff6-2854-4cd6-9cf8-5189190776c1", "page": 25, "type": "paragraph", "text": "on Immunization Practices (ACIP). MMWR Recomm Rep"}
{"id": "a4fdabb9-94fb-4013-96e5-ca81180a55d6", "page": 25, "type": "paragraph", "text": "2006;55(No. RR-2):1\u201316. PMID:16498385"}
{"id": "2c96b4ff-54cd-4bde-8df8-2db8b4ba63b2", "page": 25, "type": "paragraph", "text": "42. Kroger A, Bahta L, Hunter P. General best practice guidelines for"}
{"id": "aea994c6-4614-4cb9-9dc4-879eeee79f0f", "page": 25, "type": "paragraph", "text": "immunization: best practices guidance of the Advisory Committee on"}
{"id": "00d42634-00b1-424f-98dc-79d14074f534", "page": 25, "type": "paragraph", "text": "Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/"}
{"id": "49ed50f4-375d-4605-b67a-0f392d08931a", "page": 25, "type": "paragraph", "text": "acip-recs/general-recs/index.html"}
{"id": "aa534c36-c7a9-4796-b29d-78e0edefd834", "page": 25, "type": "paragraph", "text": "43. Afluria Quadrivalent [Package Insert]. Parkville, Victoria, Australia:"}
{"id": "6c2478f0-72b6-4883-b2fe-109002e85ac5", "page": 25, "type": "paragraph", "text": "Seqirus; 2022."}
{"id": "9dde52b0-be4d-4bb6-b366-35ef4453f0cf", "page": 25, "type": "paragraph", "text": "44. Fluzone Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2022."}
{"id": "6f080ae3-77c9-4557-b710-a2dbb7568b4c", "page": 25, "type": "paragraph", "text": "45. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and"}
{"id": "d9c8a539-32fd-4061-adec-4f58f1a3734a", "page": 25, "type": "paragraph", "text": "reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine"}
{"id": "73bc4742-28e5-4027-a26f-07ad400b677b", "page": 25, "type": "paragraph", "text": "in vaccine-naive 5\u20138-year-old children. J Infect Dis 2006;194:1032\u20139."}
{"id": "a527fa7d-4f5d-4a30-9e4f-71e13b420df6", "page": 25, "type": "paragraph", "text": "PMID:16991077 https://doi.org/10.1086/507309"}
{"id": "415b3c37-c3bb-488c-afdc-2cb3fe84ed14", "page": 25, "type": "paragraph", "text": "46. Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness"}
{"id": "1f4ff514-4a18-414d-a8ab-a65a149db1b3", "page": 25, "type": "paragraph", "text": "in healthy 6- to 21-month-old children during the 2003\u20132004 season."}
{"id": "c079909e-e23a-4a16-9225-ce24134ab4a2", "page": 25, "type": "paragraph", "text": "J Pediatr 2006;149:755\u201362. PMID:17137887 https://doi.org/10.1016/j."}
{"id": "b6746d2f-e73a-4ba9-81ac-54a29d8a41c5", "page": 25, "type": "paragraph", "text": "jpeds.2006.06.036"}
{"id": "6d3bf385-a60e-40f9-8e99-2808a1601326", "page": 25, "type": "paragraph", "text": "47. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK."}
{"id": "b0e0e63c-1cbc-4be3-956a-9754d6e329fb", "page": 25, "type": "paragraph", "text": "Effectiveness of the 2003\u20132004 influenza vaccine among children 6 months"}
{"id": "e17e1368-f66d-4d54-9d09-2fb8e40b3fd3", "page": 25, "type": "paragraph", "text": "to 8 years of age, with 1 vs 2 doses. Pediatrics 2005;116:153\u20139."}
{"id": "a2a8cdac-1cab-45c0-8e20-33f2cd8302b0", "page": 25, "type": "paragraph", "text": "PMID:15995046 https://doi.org/10.1542/peds.2005-0049"}
{"id": "155c9242-589f-43cc-9e62-d8946af29db7", "page": 26, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "55c8e3f6-8b68-4dcf-9205-b35639ca4e8a", "page": 26, "type": "paragraph", "text": "24"}
{"id": "3356e2bd-5690-45a0-a414-8aeee43c5016", "page": 26, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "a8508a44-b83d-45cb-ab4e-0397cf8568ca", "page": 26, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "c0720e0c-239c-40d7-96cc-8a976e92e51f", "page": 26, "type": "paragraph", "text": "48. Eisenberg KW, Szilagyi PG, Fairbrother G, et al.; New Vaccine"}
{"id": "bfafecb6-a357-4d51-a9ae-56745c120c47", "page": 26, "type": "paragraph", "text": "Surveillance Network. Vaccine effectiveness against laboratory-confirmed"}
{"id": "12b0dca5-95b9-4e91-83fe-6d52e002fd02", "page": 26, "type": "paragraph", "text": "influenza in children 6 to 59 months of age during the 2003\u20132004 and"}
{"id": "2748175e-0b76-4f05-ac25-c997c59dc7ce", "page": 26, "type": "paragraph", "text": "2004\u20132005 influenza seasons. Pediatrics 2008;122:911\u20139."}
{"id": "62b89e2d-8ad7-4df9-bc2e-bcb9c1e9f4b2", "page": 26, "type": "paragraph", "text": "PMID:18977968 https://doi.org/10.1542/peds.2007-3304"}
{"id": "0e7fade9-71b2-435f-85dc-3b2990bedd9f", "page": 26, "type": "paragraph", "text": "49. Eick AA, Uyeki TM, Klimov A, et al. Maternal influenza vaccination"}
{"id": "066ebc28-0562-4390-b5b9-d541ce08b14c", "page": 26, "type": "paragraph", "text": "and effect on influenza virus infection in young infants. Arch Pediatr"}
{"id": "ede84dc0-98b4-465c-9e36-596b2398a256", "page": 26, "type": "paragraph", "text": "Adolesc Med 2011;165:104\u201311. PMID:20921345 https://doi."}
{"id": "0f94b9e8-ee7e-4585-bf51-7fcc4dba0d42", "page": 26, "type": "paragraph", "text": "org/10.1001/archpediatrics.2010.192"}
{"id": "1f576e86-9ff7-48b7-a2ff-8afb688be3c0", "page": 26, "type": "paragraph", "text": "50. ACOG Committee on Obstetric Practice. ACOG Committee opinion"}
{"id": "b934bbfc-7ff4-460a-a6e7-de8e0aa06614", "page": 26, "type": "paragraph", "text": "no. 732: influenza vaccination during pregnancy. Obstet Gynecol"}
{"id": "d67245ee-bbf3-4e9c-a0aa-75c1ccf0ad85", "page": 26, "type": "paragraph", "text": "2018;131:e109\u201314. PMID:29578985 https://doi.org/10.1097/"}
{"id": "43b39ff1-2e9a-46e4-b5d3-0898c4246a9d", "page": 26, "type": "paragraph", "text": "AOG.0000000000002588"}
{"id": "2e7ba655-5177-4f2d-a142-b6ae363ffd13", "page": 26, "type": "paragraph", "text": "51. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/"}
{"id": "a3820f54-9544-46a6-bd6a-d0ae0fa5d482", "page": 26, "type": "paragraph", "text": "H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am"}
{"id": "d7133b36-a0ab-4aef-8f23-b63650e2922d", "page": 26, "type": "paragraph", "text": "J Obstet Gynecol 2012;207:177.e1\u20138. PMID:22939717 https://doi."}
{"id": "075c8951-df93-431b-88e8-0dfe1be6a11c", "page": 26, "type": "paragraph", "text": "org/10.1016/j.ajog.2012.07.007"}
{"id": "841750d7-1817-4052-9d0c-323668270ed5", "page": 26, "type": "paragraph", "text": "52. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1)"}
{"id": "49eacf2b-a85a-4c2e-9fe0-73a1e01b9b8c", "page": 26, "type": "paragraph", "text": "v2009: a controlled observational prospective cohort study on vaccine"}
{"id": "b553301d-c38c-43d4-aced-376716cb9538", "page": 26, "type": "paragraph", "text": "safety in pregnancy. Vaccine 2012;30:4445\u201352. PMID:22564554"}
{"id": "5aa10589-1783-4a2d-a479-ba681ef8626f", "page": 26, "type": "paragraph", "text": "https://doi.org/10.1016/j.vaccine.2012.04.081"}
{"id": "fe2ded16-a1ea-476c-b23d-aa9d30930a69", "page": 26, "type": "paragraph", "text": "53. Pasternak B, Svanstr\u00f6m H, M\u00f8lgaard-Nielsen D, et al. Vaccination"}
{"id": "570549bf-3936-42d7-acf5-6ed9e0233d9e", "page": 26, "type": "paragraph", "text": "against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal"}
{"id": "2f1e6ebb-d8f3-465e-a2de-5facd2a5ccbe", "page": 26, "type": "paragraph", "text": "death: cohort study in Denmark. BMJ 2012;344:e2794. PMID:22551713"}
{"id": "7d576ecb-5998-4bea-a46a-346311ec6f95", "page": 26, "type": "paragraph", "text": "https://doi.org/10.1136/bmj.e2794"}
{"id": "8c9cb8bc-75d8-4a1b-aff8-7f4bc2d88db4", "page": 26, "type": "paragraph", "text": "54. Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the"}
{"id": "62e6d939-6183-473d-aa5b-ce18d6c914b4", "page": 26, "type": "paragraph", "text": "hazard of foetal death following H1N1 influenza vaccination; a"}
{"id": "4adf0169-6a29-489d-8b3f-59c24a107ecb", "page": 26, "type": "paragraph", "text": "population based cohort study in the UK GPRD. PLoS One"}
{"id": "6fc43b11-e4e5-4aa4-927a-9d0b7a4cca05", "page": 26, "type": "paragraph", "text": "2012;7:e51734. PMID:23341865 https://doi.org/10.1371/journal."}
{"id": "a59170b7-2c64-4056-8213-ca747e04bfef", "page": 26, "type": "paragraph", "text": "pone.0051734"}
{"id": "beb98513-cf32-4e29-aecb-520af757fc75", "page": 26, "type": "paragraph", "text": "55. Chambers CD, Johnson D, Xu R, et al.; OTIS Collaborative Research"}
{"id": "f722ba44-1c69-45f8-8d4e-c35911e23bd5", "page": 26, "type": "paragraph", "text": "Group. Risks and safety of pandemic H1N1 influenza vaccine in"}
{"id": "905afabd-58e3-400a-856e-cc911665e1f0", "page": 26, "type": "paragraph", "text": "pregnancy: birth defects, spontaneous abortion, preterm delivery, and"}
{"id": "d69f74cd-d499-4ba2-93c5-bbac6582930d", "page": 26, "type": "paragraph", "text": "small for gestational age infants. Vaccine 2013;31:5026\u201332."}
{"id": "5dfbec40-7959-45e9-a91d-94f73ebf0f33", "page": 26, "type": "paragraph", "text": "PMID:24016809 https://doi.org/10.1016/j.vaccine.2013.08.097"}
{"id": "b808a5fc-db6b-49db-ab67-f87d711859aa", "page": 26, "type": "paragraph", "text": "56. Huang WT, Tang FW, Yang SE, Chih YC, Chuang JH. Safety of"}
{"id": "31ec5565-104e-4476-8205-40c2d79e263c", "page": 26, "type": "paragraph", "text": "inactivated monovalent pandemic (H1N1) 2009 vaccination during"}
{"id": "b2279036-dbf5-43cc-bc32-e9375fa58f5e", "page": 26, "type": "paragraph", "text": "pregnancy: a population-based study in Taiwan. Vaccine 2014;32:6463\u20138."}
{"id": "99069898-a0dc-42aa-a1aa-bcb5158b282a", "page": 26, "type": "paragraph", "text": "PMID:25285884 https://doi.org/10.1016/j.vaccine.2014.09.054"}
{"id": "096529e2-fd01-4adc-b354-6e97645572da", "page": 26, "type": "paragraph", "text": "57. Ma F, Zhang L, Jiang R, et al. Prospective cohort study of the safety of"}
{"id": "8cd0781c-4453-41de-8562-f358196aabd8", "page": 26, "type": "paragraph", "text": "an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine"}
{"id": "739af1fe-db29-41cc-8cb0-983e42721393", "page": 26, "type": "paragraph", "text": "Immunol 2014;21:1282\u20137. PMID:24990911 https://doi.org/10.1128/"}
{"id": "fa541992-cadc-49cd-beb2-f2f624b889f8", "page": 26, "type": "paragraph", "text": "CVI.00375-14"}
{"id": "a47c9f34-9075-4932-a3a4-5716b7a75903", "page": 26, "type": "paragraph", "text": "58. Chambers CD, Johnson DL, Xu R, et al.; OTIS Collaborative Research"}
{"id": "934f6d92-e498-437b-bc9d-8691c9429f73", "page": 26, "type": "paragraph", "text": "Group. Safety of the 2010\u201311, 2011\u201312, 2012\u201313, and 2013\u201314"}
{"id": "c31ae605-043e-4eea-ba67-ad1897639e91", "page": 26, "type": "paragraph", "text": "seasonal influenza vaccines in pregnancy: birth defects, spontaneous"}
{"id": "809fc383-1790-451a-89b5-09a9380d8581", "page": 26, "type": "paragraph", "text": "abortion, preterm delivery, and small for gestational age infants, a study"}
{"id": "67d62e4d-d03c-43ac-bbc0-3ae53ed21a9b", "page": 26, "type": "paragraph", "text": "from the cohort arm of VAMPSS. Vaccine 2016;34:4443\u20139."}
{"id": "266a54f7-efda-44cd-8565-3a72c8345dda", "page": 26, "type": "paragraph", "text": "PMID:27449682 https://doi.org/10.1016/j.vaccine.2016.06.054"}
{"id": "c9ec33fd-c42d-4971-8424-ddc78de8aa29", "page": 26, "type": "paragraph", "text": "59. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza"}
{"id": "9ab9a5cf-82dc-48ca-acc2-a22a4e9c7d05", "page": 26, "type": "paragraph", "text": "vaccination during pregnancy: a systematic review of fetal death,"}
{"id": "3528f0eb-65f3-4472-8b20-bf00a10c81c2", "page": 26, "type": "paragraph", "text": "spontaneous abortion, and congenital malformation safety outcomes."}
{"id": "b3a18715-8a5d-48b4-b458-0800d6ad481f", "page": 26, "type": "paragraph", "text": "Vaccine 2015;33:2108\u201317. PMID:25758932 https://doi.org/10.1016/j."}
{"id": "8324c9af-e04f-43ea-a53d-40b1aebe15b9", "page": 26, "type": "paragraph", "text": "vaccine.2015.02.068"}
{"id": "4b5a5054-3f43-426a-af20-35a97725e647", "page": 26, "type": "paragraph", "text": "60. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza"}
{"id": "b549b8bf-787d-445b-bed0-d4166f2a2f90", "page": 26, "type": "paragraph", "text": "immunization and birth outcomes of stillbirth and spontaneous abortion:"}
{"id": "2703b0a2-138e-42eb-bc9b-b515040a4a6a", "page": 26, "type": "paragraph", "text": "a systematic review and meta-analysis. Clin Infect Dis 2015;60:e11\u20139."}
{"id": "d038af32-5878-433b-a3db-a71a0c257362", "page": 26, "type": "paragraph", "text": "PMID:25409473 https://doi.org/10.1093/cid/ciu915"}
{"id": "d0606402-a030-42a6-b987-9f5c3dbb1019", "page": 26, "type": "paragraph", "text": "61. Irving SA, Kieke BA, Donahue JG, et al.; Vaccine Safety Datalink."}
{"id": "5d1acf34-8b6f-4499-9b01-8061f50e2b75", "page": 26, "type": "paragraph", "text": "Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet"}
{"id": "7fecad33-591e-41b2-9a78-967e3347482f", "page": 26, "type": "paragraph", "text": "Gynecol 2013;121:159\u201365. PMID:23262941 https://doi.org/10.1097/"}
{"id": "ec6d901f-0e48-4c5e-979a-6f2435a23fe8", "page": 26, "type": "paragraph", "text": "AOG.0b013e318279f56f"}
{"id": "aa89121a-1099-4b06-9513-3be5e690555e", "page": 26, "type": "paragraph", "text": "62. Donahue JG, Kieke BA, King JP, et al. Association of spontaneous"}
{"id": "3032ce62-cabe-4946-baee-05e40636fd16", "page": 26, "type": "paragraph", "text": "abortion with receipt of inactivated influenza vaccine containing"}
{"id": "9c2a0b78-d801-43a7-83ba-1cb8177a30f2", "page": 26, "type": "paragraph", "text": "H1N1pdm09 in 2010\u201311 and 2011\u201312. Vaccine 2017;35:5314\u201322."}
{"id": "9630c03f-7000-430a-b838-5eb7def884f8", "page": 26, "type": "paragraph", "text": "PMID:28917295 https://doi.org/10.1016/j.vaccine.2017.06.069"}
{"id": "09a2dc79-250a-42b9-806d-a6aa501294f5", "page": 26, "type": "paragraph", "text": "63. Donahue JG, Kieke BA, King JP, et al. Inactivated influenza vaccine and"}
{"id": "0fe3b5d5-0a97-4c28-83bb-358258248906", "page": 26, "type": "paragraph", "text": "spontaneous abortion in the Vaccine Safety Datalink in 2012\u201313,"}
{"id": "bd21aac5-4025-4173-82a2-076de42ae432", "page": 26, "type": "paragraph", "text": "2013\u201314, and 2014\u201315. Vaccine 2019;37:6673\u201381. PMID:31540812"}
{"id": "a4043204-7537-4b14-b998-b7e5a1628be4", "page": 26, "type": "paragraph", "text": "https://doi.org/10.1016/j.vaccine.2019.09.035"}
{"id": "51a6c73d-a54c-4ee3-b518-3f49b60be9ba", "page": 26, "type": "paragraph", "text": "64. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated"}
{"id": "cc7682f6-2054-473e-a0ad-f44e3394228a", "page": 26, "type": "paragraph", "text": "with influenza and respiratory syncytial virus in the United States. JAMA"}
{"id": "4ef4a1a8-bc89-4c7e-a3f6-dc9a8f405057", "page": 26, "type": "paragraph", "text": "2003;289:179\u201386. PMID:12517228 https://doi.org/10.1001/"}
{"id": "05bc7222-afce-4292-8033-a9346ddf37ad", "page": 26, "type": "paragraph", "text": "jama.289.2.179"}
{"id": "e23c434c-ae88-4384-bb33-bd0e28010257", "page": 26, "type": "paragraph", "text": "65. CDC. Past seasons vaccine effectiveness estimates. Atlanta, GA: US"}
{"id": "80e27c15-c66e-41a3-a7d5-273815d236bc", "page": 26, "type": "paragraph", "text": "Department of Health and Human Services, CDC. https://www.cdc."}
{"id": "04cb4698-eb3b-4f8d-ad9a-e5b563589058", "page": 26, "type": "paragraph", "text": "gov/flu/vaccines-work/past-seasons-estimates.html#2021"}
{"id": "12a4bd72-20bc-44ad-8123-29b5a9ab70b0", "page": 26, "type": "paragraph", "text": "66. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose"}
{"id": "312bcf56-f87c-494b-8f62-fb074ad3341a", "page": 26, "type": "paragraph", "text": "versus standard-dose influenza vaccine in older adults. N Engl J Med"}
{"id": "13a284e8-3498-40b0-b288-43e5659f2a54", "page": 26, "type": "paragraph", "text": "2014;371:635\u201345. PMID:25119609 https://doi.org/10.1056/"}
{"id": "058bf24e-5535-4e64-aab9-7e72930968f2", "page": 26, "type": "paragraph", "text": "NEJMoa1315727"}
{"id": "f509dbf0-6c7f-4cac-ba7f-015c81988d6a", "page": 26, "type": "paragraph", "text": "67. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity"}
{"id": "5f8c1ef0-b2d1-4049-92ca-1289ce3c3edd", "page": 26, "type": "paragraph", "text": "of recombinant influenza hemagglutinin (rHA) and trivalent inactivated"}
{"id": "60400f89-dfb3-40af-8791-0d99e63c7c36", "page": 26, "type": "paragraph", "text": "vaccine (TIV) among persons > or =65 years old. Vaccine 2009;28:379\u201385."}
{"id": "a410b1e7-2449-48b6-9d44-6dd57778db21", "page": 26, "type": "paragraph", "text": "PMID:19879222 https://doi.org/10.1016/j.vaccine.2009.10.037"}
{"id": "d65791dd-900b-402f-8296-c183b527b8f2", "page": 26, "type": "paragraph", "text": "68. Dunkle LM, Izikson R, Patriarca P, et al.; PSC12 Study Team. Efficacy"}
{"id": "2d1a661a-77e1-4588-8280-72c6b858efc6", "page": 26, "type": "paragraph", "text": "of recombinant influenza vaccine in adults 50 years of age or older."}
{"id": "37149b9c-d8ef-4ec0-b8f0-d227ea66e4e1", "page": 26, "type": "paragraph", "text": "N Engl J Med 2017;376:2427\u201336. PMID:28636855 https://doi."}
{"id": "9fa474f1-cf90-4094-bd1c-23d70ee304a7", "page": 26, "type": "paragraph", "text": "org/10.1056/NEJMoa1608862"}
{"id": "ae117456-0f44-4c35-addc-956a4a6726f6", "page": 26, "type": "paragraph", "text": "69. Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of"}
{"id": "7462a329-be95-4d1a-ad5b-b5f0d7140881", "page": 26, "type": "paragraph", "text": "high-dose versus standard-dose influenza vaccines among US Medicare"}
{"id": "7aaf7454-7fae-425a-b9ee-a223d098a545", "page": 26, "type": "paragraph", "text": "beneficiaries in preventing postinfluenza deaths during 2012\u20132013 and"}
{"id": "2b980ca8-62ed-4153-b2ce-ee483b94a68c", "page": 26, "type": "paragraph", "text": "2013\u20132014. J Infect Dis 2017;215:510\u20137. PMID:28329311 https://"}
{"id": "df98fb67-a2dd-4cde-a09e-a45068d14f85", "page": 26, "type": "paragraph", "text": "doi.org/10.1093/infdis/jiw641"}
{"id": "b3e82414-4fbe-4b33-a220-f53d9e7e3533", "page": 26, "type": "paragraph", "text": "70. Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of cell-"}
{"id": "5a703d49-3165-4bac-a8be-ed60c32fe21d", "page": 26, "type": "paragraph", "text": "cultured and egg-based influenza vaccines among elderly persons in the"}
{"id": "2c133298-a9a7-4ca9-b9e7-d222e793a3b2", "page": 26, "type": "paragraph", "text": "United States, 2017\u20132018. J Infect Dis 2019;220:1255\u201364."}
{"id": "51f66513-5ab0-4551-8cec-7547bf569b28", "page": 26, "type": "paragraph", "text": "PMID:30561688 https://doi.org/10.1093/infdis/jiy716"}
{"id": "7ea6af02-2b33-47fa-9e52-42c264ecfe09", "page": 26, "type": "paragraph", "text": "71. Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of"}
{"id": "940109f1-8e0c-4b1d-8312-d09931772781", "page": 26, "type": "paragraph", "text": "influenza vaccines among the United States elderly, 2018\u20132019. J Infect"}
{"id": "d4ad90e0-2d5f-4896-81a0-6daef06d92c8", "page": 26, "type": "paragraph", "text": "Dis 2020;222:278\u201387. PMID:32100009 https://doi.org/10.1093/"}
{"id": "aaca143c-d12e-442a-b330-8efedfd88755", "page": 26, "type": "paragraph", "text": "infdis/jiaa080"}
{"id": "1ddc09a5-c1b5-48a7-a651-48098c07a1dc", "page": 26, "type": "paragraph", "text": "72. Izurieta HS, Lu M, Kelman J, et al. Comparative effectiveness of"}
{"id": "1b229c3b-5656-4105-ae89-51492cf296cc", "page": 26, "type": "paragraph", "text": "influenza vaccines among U.S. Medicare beneficiaries ages 65 years and"}
{"id": "35f42cf0-1de1-411f-834b-1d630aede7f3", "page": 26, "type": "paragraph", "text": "older during the 2019\u201320 season. Clin Infect Dis 2021;73:e4251\u20139."}
{"id": "1f703df5-ddb5-4224-bf7b-c2f54001dfe3", "page": 26, "type": "paragraph", "text": "https://doi.org/10.1093/cid/ciaa1727"}
{"id": "8aa03154-5044-4250-9216-9b52f809bd83", "page": 26, "type": "paragraph", "text": "73. Lu Y, Chillarige Y, Izurieta HS, et al. Effect of age on relative effectiveness"}
{"id": "e3205742-5764-447a-acc9-8bff44fe1efd", "page": 26, "type": "paragraph", "text": "of high-dose versus standard-dose influenza vaccines among US Medicare"}
{"id": "defa7c3d-5dbd-4000-8999-efa55f9d5fee", "page": 26, "type": "paragraph", "text": "beneficiaries aged \u226565 years. J Infect Dis 2019;220:1511\u201320."}
{"id": "93108543-7765-489a-9a25-7b2dcd1a9e17", "page": 26, "type": "paragraph", "text": "PMID:31290553 https://doi.org/10.1093/infdis/jiz360"}
{"id": "7cdacae9-997c-4214-9010-4900c5de17e7", "page": 26, "type": "paragraph", "text": "74. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of"}
{"id": "e3af9551-679b-438f-ac07-01eba61506fb", "page": 26, "type": "paragraph", "text": "high-dose versus standard-dose influenza vaccines in US residents aged"}
{"id": "a554e221-d989-405d-8e66-e1a0d8768396", "page": 26, "type": "paragraph", "text": "65 years and older from 2012 to 2013 using Medicare data: a"}
{"id": "5f193d68-a61b-4009-ae20-6a36a93052ff", "page": 26, "type": "paragraph", "text": "retrospective cohort analysis. Lancet Infect Dis 2015;15:293\u2013300."}
{"id": "1718a569-f152-4842-addc-c99f91773ca5", "page": 26, "type": "paragraph", "text": "PMID:25672568 https://doi.org/10.1016/S1473-3099(14)71087-4"}
{"id": "de165ff3-d961-4c41-877b-d82826272584", "page": 26, "type": "paragraph", "text": "75. Richardson DM, Medvedeva EL, Roberts CB, Linkin DR; CDC"}
{"id": "e4a49201-2367-45c2-99cd-d8e36b1ad0d7", "page": 26, "type": "paragraph", "text": "Epicenter Program. Comparative effectiveness of high-dose versus"}
{"id": "120ed531-c296-4c48-a564-73dee5603fb3", "page": 26, "type": "paragraph", "text": "standard-dose influenza vaccination in community-dwelling veterans."}
{"id": "235ce4f6-f4bd-4c38-902e-84f1afa762b5", "page": 26, "type": "paragraph", "text": "Clin Infect Dis 2015;61:171\u20136. PMID:25829001 https://doi."}
{"id": "c01e340e-b3d1-4f31-9479-099b5b91f1fe", "page": 26, "type": "paragraph", "text": "org/10.1093/cid/civ261"}
{"id": "2c95d64c-ea13-4926-ac7a-fbe36cc027bd", "page": 26, "type": "paragraph", "text": "76. Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative vaccine"}
{"id": "e23d3be8-9765-4adb-aabc-145bc44e3c6d", "page": 26, "type": "paragraph", "text": "effectiveness of high-dose versus standard-dose influenza vaccines among"}
{"id": "f3331485-3340-44bb-8ae1-e580354c2bea", "page": 26, "type": "paragraph", "text": "Veterans Health Administration patients. J Infect Dis 2018;217:1718\u201327."}
{"id": "a22a8bd4-3820-449a-b03c-c05c541215ee", "page": 26, "type": "paragraph", "text": "PMID:29452380 https://doi.org/10.1093/infdis/jiy088"}
{"id": "8154db75-7436-44ae-88c6-640347d8ab86", "page": 27, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "3971d1fd-64f7-4bda-9fed-625ed10f131a", "page": 27, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "90952597-e1bd-4893-8f95-ef25f65e77bc", "page": 27, "type": "paragraph", "text": "25"}
{"id": "4a755d96-05a2-46e7-8952-dce1626bfbf9", "page": 27, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "50a97f33-6157-469d-80bf-aabe306cc2ce", "page": 27, "type": "paragraph", "text": "77. Young-Xu Y, Snider JT, van Aalst R, et al. Analysis of relative effectiveness"}
{"id": "ff02c628-92aa-4f95-a345-423e86676fa8", "page": 27, "type": "paragraph", "text": "of high-dose versus standard-dose influenza vaccines using an"}
{"id": "8f31d079-348a-4642-a638-89376dccffb8", "page": 27, "type": "paragraph", "text": "instrumental variable method. Vaccine 2019;37:1484\u201390."}
{"id": "244e12ff-cec2-4a3c-98a2-30f2f78af0d8", "page": 27, "type": "paragraph", "text": "PMID:30745146 https://doi.org/10.1016/j.vaccine.2019.01.063"}
{"id": "3704a2a5-ce4e-4731-84a6-79ab23de132b", "page": 27, "type": "paragraph", "text": "78. Young-Xu Y, Thornton Snider J, Mahmud SM, et al. High-dose influenza"}
{"id": "be31bebf-d2bf-4a6b-b504-7d155b65288e", "page": 27, "type": "paragraph", "text": "vaccination and mortality among predominantly male, white, senior veterans,"}
{"id": "222efc71-bc4e-4b66-a87b-e94e183ae512", "page": 27, "type": "paragraph", "text": "United States, 2012/13 to 2014/15. Euro Surveill 2020;25. PMID:32431290"}
{"id": "1ecfd7e5-0f4e-440f-b424-cd484b02b3dc", "page": 27, "type": "paragraph", "text": "https://doi.org/10.2807/1560-7917.ES.2020.25.19.1900401"}
{"id": "40535d2a-c2b6-41f8-b3bc-e91160734f95", "page": 27, "type": "paragraph", "text": "79. Pelton SI, Divino V, Shah D, et al. Evaluating the relative vaccine"}
{"id": "11366b57-bc3b-432b-a4b4-79b80b6d8e45", "page": 27, "type": "paragraph", "text": "effectiveness of adjuvanted trivalent influenza vaccine compared to"}
{"id": "7d3a6c5a-e999-4b7e-9c65-c33ebfda1d6a", "page": 27, "type": "paragraph", "text": "high-dose trivalent and other egg-based influenza vaccines among older"}
{"id": "5e5e0db4-95b5-44fd-acc1-0ad15e27f20c", "page": 27, "type": "paragraph", "text": "adults in the US during the 2017\u20132018 influenza season. Vaccines (Basel)"}
{"id": "330d2155-b2c5-4ea1-a5db-de257c06e075", "page": 27, "type": "paragraph", "text": "2020;8:446. PMID:32784684 https://doi.org/10.3390/vaccines8030446"}
{"id": "a7543961-bd77-4f96-aaa7-d765caabb1b1", "page": 27, "type": "paragraph", "text": "80. van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of"}
{"id": "4e7e8c92-9355-4a2c-926d-b0cb3eb4c4c5", "page": 27, "type": "paragraph", "text": "high dose versus adjuvanted influenza vaccine: a retrospective cohort"}
{"id": "1ccaf144-43a7-4911-9b47-4e0393afeac1", "page": 27, "type": "paragraph", "text": "study. Vaccine 2020;38:372\u20139. PMID:31606249 https://doi."}
{"id": "340db7f4-2015-4d04-b623-0c60be9b9954", "page": 27, "type": "paragraph", "text": "org/10.1016/j.vaccine.2019.09.105"}
{"id": "8c523b95-0c41-496b-8973-f133076a651d", "page": 27, "type": "paragraph", "text": "81. Pelton SI, Divino V, Postma MJ, et al. A retrospective cohort study"}
{"id": "d72c3421-18d6-4505-bd9f-2f49e4b58b61", "page": 27, "type": "paragraph", "text": "assessing relative effectiveness of adjuvanted versus high-dose trivalent"}
{"id": "f630e32a-959e-44db-aacc-9c9e2e47f3fb", "page": 27, "type": "paragraph", "text": "influenza vaccines among older adults in the United States during the"}
{"id": "8e8ce6a8-0d4f-4afa-95ce-e29ce19bb835", "page": 27, "type": "paragraph", "text": "2018\u201319 influenza season. Vaccine 2021;39:2396\u2013407. PMID:33810903"}
{"id": "e56b1e0a-e58e-4701-aeb6-80e09494291f", "page": 27, "type": "paragraph", "text": "https://doi.org/10.1016/j.vaccine.2021.03.054"}
{"id": "39ce8a67-a738-4ed7-81ef-394b6d374ace", "page": 27, "type": "paragraph", "text": "82. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ,"}
{"id": "107d9956-38d6-4a31-a764-e68778cc2524", "page": 27, "type": "paragraph", "text": "Greenberg DP. Prevention of serious events in adults 65 years of age or"}
{"id": "1b82af8b-ce0b-43bb-986e-f4cf05126858", "page": 27, "type": "paragraph", "text": "older: a comparison between high-dose and standard-dose inactivated"}
{"id": "a6259fe5-aa18-4d9e-861f-25368bc14242", "page": 27, "type": "paragraph", "text": "influenza vaccines. Vaccine 2015;33:4988\u201393. PMID:26212007 https://"}
{"id": "fd51d657-4fac-4bcd-934a-17b194e1780b", "page": 27, "type": "paragraph", "text": "doi.org/10.1016/j.vaccine.2015.07.006"}
{"id": "f4b3bbce-0b1d-4224-b8cf-542902687e1a", "page": 27, "type": "paragraph", "text": "83. Vardeny O, Kim K, Udell JA, et al.; INVESTED Committees and"}
{"id": "fb865d2c-7a2d-4e36-9fc4-a908095f7ea2", "page": 27, "type": "paragraph", "text": "Investigators. Effect of high-dose trivalent vs standard-dose quadrivalent"}
{"id": "4ca596ce-1b95-415b-b04b-7f3a29e42651", "page": 27, "type": "paragraph", "text": "influenza vaccine on mortality or cardiopulmonary hospitalization in"}
{"id": "961ff435-34b5-4b66-a746-ab456615060e", "page": 27, "type": "paragraph", "text": "patients with high-risk cardiovascular disease: a randomized clinical trial."}
{"id": "3632014d-9902-411a-9ac7-bb5a0c4de0f4", "page": 27, "type": "paragraph", "text": "JAMA 2021;325:39\u201349. PMID:33275134 https://doi.org/10.1001/"}
{"id": "a26d8bde-a943-4088-a135-69b25d74bbff", "page": 27, "type": "paragraph", "text": "jama.2020.23649"}
{"id": "0a478139-da7b-456b-843c-e85f95172148", "page": 27, "type": "paragraph", "text": "84. Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness"}
{"id": "b2f731c9-8b06-4814-bd8c-6e4685e396a4", "page": 27, "type": "paragraph", "text": "of high-dose versus standard-dose influenza vaccination on numbers of"}
{"id": "04adc47d-2d82-40bc-930e-fc9e5e25fa55", "page": 27, "type": "paragraph", "text": "US nursing home residents admitted to hospital: a cluster-randomised"}
{"id": "a3b41600-ae55-452d-9e0a-31aecf346248", "page": 27, "type": "paragraph", "text": "trial. Lancet Respir Med 2017;5:738\u201346. PMID:28736045 https://doi."}
{"id": "59bc4831-16dc-4924-9cad-97406b9008d1", "page": 27, "type": "paragraph", "text": "org/10.1016/S2213-2600(17)30235-7"}
{"id": "d686320c-dc56-4a0f-9a59-e8cf77dc9aa3", "page": 27, "type": "paragraph", "text": "85. McConeghy KW, Davidson HE, Canaday DH, et al. Cluster-randomized"}
{"id": "80cfa7b6-2e26-40b7-b8e3-82864d2d22dd", "page": 27, "type": "paragraph", "text": "trial of adjuvanted versus nonadjuvanted trivalent influenza vaccine in"}
{"id": "4dfe0261-b77b-4649-bd2e-2768661e80b8", "page": 27, "type": "paragraph", "text": "823 US nursing homes. Clin Infect Dis 2021;73:e4237\u201343."}
{"id": "9c0c4584-8b69-4f57-897d-41c6a3896d9e", "page": 27, "type": "paragraph", "text": "PMID:32882710 https://doi.org/10.1093/cid/ciaa1233"}
{"id": "583305ce-3393-4365-b0bd-91db6c477040", "page": 27, "type": "paragraph", "text": "86. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized,"}
{"id": "a9ec6efc-8dea-41ab-a10b-dbff43669e84", "page": 27, "type": "paragraph", "text": "double-blind controlled phase 3 trial comparing the immunogenicity"}
{"id": "b53836de-666a-4000-a878-d0e218516bef", "page": 27, "type": "paragraph", "text": "of high-dose and standard-dose influenza vaccine in adults 65 years of"}
{"id": "138499c5-92a8-4550-8bea-70a824c06313", "page": 27, "type": "paragraph", "text": "age and older. J Infect Dis 2009;200:172\u201380. PMID:19508159 https://"}
{"id": "888ea9b6-db56-40ba-9f09-5588a04c70ad", "page": 27, "type": "paragraph", "text": "doi.org/10.1086/599790"}
{"id": "3466a162-ad82-4373-934a-8d01826b060c", "page": 27, "type": "paragraph", "text": "87. Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and"}
{"id": "2acaf2ef-75fd-4537-bd76-ce54ae55b9e2", "page": 27, "type": "paragraph", "text": "immunogenicity of an MF59\u00ae-adjuvanted with a non-adjuvanted"}
{"id": "c23528a7-f2cb-415c-be83-20bdb1b0c055", "page": 27, "type": "paragraph", "text": "seasonal influenza vaccine in elderly subjects. Vaccine 2014;32:5027\u201334."}
{"id": "971b2793-d73b-428f-9325-dc3f073ba410", "page": 27, "type": "paragraph", "text": "PMID:25045825 https://doi.org/10.1016/j.vaccine.2014.07.013"}
{"id": "caf04b86-900c-41e9-8c64-56bffcd61d1c", "page": 27, "type": "paragraph", "text": "88. Schmader KE, Liu CK, Harrington T, et al. Safety, reactogenicity, and"}
{"id": "63996606-c410-42f6-85f0-535ba570488b", "page": 27, "type": "paragraph", "text": "health-related quality of life after trivalent adjuvanted vs trivalent high-"}
{"id": "d02dd070-27e5-4274-8796-8076be45c24b", "page": 27, "type": "paragraph", "text": "dose inactivated influenza vaccines in older adults: a randomized clinical"}
{"id": "854f4870-5b39-4d98-90ba-56794f81f988", "page": 27, "type": "paragraph", "text": "trial. JAMA Netw Open 2021;4:e2031266. PMID:33443580 https://"}
{"id": "7214c84e-cb53-4c6a-94e3-425f296ab6ae", "page": 27, "type": "paragraph", "text": "doi.org/10.1001/jamanetworkopen.2020.31266"}
{"id": "4a7fbee9-78fe-474b-b6b0-ca6e20bb2cc0", "page": 27, "type": "paragraph", "text": "89. Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised"}
{"id": "644013a0-f177-448d-aa60-3335db6581b8", "page": 27, "type": "paragraph", "text": "persons. Hum Vaccin Immunother 2018;14:1311\u201322. PMID:29485353"}
{"id": "57c00fd5-3f41-4566-b80f-eb28382d65e9", "page": 27, "type": "paragraph", "text": "https://doi.org/10.1080/21645515.2018.1445446"}
{"id": "0a256c97-efd8-4030-a846-366738122f67", "page": 27, "type": "paragraph", "text": "90. Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society"}
{"id": "90414c26-07f1-4cd2-b054-2438f5f6360b", "page": 27, "type": "paragraph", "text": "of America. 2013 IDSA clinical practice guideline for vaccination of"}
{"id": "12266ef5-b9fa-4a98-b3f7-6ad0583d3fef", "page": 27, "type": "paragraph", "text": "the immunocompromised host. Clin Infect Dis 2014;58:e44\u2013100."}
{"id": "ba1b77e7-4284-4de6-a051-498279db15dd", "page": 27, "type": "paragraph", "text": "PMID:24311479 https://doi.org/10.1093/cid/cit684"}
{"id": "14254b8a-0679-4039-8a14-529040ddd9db", "page": 27, "type": "paragraph", "text": "91. CDC. Influenza antiviral medications: summary for clinicians. Atlanta,"}
{"id": "d51f8524-94ca-4a20-bedd-984e990e5cae", "page": 27, "type": "paragraph", "text": "GA: US Department of Health and Human Services, CDC. https://"}
{"id": "4c53b498-d35d-4ba6-9bfc-d1d0ec874fce", "page": 27, "type": "paragraph", "text": "www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm."}
{"id": "8b1fb305-7e5f-48ca-abc8-53502cdaf651", "page": 27, "type": "paragraph", "text": "92. Woo EJ. Allergic reactions after egg-free recombinant influenza vaccine:"}
{"id": "a84e9b80-91c5-4a55-b87b-dffa6931d443", "page": 27, "type": "paragraph", "text": "reports to the US Vaccine Adverse Event Reporting System. Clin Infect Dis"}
{"id": "21a14384-19e8-4ae6-a133-d826d9b8769e", "page": 27, "type": "paragraph", "text": "2015;60:777\u201380. PMID:25428412 https://doi.org/10.1093/cid/ciu948"}
{"id": "079c2062-0aa5-4867-97af-ec3a934b3d82", "page": 27, "type": "paragraph", "text": "93. Woo EJ, Moro PL, Cano M, Jankosky C. Postmarketing safety"}
{"id": "19a4e546-87a9-45dc-a398-db92df267148", "page": 27, "type": "paragraph", "text": "surveillance of trivalent recombinant influenza vaccine: reports to the"}
{"id": "46bf7464-7dca-4c87-b511-be745db67e42", "page": 27, "type": "paragraph", "text": "Vaccine Adverse Event Reporting System. Vaccine 2017;35:5618\u201321."}
{"id": "facd3a37-be29-408d-957a-48c08ec4ae51", "page": 27, "type": "paragraph", "text": "PMID:28886946 https://doi.org/10.1016/j.vaccine.2017.08.047"}
{"id": "2cb58f6b-6597-415e-8c9c-79a01bb975bf", "page": 27, "type": "paragraph", "text": "94. Woo EJ, Moro PL. Postmarketing safety surveillance of quadrivalent"}
{"id": "cdaa7009-61bd-4a07-9a63-88bec84c0da2", "page": 27, "type": "paragraph", "text": "recombinant influenza vaccine: Reports to the Vaccine Adverse Event"}
{"id": "f8a7137a-f656-4944-bfb0-3d0423c3ecf7", "page": 27, "type": "paragraph", "text": "Reporting System. Vaccine 2021;39:1812\u20137. PMID:33678452 https://"}
{"id": "3779f1d4-6e48-4beb-adee-74652946bea5", "page": 27, "type": "paragraph", "text": "doi.org/10.1016/j.vaccine.2021.02.052"}
{"id": "63c47469-74c6-47bb-9d71-af786b703ea2", "page": 27, "type": "paragraph", "text": "95. Uyeki TM, Zane SB, Bodnar UR, et al.; Alaska/Yukon Territory Respiratory"}
{"id": "1c3e723c-b6ed-4315-bb6e-ff9618c96de9", "page": 27, "type": "paragraph", "text": "Outbreak Investigation Team. Large summertime influenza A outbreak"}
{"id": "4e49ce11-3bdd-48cc-bcf1-4eb86562cfda", "page": 27, "type": "paragraph", "text": "among tourists in Alaska and the Yukon Territory. Clin Infect Dis"}
{"id": "16efffa4-f1d6-4653-b35c-f1b96c69d231", "page": 27, "type": "paragraph", "text": "2003;36:1095\u2013102. PMID:12715302 https://doi.org/10.1086/374053"}
{"id": "4ee4bc0c-1cf3-4efa-83ff-03405386156d", "page": 27, "type": "paragraph", "text": "96. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in"}
{"id": "a1a42a2c-4271-44c4-8909-a529f5694261", "page": 27, "type": "paragraph", "text": "travelers to tropical and subtropical countries. Clin Infect Dis"}
{"id": "edeab068-d80a-4650-be80-d6c3783c8061", "page": 27, "type": "paragraph", "text": "2005;40:1282\u20137. PMID:15825030 https://doi.org/10.1086/429243"}
{"id": "9fbe92ba-0fe2-453a-b03b-a844f480f49e", "page": 27, "type": "paragraph", "text": "97. Ratnam I, Black J, Leder K, et al. Incidence and risk factors for acute"}
{"id": "6f4c46a6-ca40-4973-b0ea-e93efeeaa226", "page": 27, "type": "paragraph", "text": "respiratory illnesses and influenza virus infections in Australian travellers"}
{"id": "ab3c2024-169e-415f-9cf6-c1b5e7aec14f", "page": 27, "type": "paragraph", "text": "to Asia. J Clin Virol 2013;57:54\u20138. PMID:23380660 https://doi."}
{"id": "9106db17-cbf5-4ed2-aa97-cd81488b3263", "page": 27, "type": "paragraph", "text": "org/10.1016/j.jcv.2013.01.008"}
{"id": "4a34f47f-8e30-4a1f-bb05-3c52f4c82d91", "page": 27, "type": "paragraph", "text": "98. Millman AJ, Kornylo Duong K, Lafond K, Green NM, Lippold SA,"}
{"id": "62d1fcf9-1826-412c-9be0-54c358ae1838", "page": 27, "type": "paragraph", "text": "Jhung MA. Influenza outbreaks among passengers and crew on two"}
{"id": "b948d747-0544-4806-af52-b4900c85b781", "page": 27, "type": "paragraph", "text": "cruise ships: a recent account of preparedness and response to an ever-"}
{"id": "81f5bc4a-a5c8-45ec-9c87-bd3fea68aed2", "page": 27, "type": "paragraph", "text": "present challenge. J Travel Med 2015;22:306\u201311. PMID:26031322"}
{"id": "7cfff5ee-1148-406b-b0ab-833761216c51", "page": 27, "type": "paragraph", "text": "https://doi.org/10.1111/jtm.12215"}
{"id": "42b2727f-68af-43a7-9b12-e68c8fa96130", "page": 27, "type": "paragraph", "text": "99. Flumist Quadrivalent [Package Insert]. Gaithersburg, MD:"}
{"id": "4c103626-0d69-4a37-b626-78e7678753b0", "page": 27, "type": "paragraph", "text": "MedImmune; 2021."}
{"id": "0573dd96-cbec-4e66-b567-ff72f3f53ef0", "page": 27, "type": "paragraph", "text": "100. Rapivab (peramivir for injection) [Package Insert]. Durham, NC:"}
{"id": "8db8cac0-f4db-4ea0-aabc-992b36237a9c", "page": 27, "type": "paragraph", "text": "BioCryst; 2017."}
{"id": "ae855b9b-98ad-45ab-b7b1-18a22bedd25f", "page": 27, "type": "paragraph", "text": "101. Xofluza (baloxavir marboxil) [Package Insert]. San Francisco, CA:"}
{"id": "8527c02b-35f1-4fbc-ad8c-011927ce405d", "page": 27, "type": "paragraph", "text": "Genentech; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/"}
{"id": "ca589c3b-d036-44a1-a0df-c4305817c0d9", "page": 27, "type": "paragraph", "text": "label/2018/210854s000lbl.pdf"}
{"id": "196654b5-193c-4234-9153-10b725aea191", "page": 27, "type": "paragraph", "text": "102. Food and Drug Administration. Guidance for industry: bioavailability"}
{"id": "57b81341-e3d0-4559-8d07-b19114bd3c41", "page": 27, "type": "paragraph", "text": "and bioequivalence studies for orally administered drug products:"}
{"id": "0d59b402-c9fa-4889-a014-a3e3779d7de4", "page": 27, "type": "paragraph", "text": "general considerations. Silver Spring, MD: US Department of Health"}
{"id": "d84a1af4-84d4-4043-aefa-d64d0d6d7ea0", "page": 27, "type": "paragraph", "text": "and Human Services, Food and Drug Administration; 2003."}
{"id": "23c3119d-c1ae-4335-a7f8-8867cd062c03", "page": 27, "type": "paragraph", "text": "103. Izikson R, Brune D, Bolduc JS, et al. Safety and immunogenicity of a"}
{"id": "4160e4b0-97a0-47b3-a1a7-3e3bc55cd089", "page": 27, "type": "paragraph", "text": "high-dose quadrivalent influenza vaccine administered concomitantly"}
{"id": "899df74c-8f60-454d-836c-448b0bc32f4f", "page": 27, "type": "paragraph", "text": "with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults"}
{"id": "bd4fa1c3-37d4-4b9c-94a7-b320177379d4", "page": 27, "type": "paragraph", "text": "aged \u226565 years: a phase 2, randomised, open-label study. Lancet Respir"}
{"id": "f21304c1-593d-4294-b53a-60d0642a7ed9", "page": 27, "type": "paragraph", "text": "Med 2022;10:392\u2013402. Epub Feb. 21, 2022. PMID:35114141 https://"}
{"id": "df19ddd3-37df-48f7-a5b8-90a3e077acd3", "page": 27, "type": "paragraph", "text": "doi.org/10.1016/S2213-2600(21)00557-9"}
{"id": "067c4183-a9c9-4a62-a328-d18025c4d12d", "page": 27, "type": "paragraph", "text": "104. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity"}
{"id": "c925b301-4a10-4913-a7f4-a288c52ffbbf", "page": 27, "type": "paragraph", "text": "profile of the concomitant administration of ZOSTAVAX and"}
{"id": "dad08490-097c-4b5e-a900-8292ae92630d", "page": 27, "type": "paragraph", "text": "inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr"}
{"id": "c32224e4-737c-4b37-ba24-107627d6462f", "page": 27, "type": "paragraph", "text": "Soc 2007;55:1499\u2013507. PMID:17908055 https://doi."}
{"id": "00fe78d4-e097-4b6f-a5d1-76cdb09deb64", "page": 27, "type": "paragraph", "text": "org/10.1111/j.1532-5415.2007.01397.x"}
{"id": "91d92403-4fa3-4570-b072-8b3d9e91cfda", "page": 27, "type": "paragraph", "text": "105. Levin MJ, Buchwald UK, Gardner J, et al. Immunogenicity and safety"}
{"id": "b0fc0a70-c22f-4f48-b01e-7a079b237fdf", "page": 27, "type": "paragraph", "text": "of zoster vaccine live administered with quadrivalent influenza virus"}
{"id": "822f43ba-e91f-4cb6-a5dc-764532d48a6f", "page": 27, "type": "paragraph", "text": "vaccine. Vaccine 2018;36:179\u201385. PMID:28830693 https://doi."}
{"id": "9e513070-4c14-4177-8a08-eef4031155b9", "page": 27, "type": "paragraph", "text": "org/10.1016/j.vaccine.2017.08.029"}
{"id": "052e3a08-37c4-4920-a170-01363422a773", "page": 28, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "953ad0e2-f186-4bd1-b8e1-f5c5a4166a7d", "page": 28, "type": "paragraph", "text": "26"}
{"id": "9a60c1ef-036d-4d46-b025-ce3db7d085ad", "page": 28, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "eb730958-4267-412c-a592-673b233997c0", "page": 28, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "d4e47f75-3072-47ad-b800-cc3dd539ecc9", "page": 28, "type": "paragraph", "text": "106. Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled"}
{"id": "5f06e2c4-4abb-4040-9420-9f6b081bbbb5", "page": 28, "type": "paragraph", "text": "trial of a 13-valent pneumococcal conjugate vaccine administered"}
{"id": "406202a4-4a42-47ed-b230-b32f917dfe54", "page": 28, "type": "paragraph", "text": "concomitantly with an influenza vaccine in healthy adults. Clin Vaccine"}
{"id": "7e9ce1aa-1247-484e-8d4b-75c12303ae95", "page": 28, "type": "paragraph", "text": "Immunol 2012;19:1296\u2013303. PMID:22739693 https://doi."}
{"id": "5005cf4e-5d56-44b9-a190-3579fcf444b7", "page": 28, "type": "paragraph", "text": "org/10.1128/CVI.00176-12"}
{"id": "6e62094b-c9e8-4d10-a0d4-2fb5e4d488f9", "page": 28, "type": "paragraph", "text": "107. Schwarz TF, Flamaing J, R\u00fcmke HC, et al. A randomized, double-blind"}
{"id": "cd0fe9a8-74f6-4cd0-a583-edf9a2c60a66", "page": 28, "type": "paragraph", "text": "trial to evaluate immunogenicity and safety of 13-valent pneumococcal"}
{"id": "b683d845-6487-4655-ade6-606b7aeaddcc", "page": 28, "type": "paragraph", "text": "conjugate vaccine given concomitantly with trivalent influenza vaccine"}
{"id": "7853b7e9-f64d-4d0d-94a0-1aedbd146b81", "page": 28, "type": "paragraph", "text": "in adults aged \u226565 years. Vaccine 2011;29:5195\u2013202. PMID:21619909"}
{"id": "f328db77-1c72-4b6a-809f-b61f750b379b", "page": 28, "type": "paragraph", "text": "https://doi.org/10.1016/j.vaccine.2011.05.031"}
{"id": "f2f656cf-87af-4529-94cd-aff4f5621385", "page": 28, "type": "paragraph", "text": "108. McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and"}
{"id": "da1da533-01ee-4a82-bae1-4f6c10c07e5b", "page": 28, "type": "paragraph", "text": "immunogenicity of concomitant and sequential administration of an"}
{"id": "79563c81-3096-45b7-9b33-1bce96f66623", "page": 28, "type": "paragraph", "text": "adult formulation tetanus and diphtheria toxoids adsorbed combined"}
{"id": "491fd165-6f85-4623-b6cf-73fd8bfec191", "page": 28, "type": "paragraph", "text": "with acellular pertussis (Tdap) vaccine and trivalent inactivated"}
{"id": "d19e5051-a18f-48d4-9489-3a7d7eaee3b6", "page": 28, "type": "paragraph", "text": "influenza vaccine in adults. Vaccine 2007;25:3464\u201374. PMID:17270320"}
{"id": "534f65cb-3228-4ef1-8af1-912160c3b28a", "page": 28, "type": "paragraph", "text": "https://doi.org/10.1016/j.vaccine.2006.12.047"}
{"id": "0750fac5-7f2e-457b-b998-f04f6b153546", "page": 28, "type": "paragraph", "text": "109. Nakashima K, Aoshima M, Ohfuji S, et al. Immunogenicity of"}
{"id": "8b3b69e0-4466-4291-9833-40aa86ac0ffe", "page": 28, "type": "paragraph", "text": "simultaneous versus sequential administration of a 23-valent"}
{"id": "5a2d9740-b423-4419-a582-8e4118498af6", "page": 28, "type": "paragraph", "text": "pneumococcal polysaccharide vaccine and a quadrivalent influenza"}
{"id": "dc53ac6f-f02c-4fd7-86b1-7567e820800d", "page": 28, "type": "paragraph", "text": "vaccine in older individuals: A randomized, open-label, non-inferiority"}
{"id": "7a6ea323-2aab-420f-8013-c547826809e6", "page": 28, "type": "paragraph", "text": "trial. Hum Vaccin Immunother 2018;14:1923\u201330. PMID:29561248"}
{"id": "267dc448-899d-459c-99b8-64bed3057403", "page": 28, "type": "paragraph", "text": "https://doi.org/10.1080/21645515.2018.1455476"}
{"id": "e0622bf4-8017-4c7c-a961-4af38e2777cd", "page": 28, "type": "paragraph", "text": "110. Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of"}
{"id": "75a27b76-3040-4937-bd2a-f5d05c8bb6a5", "page": 28, "type": "paragraph", "text": "concomitant MF59-adjuvanted influenza vaccine and 23-valent"}
{"id": "2e826e08-f252-4a87-ade2-a956da8438fb", "page": 28, "type": "paragraph", "text": "pneumococcal polysaccharide vaccine administration in older adults."}
{"id": "ec0bb54e-0de0-4446-bc19-446013754445", "page": 28, "type": "paragraph", "text": "Vaccine 2015;33:4647\u201352. PMID:25980426 https://doi.org/10.1016/j."}
{"id": "60656498-4b30-4917-a993-79d6fa12ed5c", "page": 28, "type": "paragraph", "text": "vaccine.2015.05.003"}
{"id": "fa28e133-6791-4838-956e-b87087207e12", "page": 28, "type": "paragraph", "text": "111. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Safety of tetanus"}
{"id": "e2c254af-c377-4889-b52c-766f907626af", "page": 28, "type": "paragraph", "text": "toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza"}
{"id": "f39733e7-5f56-4a5b-a3b1-368cc02c400b", "page": 28, "type": "paragraph", "text": "vaccinations in pregnancy. Obstet Gynecol 2015;126:1069\u201374."}
{"id": "03a5290c-bc82-44c1-aee9-a8f5f886323e", "page": 28, "type": "paragraph", "text": "PMID:26444109 https://doi.org/10.1097/AOG.0000000000001066"}
{"id": "14042320-9c66-4e21-82f9-0393a37a6030", "page": 28, "type": "paragraph", "text": "112. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric"}
{"id": "ecdb92b9-a5f3-4929-ba9b-e63424d0eb17", "page": 28, "type": "paragraph", "text": "trivalent inactivated influenza vaccine and 13-valent pneumococcal"}
{"id": "404806b4-19c7-4e06-aaa8-6876ef31e031", "page": 28, "type": "paragraph", "text": "conjugate vaccine. JAMA Pediatr 2014;168:211\u20139. PMID:24395025"}
{"id": "1db1425b-a747-42ee-897c-2c1cf205000c", "page": 28, "type": "paragraph", "text": "https://doi.org/10.1001/jamapediatrics.2013.4469"}
{"id": "0ac8f199-42b5-46b0-bb07-9ffa950f6843", "page": 28, "type": "paragraph", "text": "113. Walter EB, Klein NP, Wodi AP, et al. Fever after influenza, diphtheria-"}
{"id": "6cf44539-e987-4e5a-9e91-b750211282a2", "page": 28, "type": "paragraph", "text": "tetanus-acellular pertussis, and pneumococcal vaccinations. Pediatrics"}
{"id": "febd90a6-99b5-485d-b72d-c9f52597270a", "page": 28, "type": "paragraph", "text": "2020;145:e20191909. PMID:32029684 https://doi.org/10.1542/"}
{"id": "23f0d751-8cff-4da2-9340-f8779dec7ff3", "page": 28, "type": "paragraph", "text": "peds.2019-1909"}
{"id": "76918a59-49ef-4e4e-8c36-2fa2a408bb7a", "page": 28, "type": "paragraph", "text": "114. Duffy J, Weintraub E, Hambidge SJ, et al.; Vaccine Safety Datalink."}
{"id": "3acabfcf-aa24-4f34-ad31-84da1e3e016f", "page": 28, "type": "paragraph", "text": "Febrile seizure risk after vaccination in children 6 to 23 months."}
{"id": "35e489e7-8205-4b55-84c9-6fe6be33845f", "page": 28, "type": "paragraph", "text": "Pediatrics 2016;138:e20160320. PMID:27273711 https://doi."}
{"id": "b408d0d7-c9c2-4ac0-a40b-3fc2a2329881", "page": 28, "type": "paragraph", "text": "org/10.1542/peds.2016-0320"}
{"id": "3e100f7a-27b8-4506-9cdf-3874751e6e2f", "page": 28, "type": "paragraph", "text": "115. Li R, Stewart B, McNeil MM, et al. Post licensure surveillance of"}
{"id": "f50f541f-cfa5-4ead-97dc-118d1b79da8b", "page": 28, "type": "paragraph", "text": "influenza vaccines in the Vaccine Safety Datalink in the 2013\u20132014"}
{"id": "ce40b757-e89e-4cbd-b8c5-32b3c875faad", "page": 28, "type": "paragraph", "text": "and 2014\u20132015 seasons. Pharmacoepidemiol Drug Saf 2016;25:928\u201334."}
{"id": "23e899fd-7b81-486b-ab8d-75ae263681ad", "page": 28, "type": "paragraph", "text": "PMID:27037540 https://doi.org/10.1002/pds.3996"}
{"id": "b62fab9f-f4b7-4dad-aede-39f736418a92", "page": 28, "type": "paragraph", "text": "116. Patterson JL, Carapetian SA, Hageman JR, Kelley KR. Febrile seizures."}
{"id": "bac89eb8-3237-43c4-bda0-c9e193e502ea", "page": 28, "type": "paragraph", "text": "Pediatr Ann 2013;42:249\u201354. PMID:24295158 https://doi."}
{"id": "c568dac0-b447-4560-ba58-9bb1fab9bce8", "page": 28, "type": "paragraph", "text": "org/10.3928/00904481-20131122-09"}
{"id": "6ea36495-dd7c-45e9-9756-e0ba1ed1f60c", "page": 28, "type": "paragraph", "text": "117. Nolan T, Bernstein DI, Block SL, et al.; LAIV Study Group. Safety"}
{"id": "c93c7a0c-f673-4fdc-96b5-ed138d635613", "page": 28, "type": "paragraph", "text": "and immunogenicity of concurrent administration of live attenuated"}
{"id": "92792d96-ff18-4c7e-927e-26ed5e03c21f", "page": 28, "type": "paragraph", "text": "influenza vaccine with measles-mumps-rubella and varicella vaccines"}
{"id": "75a87916-cbac-4b46-90f4-b087e08020f0", "page": 28, "type": "paragraph", "text": "to infants 12 to 15 months of age. Pediatrics 2008;121:508\u201316."}
{"id": "f5fb7bce-384a-4f2e-9560-8be43f9693ae", "page": 28, "type": "paragraph", "text": "PMID:18310199 https://doi.org/10.1542/peds.2007-1064"}
{"id": "044aed2b-025a-4045-b42b-bbb183e43545", "page": 28, "type": "paragraph", "text": "118. Lum LC, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine"}
{"id": "71366f54-189f-4723-8b4d-330f41ebe894", "page": 28, "type": "paragraph", "text": "concurrently administered with a combination measles, mumps, and"}
{"id": "31befa5d-dcce-4568-b555-774f63e21d49", "page": 28, "type": "paragraph", "text": "rubella vaccine to young children. Vaccine 2010;28:1566\u201374."}
{"id": "381ae0dd-b475-472c-a04b-9abb0d83cd4f", "page": 28, "type": "paragraph", "text": "PMID:20003918 https://doi.org/10.1016/j.vaccine.2009.11.054"}
{"id": "9c715644-8179-4558-b894-85b1f5a717f3", "page": 28, "type": "paragraph", "text": "119. Shingrix [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline;"}
{"id": "9686172a-579f-45b8-9319-fc6478fbdc48", "page": 28, "type": "paragraph", "text": "2017."}
{"id": "8c933010-c695-4c19-8123-51f40c9ffe33", "page": 28, "type": "paragraph", "text": "120. Fluad Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022."}
{"id": "eea03155-0238-42cf-8d6c-c19481d77f21", "page": 28, "type": "paragraph", "text": "121. Heplisav-B [Package Insert]. Emeryville, CA: Dynavax; 2017."}
{"id": "2f0d5f6e-40f8-4542-a9d5-4f05f1a1ed91", "page": 28, "type": "paragraph", "text": "122. Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and"}
{"id": "999a140d-37b1-48dc-8b5d-a628b6e68b81", "page": 28, "type": "paragraph", "text": "safety of an adjuvanted herpes zoster subunit vaccine coadministered"}
{"id": "d9a160a4-e5f5-4d51-9da8-4e194b5a14f8", "page": 28, "type": "paragraph", "text": "with seasonal influenza vaccine in adults aged 50 years or older. J Infect"}
{"id": "3872a794-102b-4dc0-88f1-e513dc41234b", "page": 28, "type": "paragraph", "text": "Dis 2017;216:1352\u201361. PMID:29029224 https://doi.org/10.1093/"}
{"id": "62d52933-20a2-45b8-b4b8-b46235851026", "page": 28, "type": "paragraph", "text": "infdis/jix481"}
{"id": "f144964d-e811-41a5-a53b-6c9cbeb061f1", "page": 28, "type": "paragraph", "text": "123. Fluarix Quadrivalent [Package Insert]. Dresden, Germany:"}
{"id": "d9e04387-be5e-4281-9d86-061b3d972b36", "page": 28, "type": "paragraph", "text": "GlaxoSmithKline; 2022."}
{"id": "d1da807e-89f3-4dd6-bda7-216ba9221525", "page": 28, "type": "paragraph", "text": "124. FluLaval Quadrivalent [Package Insert]. Quebec City, QC, Canada:"}
{"id": "28e5c97c-9b1f-41a9-9e49-31db32de5cd2", "page": 28, "type": "paragraph", "text": "ID Biomedical Corporation of Quebec; 2022."}
{"id": "0ac9fba5-eff0-4c76-938d-90fea1923e61", "page": 28, "type": "paragraph", "text": "125. Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022."}
{"id": "a3f19eb4-1da2-4062-9f68-d9de49bca6db", "page": 28, "type": "paragraph", "text": "126. Fluzone High-Dose Quadrivalent [Package Insert]. Swiftwater, PA:"}
{"id": "7a7ed093-29e0-43cc-abff-cfae4e84e14f", "page": 28, "type": "paragraph", "text": "Sanofi Pasteur; 2022."}
{"id": "575bdb53-1e63-4464-9230-0c7828159664", "page": 28, "type": "paragraph", "text": "127. Flublok Quadrivalent [Package Insert]. Meriden, CT: Protein Sciences; 2022."}
{"id": "775e79a9-72bf-47e9-88ed-3b9170ce4770", "page": 28, "type": "paragraph", "text": "128. Food and Drug Administration. Clinical review: Flucelvax"}
{"id": "25163284-4404-402b-a5d1-09fbb35984d1", "page": 28, "type": "paragraph", "text": "Quadrivalent. Silver Spring, MD: US Department of Health and"}
{"id": "c21f5a9f-6396-4256-9b74-cfe669779719", "page": 28, "type": "paragraph", "text": "Human Services, Food and Drug Administration; 2016."}
{"id": "1c014105-adb3-45b5-ab08-c84e9de84ae5", "page": 28, "type": "paragraph", "text": "129. Food and Drug Administration. Clinical review: Flucelvax"}
{"id": "e158624e-dda1-47f0-b487-3d28b4d6cd51", "page": 28, "type": "paragraph", "text": "Quadrivalent. Silver Spring, MD: US Department of Health and"}
{"id": "83867b70-f869-4640-94a4-1b9d8074ef79", "page": 28, "type": "paragraph", "text": "Human Services, Food and Drug Administration; March 2021."}
{"id": "c558f8cf-d23d-42a5-9238-d087c4672d9d", "page": 28, "type": "paragraph", "text": "130. Food and Drug Administration. Clinical review: Flucelvax"}
{"id": "b1efcd7d-1cba-4ef7-b40c-50ffa9a31db0", "page": 28, "type": "paragraph", "text": "Quadrivalent. Silver Spring, MD: US Department of Health and"}
{"id": "b9690590-2ad1-4d58-bd05-e3a4dcc6ad06", "page": 28, "type": "paragraph", "text": "Human Services, Food and Drug Administration; October 2021."}
{"id": "871a429f-d18f-45c7-81b9-09728f4bc91e", "page": 29, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "c0b11e72-ff93-48b0-916d-bfe02265e483", "page": 29, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "9467a2c5-37f4-49ee-a382-2c63f33abca6", "page": 29, "type": "paragraph", "text": "27"}
{"id": "02b10421-4a11-4309-b782-72fe44f3d223", "page": 29, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "a37b87d8-f471-4602-97cc-fcbf8acac3cc", "page": 29, "type": "paragraph", "text": "Disclosure of Relationship and Unlabeled Use"}
{"id": "209c22e7-c840-4197-ae13-509097f9a0bd", "page": 29, "type": "paragraph", "text": "All authors have completed and submitted the International Committee of Medical Journal Editors form for the disclosure of potential conflicts of interest."}
{"id": "5cb699c2-04d1-4339-87d6-f1aa1f73b7cf", "page": 29, "type": "paragraph", "text": "Helen Keipp Talbot reports receiving financial support from CDC. No other potential conflicts of interest were disclosed. This report includes discussion of"}
{"id": "402dbdeb-c888-4cf7-8f41-363de3ef45b7", "page": 29, "type": "paragraph", "text": "the unlabeled use of influenza vaccines in the instance of influenza vaccination of persons with a history of egg allergy. A history of severe allergic reaction"}
{"id": "311030ee-3696-457c-9568-9f3219e379e0", "page": 29, "type": "paragraph", "text": "(e.g., anaphylaxis) to the vaccine or any of its components (which include egg for certain vaccines) is a labeled contraindication to receipt of most IIV4s"}
{"id": "f9a98164-8b9f-4eee-8332-cf633e76dfe8", "page": 29, "type": "paragraph", "text": "and LAIV4. However, ACIP recommends that persons with a history of allergic reaction of any severity to egg should receive any licensed, recommended"}
{"id": "4b6f886d-160e-487e-bf18-dae15da93d83", "page": 29, "type": "paragraph", "text": "influenza vaccine that is appropriate for their age and health status. Persons with a history of severe allergic reaction to egg who receive egg-based vaccines (i.e.,"}
{"id": "cd37284c-8cd0-4c73-bcd4-7f6922d28c2f", "page": 29, "type": "paragraph", "text": "vaccines other than cell culture\u2013based inactivated influenza vaccine [ccIIV4] or recombinant influenza vaccine [RIV4]) should be vaccinated in an inpatient"}
{"id": "6dadb40c-9a7e-41e6-8a96-eed1580d33f6", "page": 29, "type": "paragraph", "text": "or outpatient medical setting (including, but not necessarily limited to, hospitals, clinics, health departments, and physician offices); vaccine administration"}
{"id": "aa527e6a-61e3-466f-952e-134cc352b046", "page": 29, "type": "paragraph", "text": "in such instances should be supervised by a health care provider who is able to recognize and manage severe allergic reactions. No postvaccination waiting"}
{"id": "1850b3e9-9194-40b6-b77c-24c433e19272", "page": 29, "type": "paragraph", "text": "period is recommended specifically for egg-allergic persons. However, ACIP recommends that vaccine providers consider observing patients seated or supine"}
{"id": "1801f46b-b3df-4fa4-9705-ce402df48e16", "page": 29, "type": "paragraph", "text": "for 15 minutes after administration of any vaccine (regardless of allergy history) to decrease the risk for injury should syncope occur."}
{"id": "1841ebee-bf81-4fcf-81b6-158d3bab974e", "page": 30, "type": "paragraph", "text": "Recommendations and Reports"}
{"id": "b9068c2d-3f75-4c96-8730-cb139bb6eb59", "page": 30, "type": "paragraph", "text": "28"}
{"id": "0bd81d80-74d7-4e01-ac1f-df4fc9e2b7dd", "page": 30, "type": "paragraph", "text": "MMWR / August 26, 2022 / Vol. 71 / No. 1"}
{"id": "7c87ecd2-6850-4fbf-84e9-6a5003350041", "page": 30, "type": "paragraph", "text": "US Department of Health and Human Services/Centers for Disease Control and Prevention"}
{"id": "b174de4b-3eb5-4bc9-b7db-a6708d878577", "page": 30, "type": "paragraph", "text": "Advisory Committee on Immunization Practices (ACIP), July 1, 2021\u2013June 30, 2022"}
{"id": "0df63a13-8e6d-4961-a447-31e6a0675961", "page": 30, "type": "paragraph", "text": "Chair: Grace M. Lee, MD, Stanford University School of Medicine, Stanford, California."}
{"id": "316e677c-bae7-4f7e-a794-39edac9a3624", "page": 30, "type": "paragraph", "text": "Executive Secretary: Melinda Wharton, MD, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia."}
{"id": "11564d72-895a-4055-891d-3f074537053c", "page": 30, "type": "paragraph", "text": "Members: Kevin A. Ault, MD, University of Kansas Medical Center, Kansas City, Kansas; Lynn Bahta, MPH, Minnesota Department of Health, St. Paul,"}
{"id": "4fdd1b83-e069-4828-ba56-30416f9bb010", "page": 30, "type": "paragraph", "text": "Minnesota; Beth P. Bell, MD, University of Washington, Seattle, Washington; Oliver Brooks, MD, Watts HealthCare Corporation, Los Angeles, California;"}
{"id": "637c5069-3d32-4273-be3d-90d680e0626a", "page": 30, "type": "paragraph", "text": "Wilbur H. Chen, MD, University of Maryland School of Medicine, Baltimore, Maryland; Sybil Cineas, MD, Warren Alpert Medical School of Brown"}
{"id": "e3b1c365-466b-4bca-bf18-34d09f58cef5", "page": 30, "type": "paragraph", "text": "University, Providence, Rhode Island; Matthew F. Daley, MD, Kaiser Permanente Colorado, Aurora, Colorado; Camille Nelson Kotton, MD, Harvard"}
{"id": "b1de6e13-37f5-4bdb-9ffe-c1978aa8eca4", "page": 30, "type": "paragraph", "text": "Medical School, Boston, Massachusetts; Jamie Loehr, MD, Cayuga Family Medicine, Ithaca, New York; Sarah S. Long, MD, Drexel University College of"}
{"id": "43bbd0f3-7b3e-4ef4-a2ad-728c23593378", "page": 30, "type": "paragraph", "text": "Medicine, Philadelphia, Pennsylvania; Veronica V. McNally, JD, Franny Strong Foundation, West Bloomfield, Michigan; Katherine A. Poehling, MD, Wake"}
{"id": "256f2c13-20f7-4050-8ee6-242005f71775", "page": 30, "type": "paragraph", "text": "Forest School of Medicine, Winston-Salem, North Carolina; Pablo J. S\u00e1nchez, MD, The Research Institute at Nationwide Children\u2019s Hospital, Columbus,"}
{"id": "a7ba8d04-4f28-45f4-9343-1ba19714d041", "page": 30, "type": "paragraph", "text": "Ohio; Helen Keipp Talbot, MD, Vanderbilt University, Nashville, Tennessee."}
{"id": "70e1bdbb-8ccb-4d31-8ee5-947593b63744", "page": 30, "type": "paragraph", "text": "Ex Officio Members: Centers for Medicare and Medicaid Services, Mary Beth Hance, Baltimore, Maryland; Food and Drug Administration, Doran Fink,"}
{"id": "db4bbe68-33bc-4e4b-8f72-fca66a869759", "page": 30, "type": "paragraph", "text": "MD, PhD, Silver Spring, Maryland; Health Resources and Services Administration, Mary Rubin, MD, Rockville, Maryland; Indian Health Service, Matthew"}
{"id": "0fa233f9-5678-49ea-8066-3fffdfdf2e8a", "page": 30, "type": "paragraph", "text": "Clark, MD, Durango, Colorado; Office of Infectious Disease and HIV/AIDS Policy, David Kim, MD, Washington, DC; National Institutes of Health, John"}
{"id": "631ec119-46ec-4e78-a82a-85549d503b18", "page": 30, "type": "paragraph", "text": "Beigel, MD, Bethesda, Maryland."}
{"id": "9399151d-c970-4689-b0d0-778c3385b57d", "page": 30, "type": "paragraph", "text": "Liaison Representatives: American Academy of Family Physicians, Pamela G. Rockwell, DO, Ann Arbor, Michigan; American Academy of Pediatrics,"}
{"id": "6812159a-8a1f-4e8e-aed2-0506f271422f", "page": 30, "type": "paragraph", "text": "Committee on Infectious Diseases, Yvonne Maldonado, MD, Stanford, California; American Academy of Pediatrics, Red Book Editor, David Kimberlin, MD,"}
{"id": "96364d3a-d66d-42fd-a13d-484d30cdb570", "page": 30, "type": "paragraph", "text": "Birmingham, Alabama; American Academy of Physician Associates, Marie-Mich\u00e8le L\u00e9ger, MPH, Alexandria, Virginia; American College Health Association,"}
{"id": "fc94dfeb-d859-408d-8191-b60d5a8862a2", "page": 30, "type": "paragraph", "text": "Thevy Chai, MD, Chapel Hill, North Carolina; American College Health Association, (alternate) Sharon McMullen, MPH, Ithaca, New York; American"}
{"id": "1b687949-c0ae-4ba7-807b-a7450f55bbcb", "page": 30, "type": "paragraph", "text": "College of Nurse Midwives, Carol E. Hayes, MN, MPH, Atlanta, Georgia; American College of Nurse Midwives, (alternate) Pamela M. Meharry, PhD,"}
{"id": "548505bb-5247-4923-9c76-b40d07125c71", "page": 30, "type": "paragraph", "text": "Chicago, Illinois; American College of Obstetricians and Gynecologists, Linda O\u2019Neal Eckert, MD, Seattle, Washington; American College of Physicians,"}
{"id": "bb70cb5f-6ea2-43af-92fa-bf55acfeb0c6", "page": 30, "type": "paragraph", "text": "Jason M. Goldman, MD, Boca Raton, Florida; American Geriatrics Society, Kenneth Schmader, MD, Durham, North Carolina; America\u2019s Health Insurance"}
{"id": "fbf39ecb-be01-4e29-b843-25ea71d6a186", "page": 30, "type": "paragraph", "text": "Plans, Robert A. Gluckman, MD, Beaverton, Oregon; American Immunization Registry Association, Rebecca Coyle, MSEd, Washington, DC; American"}
{"id": "084e3d42-d677-40d9-95ed-9ae4cc381de9", "page": 30, "type": "paragraph", "text": "Medical Association, Sandra Adamson Fryhofer, MD, Atlanta, Georgia; American Nurses Association, Charles (Chad) Rittle, DNP, Pittsburgh, Pennsylvania;"}
{"id": "d564e90e-a8a3-4dcb-a7c0-1f3d4876198b", "page": 30, "type": "paragraph", "text": "American Osteopathic Association, Stanley E. Grogg, DO, Tulsa, Oklahoma; American Pharmacists Association, Michael D. Hogue, PharmD, Loma Linda,"}
{"id": "a3befd70-d613-4ae0-9f19-d941e64b2249", "page": 30, "type": "paragraph", "text": "California; Association of Immunization Managers, Molly Howell, MPH, Bismarck, North Dakota; Association for Prevention Teaching and Research, Richard"}
{"id": "1b2b70df-9cb8-42b8-b7f5-58d8e705634e", "page": 30, "type": "paragraph", "text": "Zimmerman, MD, Pittsburgh, Pennsylvania; Association of State and Territorial Health Officials, Nirav Shah, MD, JD, Augusta, Maine; Biotechnology Industry"}
{"id": "0664f1df-d29c-4e79-b3f8-968e2c633fa5", "page": 30, "type": "paragraph", "text": "Organization, Phyllis A. Arthur, MBA, Washington, DC; Council of State and Territorial Epidemiologists, Christine Hahn, MD, Boise, Idaho; Council of State"}
{"id": "3da4ddc8-d8ff-4a8a-85aa-1d519b6c0e53", "page": 30, "type": "paragraph", "text": "and Territorial Epidemiologists, (alternate) Susan Lett, MD, Boston, Massachusetts; Canadian National Advisory Committee on Immunization, Shelley Deeks,"}
{"id": "0c0a870a-636a-4b7f-bc72-8ea1fc22a799", "page": 30, "type": "paragraph", "text": "MD, Halifax, Nova Scotia, Canada; Infectious Diseases Society of America, Carol J. Baker, MD, Houston, Texas; International Society for Travel Medicine,"}
{"id": "4ee41591-0ad6-4898-a6b0-00c1b216e2a6", "page": 30, "type": "paragraph", "text": "Elizabeth D. Barnett, MD, Boston, Massachusetts; National Association of County and City Health Officials, Matthew Zahn, MD, Santa Ana, California;"}
{"id": "1c37fb5a-f40a-410a-94ac-47ebe20ec1dc", "page": 30, "type": "paragraph", "text": "National Association of County and City Health Officials, (alternate) Jeffrey Duchin, MD, Seattle, Washington; National Association of Pediatric Nurse"}
{"id": "9adc8e09-1987-4004-b3f1-ca6394eabc4a", "page": 30, "type": "paragraph", "text": "Practitioners, Patricia A. Stinchfield, MS, St. Paul, Minnesota; National Foundation for Infectious Diseases, William Schaffner, MD, Nashville, Tennessee;"}
{"id": "8590a103-75dc-46da-a565-5fd9308d708e", "page": 30, "type": "paragraph", "text": "National Foundation for Infectious Diseases, (alternate) Marla Dalton, Bethesda, Maryland; National Medical Association, Patricia Whitley-Williams, MD,"}
{"id": "a59881c1-6d20-4f1f-bb57-9526e30acf95", "page": 30, "type": "paragraph", "text": "New Brunswick, New Jersey; Pediatric Infectious Diseases Society, Sean O\u2019Leary, MD, Aurora, Colorado; Pediatric Infectious Diseases Society, (alternate)"}
{"id": "e03cfe9a-6d26-4e52-81bb-8031c85dc95c", "page": 30, "type": "paragraph", "text": "Mark H. Sawyer, MD, San Diego, California; Pharmaceutical Research and Manufacturers of America, Corey Robertson, MD, Swiftwater, Pennsylvania;"}
{"id": "af881661-22ed-48c8-90ea-a6ad58b5defe", "page": 30, "type": "paragraph", "text": "Society for Adolescent Health and Medicine, Amy B. Middleman, MD, Oklahoma City, Oklahoma; Society for Healthcare Epidemiology of America, Marci"}
{"id": "fa73dbac-0411-48e6-b9ea-cd1e4cc89ccd", "page": 30, "type": "paragraph", "text": "Drees, MD, Philadelphia, Pennsylvania."}
{"id": "d6b48563-a0b2-457b-9721-9fd2d39b71a5", "page": 30, "type": "paragraph", "text": "ACIP Influenza Vaccine Work Group"}
{"id": "8e6ebf85-71cb-4742-9892-f837b5974cf3", "page": 30, "type": "paragraph", "text": "Chair: H. Keipp Talbot, MD, Nashville, Tennessee."}
{"id": "5baf9913-2b3f-41d6-81ba-67406545c3fe", "page": 30, "type": "paragraph", "text": "Members: Robert Atmar, MD, Houston, Texas; Kevin Ault, MD, Kansas City, Kansas; Edward Belongia, MD, Marshfield, Wisconsin; Henry Bernstein, DO,"}
{"id": "b9213767-4de3-49fd-a8fd-5582211446d4", "page": 30, "type": "paragraph", "text": "Hempstead, New York; Kristina Angel Bryant, MD, Louisville, Kentucky; Sarah Coles, MD, Phoenix, Arizona; Michael Cooper, PhD, Bethesda, Maryland;"}
{"id": "2c6eb87a-59bf-46cf-8e77-eda54cb2add6", "page": 30, "type": "paragraph", "text": "Jeffrey Duchin, MD, Seattle, Washington; Sandra Adamson Fryhofer, MD, Atlanta, Georgia; Denise Jamieson, MD, Atlanta, Georgia; Krissy Moehling Geffel,"}
{"id": "04317e23-291b-4535-8dc5-1fdc418683f3", "page": 30, "type": "paragraph", "text": "PhD, Pittsburgh, Pennsylvania; Wendy Keitel, MD, Houston, Texas; Camille Kotton, MD, Boston, Massachusetts; Marie-Mich\u00e8le L\u00e9ger, MPH, Alexandria,"}
{"id": "baba1ea5-c4d9-4b84-9aaa-a8bdabf9abd1", "page": 30, "type": "paragraph", "text": "Virginia; Susan Lett, MD, Boston, Massachusetts; Jamie Loehr, MD, Ithaca, New York; Valerie Marshall, Washington, DC; Mark Mulligan, MD, New York,"}
{"id": "1a5b797b-6e34-4652-abf3-be6036cf02a7", "page": 30, "type": "paragraph", "text": "New York; Kathleen M. Neuzil, MD, Baltimore, Maryland; Cynthia Nolletti, MD, Silver Spring, Maryland; Jesse Papenburg, Montreal, Quebec, Canada;"}
{"id": "9d26def7-4342-46a3-bb02-e3b53265dfad", "page": 30, "type": "paragraph", "text": "William Schaffner, MD, Nashville, Tennessee; Robert Schechter, MD, Richmond, California; Kenneth Schmader, MD, Durham, North Carolina; Tamara"}
{"id": "b0b58ccb-1ea0-4179-a5ec-ebbfc66967f2", "page": 30, "type": "paragraph", "text": "Sheffield, MD, Salt Lake City, Utah; Angela Sinilaite, MPH, Ottawa, Ontario, Canada; Patricia Stinchfield, MS, St. Paul, Minnesota; Peter Szilagyi, MD,"}
{"id": "6a9a5021-f52b-459a-a168-8879c33326a5", "page": 30, "type": "paragraph", "text": "Los Angeles, California; Susan Wollersheim, MD, Silver Spring, Maryland; Matthew Zahn, MD, Santa Ana, California."}
{"id": "fe948e00-1c01-4895-8b0d-9c4ca3d00c6e", "page": 32, "type": "paragraph", "text": "ISSN: 1057-5987 (Print)"}
{"id": "74630fcf-4a29-4349-b121-70e23286e169", "page": 32, "type": "paragraph", "text": "The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free"}
{"id": "169dcad6-e04d-4cc4-9cfa-7862458cba6e", "page": 32, "type": "paragraph", "text": "of charge in electronic format. To receive an electronic copy each week, visit MMWR at https://www.cdc.gov/mmwr/index.html."}
{"id": "46f59680-eaf2-45fa-9b7d-8830b75b454a", "page": 32, "type": "paragraph", "text": "Readers who have difficulty accessing this PDF file may access the HTML file at https://www.cdc.gov/mmwr/volumes/71/rr/rr7101a1.htm?s_"}
{"id": "98458e53-e849-4ec7-9862-5de378539312", "page": 32, "type": "paragraph", "text": "cid=rr7101a1_w. Address all inquiries about the MMWR Series to Editor-in-Chief, MMWR Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E.,"}
{"id": "af25adba-9a5a-47fd-8d2d-05fc0ff062ca", "page": 32, "type": "paragraph", "text": "Atlanta, GA 30329-4027 or to mmwrq@cdc.gov."}
{"id": "adc4d8cb-22af-439f-ad5d-cb1017e545a3", "page": 32, "type": "paragraph", "text": "All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated."}
{"id": "ff929ee6-e4e3-4ad9-8ed3-47ed45578d28", "page": 32, "type": "paragraph", "text": "MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services."}
{"id": "66005a4b-c8fb-44bd-9d29-bb370e3994e7", "page": 32, "type": "paragraph", "text": "Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services."}
{"id": "18e829f7-eb05-45bd-9e76-09cdd6b9f365", "page": 32, "type": "paragraph", "text": "References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations"}
{"id": "325647ab-e1c3-4788-a35c-f56137d639fc", "page": 32, "type": "paragraph", "text": "or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses"}
{"id": "b90d1971-02a5-49c7-b42e-c676be450b6f", "page": 32, "type": "paragraph", "text": "listed in MMWR were current as of the date of publication."}
